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Abstract 
The major merozoite surface protein of Plasmodium falciparum (PfMSP1) is a 
malaria vaccine candidate antigen. The C-terminal processing product of 
PfMSP1 (PfMSP119) has a highly conserved amino acid sequence and is 
composed of two epidermal growth factor (EGF)-like motifs due to the 
characteristic spacing of cysteine residues. PfMSP1 19 is the only part of the 
molecule to be taken into the newly invaded erythrocyte. 
Monoclonal antibodies (mAb) which bind to disulphide-constrained 
epitopes of PfMSP119 inhibit parasite growth in vitro and immunisation of 
animals with recombinant proteins representing this region of the molecule 
protects animals against challenge infection. Epidemiological data 
demonstrate that antibody responses to the C-terminus of PfMSP1 are 
associated with protection. To further evaluate the potential of this antigen as a 
vaccine candidate, I have measured human immune responses to recombinant 
proteins representing the C-terminus of PfMSP1. I have found that PfMSP1 19 is 
naturally antigenic in individuals living in a malaria endemic area, and that 
antibody is cross-reactive between the two major allelic prototype sequences of 
PfMSP1 ig. However, some individuals consistently remain non responsive to 
PfMSP1 19 despite life long exposure. To determine whether this is due to a lack 
of T cell help, I have evaluated T cell responses to PfMSP1 19 in malaria 
exposed adults. T cell responsiveness to PfMSP119 is low, I have investigated 
whether this is due to the disulphide structure of PfMSP1 19 which may hinder its 
presentation to, and therefore stimulation of, T helper cells for the production of 
protective antibodies. 
I have found that antibody responses to PfMSP1 19 are associated with 
resistance to clinical malaria in two populations of children actively acquiring 
immunity to malaria. However, not all antibody positive children were protected 
from malaria, suggesting that the fine-specificity of the antibody response may 
be important in determining its ability to provide protection against clinical 
malaria. I was able to demonstrate that human PfMSP119-specific antibody can 
be protective as malaria immune lgG affinity purified to PfMSP1 19 inhibits 
1 
parasite growth. in vitro, and is equally effective against parasites from either 
PfMSP1 family. This suggests that if protective antibodies could be induced 
with vaccination with one or the other allelic form of the protein, all strains of P. 




Malaria: a problem not solved 
Although malaria has been eradicated in many regions of the world, 
primarily in temperate and subtropical areas rather than the African tropical 
heartland, there has been a recent resurgence in the disease due to the 
failure or premature termination of control measures against the mosquito 
vector, and the increasing prevalence of drug resistance. As residents in 
malarious areas do develop some form of protective immunity it should be 
possible to produce a vaccine against malaria. The aim would be to speed 
up the development of immunity and protect against the pathological effects 
of the disease. A safe, cheap vaccine would provide an attractive alternative 
to drug treatment for the hundreds of millions of people at risk of malaria, 
especially as these people live predominantly in rural areas in countries with 
poor infrastructure and limited health care facilities. This thesis concentrates 
on attempts to produce a synthetic, recombinant vaccine which may fulfil 
these criteria. 
What is malaria? 
Malaria is a disease caused by parasites of the genus Plasmodium. Malaria 
occurs in a wide belt around the world including tropical, subtropical and 
temperate zones, wherever conditions are suitable for the maintenance of 
the anopheline mosquito vector. The pathology of the disease is associated 
with the repeated cycles of parasite growth in the RBC. The disease has a 
complex of symptoms making it difficult to estimate how much morbidity and 
mortality malaria causes. In naive individuals, parasitization results in 
clinical disease, but in endemic areas the outcome of infection is more 
complicated, with various disease resistance factors (immunity) coming into 
effect during the individuals' life. 
2a. Malaria life cycle 
The infection is begun by the injection of sporozoites into the host while the 
female Anopheles mosquito takes a blood meal (see figure 1.1. for life 
cycle). Sporozoites migrate to the liver and invade hepatocytes where they 
differentiate and multiply by asexual nuclear division (schizogony). During 
this exo-erythrocytic stage, each intracellular parasite develops into a 
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Figure 1.1. Life cycle of Plasmodium falciparurn. 
from Good eta! (1988d) Ann. Rev. Immunol. 6, 633-688. 
Approximately eight days after the parasite first enters the human host, the 
schizonts burst releasing merozoites into the blood stream. It has been 
estimated that most infective bites inject 20 or less sporozoites, which 
produce approximately 800,000 merozoites (Lines and Armstrong 1992). 
These merozoites rapidly invade RBCs, probably within minutes after 
release from the liver, to begin the blood stage infection. (The invasion 
process is reviewed in Hadley et a! 1986.) Merozoites interact with the RBC 
at any point on the merozoite surface. The parasite reorientates to bring a 
pair of tear-shaped organelles, called rhoptries (located at the apical end of 
the merozoite and associated with the electron dense micronemes), into 
contact with the RBC membrane. The rhoptries release their contents on to 
the RBC surface. The RBC invaginates and the merozoite enters the RBC. 
The internalised parasite is encapsulated within a parasitophorous vacuole. 
The intraerythrocytic parasite forms a 'ring' shape and gradually, over 24 
hours, develops to form a trophozoite. Within the next 24 hours, the parasite 
nucleus divides to form the mature multinucleate 'segmented' schizont 
which contains 8-32 (on average 16) merozoites. 
Only ring stage parasites and early trophozoites are present in the 
peripheral blood, mature parasites are sequestered in the deep capillary 
beds of the spleen, liver, heart, brain and other organs, where they cause 
most of the pathology of severe and cerebral malaria. Merozoites released 
by RBC rupture invade new RBCs. If not controlled by the immune system or 
by chemotherapy, each successive wave of rupturing schizonts, every 48 
hours in the case of P. falciparum, causes the parasitaemia to rise and 
coincides with paroxysmal fever. 
Some parasites, which have invaded the RBC, do not undergo 
asexual division but differentiate into male and female crescent-shaped 
gametocytes and remain in the peripheral blood. These, when taken up by 
the mosquito, mature into gametes and undergo fertilisation in the gut of the 
insect. Sexual reproduction results in zygote (ookinete) formation. The 
ookinetes migrate through the gut wall and develop into an oocyst on the 
outside of the gut wall. Further division occurs, resulting in the production of 
sporozoites which migrate to the salivary glands of the mosquito and await 
inoculation into the vertebrate host to repeat the cycle. 
2b. Malaria pathology 
The major clinical manifestations of malaria are chills, fever (associated with 
schizont rupture of the RBC), headaches, anorexia and nausea. Severity of 
the disease differs with each species. Falciparum malaria is the most severe 
and ovale the least dangerous, though the impact of all the malarial species 
plays an important role in the socio-economic development of the country 
and drains health resources. It has been estimated that a single episode of 
malaria causes a two week loss of work and results in one-quarter of 
hospital admissions in Sri Lanka (Mendis and Carter 1995). 
Severe and complicated malaria are caused almost exclusively by 
erythrocytic stages of Plasmodium falciparum. Pre-erythrocytic and 
gametocyte stages do not cause any pathology. The majority of P. 
falciparum infections do not result in life threatening disease, but those that 
do cause a whole spectrum of symptoms such as severe anaemia, acidosis, 
respiratory distress, renal failure, pulmonary oedema and cerebral 
pathology with convulsions and coma. The spectrum of symptoms can vary 
geographically and with age. Cerebral malaria and anaemia are the main 
contributors to malarial death in Africa, while in Asia and South America 
organ failure (other than the brain) is the main feature of severe disease 
(Mendis and Carter 1995). In endemic parts of Africa, younger children 
suffer predominantly with severe malarial anaemia (average age 27 months 
in The Gambia), whereas older children suffer more from cerebral malaria 
(average age 45 months in The Gambia) (Brewster et a! 1990). 
Malaria fever coincides with the rupture of schizonts. At this time, the 
parasite releases a wide range of antigens which induce cytokine 
production by the host. Cytokines may play a direct pathogenic role in 
severe malaria. In rodents, the cytokine tumour necrosis factor (TNF(X) can 
stimulate clinical symptoms, and can be blocked with TNF-specific mAbs 
and other cytokines, and the level of TNF, and other cytokines including 
interleukin -1 (IL-1) and IL-6, increases in acute infection in humans 
(reviewed in Kwiatkowski 1995). There is a clear relationship between 
clinical severity of the disease and the level of circulating cytokines. It has 
been suggested that while cytokines result in the characteristic fever and 
associated pathology, this fever controls the density of the infection by 
inhibiting parasite growth (Kwiatkowski and Greenwood 1989). 
Pathology caused by malaria is reviewed in Miller eta! (1994); the 
main symptoms include; 
Hypoglycaemia (caused by increased insulin secretion) can result in 
coma. This condition is probably exacerbated by increased demands for 
glucose by the parasite. 
Lactic acidosis resulting from a restriction of oxygen supply to the tissues. 
1.1 
Renal failure due to the damage of the kidneys by renal anoxia which 
reduces the efficiency of glomerular filtration and tubular resorption, and 
usually results in death. 
Raised intracranial pressure during a malarial attack results in headache, 
drowsiness and vomiting. Pressure within the intracranial space leads to a 
reduction of cerebral blood flow leading to respiratory arrest and 
e nce ph a lo pathy. 
Severe malarial anaemia which is caused by the destruction of both 
parasitised and non-parasitised RBCs and the inability of the body to recycle 
iron bound in the insoluble parasite pigment haemazoin, and also an 
inadequate erythropoietic response of the bone marrow. Severe anaemia is 
the predominant symptom of severe malaria in areas of high endemicity and 
is one of the main causes of malarial death of African children, affecting 
mainly infants to 3 year olds. After 3 years of age, the prevalence of severe 
anaemia decreases, at the time when the prevalence of cerebral malaria is 
increasing in African children. 
Cerebral malaria causes death but occurs infrequently. In African 
children its incidence peaks in 3 to 4 year old children. It is paradoxical that 
as the child is beginning to build up its own natural immunity and control its 
parasitaemia, its susceptibility to cerebral malaria increases. Cerebral 
malaria is associated with the accumulation of mature parasitised RBCs in 
the cerebral microvasculature. The direct connection between sequestration 
of parasites within the brain and cerebral malaria has not been 
demonstrated. It is not known whether clinical features of cerebral malaria 
stem directly from histopathological ones, i.e. the physiological blocking of 
blood vessels. Cytoadherence of infected RBCs may lead to cerebral 
anoxia. The parasite modifies the surface of the infected RBC, which 
cytoadheres to endothelium and to uninfected RBC5 (the latter process is 
known as rosetting, see Wahlgren eta! 1994). Knob protrusions occur on 
the parasitised RBC surface as the parasite matures and are areas of 
cytoadherence. It is thought this allows the parasite to avoid clearance by 
the spleen. Cytokines, such as TNF, may up regulate cell adhesion 
molecules on cerebral vessels and children with cerebral malaria have high 
concentrations of TNF (reviewed in Miller et a! 1994). Malarial molecules 
may induce the release of TNFa from macrophages; cytokines are inducers 
of NO and superoxides from host cells. It has been suggested that NO could 
be one of the final mediators in cytokine-induced pathology and coma 
(reviewed in Clark et a! 1991, 1994). 
7 
3. What type of malaria vaccine? 
Of the four malaria species that infect humans, P. falciparum and P. vivax 
are the most prevalent. However, P. falciparum is the only species that can 
directly result in death and was estimated to cause half of the 500 million 
cases of malaria world-wide in 1986 (Sturchler 1989). For this reason, most 
of the vaccine research has been directed to controlling falciparum malaria. 
However, it is hoped that antigens identified to be protective against P. 
falciparum will have analogues in P. vivax which will prove to be protective 
against vivax malaria. This seems highly plausible, as analogues of P. 
falciparum antigens, which appear to be associated with protection in 
humans, experimentally protect mice against rodent malarias (Daly and 
Long 1993, 1995, Ling eta! 1994). 
Most research into malaria vaccines has aimed to control the parasite, 
to limit its numbers and therefore reduce the clinical symptoms of the 
disease. However, interest has now grown in developing an anti-disease 
vaccine as well as an anti-parasite vaccine (reviewed in Playfair eta! 1990). 
Clinical symptoms of malaria in children decline before parasite densities 
do, suggesting that immunity develops to control the disease as well as the 
parasite. Toxins released by the parasite, especially at schizont rupture, are 
thought to induce the pathology caused by malaria. A vaccine based on 
controlling these toxins may prove protective. However, the induced 
cytokines are both mediators of protection and pathology in malaria, and 
much more needs to be known about the effector mechanisms of immunity 
before an anti-disease vaccine can be used in humans. On the other hand, 
an anti-disease vaccine would not affect parasites, so severe malaria may 
still occur, and the population will still be infective to the mosquito vector, 
allowing continued transmission of the parasite. Therefore an anti-disease 
vaccine cannot be used on its own. 
Early vaccine research used attenuated or killed parasites, but due to 
the large scale culture of parasites that would be required, and because of 
cost, stability and safety, an attenuated parasite vaccine is a practical 
impossibility. The development of recombinant DNA technology, however, 
has made it feasible to characterise and express specific genes and 
produce recombinant proteins that could be used in a vaccine. Many 
proteins have been identified which are antigenic and appear to be involved 
in inducing protective immune responses, and have reached varying stages 
of development towards inclusion in a vaccine (reviewed in Romero 1992, 
Holder 1993, Pasloske and Howard 1994). 
It is not clear whether a vaccine should aim to mimic naturally 
acquired immunity to malaria, or whether novel mechanisms should be 
sought. As natural immunity, when it develops, is very effective, most 
attention in vaccine research has been to mimic the mechanisms of 
protective immunity, but to speed up the process. 
The only malaria vaccine to have undergone large scale testing in 
humans is SPf66 (reviewed in Tanner eta! 1995). It is made up of three 
synthetic peptides; one being from the merozoite surface protein 1 (PfMSP1) 
and the other two from two poorly characterised merozoite proteins. The 
peptides are linked by a sequence representing part of the circumsporozoite 
protein (CSP). Initial studies of vaccine trials in monkeys and humans were 
encouraging but were unrepeatable by other groups. Large scale, 
independent randomised, double-blind, placebo-controlled trials in The 
Gambia and Tanzania indicate that the vaccine has a maximum of 30% 
efficacy, and that SPf66-specific antibodies are short lived (reviewed in Riley 
1995). On the other hand, the introduction of bednets has proved to be 
effective in preventing malaria-related morbidity and mortality (Bermejo and 
Veeken 1992), so a vaccine which is introduced will have to better the 
protection provided by bed nets. An introduced vaccine should supplement, 
rather than replace, existing malaria control efforts. 
A major worry for introduction of a vaccine is that as the vaccine will. 
alter the epidemiology of malaria, causing a decrease in transmission, 
naturally acquired immunity will decrease. Naturally acquired immunity 
requires continual antigenic stimulus, as seen with African nationals who 
live in Europe for a number of years, and also in areas of low malaria 
transmission which are subject to malaria epidemics. So the introduction of 
a vaccine could potentially worsen the situation. 
4. Effector mechanisms of anti-parasite immunity 
People living in endemic areas do develop resistance to malaria but the 
protective mechanisms are complex and poorly understood. They are 
essentially of two types; natural innate resistance to the infection, which is 
inherited, and immunity which is at first non-specific but acquires specificity 
after exposure to the parasite. 
4a. Innate resistance 
Innate resistance is expressed regardless-of malarial exposure. Individuals 
born of parents whose ancestors have undergone genetic selection, through 
immune pressure exerted by exposure to malaria, have certain genetic 
polymorphisms which provide a degree of protection from malaria. There are 
many host factors which influence resistance to malaria (reviewed in Miller 
and Carter 1976). For example, the RBC surface Duffy antigen is the 
receptor for the attachment of P. v/vax merozoites. Populations which are 
Duffy antigen negative (such as West Africans) are completely resistant to P. 
vivax infection. 
A number of haemoglobin polymorphisms are associated with 
resistance to malaria; 
Sickle haemoglobin (HbS) is a polymorphism in the molecular structure of 
haemoglobin, resulting from a single amino acid substitution. As the genetic 
defect is often fatal in homozygotes, the degree of protection in the 
heterozygous state must be high to maintain the gene frequency of over 
20% in some parts of Africa. Malaria infection per se does not appear to be 
affected, but the protective affect against severe malaria is enormous, with 
over 90% protection against cerebral malaria and anaemia in Africa (Hill et 
a! 1991). Possible mechanisms include merozoite failure to invade HbAS 
cells, inability of parasites to metabolise HbS, or rapid clearance of 
parasitised HbAS RBCs from the circulation (parasitised HbAS cells adhere 
to each other). 
Resistance of neonates to malaria may be associated with high levels of 
foetal haemoglobin (HbF); 80% of the Hb is HbF at birth and declines slowly 
to be replaced by HbA by the age of 4 months. The mechanism is unclear, 
but parasites grow less well in HbF RBCs (Pasvol eta! 1976). 
Haemoglobin E (HbE) is a structural variant which is also linked with a 
defect in globin synthesis. Haemoglobin C (HbC) is another genetic variant 
found in West Africa which is thought to limit parasite growth. 
Thalassaemia is a hereditary anaemia which is caused by a decrease in 
globin synthesis within RBCs; a and 3 thalassaemias result from either one 
of the two globin chains being affected. Mechanisms of protection include 
resistance of RBC to merozoite invasion and decreased intracellular 
parasite growth (Yuthavong and Wilairat 1993). 
Glucose 6-phosphate dehydrogenase deficiency (G-6-PD) occurs in 
many malaria endemic areas, and is X chromosome-linked. 
Epidemiological studies indicate heterozygote females have some 
protection against malarial growth, but hemizygote males do not. Genes 
controlling host immune responses to infection are also a form of innate 
resistance. Heterogeneity in immune response genes may have evolved in 
response to disease, including malaria. Possible HLA associations with 
protection from the risk of developing severe malaria have been examined 
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in a large study in The Gambia, where the HLA class I antigen BW53 and the 
HLA class II haplotype DRBI 1302-DQBI 0501 were found to be associated 
with protection (Hill et al 1991). Other host genes coding for molecules 
involved in immunity against malaria may also have undergone selective 
pressure, for example genes encoding complement, cytokines and T cell 
receptors. 
4b. Immune resistance 
Only non-specific immune responses are stimulated on first contact with the 
parasite. During this time, antigenic information is being imprinted into the 
specific arm of the immune system, so that the next encounter with the 
pathogen will be more rapid as there is now a specific memory-primed 
immune system. Non-specific immune responses are often enhanced by 
this adaptive immunity. 
4bi. Innate/non-specific immunity 
Non-specific immune responses are antigenically unrestricted. Such 
mechanisms may  be stimulated by parasite 'toxins' that induce a cytokine 
response in non-immune individuals. Cytokines may protect against an 
overwhelming parasitaemia but also cause many of the symptoms of 
malaria, such as fever. Non-specific immune responses are effective 
against all stages of the parasite. IFN-y kills parasites non-specifically in the 
liver stage (but may also be specifically induced), by stimulating hepatocytes 
to synthesise reactive nitrogen intermediates (RNIs) (reviewed in 
Kwiatkowski 1992). IL-6 can also kill intrahepatocytic parasites, but its 
production is down-regulated by the parasite (reviewed in Kwiatkowski 
1992). IFNy and TNFa can also stimulate neutrophils to phagocytose and 
kill intraerythrocytic parasites (Kumaratilake et a! 1992), this is most effective 
in the presence of immune serum. 
Experiments with murine malaria indicate that T cells are required for 
initial control of asexual, intraerythrocytic parasitaemia. This appears to be a 
Thl/IFNy-dependent process. However, B cells are necessary to clear the 
infection; Th2 cell activation promotes B cells to produce specific lgG 
antibodies (reviewed in Taylor-Robinson 1995). Both types of T cell 
response are needed to survive initial challenge and to clear the infection. It 
is difficult to study the cytokine secretory phenotype of T cells in human 
malaria as activated T cells appear to migrate from the peripheral circulation, 
possibly to the spleen and other organs, during acute infection. 
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Gametocytes are vulnerable to attack by cytokines. Crisis serum 
inhibits the ability of gametocytes to infect mosquitoes. This inhibition can 
be blocked by a combination of antibodies against TNFa and IFN'y 
(Naotunne eta! 1991). However, normal serum spiked with recombinant 
TNFx and IFN1 does not inhibit infectivity, suggesting there is some 
complementary gametocyte-killing factor in crisis serum. Sera taken from 
patients with vivax malaria during fever paroxysm, but not at other times, 
also inhibit gametocyte infectivity (Karunaweera et a! 1992). 
The spleen is very important in the immune response to malaria. 
Removal of this organ exacerbates malarial infection in animals and 
humans. The spleen is thought to act as a trap for abnormally-shaped 
infected RBCs. Activated macrophages may also have a cytotoxic effect on 
infected ABCs (reviewed in Good 1992). 
4bii. Adaptive/specific immunity 
It appears that exposure to relatively frequent infection is needed as 
immunity fails to develop where malaria in not endemic. Naturally acquired 
immunity fails to develop, or once developed, is lost with interrupted 
exposure (i.e. in children with seasonal exposure to malaria, or adults with 
extended travel out of an endemic area). Naturally acquired immunity does 
not sterilise against infection. Children in endemic areas exhibit higher 
asexual parasitaemias than do adults, however, parasitised adults rarely 
experience clinical attacks. Children progressively experience fewer and 
less severe attacks of malarial fevers with increasing age. This decrease in 
clinical symptoms occurs before parasitaemia decreases, suggesting an 
'anti-disease' immunity develops first, with an 'anti-parasite' immunity 
developing later (Playfair eta! 1990). 
Development of naturally acquired immunity is thought to be a slow 
process requiring the years of life between infancy and adulthood to 'see' 
the local repertoire of strains (Day and Marsh 1991). This presumption has 
recently been challenged by Baird (1995). In his review article, he points out 
that with experimental infection of humans with malaria, naturally acquired 
immunity may develop after fewer than ten episodes of infection in adults. 
However, he suggests that immunity takes longer to develop in children due 
to their immune system being constitutionally less capable of mounting a 
protective response against the parasite. Measuring the incidence of 
infection in malaria-naive immigrants moving into an endemic area in Java, 
Baird and co-workers were able to demonstrate that adults become clinically 
immune relatively quickly compared to their children. 
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Immune evasion strategies of the parasite may account for the long 
period required to develop immunity, including mechanisms such as; 
immunodominant molecules acting as 'smoke screens' (Anders eta! 1989); 
common repeat structures that are T-independent antigens that protect 
critical antigens (or regions of antigens) by 'epitopic suppression' (Schofield 
1991); antigenic variation of the parasite antigens to frustrate the immune 
system (Mendis eta! 1991). Individuals with high levels of antimalarial 
antibodies can still be susceptible to clinical infection. These sera may lack 
antibody specificities that are critical for resistance, or are of low affinity or 
the wrong lgG subclass to confer protection. It has been found that some 
antibodies cross-react with antigens from different stages of the parasite life-
cycle; the parasite may present an extensive network of cross-reactive 
epitopes to the host in order to prevent affinity maturation of responses to 
less immunogenic but protective epitopes (Moelans and Schoenmakers 
1992). 
The actual mechanisms of naturally acquired immunity to malaria are 
poorly understood and there is no agreed way to measure it. Passive 
transfer of Ig from immune adults to non-immune children demonstrates that 
Ig is a component of naturally acquired immunity (Cohen eta! 1961). It has 
been demonstrated that antibodies (polyclonal and monoclonal) can inhibit 
the in vitro growth of P. falciparum parasites. This could be due to a 
number of mechanisms; inhibition of intracellular parasite development, 
inhibition of schizont rupture, inhibition of RBC invasion by merozoites, 
agglutination of merozoites or inhibition of merozoite binding to the RBC. 
However, Bouharoun-Tayoun eta! (1990) demonstrated that an Ig 
preparation from 'immune' adults (which could passively protect non-
immune individuals; Sabchareon eta! 1991) could only inhibit parasite 
growth in vitro in co-operation with blood monocytes. There is evidence that 
the protective effects of lgG may be mediated by cytophilic antibodies 
(Bouharoun-Tayoun and Druilhe 1992). Non-immunoglobulin components 
of passively transferred immune serum, such as complement, may also be 
responsible for the protection afforded. 
There is evidence that T cell derived lymphokines are an important 
mechanism in immunity (reviewed in Kwiatkowski 1992, 1995); 
Lymphokines can activate the killing of intracellular malaria parasites by 
macrophages in vitro, and can be neutralised using anti-IFN'y mAb 
(Ockenhouse eta! 1984). 
Serum containing the monocyte-de rived cytokine TNFcc can destroy 
murine (Taverne et al 1981) and human (Haidaris eta! 1983) blood stage 
13 
parasites in vitro and inhibit the growth of P. yoelii in vivo (Taverne et a! 
1982), suggesting that TNF(x secretion results in a cytotoxic mechanism that 
kilts intracellular parasites. 
Parasite antigens induce production of IFNy/n vitro in immune adults 
(Troye-Blomberg eta! 1985, Riley eta! 1988). 
Immunity to malaria probably involves an immediate 
monocyte/macrophage derived TNF response to parasite 'toxins' that acts 
through fever and other non-specific mechanisms to constrain parasite 
growth. Then I cell-derived IFNy, together with TNF, stimulate macrophages 
and neutrophils to attack parasites with nitric oxide toxic radicals. Then a 
more slowly evolving B cell response develops which is eventually capable 
of reducing parasitaemia to levels below those resulting in clinical symptoms 
(Marsh 1992) 
4biii. Immunity during pregnancy 
Pregnant women have an increased susceptibility to clinical malaria 
(reviewed in Menendez 1995). Immune depression, probably due to 
immune adaptations developed to prevent rejection of the immunologically 
different foetus, is especially associated with a first pregnancy and is strong 
enough to partially overcome anti-disease immunity. 
Detrimental effects on the mother include anaemia, which contributes 
to maternal death, probably by leading to post-partum haemorrhage. 
Detrimental effects on the foetus/infant include; 
Maternal hypoglycaemia and anaemia, resulting in a reduction in foetal 
birth weight, which may influence the infant's mortality and morbidity during 
the first year of life by directly inducing growth retardation and/or prematurity 
and causing impaired cell-mediated immunity. 
Maternal malaria can cause foetal death by interfering with transplacental 
transfer of nutrients leading to anaemia. 
Transmission of parasites from mother to child may occur during pregnancy. 
There is insufficient information on the effects of malaria during pregnancy 
on subsequent mortality or morbidity in the infant (reviewed in Carlier and 
Truyeus 1995). Conversely, passively acquired immunity from mothers to 
the foetus may play an important role in preventing or controlling the 
parasitic infection in the infant. It is still unknown whether placental infection 
during pregnancy is harmful or beneficial for the infant. However, there are 
high rates of premature deliveries, abortions and still births during a malaria 
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epidemic. An important question in a malaria vaccination campaign is 
whether immunosuppression during pregnancy will affect the effectiveness 
of a vaccine and whether pregnant women should be vaccinated at all. 
Avoiding infections from the onset of pregnancy may prevent the induction of 
immunological tolerance in the foetus. However, an asexual vaccine would 
control parasite densities to subclinical levels, so stimulating naturally 
acquired immunity in mother and foetus, and transplacental transfer of 
malaria-specific antibodies would occur. 
5. Candidate vaccine antigens 
The pre-erythrocytic stage of the infection appears to be asymptomatic with 
clinical symptoms of the disease associated with the asexual blood stage 
parasites. A prophylactic vaccine, to prevent clinical manifestations of the 
disease, must be directed against the blood stages of malaria. Immunity is 
thought to be stage-specific. A vaccine to control the initial infection by 
sporozoites would have to be 100% effective, as a single sporozoite could 
still initiate asexual pàrasitaemia. A vaccine which just controls the asexual 
stage may not suppress the formation of sexual stage parasites, so the 
disease would continue to be transmitted. A vaccine against sexual stages 
alone would not protect the vaccinated individual from the current malarial 
infection. So an ideal malaria vaccine will be a mixture of these, blocking all 
stages of the parasite life cycle. An added advantage of a multi-stage 
vaccine is that if the parasite develops resistance to one of the components 
of the vaccine (i.e. through antigenic variation in a protective epitope), 
parasite proliferation would still be inhibited by the parts of the vaccine 
controlling the other stages of the life cycle. The vaccine may also contain 
some anti-disease components too, directed against malarial toxins. 
There are many potential vaccine candidate antigens (Howard and 
Pasloske 1993) and it would be impossible to study every one in detail, 
however there are enough potentially protective antigens now identified to 
warrant the formation of a multistage cocktail vaccine. Several studies have 
demonstrated that immunisation with even a single purified protein, or 
fragment of it, can protect against an experimental challenge infection. 
The following section is a description of the currently most promising 
antigens identified in regards to vaccine development. The general 
characteristics of these antigens are summarised in table 1.1. 
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antigen size in location general features main review reference 
P. falciparum  
central region of 37 
circumsporozoite sporozoite repeats of Asn-Ala- Aikawa eta! 1981 
protein (CSP) 44kDa surface Asn-Pro (NANP) and 4 Yoshida eta! 1981 
repeats of Asn-Val- 
_________________  Asn-Pro_(NVNP)  
sporozoite surface shares sequence 
protein-2 (SSP2) sporozoite motifs common to Charoenvit eta! 1987 
thrombospondin- 140kDa surface thrombospondin and Robson eta! 1988 
related anonymous properdin 
protein (TRAP)  
liver stage antigen-1 sporozoite 86 amino acid repeats Zhu and Hollingdale 
(LSA) 230kDa surface flanked by conserved 1991 
regions  
Sporozoite and liver sporozoite 87 amino acids Druilhe and Marchand 
stage antigen 70kDa surface 1989 
(SALSA)  
released antigenically diverse 
soluble antigen 220kDa during repeats of 11 amino Anders eta! 1989 
(S AG) schizont acids 
rupture  
serine repeat released 
antigen(SERA) 126-140kDa during 35 serine residues lnselburg eta! 1991 
serine rich protein schizont 
(SERP)  rupture  
Histidine-rich protein- 65-75kDa secreted into 35% histine Wellems and Howard 
2 (PfHRP-2)  plasma 40% alanine 1986 
non polymorphic, 
rhoptry associated serine rich, conserved 
protein-1 (RAP-11) 8OkDa rhoptries repeat sequence, Ridley eta/ 1990b 
proteolytically 
processed  
rhoptry associated conserved 
protein-2 (RAP-2) 42kDa rhoptries no repeats Saul eta! 1992a 
hydrophobic  
apical merozoite 83kDa rhoptries 16 conserved Peterson eta! 1989 
antigen - 1 (AMA-1)  cysteines  
ring infected merozoite 
erythrocyte surface 155kDa dense 2 blocks of tandem Culvenor eta! 1991 
antigen granules repeats 
(Pf 1 55/R ESA)  
erythrocyte binding merozoite antigenically 




merozoite surface 1 95kDa merozoite polymorphic repeats, Cooper 1993 
protein-1 (MSP1) surface conserved cysteine 
residues, 2 EGF-like 
regions  
merozoite surface merozoite 2 conserved regions 
protein-2 (MSP2) 45kDa surface flank central variable Al-Yaman eta! 1994  
area _with _repeats  
identified by antibody 
merozoite surface 48kDa merozoite dependent cellular 
protein-3 (MSP3) doublet surface cytotoxicity assay, Oeuvray eta! 1994 
appears to be non 
polymorphic  
erythrocyte infected RBC undergoes antigenic 
membrane protein-1 250-300kDa surface variation Leech eta! 1984 
(PfEMP1)  
Pf230kDa 230kDa gamete disulphide Rener eta! 1983 
surface constrained  
Pf48/45kDa 48/45kDa gamete disulphide Rener eta! 1983 
doublet surface constrained  
ookinete disulphide 
Pfs25 25kDa surface constrained Kaslow eta! 1988 
4 EGF- like_regions 
Table 1.1. Summary of the main malaria vaccine candidate antigens. 
W. 
5a. Pre-erythrocytic stage vaccine candidate antigens 
The sporozoite has been intensively studied for vaccine development. 
Immunising mice, chickens and humans with attenuated sporozoites 
protected vaccinees against sporozoite challenge (reviewed in 
Nussenzweig and Nussenzweig 1985). The sporozoite is covered in a 
surface antigen, the circumsporozoite protein (CSP), which contains an 
immunodominant repeat region (Aikawa et al 1981, Yoshida et a! 1981). 
Reasons for the sporozoite stage being promising as a vaccine candidate 
include; 
MAbs specific to the CSP repeats passively protect mice from challenge 
infection. 
Antibodies raised to a synthetic peptide representing the (NANP)n repeat 
of the Plasmodium falciparum CSP inhibit sporozoite invasion in vitro. 
However, immunisation of humans with a peptide vaccine induced limited 
protection (reviewed in Good et a! 1988c). 
It was noted that attenuated sporozoites could induce immunity, but 
that killed sporozoites could not. This suggested that hepatocyte invasion 
was important for an effective immune response. It was found, through 
depletion experiments, that cytotoxic CD8+ T cells are important to this 
immunity and that cytokines, in particular IFN'y, released from T cells can 
inhibit the development of intrahepatocytic stages (reviewed in Subrbier 
1991). It has yet to be shown that sporozoite CTL responses are important 
in protective immunity in humans although human CD8+ cytotoxic T cells 
have been identified which are directed against the CSP (Sedegah et a! 
1992). 
A second protein on the sporozoite surface has been identified in P. 
yoe!ii(SSP2) (Charoenvit eta! 1987). Mice immunised with both CSP and 
SSP2, but not each alone, were completely protected against challenge 
infection (Khusmith eta! 1991). Antibodies raised to recombinant proteins 
representing PfSSP2 inhibit sporozoite invasion and development in 
hepatocytes in vitro (Rogers eta! 1992). 
5b. Liver stage vaccine candidate antigens 
A liver stage antigen-1 (LSA-1) has been identified in P. falciparum (Guerin-
Marchand eta! 1987, Zhu and Hollingdale 1991). It has been found that 
CTLs recognise a conserved peptide from LSA-1 adding to its attractiveness 
as a vaccine candidate (Hill eta! 1992). As well as CSP and LSA-1, other 
sporozoite antigens are present in, and synthesised by, liver- 
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stage parasites. Sporozoite and liver stage antigen (SALSA) is highly 
antigenic in human populations and so may be a possible vaccine 
candidate (Druilhe and Marchand 1989). 
Some blood stage antigens also occur in the liver stage (such as the 
merozoite surface protein 1), so a vaccine developed against blood stages 
may also be effective against liver stage parasites. 
5c. Blood stage vaccine candidate antigens 
There are a multitude of potential antigens expressed during the blood 
stage, identified by immune sera, that are candidates for a vaccine (table 
1.1.). Merozoite surface antigens may be involved in merozoite attachment 
to the RBC. Secretions of proteins from internal merozoite organelles may 
be important in ABC invasion and/or development within the RBC. Parasite 
antigens are expressed on the infected RBC surface and may be involved in 
cytoadherence, rosette formation with other RBCs and transport functions. 
Finally, when the synchronised schizonts rupture, large quantities of soluble 
antigens, called exoantigens, are released into the plasma. As clinical 
symptoms of malaria, such as fever, are associated with schizont rupture, it 
is likely that materials released at the time elicit the host responses. These 
antigens/toxins are targets for an anti-disease vaccine, reducing morbidity 
and mortality without necessarily reducing parasitaemia (Playfair et a! 
1990). 
The selection of suitable candidates has been directed by studying 
the biological effects of antibodies induced to the natural infection or to 
purified or recombinant parasite proteins. In vitro functional assays have 
been used to define protective antigens by assaying antibody effects on 
parasite growth, invasion of ABCs and cytoadherence and the ability to 
stimulate I cell proliferation and cytokine production. In vivo functional 
assays include measuring the effects of passive transfer of immune 
antibodies and immunisation of animals with native or recombinant parasite 
proteins. Antibody and cellular immune responses to candidate antigens in 
malaria-exposed children and adults have been measured to determine 
whether responses correlate with the development of clinical immunity. 
5ci. Soluble antigens 
Antigens released at schizont rupture include the soluble S-antigens, but 
due to the wide diversity of repetitive amino acid sequence between 
different isolates, they have not been proposed as a vaccine candidate 
in 
(Anders eta! 1989). However, a number of soluble antigens are serious 
vaccine candidates: 
SERA: the soluble serine repeat antigen. SERA-specific mAbs can inhibit 
parasite growth in vitro (Perrin et a! 1981, 1984) and monkeys immunised 
with native (Perrin eta! 1984) or recombinant (lnselburg eta! 1991) SERA 
were immune to subsequent challenge infection. 
HRP2: Histidine-rich protein 2. Immunisation with the recombinant C-
terminal half of HRP2 partially protected monkeys against challenge 
infection (Knapp et a! 1988), while monkeys immunised with HRP2 plus 
SERA and MSP1 were totally protected (Knapp eta! 1992). 
Apical complex proteins: proteins released from the apical secretory 
complex, consisting of the large paired rhoptries and the smaller 
micronemes, are thought to be involved in RBC invasion. Immunisation of 
monkeys with the rhoptry protein complex provided protection from lethal 
challenge infection (Ridley et a! 1990a) and antibody specific to the 
complex was able to inhibit parasite growth in vitro (Schofield et a! 1986). 
Genes from two of these rhoptry associated proteins (RAP) have been 
identified; RAP-1 and RAP-2. RAP-1 is highly conserved and appears to be 
protective. 
AMA-1: apical merozoite surface antigen-1 is exported to the merozoite 
surface from the rhoptries. Pk66 is the equivalent protein in P. know!esi. 
Pk66-specific mAbs inhibit merozoite invasion in vitro (Deans eta! 1984), 
and monkeys immunised with Pk66 were protected from challenge infection 
(Deans eta! 1988). 
RESA: the ring-infected erythrocyte surface antigen is localised in the 
dense granule organelles of the merozoite and is transferred to the 
cytoskeleton of the newly invaded RBC. RESA-specific antibodies, 
especially those directed to the repeat sequences, inhibit invasion in vitro 
but immunisation of monkeys with recombinant proteins representing RESA 
has produced disappointing results (reviewed in Romero et a! 1992). 
Epidemiological studies have also given conflicting results regarding the 
correlation of RESA-specific antibodies with protection from clinical malaria 
(Riley eta! 1991b, Deloron and Chougnet 1992). It is possible that the in 
vitro growth inhibition and the slight protection in monkeys is due to cross-
reactivity of anti-RESA antibodies with other malarial antigens (Mattei et a! 
1989). 
EBA-175: the 175kDa erythrocyte binding antigen binds to sialic acid on 
the ABC surface and the level of binding appears to correlate with the 
efficiency of parasite invasion, and antibodies raised to a synthetic EBA 
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peptide prevent the binding of purified EBA-175 to RBCs and inhibit 
merozoite invasion in vitro (reviwed in Sim 1995). 
5cii. Merozoite surface proteins 
There are at least three vaccine candidate antigens on the merozoite 
surface. 
The merozoite surface protein-1 (MSP1) is discussed in detail below 
(p21). 
The merozoite surface protein-2 (MSP2) consists of two conserved 
regions flanking a variable repetitive region. MSP2-specific antibodies 
inhibit parasite growth in vitro (Clark et a! 1989) and mice immunised with 
recombinant proteins representing conserved regions of MSP2 are 
protected from a lethal challenge infection (Saul et a! 1992b). 
Epidemiological studies indicate that some MSP2 antibodies are correlated 
with decreased susceptibility to clinical malaria (Al-Yaman eta! 1994, R. 
Taylor 1995 Ph.D. thesis, University of Edinburgh). 
The 48kDa merozoite surface protein-3 (MSP3) has recently been 
described (Oeuvray eta! 1994). Antibodies to this protein label the 
merozoite surface and co-operate with monocytes to kill parasites. The 
antigen appears to be relatively conserved but further characterisation is 
required. 
5ciii. Erythrocyte surface neo-antigens 
Antigens expressed on the surface of the infected RBC are involved in 
cytoadherence and are thought to mediate sequestration of infected RBCs. 
Variant erythrocyte surface antigens, denoted schizont-infected cell 
agglutinins (SICA), were first discovered in P. know!esi (Brown and Brown 
1965). The equivalent antigen in P. falciparum, erythrocyte membrane 
protein-1 (PfEMP1), is recognised by agglutinating antibodies (Leech et a! 
1984). They appear to display considerable antigenic variation (Biggs et a! 
1991, Roberts et a! 1992) as cloned lines appear to be able to change their 
phenotype in vitro. Although interesting with regard to its role in 
cytoadherence, this protein appears to be involved in immune evasion 
(similar to the surface variant antigens of trypanosomes; reviewed in Mendis 
eta! 1991) and may not be an ideal vaccine antigen. The genes for this 
family of related antigens have now been identified (Baruch eta! 1995). 
Antigens expressed on the surface of the intracellular asexual 
parasite have received little attention as they are thought to be inaccessible 
to antibody. However, the identification of a parasitophorous duct (Elford et 
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a! 1985, Pouvelle eta! 1991) raised the possibility that antibody may be 
able to access the intracellular parasite. It has been suggested that antibody 
can inhibit parasite growth before schizont rupture and merozoite release 
(Perrin eta! 1981), so proteins on the intracellular parasite surface are 
beginning to receive more attention as potential antigens for vaccine 
development. 
5d. Transmission blocking vaccine candidate antigens 
The idea of a transmission blocking vaccine is to prevent the continuation of 
the parasite life cycle in the mosquito vector by interfering with the sexual 
development of the parasite in the mosquito gut and thus reduce sporozoite 
numbers. Immunisation of the host with sexual stage parasites (expressing 
stage-specific antigens) can suppress the infectivity of subsequent blood 
infection to the mosquito (Carter and Chen 1976), suggesting that inhibitory 
agents, such as antibodies, are ingested by the mosquito during the blood 
meal. Gametocyte surface antigens of P. falciparum, 230kDa and a 
45/48kDa doublet, have been identified as vaccine candidates as they are 
targets of transmission blocking mAbs (reviewed in Kaslow eta! 1992). It is 
thought that antibody activates complement-mediated lysis of gametes or 
directly inhibits fertilisation. However, it has been suggested that frequent 
reinfection would be needed to maintain transmission-blocking immunity, so 
an efficient immunity induced by the vaccine may limit its own usefulness 
(Ranawaka eta! 1988). 
A 25kDa protein (Pfs25) was found to be expressed on the zygote 
and ookinete surface after fertilisation (Rener et a! 1983). It has been 
suggested that Pfs25 is a ligand for an ookinete receptor on the mosquito 
gut wall. The deduced amino acid sequence of Pfs25 shows that it is a 
cysteine-rich protein consisting of four EGF-like motifs (Kaslow eta! 1988). 
These EGF-like motifs have been found in Pfs25's analogue (Pgs25) in P. 
gallinaceum, an avian malaria (Kaslow eta! 1989). The position of the 
cysteine residues are highly conserved between these two Plasmodium 
species. Correctly folded yeast recombinant proteins representing Pfs25 
induced transmission-blocking antibodies when used to immunise mice or 
monkeys (Barr eta! 1991). The adjuvant used, murarnyl tripeptide, is safe to 
use in humans and preclinical trials of this vaccine are imminent. 
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6. The Merozoite Surface Protein-1 (MSPi) as a vaccine 
candidate 
MSP1 is also known as the Precursor to the Major Merozoite Surface 
Antigen (PMMSA), gpl 95, P195, MSA-1; reviewed in Holder et a! (1988). It 
is one of the most studied antigens of the parasite life cycle, and is 
synthesised from the beginning of schizogony in the liver and in blood 
stages of the parasite (Holder and Freeman 1981, 1982, Hall et a! 1 984a, 
Szarfman eta! 1988). 
The first complete gene sequence of Plasmodium falciparum MSP1 
(PfMSP1) was determined in 1985 and shown to encode a protein of 
approximately 1700 amino acids (Holder et a! 1985). Seven full length and 
at least 37 partial PfMSP1 sequences have been determined (reviewed in 
Miller et a! 1993). Sequences have also been obtained for the PfMSP1 
analogues in P. yoe!ii (Burns et a! 1988, Lewis 1989), P. chabaudi (Lew et 
a! 1989a, Deleersnijder eta! 1990) and P. vivax (del Portillo eta! 1991, 
Gibson eta! 1992).. Primary sequences deduced from these genes have 
certain features in common; a 19 amino acid N-terminal signal sequence 
and a putative hydrophobic membrane anchoring domain at the C-terminus 
of the molecule. The hydrophobic sequence is thought to be removed 
during biosynthesis and replaced with a glycolipid, binding MSP1 to the 
merozoite surface via a glycosylphosphatidylinositol (GPI) anchor (Haider et 
a! 1985). 
Studies with PfMSP1 -specific murine mAbs suggested that the 
PfMSP1 molecule contained both conserved and dimorphic amino acid 
sequences (McBride eta! 1982, 1985). Tanabe eta! (1987) demonstrated 
that the PfMSP1 primary sequence can be divided into 17 blocks (see figure 
1.2.), in which the amino acid sequence was either highly conserved (91-
96% homology), semi conserved (65-75% homology) or variable (10-38% 
homology). The variable blocks were found to be of two versions, i.e. amino 
acids could be only one of two possibilities such that PfMSP1 sequences 
from parasite isolates fall into one of two dimorphic types.. This lead Tanabe 
and co-workers to suggest a dimorphic allele model, where Ki and MAD20 
sequences are the two allelic prototypes for all isolates of PfMSP1. They 
proposed that the two dimorphic forms of PfMSP1 were the result of limited 
intragenic recombination between two parental PfMSP1 alleles. 
Dimorphism at the amino acid level is strictly maintained in the nucleotide 
gene sequence as variation is not random; only one base differs at positions 
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Figure 1.2. Schematic representation of the primary sequence of the PfMSP1 gene, and 
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semi conserved 	 proteolytic processing of the PfMSP1 protein. 
Comparison of the amino acid composition of PfMSP1 from different strains indicates that the 
II conserved 	 polypeptide can be divided into 17 blocks with conserved, semi-conserved or variable sequence 
(Tanabe eta! 1987). Variable areas are one of two dimorphic sequences. The precursor protein 
undergoes proteolytic processing to form four proteins on the merozoite surface (PfMSP183, 
PfMSP128-30, PfMSP138, PfMSP142). PfMSP142 undergoes secondary processing to form two 
peptides; PfMSP133 and PfMSP1tg. 
There are exceptions to the dimorphic rule. Block 2 is the only truly 
polymorphic region of the molecule, made up of degenerate tandem repeats 
of amino acids, of which there are two distinct allelic prototypes. However, 
there is a third form of block 2 which lacks the repeats, as found in the R033 
(Certa et a! 1987) and CSL-2 (Peterson et a! 1988) isolates. This third form 
of block 2 is highly prevalent in field isolates in certain geographical regions. 
Kimura eta! (1990) found that 53% of 30 Brazilian malaria patients were 
infected with isolates which contained the R033 allelic form of block 2. 
Scherf eta! (1991) found that 15 out of 16(94%) blood samples from 
Senegal contained the R033 allelic form, compared with 56% for Ki and 
13% for MAD20 allelic forms. It seems likely that in vitro culturing of 
parasites may bias the growth rate of strains, by increasing the relative 
growth rate of strains which do not contain the R033 version of block 2, 
suggesting that host factors, absent in in vitro cultures, could play a role in 
either limiting MAD20 and Wellcome block 2 type parasites and/or 
promoting R033 block 2 type parasites. On the other hand, Jongwutiwes et 
a! (1992) analysed 25 gene clones derived from 19 Thai wild isolates, and 
found that only 3 clones were, of the R033 block 2 type, while 16 were of the 
MAD20 and 6 were of the Ki type of block 2. 
The reason why there are three forms of block 2, contrasting to the 
two forms of the rest of the molecule, is unknown. It has been suggested that 
the third form of block 2 may be an ancestral sequence from which the hyper 
variable tripeptide repeats have evolved to escape immune attack (Certa et 
a! 1987). However, Kimura eta! (1990) suggest that, due to the high 
conservation of the 52 amino acids of the R033 version of block 2 among 
isolates from around the world, that this form of block 2 may have evolved 
from the repeats to form a new functional unit with as yet unknown function. 
Comparison of MSP1 sequences from different P. vivax strains 
indicates there are also areas of conserved, semi-conserved and variable 
sequence homology within PvMSP1 (Gibson et a! 1992). Interspecies 
comparisons of amino acid homology between MSP1 of different 
Plasmodium species show there is only limited sequence homology (Lewis 
1989, Deleersnijder et a! 1990, del Portillo et a! 1991, Gibson et a! 1992). 
However, there are regions of inter-species conservation which may indicate 
regions of MSP1 associated with essential structural or functional roles 
(Cooper 1993). These interspecies conserved blocks reside within the 
conserved regions identified by Tanabe eta! (1987) with especially high 
homology in the C-terminus. 
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In aligned PfMSP1 amino acid sequences, the position of the 19 
cysteine residues are conserved, 12 are found in the highly conserved block 
17 sequence at the C-terminus of the molecule. In all Plasmodium MSP1 
sequences (when divided into 17 blocks and aligned) the position of 14 
cysteine residues are conserved, 10 of which are located within the C-
terminal, block 17 (Miller eta! 1993). In PfMSP1 this cysteine-rich region 
contains two EGF-like motifs (Blackman eta! 1991a), with the characteristic 
spacing of cysteines and a glycine residue (Appella et a! 1988, Engel 
1989). In EGF the cysteines are linked by disulphides; Cl to C3, C2 to C4, 
and C5 to C6 (see figure 1.3.). In species other than P. falciparum, one pair 
of cysteines (C2 to C4) are absent from the first EGF-like motif (Blackman et 
a! 1991a, Daly eta! 1992), so not forming a true EGF-like structure. 
The size of PfMSP1 has been estimated to be between 185 and 205 
kDa depending on the strain of origin (McBride et a! 1985, Schwartz et a! 
1986). Higher molecular weight homologues of PfMS.P1 occur in other 
Plasmodium species; 25OkDa in P. chabaudi (PcMSP1; Boyle et a! 1982, 
Holder et a! 1983), 230kDa in P. yoelii (PyMSP1; Holder et a! 1983, Oka et 
a! 1984), 230-25OkDa in P. knowiesi (PkMSP1; Epstein eta! 1981, David 
eta! 1984)and 200kDa in P. v/vax (PvMSP1; del Portillo eta! 1991, Gibson 
eta! 1992). MSP1 is a precursor molecule which undergoes post-
translational proteolytic processing at the end of schizogony, prior to the 
release of merozoites from the mature schizont, to form a number of 
fragments on the merozoite surface (see figure 1.2.). 
The exact size of the fragments depends on the parasite isolate (Lyon 
et al 1986, 1987, McBride and Heidrich 1987), but for convenience the 
proteins will be referred to here as PfMSP183, PfMSP128-30, PfMSP138 and 
PfMSP142. N-terminal amino acid sequencing of purified PfMSP183 (Holder 
eta! 1985, Strych eta! 1987, Cooper and Bujard 1992), PfMSP138 
(Heidrich eta! 1989) and PfMSP142 (Heidrich eta! 1989, Blackman eta! 
1991 b) confirmed that these fragments are derived from PfMSP1, and also 
identified the exact location of the proteolytic cleavage sites for the 
Wellcome and MAD20 alleles (Stafford et a! 1994). McBride and Heidrich 
(1987) demonstrated that these major products of PfMSP1 proteolysis, but 
not uncleaved PfMSP1, are associated on the merozoite surface in the form 
of a non-covalently associated complex, which also includes a 22kDa and a 
36kDa protein not derived from PfMSP1 (Stafford et al 1994). PfMSP2 is 
not associated with the PfMSP1 complex and PfMSP128-3o has not been 
definitively demonstrated within the complex, due to lack of a suitable 
antibody probe. 
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Figure 1.3. Schematic representation of the postulated EGF-like structure of PfMSP1 19 
Expected disulphide-bonding is indicated by dashed line. 
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Dimorphic amino acid residues are indicated. 
It was found that mAbs which recognise PfMSP142 on a Western blot 
also recognise a 19kDa protein, and that unlike mAbs to other parts of 
PfMSP1, PfMSP142-specific mAbs did not recognise the reduced form of the 
protein, suggesting that epitopes bound by these mAbs were disulphide 
bond-dependent (McBride and Heidrich 1987, Blackman eta! 1991b). 
Metabolic labelling of PfMSP142 demonstrated that the 19kDa protein 
(henceforth referred to as PfMSP1 19) is derived from PfMSP142 (Holder et al 
1987, McBride and Heidrich 1987); this was later confirmed by N-terminal 
amino acid sequencing (Blackman eta! 1991b). The PfMSP119 protein 
consists of 96 amino acids, which gives a predicted size of 12kDa, which is 
smaller than its apparent molecular weight of 19kDa on SIDS PAGE. It is 
difficult to predict the size of PfMSP1 19 as the protein is modified by a GPI 
anchor and is disulphide-constrained. After reduction and alkylation of 
recombinant proteins representing PfMSP1 19, its mobility on SIDS PAGE 
increases from 19kDa to 17kDa; this is unusual as reduction of disulphide 
bonds usually decreases protein mobility (Burghaus and Holder 1994). 
Blackman et a! (1990) demonstrated that PfMSP1 19 is the only 
fragment of PfMSP1 which remains on the merozoite surface during RBC 
invasion. PfMSP119-specific mAbs bind to the parasite membrane of newly 
formed ring stages whereas a human mAb (X509) specific for the N-terminus 
Of PfMSP142 did not (Blackman eta! 1990). MAb reactivity with ring stages 
decreases with the age of the rings, with no antibody reaction with rings 
older than 2 hours, suggesting that the antigen is degraded. 
Immunoprecipitation of culture supernatants with mAb X509 demonstrated 
the presence of a 33kDa fragment. Together with the location of the epitope 
bound by mAb X509, this suggested that PfMSP133 and PfMSP119 are 
produced by a single proteolytic event at a site within PfMSP142. Henceforth 
this 33kDa protein will be referred to as PfMSP133. The absence of 
PfMSP133 in mature schizont preparations suggests that the proteolysis of 
PfMSP142 to PfMSP133 and PfMSP11 is the result of a secondary 
processing event, distinct from the primary processing of the PfMSP1 in 
sch izonts. 
Extracellular calcium is essential for RBC invasion by merozoites; the 
presence of the chelating agent EGTA inhibits RBC invasion (McCallum-
Deighton and Holder 1992). Secondary processing of PfMSP142 was also 
found to be inhibited by the chelating agents EGTA and EDTA, and this 
inhibition is reversed by the addition of calcium but not magnesium 
(Blackman and Holder 1992, Blackman eta! 1993). Primary processing 
was found not to be affected. This calcium-dependent proteolytic activity 
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was inhibited by serine protease inhibitors. It has not been proven that 
inhibition of secondary processing of PfMSP142 causes the inhibition of RBC 
invasion but, as the only fragment of PfMSP1 taken into the RBC is 
PfMSP119, complete proteolysis of PfMSP142 may be a prerequisite for RBC 
invasion. 
At the time this project began there was considerable evidence that 
MSP1 might play a role in clinical immunity to malaria, and some evidence 
that the C-terminus of MSP1 might be particularly important. Immunisation 
of mice with native MSP1 (reviewed in Holder 1988), or passive transfer of 
MSP1-specific mAbs (Burns eta! 1988, Lew eta! 1989a), could protect 
against a challenge infection. The conserved regions of the protein contain 
both I and B cell epitopes (Gentz et a! 1988, Sinigaglia et al 1988, Crisanti 
eta! 1988). Vaccination of monkeys with native or recombinant proteins 
representing MSP1 protects against a lethal challenge infection (Siddiqui et 
a! 1987, Holder eta! 1988, Etlinger eta! 1991). The C-terminal region of 
MSP1 is the target of the majority of the MSP1-specific invasion inhibitory 
mAbs (Cooper eta! 1992, Chappel and Holder 1993), and antibodies 
raised to recombinant proteins representing the C-terminus inhibit parasite 
invasion in vitro (Chang et a! 1992). Seroepidemiological studies indicated 
that antibody responses to PfMSP1 (Riley et a! 1992a, 1993, Tolle et a! 
1993), and especially to the C-terminal region (Riley eta! 1992a), were 
associated with resistance to clinical malaria. So PfMSP1, and especially 
the C-terminal region, was considered to be a major candidate for a vaccine 
against malaria. 
7. Aims of this project 
The aim of this study was to investigate human humoral and cellular immune 
responses to the C-terminus of PfMSP1. Firstly, to investigate the epitope 
specificity and the age profile of acquired antibody responses that occur 
following natural infection. Secondly, to assess the biological function of 
PfMSP1 19-specific antibodies. Thirdly, to determine whether these antibody, 
responses are associated with resistance to clinical infection in children, and 
finally, to begin to evaluate cellular immune responses to PfMSP1 19. 
CHAPTER TWO: 
Production and antigenic integrity of recombinant proteins 
representing the C-terminus of PfMSP1 
Introduction 
Production of recombinant proteins representing PfMSP1 is necessary for; 
characterisation of the protein and identification of immunogenic and 
potentially protective epitopes, 
the production of subunits of PfMSP1 for experimental vaccination of animals 
(to determine whether a recombinant form of the antigen can confer a degree of 
immunity similar or better to that obtained with the native antigen) and 
for an eventual large scale human vaccination trial, for which the use of 
killed/attenuated parasites would be impractical and uneconomical. 
For these purposes it is critical to produce the synthetic antigens in the 
same form as their native counterparts. In the case of PfMSP1 this includes 
producing proteins with the correct formation of disulphide bonds to ensure 
formation of dominant B cell epitopes. The secondary (conformational) 
structure of PfMSP1 is essential for recognition of recombinant proteins 
representing the cysteine-rich PfMSP11 by murine mAbs (McBride and 
Heidrich 1987, Cooper eta! 1992, Chappel and Holder 1993). Also, the 
protective effect of a recombinant E. coil-derived glutathione S-transferase 
(GST) fusion protein, representing the equivalent region in PyMSP1, was 
conformation-dependent as reduction and alkylation of this recombinant protein 
totally inhibited its protective effect (Ling et a! 1994). E. coil-derived 
recombinant proteins representing PfMSP1 19 and its constituent EGF-like motifs 
have also been shown to display conformation-dependent determinants 
(Chappel and Holder 1993, Burghaus and Holder 1994). 
Fragments of PfMSP1 have been expressed as recombinant proteins in 
E. coil and used to immunise monkeys (Holder et a! 1988, Herrera et a! 1990, 
Etlinger et a! 1991, Herrera et a! 1992). These bacterial recombinant proteins 
provided partial protection from challenge infection. However, in the majority of 
experiments, despite prolonging the prepatent period or decreasing the peak 
parasitaemia compared to the control animals, vaccinated animals eventually 
required drug treatment, and their serum IFA titres compared to native PfMSP1 
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were often low. A high degree of protection, and higher anti-PfMSP1 FA titres, 
were obtained by immunisation of animals with purified native PfMSP1 
(Siddiqui et a! 1987, Etlinger et a! 1991), suggesting that the bacterial 
recombinant polypeptides may not fully represent the native molecule in terms 
of correct secondary structure, i.e. correct folding of disulphide bonds, and other 
post-translational modifications such as glycosylation, phosphorylation, 
acylation and amidation. 
Bacterial recombinant polypeptides are generally intracellular products. 
Due to the internal reducing environment of bacteria, proteins with 
intramolecular disulphide bridges may not fold properly inside the cell. This 
may be why the above immunisations with E. co/i-derived PfMSP1 did not 
confer as much protection from infection as did native purified PfMSP1. The E. 
co/i-derived PfMSP1 recombinant protein of the Holder eta! (1988) study was 
later noted to be in a denatured configuration (Holder eta! 1992); the 
immunising proteins were not tested for correct conformation in the other 
studies. 
Due to the lack of protection conferred on monkeys immunised with 
bacterial recombinant proteins, investigations have turned to eukaryotic 
expression systems. Eukaryotic expression systems such as yeast, insect and 
mammalian cells produce recombinant polypeptides via the secretory pathway 
in a microenvironment that promotes appropriate folding and post-translational 
modifications of foreign eukaryotic proteins. However, some yeast cells also 
produce cytoplasmic proteins rather than secreted proteins, resulting in 
abnormal disulphide bond formation in cysteine-rich polypeptides and 
inappropriate glycosylation (Bathurst 1994). Mammalian cells do not have 
these draw backs but produce rather low yields rendering this approach 
impractical. Baculovirus transfected insect cells, however, produce correctly 
folded peptides, which appear to be appropriately glycosylated. This system 
also promotes other post-translational modifications such as phosphorylation, 
acylation and amidation (VIak and Keus 1990). 
Chang eta! (1992) have demonstrated that the antigenic integrity of the 
recombinant protein is determined by the expression system used for its 
formation. They produced the cysteine-rich PfMSP142 antigen in both yeast and 
baculovirus systems. The baculovirus, but not the yeast, PfMSP142 
recombinant protein was recognised by anti-PfMSP1 antibodies of animals 
immunised with purified native PfMSP1. Immunisation of rabbits with the 
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baculovirus, but not the yeast, recombinant PfMSP142 induced high titres of 
antibodies that were cross-reactive with purified native PfMSP1 in ELISA, and 
with schizonts and merozoites in IFA. Binding of anti-PfMSP1 antibodies to 
native PfMSP1 was effectively blocked in the presence of native PfMSP1 or 
baculovirus PfMSP142, while similar concentrations of yeast PfMSP142 were 
much less effective in competition binding assays. Yeast PfMSP142 was poorly 
recognised by conformation-dependent mAbs specific to PfMSP142. Rabbit 
polyclonal anti-baculovirus PfMSP142 antibodies completely inhibited the in 
vitro growth of parasites, whereas the anti-yeast PfMSP142 antibodies did not. 
This suggests that the antigenicity of the baculovirus PfMSP142 was very similar 
to native PfMSP1, while yeast PfMSP142 was antigenically distinct. 
Since a major difference between the intracellular yeast polypeptide and 
the secreted baculovirus PfMSP142 seems to be the result of protein folding 
(demonstrated by the lack of mAb reactivity to the yeast PfMSP142). It is likely 
that native conformation-dependent determinants of the PfMSP142 polypeptide 
are critical for the optimal antigenicity and stimulation of B cells which produce 
growth inhibitory antibodies. 
It has been suggested that the conformation of a protein also influences 
recognition of T cell epitopes (Atassi et a! 1989, Vidard et a! 1992, see chapter 
7). T cell epitopes are usually short, linear peptides, however, their processing 
can be dependent on protein conformation, particularly, the presence or 
absence of disulphide bonds. The ability of a protein to activate T cells will affect 
the quality of antibody produced, as T cell help is required for memory 
responses, affinity maturation of Ig and Ig class switching. 
In this chapter I report on investigation into the antigenic integrity of 
recombinant antigens produced by different expression systems. Some of 
these proteins were later used in immunological assays (presented in chapters 
3, 4, 5, 6 and 7). I have used E. co/i-derived GST fusion proteins (Chappel and 
Holder 1993), insect cell-secreted baculovirus recombinant proteins (Murphy et 
a! 1990), and yeast-derived recombinant proteins (Kaslow eta! 1994) to 
represent the C-terminus of PfMSP1. I have also produced an E. co/i-derived 
GST fusion protein of the PfMSP133 processing fragment to further analyse 
human immune responses to epitopes within PfMSP142. 
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Materials, methods and results 
Monoclonal antibodies 
MAbs used in this thesis are indicated in table 2.1. MAbs were kind gifts of Dr. 
J. McBride (University of Edinburgh, Scotland, UK), Drs. A. Holder and M. 
Blackman (NIMR, London, UK), Dr. M. Perkins (Rockefeller University, New 
York, USA), Drs. A. Saul and J. Cooper (Queensland Institute of Medical 
Research, Brisbane, Australia), and Dr. A. Reese (Agouron Institute, La Jolla, 
California, USA). 
SOS-PAGE 
Samples were solubilised by boiling in SDS sample buffer (0.125M Tris-HCI pH 
6.8, glycerol 20%[v/v], sodium dodecyl sulphate [SDS] 4.6% [w/v], bromophenol 
blue 0.01% [w/v]), with or without 0.1M dithiothreitol (DTT; Sigma) as a reducing 
agent, then fractionated on a 10% polyacrylamide gel by the method of Laemmli 
(1970). Low molecular weight markers were used (Pharmacia and BioRad). 
Following electrophoresis, proteins were visualised by staining with Coomassie 
blue (Coomassie Brilliant Blue R-250; Sigma), or by Western blotting. 
Western (immuno-) blotting 
Standard procedures were used for Western blotting (Harlow and Lane 1988). 
Electrophoresed proteins were transferred to nitrocellulose paper (NCP; 
Schleicher and Schuell, 0.2pm pore size) by the method of Towbin et a! (1979). 
When non-prestained markers were used, blots were stained with Ponceau-S 
(Sigma) to visualise the protein positions and size (Harlow and Lane 1988). 
Blots were blocked with 1% milk powder in phàsphate buffered saline (PBS 
pH7.2)/0.05% (v/v) Tween-20, and then washed three times in 0.05% (v/v) 
Tween-20 in PBS (PBS/T). Antibody was diluted in blocking buffer, and 
incubated with the blots for one hour. Blots were then washed three times in 
PBS/T. Bound antibody was detected by incubation with horse radish 
peroxidase (HRP)-conjugated anti-mouse, anti-rabbit or anti-human lgG (Dako 
Ltd, High Wycombe, UK). Blots were then washed three times in PBS/T and 




mAb epitope isotype function reference 
12.8 EGF1 -both lgG invasion inhibitory McBride and Heidrich 1987 
12.10 double EGF-both lgG invasion inhibitory McBride and Heidrich 1987 
2.2 EGF1 -both lgG block invasion inhibition McBride and Heidrich 1987 
7.5 EGF1-both lgG block invasion inhibition McBride and Heidrich 1987 
111.2 double EGF-both lgG non-invasion inhibitory Holder eta! 1985 
111.4 EGF1-Well lgG nd Holderetal 1985 
5B1 EGF1 -both 1gM invasion inhibitory Pirson and Perkins 1985 
14-1C EGF1 -both lgG n  R. Reese 
4H4/19 EGF2-both lgG invasion inhibitory Cooper eta! 1992 
4H4/34 double EGF-MAD lgG • non-invasion inhibitory Cooper eta! 1992 
X509 MAD-33 lgG non-invasion inhibitory Blackman etall99l b 
Table 2.1. MAbs specific to the C-terminus of PfMSP1. 
nd=not determined. 
(4) Recombinant PfMSP1 proteins 
Recombinant proteins representing PfMSP142, (yeast) PfMSP11 and GST 
cleaved (bacteria) PfMSP1 19 used in this study were kind gifts of Drs Holder, 
Kaslow and Burghaus respectively. Transfected E. coil cells expressing 
PfMSP1 19 and its constituent EGF-like motifs were kind gifts of Drs Holder, 
Burghaus and Chappel, see table 2.2. and figure 2.1. All residue numbers are 
derived-from the sequence numbers of Miller eta! (1993). 
Bacu lovirus-infected insect cell-derived PfMSP1 42-S42DA 
The purified protein, produced according to the method of Murphy eta! (1990) 
was kindly provided by Dr. A. Holder, and represents most of the C-terminal 
42kDa processing product of the Wellcome allele of PfMSP1. Spodoptera 
frugiperda cells were infected with the recombinant baculovirus encoding 
S42DA and were grown at 27°C in medium for one week. Protein is secreted 
by the insect cells into the culture supernatant, which was harvested for protein 
purification. S42DA was purified from the culture supernatant by absorption on 
to a mAb (111.4 specific for the Wellcome first EGF-like motif) affinity column 
and ion-exchange chromatography. The protein produced represents the first 
34 amino acids of the N-terminus of PfMSP1 (the first 19 of which are the signal 
peptide) and 271 amino acids from the C-terminus, beginning at the aspartic 
acid residue (1433) and terminating at the serine residue (1723), which equals 
178 amino acids of the C-terminus of PfMSP133 and 93 amino acids of 
PfMSP119. 84 amino acids from the N-terminus of PfMSP133 (i.e. approximately 
one third of PfMSP133) are not represented by this recombinant protein. Three 
amino acids from the C-terminus of PfMSP1 19 are also missing, however the 
protein contains all 12 cysteine residues. 
Throughout this thesis, this protein will be referred to as Well-42, see 
table 2.2 and figure 2.1. 
Yeast-derived recombinant proteins representing PfMSP1 19: 
FVO, FVO/E and 3D7 
Purified yeast proteins, kindly provided by Dr. D. Kaslow, were produced as 
described below (Kaslow et a! 1994). Genes encoding PfMSP1 19 (asparagine 
1631 to serine 1723) were PCR-amplified from 3D7 genomic DNA and from a 




antigen code domains allele expression fused to: insert size insert size estimated molecular plasmid 
represented represented system in in amino weight of recombinant source 
nucleotide acids fusion protein (in Da) 
base pairs  
MAD-EGF1 PfMSP1t9 MAD20 bacteria GST 144 .48 33,330 Chappel and 
(l B)0 -1st EGF Holder 1993 
MAD-EGF2 PfMSP1Iq MAD20 bacteria GST 162 54 33,990 
(213) -2nd EGF  
Well-EGF1 PfMSPIIq Wellcome bacteria GST 144 48 33,330 
(1A) -1stEGF  
Well.EGF2* PfMSP1I9 Wellcome bacteria GST 162 54 33,990 
(2A) -2nd EGF  
Well-1 9/GST PfMSP11 Wellcome bacteria GST 288 96 38,610 Burghaus and 
(Pf19111)  Holder 1994 
Well-19 PfMSP119 Wellcome yeast [His]6 279 93 10,890 Kasloweta! 
(FVO) . 1994 
MAD/Well-19 PfMSP119 MAD20-1stEGF yeast [His]6 279 93 10,890 
(FVO/E) Wellcome-2nd 
EGF  
MAD-19 PfMSP119 MAD20 yeast [His]6 279 93 10,890 II 
(3D7)  
MAD-33 PfMSP133 MAD20 bacteria GST 843 281 58,960 A. Egan 
(MAD -33)  
Well-42 PfMSP142 Wellcome baculovirus - 915 305 33,550 Murphy etal 
(S42DA)  1990 
GST - - bacteria - 764 255 28,050 Chappel and 
(GST)  Holder 1993 
Table 2.2. Recombinant proteins representing the C-terminus of PfMSP1. 
0 Author's code names for the recombinant proteins are indicated in brackets. 
* insoluble, not used in immunological assays. 
Scheme of processing of PfMSP1 :- 
Primary processing:- 	 I 	 I 	I 	1 
PfMSP1 83 	PfMSP1 28-30 	PfMSP1 38 	 PfMSP1 
I 	II Secondary processing:- 	
PfMSP1 33 	PftblSPl 19 
EGF-Uke motifs of PfMSP1 19:- 	
EIQ 	 TSR/KNG 
	
motif I 	motif 2 
C-terminal PfMSP 1 recombinant proteins 
used as antigens in immunological assays:- 





GST' • 	 : Imott 2  I 
derived MAD-EGFZ 
• 	GST 	 PfMSP11 
Well-1 9/GST 
GST 	 I 	PfMSP133 	 I 
MAD-33 
yeast 	 PfMSP1 19 	 I I [His] derived 
MAD-1 9 
MAD/Well-i 9 
baculovirus 	 I 	PIMSP14Z 	 I derived 
Well-42 
Figure 2.1. Processing of PfMSP1. 
PfMSP1 is processed from a precursor molecule (gpl 90, PMMSA) to form four fragments 
(PfMSP183, PfMSP128-30, PfMSP138 and PfMSP142) which form a non-covalently linked 
complex on the merozoite surface. Secondary processing of PfMSP142 produces a 
membrane-bound 1 9kDa fragment (PfMSP1 19) which remains on the merozoite surface 
during RBC invasion, and a 33kDa fragment (PfMSP133) which is shed into the plasma. 
PfMSP1 19 is formed of two EGF-like motifs. 
Recombinant proteins representing PfMSP142, PfMSP133, PfMSP1 19 and its 
constituent EGF-like motifs were expressed in E. co/i (fused to glutathione S-transferase 
[GST] of Schistosoma japonicum), or as secreted, soluble free protein in yeast 
(Saccharomyces cerevisiae) or in baculovirus infected-insect cells. 
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plasmid p1XY154 to form the constructs 3D7 (the MAD20 version of PfMSP119 
with the four dimorphic amino acids; E-TSR) and FVO (the Wellcome version, 
with the 4 dimorphic amino acids; Q-KNG). Through oligonucleotide-directed 
site-specific mutations by PCR-amplification, the hybrid construct FVO/E 
(representing the MAD20 first EGF-like motif, and the Wellcome second EGF -
like motif; E-KNG) was formed. The proteins produced represent PfMSP1 19 
minus the last 3 amino acids from the C-terminus. The addition of a 6 histidine 
tag to the C-terminus of these fusion proteins enabled them to be purified on 
nickel-nitrilo-triacetic acid-agarose (Ni-NTA). 
The recombinant plasmids were electroporated into the YP47 strain of 
Saccharomyces cerevisiae. Yeast cells were grown at 30°C in medium, in a 
shaking incubator at 250 revs/minute for 48 hours. Recombinant protein was 
secreted into the culture supernatant, which was dialysed and filter-sterilised. 
The resultant supernatant was incubated at 4°C for one hour with Ni-NTA 
agarose. Centrifuged resin was loaded into a chromatography column. 
Recombinant protein was eluted from the resin by a low pH solution. 
I was provided with purified protein. Throughout this thesis 3D7, FVO/E 
and FVO recombinant proteins will be referred to as MAD-19, MAD/Well-19 and 
Well-19 respectively, see table 2.2 and figure 2.1. 
(4c) Bacteria-derived recombinant fusion proteins representing 
PfMSP119 and its constituent EGF-like motifs: Pf19111, 1A, 1B, 2A, 
and 2B 
Recombinant E. co/i expressing 1A, 1B, 2A and 213 were kindly provided by Dr. 
J. Chappel (Chappel and Holder 1993). Pf1911I was kindly provided by Dr. P 
Burghaus (Burghaus and Holder 1994). DNA from T9/94 (Wellcome-like) or 
MAD20 PfMSP1 genes were PCR-amplified with either Wellcome or MAD20 
sequence-specific primers and inserted into pGEX vectors (Smith and Johnson 
1988), such that they can be expressed as glutathione S-transferase (GST) 
fusion proteins in Escherichia co/i (Smith and Johnson 1988). Recombinant 
proteins representing the first EGF-like motif start from asparagine 1631 ending 
at threonine 1678; the second-motif begins at asparagine 1674 and ends at 
asparagine 1726. The two constructs thus share a five amino acid overlap. The 
double-motif construct represents the whole of PfMSP119 (asparagine 1631 to 
asparagine 1726). I was also provided with GST cleaved (by digestion with 
Factor Xa; Boehringer) double-motif protein. As a control (for use in 
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immunological assays, see chapters 4, 5, 6, and 7), GST was produced using 
the pGEX plasmid without any insert. 
I produced proteins from these transfected bacteria as described below. 
Individual colonies of ampicillin-resistant recombinant bacteria were grown 
overnight in 50m1 of L-broth containing ampicillin at lOOpg/ml, at 37°C in a 
shaking incubator at 180 revs/minute. Overnight cultures were diluted (1:100) 
into 500m1 of fresh pre-warmed L-broth containing ampicillin at lOOpg/ml, and 
grown until the absorbance of the cell suspension equalled 0.4-0.6 OD at 
600nm (A600), measured by a spectrophotometer. Protein synthesis was 
induced by the addition of iso propyl l3-D-thio-galactopyranoside (IPTG; Sigma) 
to equal 0.1 mM final concentration. After a further three hours growth, cells 
were harvested by centrifugation at 5,000g for 15 minutes. Cell pellets were 
resuspended in lOmI ice cold PBS and underwent six x 30 second bursts of 
sonication. Triton X-100 (Sigma) was added to equal a final concentration of 
10% (v/v), and the suspension was centrifuged for 5 minutes at 13,000g. 
Supernatant was incubated with 2ml of a suspension of glutathione agarose 
beads (Sigma) for 30 minutes on a rotator. After three washes with PBS, beads 
were incubated with 2m1 'elution buffer' (5mM reduced glutathione; Sigma, 
50mM Tris-HCI) for 10 minutes on a rotator. After centrifugation, the 
supernatant, containing the eluted fusion protein, was collected (see figure 2.2. 
of SDS-PAGE gel of samples taken during purification). 
Protein concentration of the fusion proteins was estimated visually in 
comparison with bovine serum albumin standards on a coomassie blue stained 
SDS-PAGE gel or spectrophotometrically by absorbance at 280nm (A280) 
where an OD of 0.5 is assumed to equal 1 mg/ml of protein (Dr. Holder, personal 
communication). 
The double EGF-like motif and three of the four single EGF-like motif 
constructs were expressed as soluble fusion proteins. The Wellcome second 
EGF-like motif was insoluble in aqueous solutions and so was not used in 
subsequent immunological assays. (Steps taken to solubilise this protein were 
the same as described in 5g.) 
GST-cleaved purified Pf191II was a kind gift of Dr. P. Burghaus. Purified 
protein had been incubated overnight with the restriction protease factor Xa 
(Boehringer) which cleaves the GST from the protein from the desired protein at 
a site-specific sequence located immediately upstream from the multicloning 
site on the pGEX-3X plasmid. 
Figure 2.2. SIDS PAGE gel of GST fusion protein purification steps. 
Lane 1 =sample of 2 hour growth of an overnight bacterial culture with the GST-fusion protein 
insert; pre IPTG induction. 
Lane 2=sample of one and a half hours growth post IPTG induction. 
Lane 3=sample of three hour growth post IPTG induction. 
Lane 4=sonication supernatant. 
Lane 5=sonication pellet. 
Lane 6supernatant from incubation of agarose beads with the sonication supernatant. 
Lane 7=31.il sample of purified protein (post glutathione elution). 
Lane 8=15p1 sample of purified protein (post glutathione elution). 
Lane 9=agarose beads post glutathione elution. 
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Throughout the thesis 1A, 1B, 2A, 2B and Pf191l1 recombinant proteins 
will be referred to as Well-EGF1, MAD-EGF1, Well-EGF2, MAD-EGF2 and Well-
19/GST respectively, see table 2.2 and figure 2.1. 
(5) Bacteria-derived recombinant fusion proteins representing 
PfMSP133: Construction of plasmids to express MAD20 and 
Wellcome versions of PfMSP133: 
(5a) Synthetic oligonucleotides 
Synthetic oligonucleotide primers were used to amplify DNA coding for 
PfMSP133. DNA was amplified using sense oligonucleotide primers (MAD20: 5' 
CCGCGTTGGATCCGGGCAATATCTGTCACAATGGATAAT 3', Wellcome: 5' 
CGGACGAGGATCCGGGCAGTAACTCCTTCCGTAATTGAT 3') and antisense 
oligonucleotide primers (MAD20: 5' 
AGAAAGGAATGATCATTATAACATATCTTGGAA I I FTCCTTC 3', Wellcome: 5' 
GGGGGCGGGAATTCATAACATACCTTGCAAGTTTCCATC 3'). Both of the 
sense primers had an extension to introduce a site for the restriction enzyme 
Barn Hi adjacent to the start of the PfMSP1 coding sequences, at alanine 
1349. Each of the antisense primers had an extension to introduce sites for 
restriction enzymes; Eco Ri for the Wellcome primer and Bc! 1 for the MAD20 
primer, and a stop codon after the sequence corresponding to leucine 1630. 
(Eco Ri was not used as a restriction enzyme site for the MAD20 sequence as 
this stretch of DNA contains a natural Eco Al site). 
(Sb) PCR amplification procedure 
DNA encoding PfMSP133 was PCR-amplified from purified plasmid DNA in the 
form of recombinant pUC119 containing blocks 13-17 from either the MAD20 
(Thai isolate 946) or Wellcome (T9/94) gene (kind gifts of Dr S. Jongwutiwes, 
Nagasaki University, Japan). Standard lOOpI volume PCR reactions (Maniatis 
et a! 1982) contained 1 Ong of template DNA plus the specific primer 
combinations (100pM of each); either MAD20 sense and antisense, or 
Wellcome sense and antisense. Amplification was accomplished using 
Therrnus aquaticus DNA polymerase (Taq polymerase; Cetus) by denaturing 
DNA at 95°C for 3 minutes, followed by 30 cycles of annealing at 62°C for 2 
minutes, extending at 72°C for 2 minutes and denaturing at 94°C for 1 minute. 
This was followed by one extension and one annealing period. 
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Cloning PCR amplified DNA 
The PCR products were cloned into a TA cloning vector according to 
manufacturer's instructions (Invitrogen). Through heat shock methods, TA 
plasmids ligated with PCR amplified DNA were used to transform either TA 
Cloning One Shot (provided with the TA kit) or JM1 10 (Stratagene) competent 
E. co/i cells. The MAD20 PCR product contained the Bc! 1 restriction enzyme 
site, which can only be digested from unmethylated DNA; most bacterial strains 
methylate DNA, therefore a strain which does not, i.e. JM1 10, had to be used. 
Selection of recombinant bacteria and subcloning of DNA into 
expression plasmids 
The TA plasmid contains an ampicillin resistance gene. Recombinant bacteria 
were selected on L-agar containing lOOpg/ml ampicillin. Individual colonies on 
the ampicillin L-agar plates were selected, and grown up overnight in L-broth 
containing lOOpg/ml ampicillin. Plasmid DNA was purified by a Mini Prep 
(Promega) purification system according to manufacturer's instructions. Purified 
plasmid DNA was digested with either Eco Ri and Barn Hi restriction enzymes 
for the Wellcome insert, or Bc/i and Barn Hi for the MAD20 insert. Digested 
DNA was separated by electrophoresis on a 1% agarose gel. A band of 4kb 
(i.e. linearised TA vector plasmid) plus a band of approximately 800bp (i.e. 
insert) indicated that the bacterial colony contained plasmid with an insert. 
Glycerol stocks were made of plasmids with an insert from the remainder of the 
overnight culture. 
The 800bp insert DNA was excised from the gel, and recovered from the 
agarose by electroelution into dialysis tubing and then purified using an Elutip-
d-column (Schleicher and Schuell) according to manufacturer's instructions. 
This DNA was then ligated into the bacterial expression vector pGEX-3X 
(Pharmacia Biotech), which had previously been digested with either Barn Hi 
restriction endonuclease and treated with calf intestinal phosphatase to prevent 
self-ligation (CIP; Boehringer) for the MAD20 insert, or with Barn Hi and Eco 
Ri restriction enzymes for the Wellcome insert (see figure 2.3.). Ligation mixes 
were used to transform competent bacteria (E. co/i, strain DH5(X) to ampicillin 
resistance and then selected on ampicillin/agar plates. Colonies containing 
inserts were selected as before; glycerol stocks were made. 
Figure 2.3. Expression plasmid pGEX-3X with DNA insert encoding for Wellcome and 
MAD20 PfMSP133. 
General features of the pGEX plasmid are shown: ampicillin resistance gene for recombinant 
bacteria selection, the taG promoter, the /aclq gene, the origin of replication, and glutathione 
S-transferase [GST] for the purification of recombinant protein. The Barn Hi and Eco Ri cut 
Wellcome DNA was inserted into the multicloning site of pGEX-3X cut with Barn Hi and Eco 
Ri. Due to an Eco Ri site in the MAD20 DNA, this insert had to be cut with Barn HI and Bc/i 
and inserted into the pGEX-3X multicloning site cut with Barn Hi. Compatible DNA fragments 
for ligation are formed when DNA is cut with Bc/i and Barn Hi: DNA cut with these two 
restriction enzymes will join, but neither restriction site is reformed, so this site cannot 
















Wellcome = 786 base pairs 
262 amino acids 
56,820 Da (+GSI) 
28,820 Da (GST cleaved) 
GST = 764 base pairs 
255 amino acids 
28,050 Da 
MAD20 = 843 base pairs 
281 amino acids 
58,910 Da (+GST) 
30,910 Da (GST cleaved) 
Expression of DNA encoding PfMSP133 
Bacterial colonies with the PfMSP133 DNA insert were tested for the production 
of GST fusion proteins induced in the presence of IPTG (as in section 3c). 
A GST fusion protein could not be induced in any of the bacterial clones 
with the Wellcome insert. When this DNA was sequenced (see section 5f), I 
found it contained a thymidine nucleotide deletion coding for a leucine residue 
at position 1523 which caused a frame shift in the DNA resulting immediately in 
a stop codon. 
The MAD20GST fusion protein could be detected by anti-GST and anti-
PfMSP133 antibodies (including mAb X509 which is specific for the MAD20 
PfMSP133) in Western blot, but the protein was found to be insoluble, see figure 
2.4. Throughout the thesis the MAD20 PfMSP133 recombinant protein will be 
referred to as MAD-33, see table 2.2 and figure 2.1. 
Sequencing of PfMSP133 DNA inserts 
Both inserts were sequenced in both directions across the junctions of the insert 
and the plasmid, to confirm the correct frame orientation and nucleotide 
sequence of the insert. Double stranded sequencing of purified plasmid DNA 
was carried out using a Sequenase kit (United States Biochemical) according 
to manufacturer's instructions (Chen and Seeburg 1985). Primers used were 
pGEX universal primers; forward primer 5' GCATGGCCTTTGCAGGG 3', 
reverse primer 5' ATGGCCTTTGCAGGGCT 3', plus internal primers; MAD20 
forward first 5' ATCTTAAATTCACGTCTT 3', second 5' 
GATGATTTAGAATCAATT 3', MAD20 reverse 5' ACGAAGCTTCAGCAATCA 3', 
Wellcome forward first 5' ATTTTAAATTCACGATTT 3', second 5' 
TCAGATTTAGATTCAATT 3', reverse 5' AGGTTGCTTTAACAATAA 3'. The 
MAD20 DNA template used to make this recombinant protein was from a Thai 
field isolate, I found two amino acid differences from published MAD20 
sequences (Jongwutiwes eta! 1993); 1) glutamic acid at 1443 instead of lysine, 
2) isoleucine at 1445 instead of leucine (these are not the dimorphic 
equivalents). 
Solubilisation of MAD-33 
A number of methods were used to try and solubilise MAD-33: using different 
cell lines; inducing protein synthesis at a lower OD of cell suspension so that 
more cells were in the log phase; inducing at lower temperatures, for less time, 
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Figure 2.4. Western blot analysis of MAD-33. 
Lane O=MW markers (in kDa). 
Lane 1=sample of 2 hour growth of an overnight bacterial culture with the MAD-33 insert; pre 
IPTG induction. 
Lane 2=sample of three hour growth post IPTG induction. 
Lane 3=sonication supernatant. 
Lane 4=lysis supernatant. 
Lane 5=sonication and lysis pellet. 
Lane 6=agarose beads incubated with pooled sonication and lysis supernatants; post 
glutathione elution. 
Lane 7=purified protein eluted from incubation of agarose beads with glutathione. 
Lane 8=purified GST protein. 
Samples were run on 10% SIDS PAGE gel under reducing conditions and immunoblotted. 
Western blot was probed with mAb X509 which specifically recognises the MAD20 form of 
PfMSP133. A product of approximately 60kDa is recognised by the mAb, the GST protein is 
not. The majority of the MAD-33 product is insoluble. 
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and with a lower IPTG concentration; sonicating in PBS containing 1.5% 
sarcosyl (Sigma), sonicating in 50mM Tris/lOOmM NaCl/0.1% J3-
mercapthoethanol (I3ME;  Sigma), lysing cells with lysozyme (Sigma) instead of 
sonication and cleaving GST with Factor Xa (Boehringer) (Frangioni and Neel 
1993, Smith 1993). However, none of these methods solubilised the protein. 
The protein became slightly soluble in 8M urea, but precipitated out after 
dialysis to remove the urea. 
The method that worked, finally in the end, was electroelution of the lysis 
pellet from SDS-PAGE into dialysis bags, then precipitation with KCI to remove 
the SIDS. Cell paste from a 500ml induced culture was resuspended on ice in 
lOmi 'cell lysis buffer' (25mM Tris-HCI pH8.0, 0.2% [v/v] NP-40 [nonidet P40; 
Boehringer], 1mM EDTA), containing 1mM PMSF (Sigma). Lysozyme (Sigma) 
was added to achieve a 1 mg/ml final concentration, and after two hours on ice, 
MgSO4 and DNase (deoxyri bon uclease type 1; Sigma) were added to equal 
final concentrations of 2mM and 20pg/ml respectively. After a further two hours 
on ice, the cell lysate was centrifuged at 40,000g for 20 minutes. The lysis 
pellet was then run on SDS-PAGE with a single trough comb. After 
electrophoresis, thin strips at either side of the gel were cut off, stained with 
Coomassie blue, destained, and realigned with the rest of the gel. The band of 
approximately 60kDa was cut from the rest of the gel, put in dialysis bags with 
5ml PBS and electroeluted in a blotting tank (Hoefer) for one hour, after which 
the protein solution was collected from the dialysis tubing. Addition of 500pl of 
3M KCI precipitated the SIDS, the solution was then centrifuged and the 
supernatant contained soluble protein. 
(6) ELISA to determine the antigenic integrity of MAD-33 
Electroelution of the MAD-33 protein resulted in slight contamination of the 
purified protein with co-migrating E. co/i peptides. Since these bacterial 
proteins could be recognised by human serum in immunoassays, background 
binding had to measured. This was done by measuring antibody responses to 
the protein in ELISA. A few human immune sera were first tested to see if they 
contained antibodies to MAD-33. A high and a low titre human serum, the 
MAD-33 specific mAb X509 and two malaria non-exposed European sera were 
titrated on the MAD-33 antigen (figure 2.5.). 
This titration shows that MAD-33 is not recognised by European sera, 
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10 	 1 	 0.1 	 0.01 
AG con. pg/mi 
Figure 2.5. Titration of MAD-33 antigen with specific and non-specific antibodies. 
High concentration of antibody (1:1000 dilution) was added to a titration of MAD-33. See chapter 
3 for more details about the ELISA.•high titre serum, low titre serum,mAb X509,O European 
serum no. s28,D European serum no. s29. 
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antibodies. A second titration, this time of the high affinity MAD-33 positive 
serum, was carried out on MAD-33 and GST saturated plates (figure 2.6.). It is 
clear from this titration that the malaria-exposed serum was binding specifically 
to MAD-33, and there was a clear difference between specific (MAD-33) and 
non-specific (GST) binding. 
ELISA to determine the antigenic integrity of PfMSP119 proteins 
To determine whether the PfMSP119 recombinant proteins had assumed the 
correct disulphide-dependent conformation for recognition by monoclonal and 
human polyclonal antibody, ELISAs were performed with reduced and alkylated 
or non-reduced recombinant antigens. 
To prepare reduced and alkylated protein, 0.5mg of antigen was 
incubated at 37°C for 1 hour in 0.5M Tris-HCI pH 8.1 containing 2mM EDTA and 
60mM dithiothreitol (DIT; Sigma). lodoacetic acid (Sigma), dissolved in 1 M 
NaOH, was then added at a 2.5 molar excess over DTT. The samples were kept 
in the dark, pH was monitored and maintained at 8.1 for 30 minutes and then 
the proteins were dialysed overnight at 4°C. For ELISA, plates were coated 
with the appropriate saturating concentration of the reduced or non-reduced 
protein (for details see chapter 3). 
Both human immune sera and mAbs recognised all the non-reduced 
GST recombinant proteins, indicating that disulphide-dependent conformational 
epitopes were appropriately expressed. This was confirmed by the observation 
that reduction of the proteins (and thus disruption of the disulphide bonds) lead 
to the loss of sero-reactivity (see table 2.3.). Recognition of the individual EGF-
like motifs is entirely abolished after reduction though some reactivity to the 
double-motif proteins remains. This suggests that minor, linear epitopes are 
also recognised by polyclonal human antibodies. In contrast, all the mAbs 
tested recognised only non-reduced antigen. 
ELISA to examine antigenic differences between bacterial and 
yeast-derived recombinant proteins 	 - 
Human polyclonal antibody responses to the Wellcome PfMSP1 19 double-motif 
protein produced in E. co/i (Well-19/GST) and to the same sequence produced 
in S. cerevisiae (Well-19) were compared and found to be highly correlated 
(Spearman's rank correlation coefficient r= 0.901, n=195, p<0.001), indicating 
1i 
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Figure 2.6. Titration of MAD-33 specific sera on specific and non-specific antigen. 
Plates were coated with 1 pg/mI of antigen, high to low concentrations of a high affinity serum were added 




mAbs human sera 
14-1C 	7.5 	111.4 	6E2/53 	12.10 	'4H4/34 1559 	1572 	1579 	1584 	1592 1599 
Well-EGF1 
non-reduced 2.531 2.688 2.658 0.170 0.150 0.193 1.433 0.129 0.153 0.145 1.856 1.188 
reduced 0.117 0.199 0.172 0.102 0.137 0.113 0.089 0.127 0.112 0.121 0.151 0.403 
MAD-EGF1 
non-reduced 2.475 0.479 0.137 0.181 0.199 0.130 1.859 0.184 0.100 0.126 1.878 1.168 
reduced 0.124 0.118 0.106 0.114 0.135 0.109 0.095 0.125 0.113 0.113 0.160 0.353 
MAD-EGF2 
non-reduced 0.311 0.123 0.148 1.496 0.309 0.133 1.491 0.329 0.194 1.405 0.163 2.392 
reduced 0.159 0.138 0.113 0.191 0.135 0.125 0.198 0.251 0.284 0.355 0.108 0.410 
MAD-19 
non-reduced 1.914 0.995 0.142 2.130 0.710 1.721 1.899 0.824 2.516 1.270 1.655 2.623 
reduced 0.157 0.114 0.086 0.099 0.104 0.093 0.295 0.220 0.282 0.222 0.612 0.813 
MAD/Well-19 
non-reduced 1.932 0.241 0.152 0.140 0.309 0.104 1.828 0.691 2.333 0.829 1.521 2.334 
reduced 0.287 0.106 0.089 0.092 0.104 0.108 .0.664 0.316 0.851 0.132 1.016 1.486 
Well-19 
non-reduced 1.998 1.971 2.124 0.126 1.712 0.105 1.712 0.627 2.408 0.820 1.410 2.412 
reduced 0.211 0.158 0.249 0.094 0.132 0.087 0.523 0.272 0.655 0.121 0.824 1.314 
Well-1 9/GST 
non-reduced 2.549 2.403 2.449 0.125 2.324 0.225 2.176 0.646 2.553 1.159 1.747 2.480 
reduced 0.138 0.138 0.188 0.091 0.178 0.080 0.686 0.272 0.593 0.143 0.660 0.905 
GST 
non-reduced 0.262 0.119 0.208 0.235 0.234 0.169 0.105 0.101 0.108 0.102 0.121 0.120 
reduced 0.134 0.124 0.101 0.122 0.128 0.116 0.078 0.084 0.087 0.078 0.105 0.120 
Table 2.3. Comparison of OD values for ELISA assay using non-reduced and reduced recombinant antigens. 
Underlining is used to highlight values for positive antigen/antibody combinations. (Human sera were tested at a dilution of 1:3000, which 
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Figure 2.7. Comparison of antibody recognition of yeast derived Well-19 vs E. co/i-derived Well-
1 9/GST. 
Each point represents reactions of a single immune human serum from one individual (dilution 
1:3,000). For more details on this type of ELISA see chapter 4. 
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Discussion 
Proteins expressed as intracellular products in E. co/i are not generally thought 
to form appropriate intramolecular disulphide bonds (reviewed in Marston 
1986). This is potentially a serious problem for expression of the C-terminus of 
PfMSPlwhich contains 12 cysteine residues thought to make up 6 
intramolecular disulphide bonds (Blackman et a! 1991 a). Indeed, Holder et a! 
(1988) found that vaccination of monkeys with two recombinant proteins (trp E' 
and -galactosidase hybrid fusion proteins) representing the C-terminus of 
PfMSP1, including the two EGF-like motifs, induced only partial protection 
against subsequent challenge infection. Native PfMSP1 was poorly recognised 
by serum from these vaccinated monkeys and the authors concluded that the 
recombinant proteins were not correctly folded. In contrast, Muller eta! (1989), 
Chappel and Holder (1993), and Burghaus and Holder (1994) have all been 
able to produce E. co/i-derived recombinant proteins representing the C-
terminus of PfMSP1 (including the EGF-like motifs) which were recognised by 
conformation-dependent mAbs. In confirmation, the binding of all these mAbs 
was abolished by the prior treatment of the proteins with a reducing agent. The 
fact that E. co/i-derived GST fusion proteins representing PfMSP1 19 are 
recognised by conformation-dependent mAbs suggests that the correct tertiary 
structure had been obtained by this prokaryotic expression system. Correct 
cysteine pairing has also been demonstrated for recombinant proteins 
representing the C-terminus of PfMSP1 produced in eukaryotic expression 
systems (Murphy et a! 1990, Kaslow et a! 1994). It appears therefore that, 
once placed in a non-reducing environment, PfMSP119 proteins automatically 
fold, and disulphide-bond, into the native conformation. Indeed, if the proteins 
are artificially reduced but not alkylated, they will spontaneously refold into 
native conformation once returned to a non-reducing environment (Dr. A. 
Holder and A. Egan, unpublished observations). It is fortuitous, therefore, that 
the native conformation of PfMSP1 19 is also the most stable conformation. This 
has made expression of PfMSP119 in bacteria much easier than might have 
been anticipated. 
A potential draw back of eukaryotic expression systems could actually be 
their ability to glycosylate proteins (Bathurst 1994), as there is no direct 
evidence of glycosylation in PfMSP1 despite the presence of potential sites 
(Dieckmann-Schuppert et a! 1992). So, despite their apparent similarity, 
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eukaryotic expression systems may not produce proteins with exactly the same 
antigenicity as native PfMSP1 (reviewed in Chang 1994).. 
E. co/i-derived PfMSP1 19 recombinant proteins were used to vaccinate 
Aotus monkeys against subsequent homologous and heterologous challenge 
infection. However, no protection (relative to control animals) was observed. 
Only three of the five post vaccination/prechallenge sera were able to inhibit 
parasite invasion of RBCs in vitro, but all were able to compete with the binding 
of conformation-dependent mAbs to the recombinant protein (Burghaus et a/, 
manuscript in preparation, also see chapter 5). Kumar et a! (1995), vaccinated 
Aotus monkeys with either an E. co/i-derived PfMSP142 GST fusion protein or a 
PfMSP1 19 recombinant protein secreted from yeast. One of the three monkeys 
immunised with the bacteria-derived PfMSP142 GST fusion protein was able to 
control its parasitaemia but eventually needed drug treatment; the other two 
monkeys were unprotected. Two of the four monkeys immunised with the yeast 
PfMSP1 19 protein resolved an otherwise lethal infection without treatment, a 
third monkey eventually required drug treatment after a prolonged prepatent 
period and the fourth monkey was unprotected. Both bacterial PfMSP142 and 
yeast PfMSP119 were recognised in ELISA and on Western blot by reduction-
sensitive mAbs. Sera from the protected monkeys were unable to inhibit 
parasite invasion of RBC5 in vitro. Thus, although both proteins were 
conform ationally correct, and although PfMSP1 proteins produced in the yeast 
expression system proved to be more protective than those produced in the 
bacteria, in neither case was complete protective immunity induced. Whether 
this was due to the expression system, or to the failure of the immune response 
to focus on critical epitopes within PfMSP1 19 is not known. 
In summary, there is definitely some confusion over which is the best 
expression system for the production of PfMSP1 recombinant proteins for use in 
vaccines. Recombinant proteins from all three expression systems described 
here were recognised by conformation-dependent mAbs, suggesting that all 
three systems are capable of producing proteins with correctly formed 
disulphide bonds. Direct comparison of human antibody responses to the 
bacteria- and yeast-derived recombinant proteins, representing the same 
sequence of the Wellcome PfMSP1 19, indicate that recombinant protein 
produced in either expression system is suitable for the detection of antibody 
responses by ELISA. However, differences in protein structure may have more 
profound effects in vaccination of animals than in immunological detection of 
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pre-formed antibody. Correct disulphide bond formation appears to be the most 
easily rectified problem with PfMSP11 expression, and the mAbs provide a 
quick and easy way of assessing disulphide-dependent conformation. 
However, other post-translational modifications, which are more difficult to 
assess, may be crucial in determining the immunogenicity of the molecule and 
may explain the difference between vaccination with native PfMSP1 (which 
protects) and recombinant PfMSP1 (which does not always protect). Also, the 
stimulation of T cell help may be greatly affected by post-translational 
modifications of the vaccinating protein. 
PfMSP133 contains no cysteine residues and recognition of the protein 
by the mAb X509 is not reduction-sensitive (Blackman et a! 1991 b). Therefore I 
decided that the bacterial expression system would be an appropriate method 
for the production of recombinant proteins representing PfMSP133. Only the 
MAD20 allelic form of the protein was expressed. DNA encoding the Wellcome 
allelic form was found to contain a nucleotide deletion which resulted in a stop 
codon terminating protein expression. This deletion probably occurred as a 
result of a PCR-induced mutation (PCR technology-Principle and applications of 
DNA amplification, Ed. Erlich, H. A., Stockton press, 1989). Successful 
expression of this protein would therefore require that the whole cloning 
process be repeated from the original pUC119 plasmid. An expression product 
was obtained for the MAD20 construct. Sequencing confirmed that the whole 
sequence was present, correct and in-frame. However, a problem was 
encountered with the expression of this relatively large recombinant protein, in 
that the product was insoluble. This is a common problem in the expression of 
large proteins in E. co/i but was eventually solved. The resulting protein was 
slightly contaminated with E. co/i peptides which migrate at the same molecular 
weight as the fusion protein. However, in ELISA assays only low ODs were 
obtained with serum from malaria-unexposed individuals indicating that the 
bacterial peptides were not recognised by human serum and therefore had little 
effect on antibody responses to this protein. 
These recombinant proteins were used to measure human immune 
responses to the C-terminus of PfMSP1 (chapters 3, 4, 5, 6 and 7). 
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CHAPTER THREE: 
Detection of malaria-specific antibody responses by Enzyme Linked 
Immunosorbent Assay (ELISA) 
Introduction 
The development of the enzyme-linked immunosorbent assay (ELISA) by 
Engvall and Perlmann in 1971 revolutionised the experimental detection of an 
analyte in a sample, and is now used to measure a wide range of antigens, 
antibodies, cytokines and hormones. Before the development of ELISA the 
main method of detection of an antibody/antigen reaction was by 
radioimmunoassay, which has several draw backs; the main one being that it 
requires the use of hazardous reagents. The ELISA technique takes advantage 
of the fact that proteins stick to plastic, presumably via hydrophobic forces 
(Kemeny 1992). The use of multiwell microtitre plates was developed as a solid 
phase, instead of tubes, which facilitates easy handling and can be used with 
automated well washers, readers and multiple well dispensers, allowing large 
numbers of samples to be assayed. ELISA is now a standard laboratory 
technique and a very useful tool in the study of parasitology. 
ELISA has enabled the large scale study of serological responses to 
parasitic infections and has become an important device for the investigation of 
human immune responses to malaria. In this thesis I describe measurements of 
antibody responses to recombinant proteins representing the C-terminus of 
PfMSP1 in hundreds of individuals; this would have been a daunting task with a 
less automated immunological assay such as Western blot. As so many 
samples can be tested in one experiment, the antibody responses of a whole 
study population can be compared within one experiment, and if care is taken to 
standardise the parameters of the ELISA assay, results from different 
experiments can also be compared. So, ELISA has become an invaluable 
technique for large-scale batch testing of immune responses in 
seroepidemiological studies. However, ELISA can be inaccurate if its 
limitations are not taken into account and controlled for. 
The indirect ELISA technique which has been used in this study, is the 
most widely used form of ELISA (see figure 3.1.). The unlabelled partner in the 








Figure 3.1. The components of a standard indirect ELISA 
From Vankatesen and Wakelin (1993), Parasitology Today,9:228. 
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the antigen can be attached to the microtitre plate; in this study, antigen was 
attached to the microtitre plate to detect antibodies in the sample solution. The 
sample antibody is detected by a second antibody which has an enzyme label 
(a direct ELISA would have the enzyme label attached to the sample antibody). 
The concentration of the primary antibody bound to the antigen is estimated by 
the addition of the second antibody's enzyme substrate and an indicator that 
changes colour when the substrate is acted upon by the enzyme. In this study, 
the detecting secondary antibody is either a rabbit anti-mouse or rabbit anti-
human IgG heavy chain antibody, depending on what primary antibody is to be 
detected. Attached to this secondary antibody is the enzyme horse radish 
peroxidase (HRP), for which the substrate is hydrogen peroxide (H202). The 
action of this enzyme on the H202 causes a colour change in the chromogen o-
phenylenediamine (OPD). This colour change/enzyme activity is stopped by 
the addition of sulphuric acid (H2SO4), and the degree of colour generation, the 
optical density (OD), of each reaction is measured at the wavelength of 492nm 
on a spectrophotometer. The OD obtained is given as a log of percentage light 
absorbance. 100% light absorbance gives an OD of 2, so an OD of 1 is not 
50% absorbance, but rather 10%, and OD readings over the value of 2 are 
inaccurate. 
It is important to include a standard curve of a positive serum on one 
antigen in every assay. This will indicate how comparable the results are from 
separate assays. A measure of this homogeneity can be determined by 
working out the coefficient of variation (CV) between assays; 
coefficient of variation (%)= SD xlOO 
mean 
This needs to be worked out within batches and between batches of ELISAs to 
find an acceptable CV for subsequent assays. It has been suggested that 
variation should not be more than 20% (Kemeny 1992). 
In this chapter I will discuss the importance of, and the procedure for, 
optimising the ELISA protocol. The solid phase system used in this study is a 
polystyrene 96-well microtitre plate. There are different types of microtitre 
plates, with different binding capacities, some are good at binding small 
peptides while others are better at binding larger peptides (Kemeny 1992). 
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Immulon 4 plates (Dynatech) are used in our laboratory as they were found to 
be the most efficient plates at binding small recombinant proteins. 
The initial binding of the antigen to the plate is the most important stage 
of the ELISA to be optimised; if this stage is not properly standardised, 
standardisation of the of the other components of the ELISA will be 
meaningless. Antigen is passively adsorbed on to the surface of the plastic in a 
carbonate buffer, which facilities this binding. Antigen should be firmly bound to 
the plate and should not be damaged by adsorption. However, conformational 
changes can occur when an antigen binds to plastic. Also proteins can become 
bound to the plate in a specific orientation, i.e. hydrophobic regions of peptides 
bind and are not available as an epitope, so some antigenic determinants fail to 
be expressed. This could also result in a change in the protein's natural tertiary 
structure (Davey and Steward 1988, Kemeny 1992). 
It is important that the concentration of the coating antigen is 
standardised. A saturating protein concentration is desired for all antigens, so 
that maximum binding of specific antibody can be achieved (Davey and 
Steward 1988). High epitope frequency (high antigen concentrations) 
encourages bivalent interactions between the two lgG heavy chains with the 
antigen. This is more stable, i.e. less susceptible to dissociation, compared to 
monovalent binding of the Fab fragment. On the other hand, bivalent 
interactions may be rare due to unsuitable orientation of epitopes on the solid 
phase. However, a plate should not be over saturated with antigen as this will 
cause concealment of epitopes (Kemeny 1992). Also protein-protein 
connections are less stable than protein-plastic, so antibody bound to an 
antigen bound to another antigen is more likely to dissociate during washing 
stages (Venkatesan and Wake tin 1993). 
It has been suggested that the detecting antibody should be used in 
excess so as to detect all specific binding (Venkatesan and Wakelin 1993). 
However, a high concentration of secondary antibody can increase non-specific 
binding and decreases the measurable analyte range (Kemeny and Chantler 
1988). A high concentration of secondary detecting antibody would cause 
many samples to go over the OD of 2, which would be an inaccurate reading so 
it would not be possible to compare these samples' OD values with one 
another. On the other hand, lower concentrations decrease the specific 
absorbance but non-specific binding is only slightly reduced (see figure 3.2.). 








measurable analyte range 
Figure 3.2. Schematic diagram to demonstrate the optimal concentration of secondary antibody. 
High concentrations of conjugated antibody (c) causes a steep titration curve, decreasing the measurable 
analyte range. Low concentrations of the secondary antibody (a) results in a shallow titration curve where 
large differences in primary antibody concentration results in a small difference in the OD. An optimal 
secondary antibody concentration (b) would result in a large measurable analyte range but which reaches 
the plateau of 100% absorbance (i.e. OD 2). 
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the antigen layer itself; diluting the detecting antibody in blocking buffer (i.e. 
excess non-specific protein) before hand reduces this affect. 
Although there is an apparently linear relationship between antibody 
concentration and binding to the antigen (Koertage and Butler 1985), increase 
in the concentration of the secondary antibody does not result in a linear 
increase in OD. With an lgG antibody, there is potential variation in binding of 
one or both of the heavy chains. This variation becomes more evident at higher 
secondary antibody concentrations as less antibodies are able to bind with both 
arms (Davey and Steward 1988). Variation in stoichiometry may be an 
important variable in day to day variation. 
A dilution of serum which results in a OD on the linear part of the titration 
curve increases the sensitivity of the assay for detecting changes in antibody 
binding and is thus the optimal concentration at which to compare large 
numbers of sera. It is not good to chose a dilution from the shallow part of the 
dilution curve as a large change in antibody concentration will only result in a 
small change in colour, making it difficult to compare individual samples within 
an assay (Kemeny 1992). 
Most problems of non-specific binding and high backgrounds occur from 
this stage of the ELISA. Non-specific binding of antibodies in the serum to 
exposed sites of the plastic plate, and to the antigen layer itself, results in high 
backgrounds. This is particularly the case with sera from malaria-exposed 
individuals as malaria infection induces production of large amounts of antibody 
(hypergammaglobulinaemia) much of which is not specific for malarial antigens 
(Crane 1986). Non-specific binding can be reduced during the washing stages, 
however over vigorous washing can wash off specifically-bound antibody too, 
especially low affinity antibody (Davey and Steward 1988). However, when 
antigen/antibody complexes have formed, their dissociation is slow (Avrameas 
1992). Detergents reduce background by interacting with hydrophobic sites on 
the plastic and so are included in the buffers (Avrameas 1992, Venkatesan and 
Wakelin 1993). Vacant sites on the plastic are blocked with non-specific protein 
(typically serum albumin or milk proteins) to reduce non-specific binding. 
Preincubation of sera with this same non-specific protein selects out non-
specific antibody in the sample as well. 
This optimised ELISA is the basis of the seroepidemiological analysis of 
antibody responses to PfMSP1 carried out in subsequent chapters in this thesis. 
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Methods and materials 
The indirect enzyme linked immunosorbent assay (ELISA) 
General method 
Antibodies reacting with recombinant PfMSP1 proteins were detected by 
ELISA. Microtitre plates (Immulon 4, Dynätech, Billingshurst, UK) were coated 
overnight at 4°C with proteins diluted in carbonate buffer (15mM Na2CO3, 
35mM NaHCO3 pH9.5). The saturating concentration of protein was from 
0.lpg/ml to 5pg/ml depending on the antigen. Plates were washed three times 
in phosphate buffered saline (PBS pH7.2)/0.05% (v/v) Tween 20 (PBS/T; 
washing buffer), blocked with a 1% (w/v) solution of non-fat powered milk in 
PBS/T (blocking buffer) and washed again. lOOpI of serum diluted in blocking 
buffer, were added to duplicate wells and incubated overnight at 4°C. 
After washing, horse radish peroxidase (HRP)-conjugated rabbit anti-
human lgG (100p1 diluted 1:5000 in PBS/Tween 20) (Dako Ltd, High Wycombe, 
UK) was added to the plates, incubated for 3 hours at room temperature and 
developed with H202 and o-phenylenediamine (OPD; Sigma) for 10 minutes at 
4°C. The reaction was stopped by the addition of 20p1 of 2M H2SO4. Plates 
were read at 492nm. For GST fusion proteins the OD value of the GST control 
was subtracted from the OD of GST-recombinant fusion proteins, to give a 
specific OD (1OD) for the response to the PfMSP1 antigens. 
Optimisation of the general method 
A saturating concentration of protein was determined by titration of antigen from 
high to low concentrations (0.005pg/ml to 1 Opg/ml). After the saturating 
concentration of each antigen was determined, the optimal concentration of the 
primary and secondary antibodies was determined. Plates were coated with 
saturating concentrations of antigen. Plates were washed and blocked as 
before. 100p1 of high, medium and low titre serum, diluted in blocking buffer, 
was titrated from high to low concentrations in duplicate wells and incubated 
overnight at 4°C as before. After washing, high to low concentrations of 
secondary conjugated antibody was added to the test wells. The rest of the 
ELISA was carried out as before. 
Results 
Antigen layer 
To determine the optimum antigen concentration (maximum binding without 
over saturating), antigen was titrated from high to low concentrations, with all 
other parameters of the ELISA in excess so that the only limiting factor was the 
antigen concentration. The resulting titration resulted in a sigmoidal curve (see 
figure 3.3.), where the topof the curve represents optimum binding, i.e. 
saturation of all available binding sites. After this level has been reached, the 
OD does not increase with increasing antigen concentration, and may even 
decrease due to overcrowding or unstable protein-protein interactions. 
A high concentration of high, medium and low titre antibody was used for 
the antigen optimisation titration, as high affinity antibody will detect antigen at 
lower antigen concentrations than lower affinity antibodies (Davey and Steward 
1988). So if an antigen concentration was chosen by only titrating with high 
affinity antibodies, the assay would not necessarily be capable of detecting low 
affinity antibodies. 
From the antigen titration graphs (figures 3.3.a-g.), the following 
concentrations of proteins were chosen to coat ELISA plates with; 0.1pg/ml of 
MAD/Well-19, Well-19 and Well-19/GST, 1g/ml of the first EGF-like motif 
proteins and MAD-19, and 5pg/ml of the second EGF-like protein. lpg/ml of 
MAD-33 is also used to saturate ELISA plates as determined from the antigen - 
titration in chapter 2 (figure 2.5.). 
Optimisation of the secondary antibody 
The next component of the ELISA to be optimised was the detecting, enzyme-
conjugated secondary antibody. The plate was coated with the saturating 
antigen concentration. Checkerboard titrations of high to low concentrations of 
high, medium and low titre sera were added. To this was added high to low 
concentrations of the secondary antibody. 
I found that a dilution of 1:5000 of the conjugated antibody resulted in a 
titration curve which is neither too shallow nor too steep, as well as resulting in 
maximal difference between the binding of high, medium and low titre primary 
antibody on specific (Well-EGF1) and non-specific (GST) antigen (see figures 
3.4.). The 1:10,000 dilution was too shallow, while the 1:500 and 1:1000 
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Well-EGF1 antigen titration 
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MAD-EGF2 antigen titration 













MAfl-EGF1 antigen titration 
1 	 0.1 	 0.01 	0.001 
AG Con.(pg/ml) 
figure 3.3.d. 	













0 •_ figure 3.3.0. 
'- - cli 3 
.2 2.5 
a) - cii 
ccii> 
— ij = 2 
o 







a; w 0.5 
c 0 = 
a) 
() 
• 0 E 0 .0 
CO Cn 





c .c 0 
E 




-c 0 C 




CIJ Cl) .. 
(Ii 
- 
0 cii c E 
C -c C • is• 
0 a) 0 0. q 





















MAD/Well-i 9 antigen titration 
1 	 0.1 	 0.01 










Well-I 9 antigen titration 
1 	 0.1 
	
0.01 










Well-i 9/GST antigen titration 
- 	 S 
I 	 0.1 































0.375 0.750 	1.5 	3 	6 	12 
	
24 	48 
human serum reciprocal dilution 
(xl O- ) 
Medium responding sera on Well-EGF1 
0.375 0.750 	1.5 	3 	6 	12 	24 	48 
Human serum reciprocal dilution 
(x1O- ) 
Low responding sera on Well-EGE1 
0.375 0.750 	1.5 	3 	6 	tz 	a4 	48 
Human serum reciprocal dilution 














































































CD CD 0 
0.  = CD 0) 
(0 C — 
0 0 = 
5 0 
rn 
dilutions resulted in very similar titration curves, which are steep and exceed the 
OD of 2 at lower concentrations of primary antibody. 
Optimisation of the primary antibody 
The last layer of the ELISA to be optimised was the sample antibody. A dilution 
of primary antibody was chosen which gave an OD on the linear part of the 
titration curve, with the 1:5000 secondary antibody concentration. 
For high, medium and low titre antibodies a 1:3000 dilution of primary 
antibody most consistently fell on the linear part of the titration curve, obtained 
with the 1:5000 dilution of secondary antibody (see figures 3.4.). OD levels 
reached the value of 2 with a 1:3000 dilution of some high titre sera, but most 
sera gave OD values within the accurate limitations of the assay, so 
comparisons of OD values would be possible. 
Time and temperature of incubation periods 
Specific binding of different affinity antibodies is time-dependent (Davey and. 
Steward 1988). The temperature during incubation also affects the rate of the 
reaction. Higher temperatures increase the rate of the reaction but also 
enhance non-specific binding and antigen desorption (Kemeny 1992). It has 
also been reported that the stoichiometric binding of the conjugated antibody is 
more likely to vary with long incubation periods (Venkatesan and Wakelin 
1993). So I carried out a number of assays varying incubation times and 
temperatures. However, I found that the antibody incubation periods of 1 hour 
at 37°C, 3 hours at room temperature, or overnight at 4°C gave almost identical 
results and caused very little difference in background binding to non-specific 
antigen (see figure 3.5. for an example). 
It has been suggested that the sensitivity of the assay can be increased 
by decreasing the temperature during the final step of the assay to prolong the 
substrate reaction (Portsmann and Kiessig 1992). As enzyme reactions are so 
dependent on temperature, I decided that this stage of the assay needed to be 
carried out at a controlled temperature to reduce day to day variation due 
differences in room temperature. Using a low temperature (4 0C), I found that I 
could prolong the substrate reaction to 10 minutes, meaning that more ELISA 
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Human serum reciprocal dilution 
(xl 0) 
Figure 3.5. Titration of a serum sample under different incubation times and temperatures. 
A serum sample was titrated on Well-19/GST antigen saturated plates, and underwent different incubatior 
conditions; 0 overnight at 4 0C,0 1 hour at 37 0C,3 hours at room temperature. Hollow symbols are the 
same titrations on GST. 
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(5) Measurement of the coefficient of variation 
It is important to know the variation in OD values obtained within and between 
batches of ELISAs. This was worked out by carrying out an initial series of 
experiments. Samples are tested on the different antigens within a batch of 
ELISAs on separate plates and on assays carried out on separate days. The 
coefficient of variation is then worked out (using the formula in the introduction) 
to measure how much a single dilution of sample varies within a batch of 
ELISAs and between batches of ELISAs. Variation up to 20% is considered 
acceptable. 
Variation within my initial test samples was between 3.8% and 10.2% 
(see tables 3.1 and 3.2.). 
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WelI-EGF1 MAD-EGF1 MAD-EGF2 MAD-19 MAD/Well-19 Well-19 Well-19/GST 
plate 1 1.323 1.352 1.244 1.524 1.582 1.537 1.750 
plate  1.363 1.389 1.289 1.686 1.650 1.595 1.651 
plate  1.237 1.265 1.118 1.587 1.678 1.470 1.510 
plate  1.285 1.267 1.103 1.410 1.560 1.484 1.571 
plate  1.198 1.210 1.112 1.516 1.424 1.451 1.510 
mean 1.283 1.267 1.173 1.545 1.579 1.507 1.598 
SD 0.066 0.072 0.088 0.101 0.099 0.058 0.103 
CV% 5.1 5.7 7.5 6.5 6.3 3.8 6.4 
Table 3.1. The coefficient of variation for samples carried out within one assay on separate plates; intra batch variation. 
Well-EGF1 MAD-EGF1 MAD-EGF2 MAD-19 MAD/Well-19 Well-19 Well-19/GST 
day  1.623 1.617 1.545 1.641 1.627 1.611 1.871 
day  1.854 1.822 1.712 1.855 1.911 1.898 1.998 
day  1.722 1.698 1.576 1.701 1.836 1.756 1.945 
day  1.599 1.578 1.489 1.589 1.587 1.574 1.742 
day  1.847 1.845 1.708 1.899 1.880 1.992 1.914 
mean 1.729 1.712 1.606 1.737 1.768 1.766 1.894 
SD 0.120 0.120 0.100 0.135 0.150 0.180 0.097 
CV% 6.9 7.0 6.2 7.8 8.5 10.2 7.1 
Table 3.2. The coefficient of variation for samples carried out in assays on separate days; inter batch variation. 
(\J 
Discussion 
It is essential to optimise the ELISA protocol to the particular needs of each 
individual test. ELISAs produce vast quantities of data, but if careful thought is 
not put into the design of the ELISA, and measures are not taken to control its 
parameters, the data generated will be invalid, unreproduceable and 
incomparable between assays. 
Specificity of ELISA assays 
Non-specific binding is a problem in IgO ELISAs as lgG has a high affinity for 
immobilised antigen (Kemeny et a! 1985). Measures taken to decrease the 
background (such as reducing the incubation period or temperature) may also 
decrease the specific response (Avrameas 1992). Measures taken to increase 
specific binding only work if non-specific binding does not increase as well, i.e. 
the sound to noise ratio should be high. 
One method to distinguish between specific and non-specific responses 
is to measure the binding of positive and negative sera to the antigen 
(Venkatesan and Wakelin 1993); conditions which result in a maximal 
difference between the OD of positive and negative sera should be chosen. A 
problem that many investigators have encountered in measuring antibody 
responses by ELISA, when applied to malarial infections, is that malaria causes 
polyclonal B cell activation which results in the increased production of non-
specific antibody; hypergammaglobulinaemia. I was not convinced, therefore, 
that using European sera, as a means to measure the difference between 
specific and non-specific binding, would be appropriate for malaria-exposed 
sera. I thought that it may be more accurate, to maximise the difference 
between specific and non-specific binding through measuring the binding of 
malaria-exposed sera on specific and non-specific antigen. So I have chosen 
the concentration of primary and secondary antibody which maximises the 
difference between binding of the sera to the test antigen and the control 
antigen (GST). 
Quantitative aspects of the ELISA assay 
Malaria immune responses can either be measured in ELISA as single 'spot 
check' dilutions to screen large numbers of sera for the presence or absence of 
specific antibodies, or by titration of each serum sample. Single OD values can 
0 
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give an indication of differences in the antibody titre, i.e. a high OD indicates a 
greater antibody titre than a lower OD. Davey and Steward (1988) suggest that 
end point titrations are least affected by affinity of the antigen. At low dilutions of 
sera (antibody in excess), high affinity antibody will bind to the antigen 
preferentially. However, at high dilutions of sera (antigen in excess), low affinity 
antibody will also bind. End point titres can be obtained from serum titrations. 
This measures the least amount of antibody needed to complex a given amount 
of antigen. When specific binding reaches the background level, the end point 
is reached. 
The choice of whether to measure antibody responses by single point 
dilution or by titration depends on the questions being asked of the assay. If 
hundreds of sera are being tested for the presence or absence of antibodies to 
an antigen, a spot check dilution is adequate, as long as the appropriate serum 
dilution is used. The appropriate dilution has to be determined by titration of a 
random sample of sera. An idea of relative antibody levels can be deduced 
from comparison of OD values. Then positive sera can be analysed in more 
detail by titration. This method is economical in time, antibody sample and 
costs (for reagents etc.). 
Single dilutions are economical but ODs are subject to plate to plate, and 
day to day variability, which can be monitored by the coefficient of variation. My 
results indicate that results do not greatly differ between experiments, but as 
there is more variation in OD values obtained in ELISAs carried out on separate 
days, any samples which are to be compared with each other should be tested 
in the same assay. Caution should be taken in making comparisons of OD 
values obtained from samples tested in separate experiments. 
Due to this day to day variation, some investigators compare the OD 
value obtained in that batch with a standard reference curve of lgG, where they 
convert the OD figure into antibody units, so antibody units can be compared 
between assays (for example; Blackman and Holder 1993). However, OD 
values can only be converted in this way if the standard reference curve has the 
same shape, as the test sample i.e. the two curves are parallel (Kemeny 1992). 
Non-parallelism with the standard curve at low test sample concentration is due 
to differences in ionic strength (molarity) between the test sera and the 
reference antibody. The test serum titration curve flattens out (at the top) with 
high serum concentrations. If the undiluted sample falls outside the useful limits 
of the standard curve, converted values would not be valid. There is also a 
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basic assumption, in the use of a standard curve, that the standard antibody and 
the test serum have the same ability to bind to the solid phase receptor 
(Hamilton and Adkinson 1988). Antisera are a heterogeneous population of 
antibodies from different B cells with different affinities. Serum samples will also 
vary from one another due to differences in serum proteins, lipids and ions, 
which give rise to non-specific effects which alter the kinetics of the 
antigen/antibody binding and result in different plateaux for different antibodies. 
Thus, a single reference curve is not going to fit every test samples' protein 
matrix. From titrating many samples I have found that no two samples have 
exactly parallel titration curves. I therefore decided that this method was not 
appropriate for comparing my samples. 
A major pitfall of ELISA is over interpretation of the results. ELISA is a 
good tool to provide qualitative information on the presence or absence of 
antibodies. However, the most desired end result is a measurement of how 
much analyte is present. Obtaining quantitative information in an indirect ELISA 
is not straight forward as antibody binding is being measured, not antibody 
levels. Antibody binding is a result of both antibody affinity and concentration, 
so an OD result does not give absolute quantitative information. Even end point 
titres are only measuring antibody binding. So only comparisons of antibody 
binding can be made. It is impossible to quantify antibody levels in ELISA, 
either by single point dilution or end point titration without making assumptions 
about the affinity of the antisera (Davey and Steward 1988). 
(3) Statistical analysis of ELISA data 
A cut off OD is needed to determine whether an individual is antibody positive 
or negative to any particular antigen. This cut off point between a specific and 
non-specific response is established by measuring antibody responses made 
by malaria-unexposed European sera. In this study, the mean plus two SD of 
European sera have been used to define the lower limit of a specific OD 
response. However this method has its limitations. As mentioned above, sera 
from malaria-exposed individuals will contain more non-specific antibodies than 
European sera; the cut off level between specific and non-specific responses 
defined by the European sera will be lower than that of malaria-exposed sera, 
so may result in false positive results. However, background/non-specific 
responses are accounted for by the subtraction of OD values obtained for the 
same sera on non-specific antigen (i.e. GST for GST fusion proteins). If a serum 
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sample has a high OD response for the non-specific antigen, the subtracted OD 
(SOD) will be counted as negative even though this sample may have 
contained specific antibody too, so resulting in a false negative result. In other 
words there is no perfect way to do this. 
In some circumstances there is a clear difference between a group of 
responders and non-responders (see figure 3.6.). In these cases the two 
groups (responders and non-responders) can be distinguished visually; for 
example age groups <5, 6-8 and 9-10. In other cases, a purely statistical 
approach has to be taken. Although this may lead to two individuals with very 
similar OD values being classified as a responder or non-responder 
respectively, any other method would be arbitrary and subjective and thus 
susceptible to unintentional bias. 
So the ELISA system has many advantages over other immunoassays in 
terms of speed, sensitivity, convenience and automation. However, it is 
important to realise that if the ELISA has not been properly optimised, this vast 
quantity of data produced will be unreliable. Another problem with ELISA is that 
it measures antibody binding, not antibody affinity, so the results must not be 
over-interpreted by making estimations of antibody concentrations. In this 
chapter I have optimised the ELISA to find the best concentration of 
components, and the best conditions, in which to perform reliable and 
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Figure 3.6. Dot plot demonstrating the difference between specific and non-specific antibody binding to a 
PfMSP11 antigen. 
A cut off value between specific and non-specific antibody responses to, in this example, the MAD-19 
antigen is determined by the mean plus 2 SD of the OD values obtained for European malaria-unexposed 
control sera. In some cases there is a clear difference between a group of responders and non-, 
responders. For example for the age group 31 to 40, the upper limit defined by the European sera would 
be too low and result in false positive responders. In these cases, where there is a clear difference 
between the responders and non-responders, this cut off can be determined by eye. However, when this 
difference is not clear, the cut off is determined by the upper limit obtained by the European sera. 
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CHAPTER FOUR: 
Characterising epitopes within the C-terminus of PfMSP1 
Introduction 
PfMSP1 is a large molecule (185-210kDa) so it would be impractical to produce the 
whole protein in native, recombinant or synthetic form. Therefore, antibody 
responses to constituent components of PfMSP1 need to be assessed in sera from 
malaria-exposed individuals in order to (1), discover whether they induce 
antibodies in a natural infection and (2), to assess whether this antibody response 
is associated with immunity to clinical malaria. 
Apart from human vaccine trials that can directly measure the 
immunogenicity of candidate vaccine antigens, the only way to assess the 
immunogenicity of potential vaccine antigens in humans is to measure antibodies 
induced by natural infection. 
PfMSP1 is considered to be an excellent candidate for inclusion in a malaria 
vaccine (reviewed by Diggs eta! 1993). However, there have been relatively few 
studies of naturally acquired immune responses to it and there seems to be 
confusion over whether human antibodies predominantly recognise conserved or 
dimorphic regions within PfMSP1 (Muller eta! 1989, Fruh eta! 1991, Riley eta! 
1992a, 1993, Tolle eta! 1993). 
It has long been known that people living in malaria endemic areas possess 
antibodies to PfMSP1, indeed it was this high degree of antibody prevalence that 
added to its attractiveness as a vaccine candidate (Perrin and Dayal 1982, Hall et 
a! 1984b, Holder and Freeman 1984). Using a panel of E. co!i-derived 
recombinant proteins representing conserved and dimorphic regions within the 
Wellcome or MAD20 sequences of PfMSP1, Muller eta! (1989) investigated 
human immune responses by Western blot in sera from 63 adults (aged 18-67 
years), 35 children (aged 1-5 years) and 14 infants (aged 3-6 months) living in 
Burkino Faso, West Africa. Antibody responses to specific regions of the protein 
differed widely between individual sera, and there was no clear relationship 
between antibody responses and age. However, they did find that PfMSP1-specific 
antibodies were generally more prevalent in parasitised than in uninfected donors. 
In a continuation of this study, Fruh et a! (1991), measured antibody responses, by 
Western blot, to the same panel of recombinant proteins in 37 adults (aged 18-73) 
and 57 children (aged 2-9) from Mali, West Africa. This study suggested that 
naturally acquired antibodies were predominantly directed against dimorphic 
sequences of PfMSP1. These immunodominant regions occurred in the C-terminus 
W. 
of the PfMSP183 processing fragment (block 6), the N-terminus of PfMSP128-30 
(blocks 6-8) and the dimorphic region of PfMSP142 (block 16), see figure 1.2. 
Other investigators have found that the N-terminal region, containing 
conserved and dimorphic sequences from the PfMSP183 processing fragment, is 
the most antigenic part of the protein (Riley eta! 1992a, 1993, Kramer and Oberst 
1993). For example, immunoblotting experiments showed that all 726 individuals 
living in The Philippines had detectable antibodies to a yeast derived recombinant 
protein representing blocks 1-5 of PfMSP183 (Kramer and Oberst 1993). However, 
only individuals with high titre antibodies against PfMSP1 had detectable 
antibodies against the C-terminal protein, suggesting that the N-terminus of 
PfMSP1 is more antigenic than the C-terminus. However, the authors do point out 
that the yeast derived PfMSP142 construct may not have correctly formed the 
internal disulphide bonds which are vital to the antigenicity (McBride and Heidrich 
1987) and immunogenicity (Chang eta! 1992) of this region. 
Previous investigations carried out in our laboratory have shown that serum 
antibodies to proteins representing highly conserved regions of the molecule were 
more prevalent than antibodies recognising dimorphic or polymorphic regions of 
PfMSP1 (Riley eta! 1992a). However, the strain of parasite from which the 
recombinant constructs were derived (Wellcome) represents the dimorphic form of 
PfMSP1 which is not commonly found in The Gambia (Conway and McBride 1991), 
from where the serum samples were collected. Thus, it is likely that this study 
underestimated the prevalence of antibodies to dimorphic epitopes. 
However, other investigators have found that, following experimental 
immunisation of animals with native PfMSP1, PfMSP1 19 is the most antigenic 
region of the molecule. For example, Cooper et a! (1992) found that 12 out of 19 
mAbs, raised in mice immunised with PfMSP1, bound to epitopes within PfMSP119. 
A number of studies by Hui and Chang have found that the antibody response of 
rabbits immunised with native PfMSP1 or baculovirus-derived PfMSP142 is focused 
on cross-reactive conformational determinates of PfMSP142 and suggest that the 
reduction-sensitive, conserved region (i.e. PfMSP1 i) is immunodominant (Chang 
et a! 1992, Hui et a! 1992, 1993). Kaslow et a! (1994) demonstrated that the 
majority of rabbit serum antibodies raised to native PfMSP1 are specific for 
conserved epitopes within PfMSP1 19. 
However, in malaria-exposed humans, the conserved region of the C-
terminus of PfMSP1 appears to be poorly recognised (Muller eta! 1989, Fruh eta! 
1991, Tolle et a! 1993). The C-terminal E. co!/-derived recombinant protein Fl 0 
used in these studies represents the Wellcome sequence of the dimorphic 
PfMSP 133 and the conserved PfMSP1 19. It was assumed that FlO adopted a 
similar conformation to native PfMSP1 19, on the basis of reactivity with mAbs 2.2, 
79 
7.5 and 12.8, which only recognise the non-reduced PfMSP119 (McBride and 
Heidrich 1987). In Burkina Faso, the level of FlO recognition was slightly higher 
than in Mali but only 30% of adults were seropositive despite life long exposure 
(Muller eta! 1989). The even lower prevalence of human antibodies to this 
Wellcome recombinant protein in Mali (25%) may result from lack of exposure of 
this population to Wellcome PfMSP1-expressing parasites (Fruh eta! 1991). The 
recombinant protein Ml 1 represents the MAD20 form of PfMSP133 and is 
immunodominant. This suggests that the low antibody prevalence to the FlO 
construct was due either to lack of exposure of the population to Wellcome 
parasites and/or, poor recognition of the conserved PfMSP1 ig. Possible 
explanations for the low prevalence of antibodies to PfMSP11 include its close 
proximity to the merozoite surface, its potential concealment by the rest of the 
molecule and its small size (96 amino acids). 
If antibodies are an important component of the protective immune response 
to malaria, it may be important that antibody levels remain high at all times, so that 
merozoites are targeted as soon as they leave the liver. It would therefore be 
important that the antigen induces a good memory response. This can be 
investigated by looking at antibody stability over time. Tolle eta! (1993) found that 
children's antibody levels were not stable through a malaria transmission season. 
During the dry season their antibody levels are low, unlike adults, who have high 
antibody levels whether they are parasitised or not. During the wet season, 
children's antibody levels are boosted to levels similar to those of adults, but this 
increase in antibody response apparently has little effect on controlling 
parasitaemia. However, the antibody may come too late, i.e. pre-existing antibody 
at the time of sporozoite invasion is what is important. Baird and co-workers 
(reviewed in Baird 1995) suggest that antibody produced by children is unable to 
protect them against new malaria infections, due to an intrinsic difference in the 
immune response between adults and children, which results in the inability of 
children to control their malarial infection. This is presumably due to fundamental 
constitutional differences in the immune system of children and adults affecting 
antibody isotype, memory and affinity as well as the cellular component. 
This chapter details the results of studies designed to address the questions 
of immunogenicity of PfMSP1 ig, the stability of the antibody response and the effect 
of age on antibody responsiveness. In order to determine whether the conserved 
domain of the C-terminus of PfMSP1 is well recognised by antibodies induced by 
natural infection, or whether the dimorphic region is immunodominant, I have used 
ELISA assays to measure the prevalence of antibodies to recombinant proteins 
representing the Wellcome form of PfMSP142, the MAD20 form of PfMSP133 and the 
two allelic forms of PfMSP1 19 and its constituent EGF-like motifs, in a malaria- 
we 
exposed population. Sera were collected from individuals aged 1-70 years living in 
The Gambia, where malaria transmission is seasonally endemic. 
In order to examine the memory response to malaria, I have measured 
antibody responses of 20 children and 22 adults in samples taken over three years, 
at the end of the rainy season (November) and at the end of the dry season (May). 
I have examined the effect of age (and therefore malaria exposure) on 
antibody prevalence and I have used correlation analysis and competition ELISAs 
to determine whether the antibodies are strain-specific or whether they recognise 
epitopes which are present in both alleles, i.e. cross-reactive. Finally I have 
attempted to determine whether antibody responsiveness is influenced by genetic 
factors. 
[:11 
Methods and materials 
Antigens 
Recombinant proteins used in this study have previously been described in chapter 
2. 
E. co/i-derived GST fusion proteins representing the first EGF-like motifs of 
the Wellcome and MAD20 sequences of PfMSP1 19 (Well-EGF1, MAD-EGF1), the 
second EGF-like motif of MAD20 PfMSP1 19 (MAD-EGF2), the double EGF-like motif 
of Wellcome PfMSP119 (Well-19/GST) and MAD20 PfMSP133 (MAD-33) were used 
in this study. 
Yeast recombinant proteins representing full length PfMSP1 19 were also 
tested; the MAD20 version of PfMSP119 (MAD-19), the Wellcome version (Well-1 9), 
and a hybrid of the first EGF-like motif of MAD20 and the second EGF-like motif of 
Wellcome (MAD/Well-19). The baculovirus recombinant protein representing the 
Wellcome version of PfMSP142 (Well-42) was also used in this study, see figure 2.1. 
Human sera from an age cross-sectional survey 
Blood collected from people living in rural areas close to the town of Farafenni in 
The Gambia was the source of serum samples, and was provided by my supervisor, 
Dr. E. Riley. Malaria transmission in this area is seasonally endemic with new 
infections occurring during and immediately following the rainy season (July - 
December) (Greenwood eta! 1987a). Serum samples were obtained at the end of 
the rainy season (October) from 195 children and adults (aged 1-70 years) and 
were stored at -20°C until used. Prior exposure to malaria was confirmed by 
serology; all sera had previously been shown to be positive (by 
immunofluorescence) for antibodies to acetone-fixed malaria schizonts with titres 
ranging from 1:160 to >1:20,000 (data not shown). Control serum samples were 
obtained from 28 European adults and 14 European children with no previous 
exposure to malaria. 
Human sera for longitudinal study of seasonal changes in antibody 
levels 
Blood collected from 20 children (aged 3-7) from Farafenni, and 22 adults (aged 
16-65) from inhabitants of a small Gambian village (Brefet), was provided by Dr. E. 
Riley. Serum samples were obtained at the end of the rainy season (November) 
and at the end of the dry season (May) over 3 years. 
WK 
Human sera from adult twins 
Serum samples collected from 36 pairs of same-sex adult Gambian twins were 
kindly provided by Dr. A. Jepson (MRC Laboratories, The Gambia). By DNA 
probing, with five separate minisatelite probes, 15 pairs were shown to be 
monozygous (mz) and 21 pairs were dizygous (dz) (Jepson et al 1994). The twins 
were raised together and were still living in the same, or nearby, villages, so it was 
assumed that their past histories of malarial infections would be very similar. 
MAbs 
The following PfMSP1 19-specific murine mAbs were used; 12.8 (McBride and 
Heidrich 1987), 111.4 (Holder et al 1985), and 14-1C (Dr. R. Reese, Agouron 
Institute, La Jolla, USA), see chapter 2. 
ELISA 
Antibodies reacting with recombinant PfMSP1 proteins were detected by ELISA. 
Microtitre plates (Immulon 4; Dynatech) were coated overnight at 4°C with proteins 
diluted in carbonate buffer (15mM Na2CO3, 35mM NaHCO3 pH9.5). The saturating 
concentration of protein, determined by titration, was from O.lpg/ml to 5pg/ml 
depending on the antigen, see chapter 3. Plates were washed three times in 
PBS/T (washing buffer), blocked with a 1% (w/v) solution of non-fat powered milk in 
PBSIT (blocking buffer) and washed again, 1 00p of serum or mAb, diluted in 
blocking buffer, was added to duplicate wells and incubated overnight at 4°C. 
Optimal dilutions of serum or mAbs were determined by titration (see chapter 3). 
For all human sera, the steepest slope of the titration curve was observed at 
concentrations between 1:1000 and 1:10,000 (data shown in chapter 3). The 
optimum concentration of human sera for the assay was thus selected as 1:3000 
(Kemeny 1992). 
After washing, HRP-conjugated rabbit anti-human lgG (1 OOpl diluted 1:5000 
in PBS/I) or HRP-conjugated rabbit anti-mouse lgG (100p1 at 1:1000 in PBS/I) 
(both Dako) were added to the plates, incubated for 3 hours at room temperature 
and developed with H202 and OPD (Sigma) for 10 minutes at 4°C. The reaction 
was stopped by the addition of 20pl of 2M H2SO4. Plates were read at 492nm. For 
GST fusion proteins the OD value of the GST control was subtracted from the OD of 
GST-recombinant fusion proteins, to give a specific OD (OD) for the response to 
the PfMSP1 antigens. 
*1 
Competition ELISAs 
To determine whether antibodies recognising individual recombinant proteins also 
recognised (cross-reacted with) other recombinant proteins, competition ELISAs 
were performed. The test serum was diluted in blocking buffer to which was added 
recombinant protein, at a range of concentrations. After incubation for 5 hours at 
room temperature, the blocked serum was added to immunoplates coated with a 
second recombinant protein. The remainder of the assay was as before. 
HLA class II determination of individuals from the age cross-
sectional study 
179 of the individuals from the age cross-sectional study had previously been 
tested for their HLA class II haplotype (Olerup eta! 1991). HLA typing for DRB, 
DQA and DQB was performed by Southern blot analysis of Taq 1 -cleaved DNA 
from peripheral blood leucocytes (Carlsson et a! 1987). 
Statistical Methods 
Specific OD values obtained for sera from malaria-unexposed European donors 
were used to establish a normal range for each antigen. The OD values for these 
control sera tended to be normally distributed; thus, Gambian sera giving an OD 
value greater than the mean plus 25D of the European sera were considered to 
contain antibody specific for the relevant recombinant protein. 
To determine whether prevalence of antibody to PfMSP1 proteins are 
associated with age, the number of seropositives for each antigen were compared 
between the age groups, using X 2 for linear trend. 
To determine whether levels of antibody of seropositive individuals to 
PfMSP1 proteins are associated with age, the distributions of OD values for each 
antigen were compared between the age groups using Kruskal-Wallis one-way 
analysis of variance. It was necessary to use a non-parametric test since the 
distributions of the OD values were highly skewed within each age group. 
Antibody responses to the chimaeric MAD/Well-19 protein versus the MAD20 
or Wellcome PfMSP11 proteins were compared by using the non-parametric 
Spearman's rank correlation coefficient, resulting in a r value. 
To determine the association between HLA class II genotype and antibody 
response, individuals were classified as either responders or non-responders to 
each antigen and the probability of an immune response in individuals of any 
particular haplotype was estimated by multiple logistic regression allowing for 
potential confounding effects of age and sex. To allow for associations between 
HLA genotype and malaria exposure within members of a single family group, the 
data was stratified by household and analysed by conditional logistic regression. 
Fisher's exact test was used to compare the proportion of discordant twin 
pairs (i.e. where one twin was seronegative and the other seropositive for a 
particular antigen) between mz versus dz twins. Absolute differences in OD values 
for each twin pair (for each antigen) were calculated and the significance of the 




(1) Recognition of recombinant PfMSP1 proteins by human antibodies 
from an age cross-sectional survey 
The mean plus 2SD of the European sera was used as a guide to distinguish 
between responders and non-responders. However, when there was an obvious 
gap between a group of responders and non-responders, the cut off OD value was 
determined visually. For example, in figure 4.1.a.; for the age group 41-50 there is 
no clear difference between a low antibody responder and a non-responder, so the 
mean plus 2SD OD value was used to distinguish this difference, while for the age 
group 21-30, there is a clear difference between these two populations of different 
responsiveness. The upper limit determined by European sera was occasionally 
too low, obviously including non-specific responses. Malarial infections induce 
high levels of non-specific antibody, which causes a problem in determining a 'true' 
antigen-specific response (see chapter 3). In these cases (see figure 4.1.f. for an 
example) I decided it would be more accurate to differentiate responsiveness 
visually. 
All the PfMSP1 constructs were recognised by antibodies induced by natural 
malaria infection. Some sera showed high levels of antibodies to the C-terminal 
PfMSP1 constructs, with end point titrations of up to 1/48,000 (see figures 3.4.a.b.c. 
presented in chapter 3). However, the prevalence of antibodies to the different 
constructs varied considerably, see figures 4.1.a-i. and table 4.1. More than 60% of 
the sera contained antibodies that recognise Well-42. MAD-33 is recognised by 
90% of individuals, indicating that this dimorphic region of PfMSP1 is 
immunodominant. The level of recognition of Well-42, which contains the 
Wellcome sequence of PfMSP133, is lower than the recognition of MAD-33. This 
lower prevalence of antibody responsiveness to Well-42 is probably due to lack of 
exposure to this sequence, as expression of the Wellcome PfMSP1 allele is rare in 
The Gambia (Conway and McBride 1991).The difference in the prevalence of 
antibodies to these two proteins indicates that the dimorphic regions of PfMSP1 are 
immunogenic, and even, immunodominant. 
The prevalence of antibodies to the double EGF-like motif of PfMSP1 19 is 
approximately 40% (see table 4.2.). There is a close correlation between antibody 
responses to Well-42 and the two allelic forms of PfMSP1 ig, indicating that much of 
the antibody response to Well-42 is directed to conserved epitopes within 
PfMSP1 19 (see figures 4.2.a.b.) and, once again, indicating that there is not much of 
an antibody response to the Wellcome dimorphic (PfMSP133) region of Well-42. 
There are a few sera which recognise Well-42 but not PfMSP1 19, see figures 
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recombinant protein (MAD20) n (%) seropositive n=1 95 
EGF1 only 10(5.1) 
EGF2 only 8(4.1) 
both EGF1 and EGF2 1 (0.5) 
19 only 26 (13.3) 
both EGF1 and19 15 (15.8) 
both EGF2 and 19 4(2.1) 
EGF1, EGF2 and 19 9(4.6) 
no response to any EGF epitope 122 (62.6) 
Table 4.1. Antibody responses to MAD20 PfMSP119 and its constituent EGF-like motifs. 
Number (percentage) of individuals with antibody responses to epitopes within the MAD20 
form of PfMSP1 19. 
Age (years) 3-8 9-15 >16 total X2 trend 	P 
n 43 60 92 195 
2.10 	0.15 Well-EGF1 5 8 19 32 
(11.6) (13.3) (20.7) (16.4) 
MAD-EGF1 3 11 19 33 3.43 	0.06 
(7.0) (18.3) (20.7) (16.9) 
MAD-EGF2 6 5 13 24 0.07 	0.79 
(14.0) (8.3) (14.1) (12.3) 
MAD-19 4 12 38 54 16.90 	0.00 
(9.3) (20.0) (43.1) (27.6) 
MAD/Well-19 7 22 53 82 22.65 	0.00 
(16.3) (36.7) (57.6) (42.1) 
Well-19 7 20 50 77 18.98 	0.00 
(16.3) (33.3) (54.3) (39.5) 
Well-19/GST 11 25 43 79 4.97 	0.03 
(25.6) (41.7) (46.7) (40.5) 
MAD-33 30 55 90 175 3.21 	0.07 
(69.8) (91.7) (97.8) (89.7) 
Well-42 15 35 68 118 18.50 	0.00 
(34.9) (58.3) (73.9) (60.2)  
Table 4.2. The relationship between age and antibody responses to the C-terminal of PfMSP1. 
Figures show the number (percentage) of antibody positive children (responders) in each 
group, for each antigen. Responders are those where the specific OD was greater than the 
mean plus 2 SD of the control (malaria non-exposed) sera or determined visually. p value at 2 
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dimorphic PfMSP133 region of Well-42. If these individuals have not been exposed 
to Wellcome PfMSP1 expressing parasites, these epitopes may be cross-reactive 
with MAD20 PfMSP133 sequences. Figure 4.2.c. once again demonstrates the 
higher prevalence of antibody responsiveness to MAD-33 than Well-42 in this 
population, with few sera recognising epitopes exclusively in the Wellcome protein. 
Less than 20% of sera show reactivity with the single EGF-like motif proteins, 
and the second EGF-like motif is particularly poorly recognised (table 4.2, figures 
4.1 .g.h.i.). Of the sera which recognise PfMSP1 ig, approximately 50% recognise 
only the double-motif construct and did not recognise any of the single EGF-like 
motif proteins (see table 4.1.). This indicates that there are epitopes recognised by 
human sera in PfMSP1 19 that are not present when either EGF-like motif is 
expressed alone. 
The prevalence of antibody responses to Well-42 and the double-motif 
proteins increases significantly with age (table 4.2.). A similar trend is seen for the 
EGF-1 proteins, and PfMSP133 although not statistically significant. There is no 
trend of increasing prevalence with age for EGF-2. In the majority of cases, once an 
individual has 'sero-converted' from a non-responder to a responder, the OD 
response of seropositive individuals does not significantly increase with age, but 
this result may the small number of seropositive individuals in each age group (see 
table 4.3.). 
(2) Competition ELISAs to demonstrate the presence of new epitopes 
created by the double-motif construct 
48% of the 54 sera which recognise the MAD20 double-motif do not recognise 
either of the MAD20 single motifs (table 4.1.). The remaining sera recognised both 
double- and single-motif proteins. To see if these sera recognise only sequences 
in the single-motif, or whether they recognise additional epitopes formed by the 
double-motif, I performed competition ELISAs between sera which recognise both 
the single- and double-motif proteins. Competition ELISAs carried out on eight 
sera showed that five recognise additional epitopes that are only present in the 
double-motif protein. Figure 4.3.a. shows an example of a serum where 
preincubation of this serum with MAD-EGF1 reduces the level of binding to MAD-
19, but does not abolish it. So in addition to epitopes within the first EGF-like motif, 
this serum recognises an epitope(s) made up of sequences from both motifs. 
Another example (figure 4.3.b.) shows a serum for which preincubation with the 
single EGF-like motif has no effect on the recognition of the double-motif, so this 




median OD by age group for seropositives Kruskal-Wallis test 
3-8 9-15 >16 total H 	 p 
n=43 n=60 n=92 n=195  
Well-EGF1 0.385 0.802 0.750 0.678 1.82 	0.39 
(4) (9) (19) (32) 
MAD-EGF1 1.344 0.783 0.733 0.978 0.04 	0.83 
(2) (12) (19) (33) 
MAD-EGF2 0.285 0.561 0.322 0.319 2.97 	0.23 
(5) (6) (13) (24) 
MAD-19 1.008 0.942 1.022 0.958 0.04 	0.98 
(3)  (38) (54) 
MAD/Well-19 0.553 0.572 0.791 0.660 1.08 	0.58 
(6) (23) (53) (82) 
Well-19 0.636 0.621 0.816 0.763 0.76 	0.69 
(6) (21) (50) (77) 
Well-19/GST 0.532 0.614 0.889 0.730 5.85 	0.05 
(8) (27) (44) (79) 
MAD-33 0.959 1.325 1.252 1.246 1.55 	0.46 
(30) (55) (90) (175) 
Well-42 0.520 0.754 0.885 0.809 6.41 	0.04 
 (36) (68) (118) 
Table 4.3. The effect of age on median levels of anti-PfMSP1 antibodies produced 
by seropositive individuals. 
Median OD levels of seropositive individuals to each antigen for each age group are shown. 
Brackets=number of seropositive in each group for each antigen. 
p value at 2 degrees of freedom. 
01 
Figure 4.3. Competition ELISAs demonstrate that additional epitopes are present within the 
double EGF-like motif protein (MAD-1 9) that are not present when either motif is expressed alone. 
Eight sera which react with the single EGF-like motif (MAD-EGF1) and with the double EGF-like 
motif (MAD-1 9) were tested; the results for two sera are shown here. 
Serum 1493: preincubation of the serum with MAD-EGF1 reduces the level of binding to MAD-
19 but does not abolish it. This serum may recognise an additional epitope in MAD-i9 which 
overlaps with an epitope in MAD-EGF1. 
Serum 1515: preincubation of the serum with MAD-EGF1 has no effect on the recognition of 
MAD-1 9. 
This serum appears to recognise an epitope(s) in MAD-i9 which is distinct from the epitope(s) in 
MAD-EGFi. 
preincubation with MAD-1 9, tested on MAD-1 9. 
0, preincubation with MAD-19, tested on MAD-EGF1. 
0, preincubation with MAD-EGF1, tested on MAD-EGF1. 
preincubation with MAD-EGF1, tested on MAD-19. 
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(3) Serological cross-reactivity between Wellcome and MAD20 
PfMSP1 antigens in the age cross-sectional survey 
Some murine mAbs can differentiate between the two allelic forms of PfMSP11 
(figure 4.4.). Thus mAb 111.4 (derived from a mouse immunised with merozoites of 
the Wellcome isolate) recognises only the Wellcome type of the first EGF-like motif, 
whereas mAb 14-1C recognises both types equally. MAb 12.8 (from a mouse 
immunised with a MAD20-type isolate) recognises both forms but has a higher 
affinity for the MAD20 type than for the Wellcome type. Due to this ability of mAbs to 
differentiate between the two allelic sequences of PfMSP119, I decided to compare 
human polyclonal antibody responses to proteins representing the two different 
forms of Pf MSP 119 to see if variant epitopes are a major component in the 
polyclonal antibody response. 
Comparison of antibody recognition of proteins representing 
different PfMSP119 sequences 
Sera which give a high OD for the Wellcome proteins also tended to give a high OD 
to the MAD20 proteins. When recognition of two double-motif proteins is directly 
compared, there is a high degree of correlation between them (see figure 4.5.a.). 
However, occasional sera do react more strongly with one sequence than the other 
(arrow). This seems to be due to differential recognition of the three dimorphic 
amino acid residues in the second EGF-like motif. Figures 4.5.b. and c. show OD 
values obtained for the Wellcome and MAD20 forms of PfMSP1 19 compared with 
OD values obtained for the chimaeric protein MAD/Well-19. The correlation is 
much closer where proteins share the same second EGF-like motif (figure 4.5.b.) 
than where they share the first-motif but differ at the second-motif (figure 4.5.c.) 
When sera are compared for recognition of single or double EGF-like 
proteins, they fall into three groups (figure 4.5.d.). Some sera react with both the 
double and the single (®) (see figure 4.5.d.), whereas other sera recognise only the 
double-motif (.). The remaining sera recognise neither (o). Similarly, occasional 
sera (®) recognise both the double-motif and the second single-motif (figure 4.5.e.), 
and a very few sera (®) recognise both the first- and second-motifs (figure 4.5.f.). 
Titration of individual human sera against the PfMSP119 proteins 
The above data seem to suggest that most human antibodies do not differentiate 
between the variant sequences of PfMSP1 ig. The two allelic forms of the first EGF-
like motif differ in sequence by only one amino acid (glutamine in the Wellcome 
form and glutamate in the MAD20 form at position 14, figure 1.3.); it is thus likely 
that the two sequences are immunologically cross-reactive. 
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Figure 4.5. Comparison of antibody recognition of different PfMSP11 sequences: 
Well-1 9 vs MAD-1 9; Wellcome sequence versus MAD20 sequence. Overall correlation is high 
(r=0.901, n=1 95, p<O.00i) but some sera (arrowed) clearly differentiate between the two 
sequences. 
MAD/Well-19 vs Well-19; proteins share the Welcome sequence at the second EGF-like 
motif, but differ at the first motif. Correlation is high (r=0.983, n=i 95, p<0.001) showing that the 
single amino acid change (E to 0) is not recognised by polyclonal sera. 
MAD/Well-1 9 vs MAD-1 9; proteins share the MAD20 sequence at the first EGF-like motif but 
differ in the second motif. The correlation (r=0.965, n=i 95, p<0.001) is similar to that in (a) but 
lower than in (b). This indicates that some sera (arrowed) clearly differentiate between the KNG 
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Figure 4.5. Comparison of antibody recognition of different PfMSP1 19 sequences: 
MAD-19 vs MAD-EGF1; proteins share the MAD20 first EGF-like motif sequence. The 
correlation is low (r=0.403, n=1 95, p<0.001) as approximately 50% of the seropositive sera 
recognise epitopes in the double-motif protein not present in the first-motif protein. 
= sera that react with the double-motif protein only, 
= sera that react with both the double- and first-motif proteins, 
o = sera seronegative for MAD20 PfMSP1 19. 	 - 
MAD-19 vs MAD-EGF2; proteins share the MAD20 second EGF-like motif sequence. The 
correlation is low (r=0.322, n=1 95, p<0.001) as the majority of seropositive sera recognise 
epitopes in the double-motif protein. 
= sera that react with the double-motif protein only! 
= sera that react with both the double- and second-motif proteins. 
o = sera seronegative for MAD20 PfMSP1 19. 
MAD-EGF1 vs MAD-EGF2; proteins represent either the first or second EGF-like motif. The 
correlation is low (r=0.335, n=195, p<0.001). There are very few sera which recognise both the 
first- and second-motif, and even less that recognise the second-motif exclusively. 
= sera that react with the first-motif protein only. 
= sera that react with both the first- and second-motif proteins. 
= sera that react with the second-motif protein only. 
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To confirm that these antibodies were recognising both sequences with the 
same avidity and affinity, six sera, previously shown to contain antibodies to the first 
EGF-like motif, were titrated against the three single EGF-like motif proteins. All six 
sera gave identical titration curves for the two allelic forms of the first EGF-like motif 
(an example is shown in figure 4.6.a.). They also gave identical titration curves for 
the two allelic forms of the double-motif protein (an example is shown in figure 
4.6.b.). This confirms that these human polyclonal sera do not differentiate between 
the two allelic forms of PfMSP1 19. 
(3c) Polyclonal sera contain cross-reactive population of antibodies 
Finally, to confirm that polyclonal human sera contain a single population of 
antibodies that recognise both sequences, competition ELISAs were performed. 
Individual sera which recognised MAD20 and Wellcome derived proteins 
with equal avidity were selected. As shown in figure 4.7.a. (serum 1592), 
preincubation of the serum with 1 to 10 pg of either the Wellcome or MAD20 first 
EGF-like motif protein per ml inhibits subsequent binding of that serum to plates 
coated with either of the two of these proteins. For another serum (1614, figure 
4.7.b.) inhibition was obtained by preincubation with less than 0.1pg of protein per 
ml. 
Seasonal changes in antibody responses 
To determine whether antibody levels are affected by boosting from infection during 
the wet season, antibody responses were measured in 20 children and 22 adults 
over three malaria transmission seasons. 
Antibody responses to MAD-EGF1, Well-1 9 and MAD-33 were measured in 
serum samples taken every six months i.e. wet and dry seasons. Responsiveness 
and OD levels to PfMSP1 proteins were more stable in adults than in children over 
the three wet and dry seasons, see table 4.4. Despite life long exposure to these 
PfMSP1 proteins, some adults were persistently antibody negative to these proteins 
over the three year period. Individual children showed clear evidence of seasonal 
variation of the antibody response (for example; E24009, 003005). 
HLA analysis of serological responsiveness to PfMSP1 proteins in 
the age cross-sectional study 
Data from the three year longitudinal study shows that some adults are persistently 
antibody negative to C-terminal PfMSP1 recombinant proteins, and data from the 
age cross-sectional study show that 40% of adults do not possess antibodies to the 
conserved PfMSP1 19 despite life-long exposure. To determine whether this non-
responsiveness is due to their HLA class II genetic make up, the relationship 
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Figure 4.6. Human sera recognise epitopes which are cross-reactive between MAD20 and 
Wellcome sequences of PfMSP1 19: 
human serum 1275 recognises both sequences of the first EGF-like motif but not the second-
motif. 
human serum 1579 recognises all three yeast double-motif PfMSP1 19 constructs. 
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Figure 4.7. Competition ELISAs to confirm the presence of cross-reactive antibodies. 
Preincubation of human serum a)1 592 or b)1 614 with 1 pg/mI of either protein Well-EGF1 or 
protein MAD-EGF1 inhibits subsequent binding of that serum to plates coated with either MAD-
EGF1 or WeIl-EGF1 respectively. 
serum preincubated with Well-EGF1 on Well-EGF1 -coated plates. 
serum preincubated with Well-EGF1 on MAD-EGF1 -coated plates. 
0, serum preincubated with MAD-EGF1 on Well-EGF1 -coated plates. 
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donor age MAD-EGF1 MAD-19 MAD-33 
E07008 5 --+ ---- ----+ --- -++ 
E08010 7 + -+ +-+ -+ +-+- + ~ ----- 
E09009 3 
E17004 3 -- -------- --- ------- 
E18003 6 -+ ---+ -+ ----+ ++ ++ -+ 
E20015 5 ----- ----+ -+ + + + 
E24008 6 ---+ ----+- + -------- 
E24009 4 - ------- ------ + --+--+--+ 
E25007 3 -- ------- --- -------- 
E25009 6 - --+ -------- 
N05034 3 
P06008 7 
P06009 4 - --+ -------- 
P06010 3 ----- ++ -+ --+ + 
P10016 6 --- -+ ---- + ++++ + 
P10017 3 + -------+ ++ +--+ 
P11005 6 
P12009 5 -+ -+---- ++-++ 
Q01008 6 ------+ -----+ 
Q03005 4 +--+ ----+--+ ----+--+ 
12 60 ----- ------- 
13 55 +++++ 
45 45 ----- ----+--- 
50 38 ------- 
79 50 +++++ 
110 17 +++++ 
167 16 ----- --------- 
109 16 ------ 
31 44 -----++ +--+++ 
104 16 -----++ ++ 
53 60 - ----- 
15 45 --+ 
120 65 - ---- --- -------- 
95 41 --------- 
4 34 ++++++ ++++++ ++++++ 
117 17 ----+ ----+ ------ 
28 55 - ---- 
69 35 ----- -- 
116 28 -------- 
125 28 +--+--+ + ------+ 
112 18 ----- -------- 
105 24 + ++ + i-++ + 
Table 4.4. Longitudinal survey of antibody responses to PfMSP1 proteins in children 
(upper half) and adults (lower half). 
Each symbol represents a separate serum sample. Samples were collected at six month 
intervals. 
-- = antibody negative, 
+ = antibody positive (higher than mean plus 2 SD of 24 European sera), 
+ = strongly antibody positive (>mean plus 6 SD). 
Blank space indicates either no sample or no data. 
First, third and fifth samples = wet season. 
Second, fourth and sixth samples = dry season. 
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between HLA class II haplotype and antibody responsiveness to MAD-EGF1, MAD-
EGF2, MAD-19 and MAD-33 was analysed for the cross-sectional cohort of 
Gambian donors (table 4.5.). Only those haplotypes which were present in at least 
10 of the 195 individuals tested were included in the analysis. No significant 
associations were seen between any of the C-terminal PfMSP1 recombinant 
proteins and any HLA class II antigen. Importantly, individuals with identical HLA 
class II haplotypes could have different antibody responses. 
(6) Serological responsiveness to PfMSP1 proteins in adult twins 
Another method of looking for genetically-determined differences in antibody 
responsiveness is to compare antibody responses in genetically identical 
individuals (i.e. mz twins) and non-identical (i.e. dz) twins. Antibody responses 
were measured in 15 pairs of adult mz twins and 21 pairs of adult dz twins to Well-
EGF1, MAD-EGF2, MAD-19, Well-19 and MAD/Well-19. 
Overall, the level of concordance of antibody responsiveness is high (36 
pairs tested against 5 antigens = 180 comparisons, of which 139 were concordant, 
= 77%), this presumably reflects the similarity of past malaria exposure within pairs. 
23% of comparisons were discordant, with one twin being seropositive to a 
particular antigen while the other twin was seronegative. If these differences were 
the result of genetic differences between twins, it would be expected that more dz 
than mz pairs would be discordant, but this is not the case (see table 4.6.). There 
was no significant difference between the number of discordant pairs between the 
mz and dz twins, (Fisher's exact test, p>0.05 for all antigens) or the median 
difference in OD values (Mann-Whitney; p>0.07 for all antigen). So mz twins are no 
more alike in their antibody responsiveness than dz twins, and genetically identical 
mz twins can have very different antibody responses. 
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Serological MAD-EGF1 MAD-EGF2 MAD-19 MAD-33 
Haplotype specificity 
no.  
DR DQ n n % n % n % n % 
1 1 w5 7 1 0.14 6 0.86 5 0.71 5 0.71 
2 w15 w6 4 2 0.50 3 0.75 4 1.00 4 1.00 
7 w17 w2 7 4 0.57 5 0.71 7 1.00 7 1.00 
8 w18 w4 1 1 1.00 1 1.00 1 1.00 1 1.00 
9 3 w4 6 1 0.17 4 0.67 2 0.33 6 1.00 
11 4 w8 4 2 0.50 3 0.75 4 1.00 2 0.50 
12 4 w2 1 1 1.00 1 1.00 1 1.00 1 1.00 
14 7 w2 10 3 0.30 10 1.00 8 0.80 10 1.00 
15 7 w2 2 1 0.50 2 1.00 2 1.00 2 1.00 
17 w8 w7 4 2 0.50 3 0.75 4 1.00 4 1.00 
18 w8 w7 3 2 0.67 3 1.00 3 1.00 3 1.00 
21 9 w2 10 3 0.30 9 0.90 9 0.90 9 0.90 
22 wlO w5 16 5 0.31 14 0.88 13 0.81 15 0.94 
23 wil w7 3 1 0.33 3 1.00 3 1.00 3 1.00 
26 wil w7 4 2 0.50 2 0.50 3 0.75 3 0.75 
29 wil w7 54 22 0.41 46 0.85 42 0.78 53 0.98 
34 w13 w6 4 0 0.00 3 0.75 2 0.50 4 1.00 
37 w13 w6 3 0 0.00 3 1.00 3 1.00 3 1.00 
38 w13 w6 27 10 0.37 23 0.85 24 0.89 27 1.00 
39 w13 w7 9 3 0.33 7 1 	0.78 6 0.67 9 1.00 
X2 2.82 6.13 2.79 4.44 
p  0.73 0.29 0.73 0.49 	1.1 
Table 4.5. The association between HLA class II haplotype and the serological 
responsiveness to PfMSP1 proteins. 
Number /percentage of individuals expressing each haplotype who were seropositive for 
each antigen. %2  is conditional logistic regression statistic for the overall association 
between HLA type and immune response. 
p value at 5 degrees of freedom. 
IM 
Well-EGF1 MAD-EGF2 MAD-19 Well-19 MAD,WeII-19 
mzl 0.170 0.065 0.069 0.135 0.123 0.138 0.127 0.155 0.126 0.146 
mz2 0.065 0.127 0.045 0.120 0.769 0.822 0.766 0.905 0.828 0.930 
mz3 0.035 0.049 0.034 0.147 0.114 0.163 0.130 0.177 0.115 0.198 
mz4 0.011 0.011 0.048 0.037 0.128 0.106 0.134 0.354 0.114 0.086 
mz5 0.009 0.006 0.030 0.057 0.289 0.138 0.227 0.149 0.173 0.140 
mz6 1.059 0.210 0.702 0.025 1.220 0.482 1.241 0.539 1.288 0.501 
mz7 0.513 0.021 0.503 0.062 0.047 0.681 0.048 1.403 0.066 1.373 
mz8 0.013 1.978 0.073 0.499 1.358 1.738 1.648 1.811 1.565 1.870 
mz9 0.018 0.012 0.024 0.019 0.079 0.341 0.076 0.380 0.091 0.407 
mzlO 0.036 0.030 0.049 0.057 0.075 0.085 0.069 0.089 0.065 0.089 
mzll 0.038 0.010 0.028 0.025 0.315 0.129 0.313 0.148 0.356 0.141 
mzl2 0.126 0.276 0.017 0.029 0.457 0.843 0.446 0.777 0.380 0.717 
mzl3 0.021 0.034 0.108 0.017 0.153 0.205 0.133 0.138 0.132 0.119 
mz14 0.044 0.359 0.003 0.053 0.230 0.571 0.171 0.454 0.210 0.541 
mz15 10.140 0.072 0.033 0.016 0.225 0.103 0.215 0.104 0.212 0.099 
dzl 0.090 0.061 0.055 0.099 0.171 0.139 0.199 0.183 0.211 0.177 
dz2 0.033 0.022 0.077 0.036 0.339 0.147 0.354 0.150 0.323 0.141 
dz3 0.035 0.039 0.071 0.149 0.146 0.157 0.159 0.168 0.150 0.157 
dz4 0.011 0.048 0.043 0.026 0.099 0.106 0.111 0.126 0.106 0.156 
dz5 0.002 0.029 0.021 0.075 0.105 0.256 0.114 0.304 0.100 0.167 
dz6 0.004 0.008 0.037 0.037 0.140 0.123 0.163 0.156 0.162 0.160 
dz7 0.022 0.082 0.040 0.018 0.369 0.806 0.509 0.951 0.448 0.888 
dz8 0.022 0.024 0.033 0.033 0.096 0.082 0.104 0.085 0.095 0.080 
dz9 0.166 0.144 0.009 0.061 0.222 0.390 0.246 0.404 0.275 0.489 
dzlO 0.043 0.049 0.033 0.042 0.097 0.076 0.088 0.094 0.081 0.100 
dzll 0.163 0.034 0.091 0.014 1.414 0.197 1.432 0.237 1.317 0.211 
dz12 0.093 0.063 0.052 0.061 0.348 0.145 1.119 0.138 0.959 0.122 
dz13 0.060 0.081 0.044 0.062 0.579 0.607 0.525 0.621 0.573 0.626 
dz14 0.035 0.109 0.037 0.445 0.181 0.332 0.153 0.302 0.165 0.383 
dz15 0.015 0.001 0.010 0.006 0.073 0.168 0.073 0.223 0.063 0.178 
dz16 0.043 0.028 0.004 0.019 0.123 0.115 0.102 0.119 0.111 0.116 
dz17 0.014 0.023 0.011 0.000 0.067 0.077 0.071 0.081 0.069 0.078 
dz18 0.003 0.010 0.017 0.034 0.086 0.080 0.083 0.106 0.084 0.093 
dz19 0.001 0.026 0.027 0.023 0.332 0.167 0.242 0.164 0.145 0.157 
dz20 0.024 0.013 0.018 0.052 0.086 0.163 0.091 0.159 0.096 0.151 
11 	dz21 0.011 0.016 0.012 0.009 0.061 0.061 0.060 0.064 0.057 0.058 
	
0.058 	 0.028 
Comparison of proportion discordant: 
% 2 	27% vs. 5% 	40% vs. 38% 
p-value1 	 0.138 0.817 
Comparison of average within-twin difference: 
0.132 	 0.110 	 0.098 
40% vs. 19% 	20% vs. 14% 	20% vs. 14% 
0.260 	 0.677 	 0.677 
medians2 	0.062 vs. 0.021 
	
0.050 vs. 0.023 	0.151 vs.0.032 	0.163 vs. 0.068 	0.113 vs.0.050 
W statistic3 320.5 
	
313.0 	 333.5 	 331.5 	 334.0 
p.vaius2 	 0.17 0.26 0.08 0.09 0.07 
1 Fishers exact test (two-sided p-value) 
2 Monozygous first 
Mann-Whitney W test 
Table 4. 6. Comparison of antibody responses to PfMSP1 19 antigens in adult 
monozygous and dizygous Gambian twins. 
The first figure in each column represents the OD value for one twin, the second figure is 
the OD value for the other twin in the pair. Discordant results (one above and one below 
the cut off) are underlined. * Cut off values for positive responses (mean plus 2SD of 
control sera OD). 
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Discussion 
I have screened sera from a population of malaria-exposed individuals from The 
Gambia for antibodies recognising recombinant proteins representing the 
Wellcome form of PfMSP142, the MAD20 form of PfMSP133 and the two allelic forms 
of the single and double EGF-like motifs of PfMSP1 19. 
This study has shown that; 1) PfMSP133, PfMSP119 and the constituent EGF-
like motifs are naturally immunogenic in humans, 2) the prevalence of antibodies 
increases with age, 3) the antibodies tend to recognise epitopes that are conserved 
or cross-reactive between the two allelic sequences, 4) antibody responses are 
stable in adults and 5) antibody responses do not appear to be genetically 
restricted. The prevalence of individuals who are seropositive to PfMSP1 proteins 
increases with age (though not always statistically significant), which may suggest 
that multiple infections are required to initiate an antibody response. 
Approximately 50% of the individuals seropositive for PfMSP1 19 had 
antibodies to the single first EGF-like motif; recognition of the second EGF-like motif 
is much lower. As the number of individuals seropositive to the single first- and 
second-motif proteins do not equal the number seropositive to the double-motif 
protein, this indicates that a major epitope(s) of PfMSP1 19 requires the presence of 
both EGF-like motifs, and is missing when either motif is expressed alone. 
Approximately 90% of individuals have antibodies to PfMSP133, 40-50% have 
antibodies to PfMSP119 and 12-17% have antibodies to the individual EGF-like 
motifs. 
Udhayakumar et al (1995) have measured antibody responses of malaria-
exposed adults to recombinant proteins representing PfMSP1 ig. They found 70-
90% of individuals were seropositive to PfMSP1 ig, which is much higher than 
reported here. It is possible that this is due to the higher malaria transmission 
intensity in Kenya, but I suspect that differences in their ELISA protocol, compared 
to the one used here, may contribute to the high seroprevalence claimed. Sera 
were tested at a very high concentration (1:100 compared to 1:3000 tested here). 
The concentration of sera used here has been optimised to detect fine differences 
in antibody binding and give low level non-specific binding (see chapter 3). 
Measuring antibody responses at such a high concentration (as in the 
Udhayakumar study) suggests that antibody responses were measured at an 
insensitive region of the antibody titration curve (see figures 3.4.). In fact sera may 
have been barely positive and their measurements probably resulted from non-
specific binding. Many of these sera would probably have been deemed negative 
in the ELISA protocol used here. Non-specific binding does appear to be a 
problem in the Udhayakumar study, as cut off values of up to 0.7 OD have been 
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used, which is very high. Also, direct comparisons of OD responses from different 
batches of ELISA5 have been made despite the evidence that OD values varied 
widely from batch to batch; cut off OD values for the same antigen, tested in different 
batches, varied from 0.1 to 0.7. Due to reasons discussed above (insensitivity of 
the ELISA protocol used) their results may be inaccurate and are a classic example 
of the pitfalls of the ELISA technique (Venkatesan and Wakelin 1993). 
Although more than 95% of parasites transmitted in The Gambia are of the 
MAD20 MSP1 genotype (Conway and McBride 1991), constructs representing the 
alternative Wellcome sequence of PfMSP1ig were well recognised by Gambian 
sera. To determine whether the human antibody response to PfMSP1 19 is allele-
specific, responses to constructs representing the two alternative sequences were 
directly compared. I found that PfMSP1 19-specific antibodies in human sera tend to 
recognise epitopes which are conserved or cross-reactive between variant 
sequences. Although occasional sera were shown to contain two separate, non-
cross-reacting populations of antibodies, the majority of positive sera clearly 
recognise an epitope which is conserved or cross-reactive between the two 
sequences. A few sera contain antibodies which appear to bind with higher avidity 
to one sequence of the protein than to the other sequence. This was particularly 
apparent when antigens which differed in the sequence of the second EGF-like 
motif (where there are three amino acid differences) were compared, suggesting 
that there is a minor epitope in the second EGF-like motif which involves the 
dimorphic residues. In contrast, substitution of glutamate for glutamine in the first 
EGF-like motif has very little affect on recognition by human antibodies. In this 
respect, human antibodies differ substantially from murine mAbs (such as 111.4) 
which recognise epitopes involving dimorphic amino acid residues. This cross-
reactivity bodes well for the development of a malaria vaccine which could provide 
protection against all variants of the parasite. 
However, Udhayakumar eta! (1995) claim that variant epitopes in PfMSP1i 
result in differential recognition by some malaria-exposed sera; actually, only 7 of 
the 65 individuals tested in ELISA did not cross-react between the two prototype 
sequences (E-TSR; MAD20 and Q-KNG; Wellcome) of PfMSP1 ig. Data presented 
here demonstrate that individuals are almost always antibody positive for the two 
allelic forms, but may have a higher OD to one allelic form. 
Antibody responses to PfMSP1 19 and Well-42 are highly correlated. This 
suggests that the majority of Well-42's recognition is due to conserved epitopes 
within PfMSP1ig. Serum from 74% of adult donors aged 16 years and above 
contained antibodies which recognised the Well-42 construct and 60% of adult sera 
recognised the double EGF-like motif. Therefore only 14% of adults exclusively 
recognised dimorphic epitopes in Well-42. However as the Well-42 construct 
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represents the allele which is not commonly expressed in The Gambia this is, 
perhaps, not surprising. 
Individuals that recognise the Wellcome PfMSP142 but not PfMSP1 19, may 
have been exposed to parasites expressing the Wellcome PfMSP1 allele. On the 
other hand they may recognise conserved or cross-reactive epitopes within the 
PfMSP133 part of Well-42. However, there are clearly epitopes within PfMSP133 
that are not cross-reactive between the two dimorphic sequences, as almost 90% of 
individuals were seropositive for epitopes within the MAD20 PfMSP133. This data 
confirms that the dimorphic region of PfMSP133 is immunodominant and that the 
Well-42 construct under-estimates antibody prevalence to PfMSP142 in The 
Gambia. This is in agreement with observations by Hui and Chang (Hui et al 1992, 
1993) who suggest that antibodies to the dimorphic PfMSP133 are not cross-
reactive while antibodies to the conserved PfMSP1 19 are. 
It has been suggested by Fruh etal (1991) that antibody responses to 
PfMSP1 are strain-specific, however their data do not really support this conclusion. 
They showed that there is an unequal distribution of the two allelic forms of PfMSP1 
in Mali, as none of the eight parasite isolates tested expressed the Wellcome allele. 
Accordingly, they found that Wellcome recombinant proteins were not well 
recognised by this population. A recombinant protein representing the Wellcome 
C-terminal region, including PfMSP1 19, was recognised by this population, but only 
at a low prevalence; this was assumed to be due to infrequent exposure to 
Wellcome-type parasites. However, I would speculate, from my own observations, 
that if they had measured antibody responses to a MAD20 version of PfMSP1 19, 
they would have found a similar (low) level of responsiveness as for their Wellcome 
PfMSP1 19 construct. 
Another area of confusion is whether or not antibody responses to PfMSP1 
are transient or long-lived. Data presented here show that antibody responses to 
the C-terminus of PfMSP1 are not stable in children but are very stable in adults. 
My data show that antibody prevalence varies with season in children but stabilises 
in adults, with little seasonal variation in immune individuals over the age of 18 
years. In Mali, it has been reported that the prevalence of anti-PfMSP1 responses 
increases in the wet (transmission) season and declines in the dry season (Fruh et 
al 1991). The authors conclude, therefore, that antibody responses are short-lived. 
However, closer analysis of their data indicates that (1), changes in antibody 
prevalence occur only for children and only for antibody to dimorphic epitopes and 
(2), that approximately half of the children remain seropositive from one wet season 
to the next. The data is not divided into small age groups, so it is not possible to tell 
whether the stable responses are seen in older children, but from my data, I would 
predict that this might be the case. 
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Riley et a! (1993) carried out a similar study of antibody prevalence through 
a malaria transmission season in adults. It was found that antibody responses to 
native PfMSP183 or Well-42 did not fluctuate during the year. There was a slightly 
higher OD response in the wet season than in the dry season, but these differences 
were not significant. When antibody responses to native PfMSP183 and Well-42 
(Riley eta! 1993) were compared at the end of the rainy season in 32 rural and 29 
urban dwellers, it was found that mean levels of antibody were slightly higher in the 
rural group, but again these differences were not significant, despite the difference 
in the parasite transmission rates between the two environments. This implies that 
in adults, intermittent exposure to infection may be sufficient to maintain serum 
antibody titres. 
In contrast, Brown et al (1991) demonstrated that the half life of antibodies to 
the N-terminus of PfMSP1 in non-immune soldiers, recovering from their first 
malarial infection, is less than one month. The pattern of antibody responsiveness 
in these non-immune adults is similar to that in Gambian children. Thus, it seems 
that effective long-term memory responses to PfMSP1 19 develop only after 
repeated exposure to malaria. 
This study also indicated that some adults remain persistently non-
responsive to essentially conserved C-terminal PfMSP1 antigens over the three 
years, despite life-long exposure. Also, in some children antibody responsiveness 
to MAD-19 was not boosted during the rainy season even though boosting 
occurred for MAD-33. To determine whether persistent non-responder status is 
genetically determined, the effects of HLA class II genes and non-HLA genes on 
antibody responsiveness were examined. However, no significant associations 
were found. This confirms previous studies indicating that immune responses to 
PfMSP1 are not HLA restricted (Guttinger eta! 1991, Riley eta! 1992b). 
The reason why 40% of adult donors from the cross-sectional study did not 
possess antibodies to PfMSP1 19 is not known. All donors are known to have been 
exposed to malaria over many years and had high titres of antibody to malaria 
schizonts. Analysis of the data with respect to the known HLA class II genotype or 
non-HLA genes of the donors does not indicate that the response to PfMSP1 19 is 
genetically restricted. It is possible that the seronegative donors may have antibody 
to other regions of PfMSP1 which inhibit the formation of antibodies to PfMSP1 19. 
Steric interference has been demonstrated between mAbs binding to apparently 
distant PfMSP1 epitopes (Wilson et a! 1987) suggesting that the N-terminal region 
of PfMSP1 may physically obscure PfMSP1 19 in the native protein. An alternative, 
but unlikely, explanation is that seronegative individuals may not have been 
recently infected with malaria and, in the absence of boosting, antibody may have 
fallen below detectable levels. 
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Another possibility for the selective antibody responsiveness to PfMSP1 19 is 
clonal imprinting, or original antigenic sin. The term 'original antigenic sin' 
describes the phenomenon where higher affinity antibodies are produced to strains 
(of an infecting agent) seen prior to the vaccinating strain. In a primary infection, 
naive T and B cells proliferate and transform into memory cells. Memory B cells 
have a higher avidity for antigen than do naive B cells as they express more surface 
Ig (sig) and somatic mutation of Ig genes results in expression of slg of higher 
affinity (Vitetta etal 1991). On secondary infection, these memory B cells compete 
successfully with naive B cells for antigens which cross-react with the original 
infecting strain, so antibodies of the original infecting specificity are produced. 
Epitopes which were not present in the original infection, or which induced memory 
cells of low affinity, are effectively ignored. 
There are many features of malaria infection which make clonal imprinting a 
possible explanation for the selective antibody responses seen in malaria-immune 
individuals, 1) malarial antigens are made up of conserved, semi-conserved and 
polymorphic epitopes (McCutchan et a! 1988), so cross-reactive immune 
responses would be expected, 2) people are infected many times with malaria, and 
polymorphism within malaria parasites is extensive, so it is highly likely that 
successive infections would be of differing genotypes, and 3), in clinically immune 
individuals, blood stage infections are of very low density so that competition for 
antigen may occur between B cells of differing affinity. If for some reason, 
PfMSP11 is not very antigenic and/or induces low affinity antibody, it may be 
ignored in favour of immunodominant regions. High affinity responses would be 
boosted and low affinity responses would eventually be lost. 
Other possible explanations for the low prevalence of anti-PfMSP1 19 
antibodies include conformational changes in the protein after secondary 
processing, such that antibodies raised against unprocessed PfMSP142 can no 
longer bind the cleaved PfMSP133 and PfMSP119. This secondary processing may 
have destroyed epitopes and created new epitopes through confirmational 
changes. So there may be a different repertoire of antibodies recognising 
PfMSP142 from those that recognise PfMSP133 and PfMSP119. 
Similarly, infrequent recognition of the EGF-like motifs by immune sera may 
be a functional consequence of the processing of PfMSP1. Although the initial 
processing of PfMSP1 occurs during the later stages of schizogony, such that 
mature merozoites carry only the processed version of PfMSP1, the secondary 
processing which cleaves PfMSP142, producing the membrane bound PfMSP11 
and PfMSP133 which is shed, seems to occur immediately prior to merozoite 
invasion (Blackman et a! 1991 b). Thus PfMSP1 19 may only be exposed to the 
immune system for a very short period of time. The protease responsible for this 
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secondary processing is parasite-derived and the cleavage site is within a highly 
conserved region of the molecule, suggesting this secondary processing is under 
functional constraint (Blackman et a! 1992, 1993). A possible function of PfMSP1 33 
could be to provide protection of PfMSP1 19 from the immune system, by for 
example physically shielding it, or by providing epitopes with high affinity for B cells, 
thereby diverting antibody responses away from PfMSP119. However, I found that 
antibody responses to MAD-19 do not negatively correlate with antibody responses 
to MAD-33 (data not shown). 
The merozoite invasion rate of RBCs is very low (Dr. N. Brown, NIMR, 
personal communication). If those merozoites which failed to invade RBCs have 
processed PfMSP119 on their surface, then the immune system will be extensively 
exposed to this protein. If, on the other hand, the reason for these merozoites' 
failure to invade RBCs is because they have not undergone secondary processing, 
these merozoites will not have processed PfMSP1 19 exposed on their surface. 
In conclusion, for whatever reason, life long exposure to the conserved 
protein, PfMSP119, can be insufficient to induce an antibody response. The low 
positivity rate is unlikely to be due to polymorphism of protective epitopes since 
most sera tend to recognise epitopes which are cross-reactive between the two 
prototypes. PfMSP1 19 is recognised less frequently and less rapidly than other 
merozoite proteins (for example PfMSP2, R. Taylor et a!, in press), suggesting that 
PfMSP1 19 is not particularly immunogenic. If this is due to a lack of exposure to 
epitopes within the processed PfMSP119, then immunisation with a recombinant 
protein may induce a significantly better antibody response than that induced by 
native protein during natural infection. There is evidence from mouse models that 
experimental vaccination with recombinant proteins does indeed induce a 
qualitatively and quantitatively better protective response than that induced with 
native MSP1 (Ling eta! 1994). The fact that the naturally immunodominant 
epitopes within PfMSP1 19 are cross-reactive between the two prototypes of the 
protein suggests that if a protective vaccine based on PfMSP1 19 could be 
produced, it would protect against all strains of P. falciparum. 
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CHAPTER FIVE: 
Characterisation of the biological significance of 	C-terminal 
PfMSP1-specific antibodies 
Introduction 
The preceding chapter describes the prevalence of antibodies to epitopes 
within the C-terminus of PfMSP1. However, the presence of antibodies to 
malarial antigens does not necessarily correlate with protective immunity 
(examples; Druithe and Khusmith 1987, Riley eta! 1992a). Individuals who 
develop clinical symptoms of malaria may have high levels of antimalarial 
antibodies. A more accurate way to identify the antibody responses involved 
in protective immunity is to assess the quality rather than the quantity of the 
antibody produced to malarial antigens. Thus, the next logical step in 
evaluating antibody responses to PfMSP119 was to assess the biological 
function of the antibody produced. 
The EGF-like motifs are found in MSP1 in all species of malaria 
parasites sequenced to date (David et a! 1984, Lewis 1989, Deleersnijder 
eta! 1990, del Portillo et al 1991), suggesting that the structure is under 
some functional constraint. Many proteins containing these EGF-like motifs 
are involved in cell surface interactions such as receptor binding, protein 
adhesion, or signalling (Appella eta! 1988, Engel 1989). If PfMSP119 fulfils 
one of these functions, this would explain why the structure is conserved. 
There is evidence to suggest that the EGF-like motifs are an important 
target of protective immunity. In studies using the rodent malaria models P. 
yoelii and P. chabaudi, three MSP1-specific mAbs (Py302, PccNIMP23 and 
Pca5C1 0/66) passively protected mice against challenge infection with 
homologous blood-stage parasites (Boyle et a! 1982, Majarian et a! 1984, 
Lew eta! 1989à). Two of these mAbs (Py302 and PccNIMP23) bind to 
epitopes within the EGF-like motifs (Burns eta! 1988, Burns eta! 1989a, 
McKean eta! 1993a). Mice immunised with this cysteine-rich region of P. 
yoelii MSP1, expressed as a fusion protein in E. coil, were partially or 
completely protected against challenge infection with P. yoelii parasites 
(Daly and Long 1993, 1995, Ling eta! 1994). Additionally, all PfMSP1-
specific mAbs which inhibit the growth of the parasites in vitro (Pirson and 
Perkins 1985, Blackman et a! 1990, Cooper et al 1992) have been shown 
to bind to conserved, conformation-dependent epitopes within PfMSP119 
(McBride and Heidrich 1987, Cooper et a! 1992, Chappel and Holder 1993, 
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Burghaus and Holder 1994). Finally, serum from rabbits immunised with a 
correctly folded, insect cell-expressed, PfMSP142 protein (but not with an 
identical but incorrectly folded yeast cell product) completely inhibited P. 
falciparum growth in vitro (Chang et a! 1992). The biological activities of 
these PfMSP142-specific antibodies were cross-reactive as sera inhibited 
the in vitro growth of homologous and heterologous parasites with equal 
efficiency (Hui eta! 1993). 
Native, recombinant and synthetic polypeptides representing 
PfMSP1, or fragments of it, have been shown to induce partial or complete 
protection, from subsequent homologous and heterologous challenge 
infection in monkeys (Hall et a! 1984a, Perrin et a! 1984, Cheung et a! 
1986, Patarroyo et a! 1987a, 1987b, Siddiqui et a! 1987, Holder et a! 1988, 
Herrera et a! 1990, Rodriguez et a! 1990, Etlinger et a! 1991, Herrera et a! 
1992, Kumar et a! 1995). In one study, carried out by Hui and Siddiqui 
(1987), where Aotus monkeys were vaccinated with mAb affinity purified 
native PfMSP1, complete protection from an otherwise lethal challenge was 
obtained. The mAb used to purify native PfMSP1 is specific for a 
conformational epitope within PfMSP142, so the antigen preparation will 
have been highly enriched for the C-terminal processing fragment. Kaslow 
and co-workers immunised Aotus monkeys with a yeast recombinant 
protein representing PfMSP1 19 which completely protected two of the four 
monkeys from a lethal challenge infection. A third monkey had a prolonged 
prepatent period but eventually required treatment, the fourth monkey was 
unprotected (Kumar et a! 1995). In the Siddiqui study, a correlation was 
seen between protection in PfMSP1-immunised monkeys and the ability of 
their serum antibodies to inhibit parasite growth in vitro; such a correlation 
was not seen in the Kumar study. 
In collaborative work, Dr. R. Ballou (Walter Reed Army Institute of 
Research, Washington DC, USA) and Dr. A. Holder have immunised Aotus 
monkeys with an E. co!i-derived, P. falciparum double EGF-like motif GST 
fusion protein (Well-19/GST). No protection was observed in any of the 
animals, relative to the GST controls, for either homologous or heterologous 
challenge infections. 3 of the 8 monkey sera were able to inhibit parasite 
invasion of RBCs in vitro (Burghaus et a!, manuscript in preparation). 
Although the antigenic specificity of the antibody produced will be 
important for protection, i.e. directed to protective epitopes, the functional 
capacity of this antibody can be compromised if it is not of a suitable 
subclass for the function required from it. Studies have shown that, when 
exposed to malaria infection, non-immune donors produced predominantly 
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non-cytophilic IgG2 antibodies but that immune adults have high levels of 
cytophilic antimalarial IgGi and IgG3 antibodies (Wahlgren eta! 1983, 
Bouharoun-Tayoun and Druilhe 1992). Bouharoun-Tayoun and Druilhe 
have shown that antibodies of different lgG subclass can have the same 
epitope specificity and suggest that competition for epitope-binding can 
cause a blocking effect, where non-cytophilic classes (lgG2 and 1gM) 
preferentially bind to the epitope preventing the binding of cytophilic (and 
presumably functional) antibodies (lgGl and lgG3). They suggest that the 
long time taken to develop effective antimalarial immunity may correspond to 
a progressive modification of the immune response from non-protective 
antibody to protective antibody. They have previously shown that 
antibodies, by themselves, are unable to directly limit parasite growth, but 
act indirectly by stimulating blood monocytes via their Fc receptor after 
binding to their parasite target (Bouharoun-Tayoun et a! 1990). They found 
that lgG from immune people co-operated efficiently with monocytes while 
lgG from non immunes did not. 
In this chapter I report experiments to determine the biological 
function of human and monkey polyclonal antibodies to PfMSP119; 
1)1 have performed competition ELISAs to investigate whether human sera 
and vaccinated monkey sera recognise the same epitopes as growth 
inhibitory mAbs; 
2)1 have characterised human anti-PfMSP1i-specific and anti-PfMSP133 
antibodies in terms of their lgG subclass; 
3) I have affinity selected antibodies from pooled adult malaria-immune lgG 
to the double-motif and to the second EGF-like motif of PfMSP119 to 
determine whether antibodies to this region are able to inhibit the in vitro 
parasite invasion of RBCs either directly or in a cell-mediated, antibody-
dependent manner. 
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Methods and materials 
Antigens 
Recombinant proteins used in this study have previously been described in 
chapter 2. E. co/i-derived GST fusion proteins representing the first EGF-like 
motif of Wellcome (Well-EGF1) and MAD20 (MAD-EGF1) sequences of 
PfMSP1 ig, the second EGF-like motif of the MAD20 PfMSP1 i (MAD-EGF2), 
the double EGF-like motif of the Wellcome PfMSP1 19 (Well-19/GST) with 
GST cleaved and uncleaved and, the MAD20 PfMSP133 (MAD-33), were 
used. 
Sera 
Human sera from the age cross-sectional survey, previously described in 
chapter 4, were used. 
Monkey sera was obtained from 14 Aotus monkeys. Three monkeys 
had undergone a malaria infection and had been drug cured. Three 
monkeys had been immunised with GST-cleaved PfMSP11 (Well-19/GST) 
and underwent a homologous challenge infection with the FVO strain of P. 
fa/ciparum (Wellcome-like). Three monkeys were immunised with Well-
19/GST and underwent a heterologous challenge infection with the CAMP 
strain of parasites (MAD20-like). Five monkeys were immunised with GST 
and challenged with either FVO or CAMP parasites. Sera was collected 
prior to immunisation (Burghaus et al manuscript in preparation). 
MAbs 
The following PfMSP119-specific.murine mAbs were used: 2.2, 7.5, 12.8, and 
12.10 (McBride and Heidrich 1987); 111.2 and 111.4 (Holder et al 1985); 
5131 (Pirson and Perkins 1985); and 14-1C (R. Reese, Agouron Institute, La 
Jolla, California), see table 2.1. 
ELISA 
Previously described in chapter 4. 
Titration ELISAs of affinity purified lgG and vaccinated 
monkey sera 
Monkeys were immunised at day 1, 30 and 60 and challenged at day 67 
with 105 parasitised ABCs (Burghaus et al manuscript in preparation). Each 
dose contained 74mg of Well-19/GST or 40mg of GST in liposome adjuvant 
absorbed to alum prior to injection. Sera were collected prior to challenge 
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infection (on day 67). Monkeys were challenged with either homologous 
(Wellcome-like [FVO]) or heterologous (MAD20-like[CAMP]) parasites. 
To assess the purity, specificity and titre of affinity selected lgG to the 
first, second- and double-motif proteins, all the antibodies were titrated from 
high to low concentrations on Well-EGF1, MAD-EGF2, cleaved Well-19/GST, 
and GST. The rest of the ELISA was performed as previously described in 
chapter 4. 
MAb competition ELISAs 
Competition ELISAs were performed to determine whether epitopes 
recognised by human antibodies or monkey sera were similar to those 
recognised by murine mAbs. To see if the human and monkey antibodies 
could inhibit binding of the mAbs, plates coated with cleaved Well-19/GST, 
were first incubated with varying concentrations of serum. After extensive 
washing, mAb (at a dilution which results in an OD just at the top of the 
sigmoidal titration curve) was added to the plate, incubated for 3 hours and 
developed with HRP-anti-mouse lgG and OPD. The reciprocal experiment 
was also performed to see if mAbs could inhibit binding of the sera. In this 
case, antigen coated plates were first incubated with varying concentrations 
of mAb, then with serum and, finally, with HRP-anti-human lgG. Anti-human 
lgG cross-reacts with Aotus lgG: OD values for HRP-anti-human lgG and 
anti-Aotus lgG were identical for monkey sera (data not shown); I was 
therefore able to carry out all ELISAs with anti-human lgG. 
Purification of human IgG 
Human IgG, derived from clinically immune adults from The Ivory Coast 
where malaria is endemic, was kindly provided by Dr. P. Druilhe (Institut 
Pasteur, Paris, France). 400-500m1 of blood was collected from 333 adults 
- aged 19-23. IgG was separated by the Cohn ethanol method and further 
treated by mild pepsin digestion at pH 4.0 (Sabchareon eta! 1991). 
European IgG, from heat inactivated sera of healthy blood group A+ donors, 
provided by Dr. A. Holder, was used as a negative control (Eur-IgG). 
Affinity purification of PfMSP119 double-motif and second 
EGF-like motif-specific IgG 
lgG was affinity purified on PfMSP119 fusion proteins immobilised on an 
insoluble matrix (Harlow and Lane 1988). Purified fusion protein (30mgs of 
MAD-EGF2 or lomgs of Well-19/GST) was bound to cyanogen bromide 
activated Sepharose (Pharmacia) at 2mg of protein/ml swollen gel, 
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according to manufacturer's instructions. Purified total-lgG was passed over 
a MAD-EGF2 and then a Well-19/GST affinity column at a rate of 30ml/hour 
for three hours (this total-lgG had previously been passed over a Well-EGF1 
column by Dr. J. Chappel). lgG which passed through both columns, and 
therefore was regarded as being non-PfMSP1 19-specific, was collected 
(void-lgG). The column was washed over night in 100mM, then 10mM, Tris-
HCI pH 8.0. Bound lgG was eluted from each column separately with two gel 
volumes of 100mM glycine pH 2.5 into 1/10 final volume 1M Tris-HCI pH 8.0, 
to restore neutral pH (OD's of eluate samples were measured by 
spectrophotometer; elution ceased when OD reached a base level).The 
columns were then washed with 100mM Tris-HCI pH 8.0 with 0.02% (w/v) 
azide to regenerate the column and stored at 4°C. 
Eluted lgG was dialysed into 100mM Tris-HCI pH 8.0 and then 
concentrated to 1-2mg/mi in an ultrafiltration unit (Amicon, PM10 filter). lgG 
purity was assessed by analysis of Coomassie blue stained SDS PAGE 
gels, and lgG yield was quantified assuming that 1 mg/ml lgG equals an OD 
of 1.4 at A280 (Harlow and Lane 1988). 
The following prefixes will be used; 'total-' refers to the total lgG 
present before the affinity purification; 'AP-' refers to the affinity purified IgG 
to a specific antigen; 'void-' refers to the remaining IgG after depletion of lgG 
specific to the PfMSP119 antigens; 'Eur-' refers to European control lgG. 
(9) In vitro parasite culture 
P. falciparum clones 3D7 and Ki were maintained in 0+ RBCs at 6% 
haematocrit in complete RPMI (RPMI 1640 medium [Gibco] supplemented 
with 25mM HEPES, 24mM NaHCO3, 25mg/mi gentamicin, 50g/l 
hypoxanthine, 10% [v/v] human 0+ serum). Culture medium was changed 
daily. Cultures were grown in a CO2 incubator at 37°C. Thin blood film 
smears (methanol fixed and Giemsa stained) were made daily. Parasite 
cultures were synchronised by a combination of sorbitol which effectively 
kills all stages apart from the 'rings' (Lambros and Vanderberg 1979) and 
percoll (Sigma) (Holder and Freeman 1982) when appropriate. 
(1 0) In vitro parasite invasion inhibition assay and 
antibody-dependent cellular-inhibition assay 
Test lgG's were dialysed into incomplete RPM I, under sterile conditions, to 
give a concentration of 2mg/mi in 0.5m1 final volume. The antibodies were 
filter sterilised (0.2pm pore size, micro-centrifuge tube filter, Whatman) 
before being aliquoted into 96-well round bottomed microtitre plates. 3D7 
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and Ki late trophozoites/early schizonts were purified, from high 
parasitaemia cultures, and diluted with RBCs to give a 1% parasitaemia and 
4% haematocrit. Parasites were purified on a 60% percoll gradient where 
'segmenters' are retained in the top band. 
Test lgG's were used at three concentrations; 1mg/mi, lOOpg/ml and 
lOpg/ml (final concentration in the well). Control wells contained either 5mM 
EGTA, pH8.0, final concentration, or complete RPMI only. EGTA at this 
concentration effectively inhibits merozoite invasion of RBC5 (McCallum-
Deighton and Holder 1992). Double the final concentration of the test lgG or 
EGTA in (50pl complete RPMI) was added to each well. To this was added 
50pl of the parasite/ABC mix to equal a final concentration of 0.5% 
parasitaemia and 2% haematocrit. Late trophozoites/early schizonts were 
used to be certain that no schizonts had ruptured and invaded new ABCs 
before being added to the test wells. 
Antibody-dependent cellular inhibition assays (see figure 5.1. for 
schematic diagram of this assay) were run in parallel to the invasion 
inhibition assays, where adherent mononuclear cells from healthy European 
blood donors were added to wells containing test lgG plus schizonts and 
RBCs: lOpI of 1x10 7/ml monocytes were added to each well, i.e. 105  cells 
per well. (1Op1 less of complete RPMI was added to these wells to equal a 
final volume of lOOpi/well as before.) Control wells contained monocytes, 
parasites and RBCs without antibody. 
Each test was performed in four identical wells. After 36 hours 
growth, at 37°C in a CO2 incubator, duplicate thin blood smears were made 
from each well of the invasion inhibition assay. Smears were made after 4 
days for the antibody-dependent cellular-inhibition assay. The final 
parasitaemia was determined by microscopic examination of the number of 
ring stage parasites within 35 fields or approximately, on average, 2000 
RBCs per methanol-fixed, Giemsa-stained smear. Multiple ring parasites 
within one RBC were recorded as a single infected cell. 
(11) ELISA to determine lgG subclass 
ELISA assays were performed as usual except that monoclonal, subclass-
specific, mouse anti-human lgG was used as the second step reagent. 
Subclass-specific assays were optimised by titration (by Dr. A. Taylor, 
University of Edinburgh, UK), such that the titration curves for each reagent 
were co-incident: i.e. that for a given absolute concentration of IgGi, lgG2, 
lgG3 or lgG4, the same OD value was obtained. The reagents used were 
mouse monoclonal anti-human lgGl(1 :2000; code 1170317; Boehringer, 
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Mannheim, Germany), IgG2 (1:500; code 1170309; Boehringer), IgG3 
(1:1000; code MCA516; Serotec, Oxford, UK) and IgG4 (1:500; code 
1170287; Boehringer). 
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Figure 5. 1. Schematic diagram of antibody-dependent cellular-inhibition assay. 
A 96-well microtitre plate contains human peripheral blood monocytes, 
uninfected RBC5, parasitised RBCs (and subsequently merozoites), and lgG 
antibody. Merozoites express PfMSP1 19 on their surface. The Fab fragment of 
the lgG may bind to this antigen, and so expose the Fc fragment to monocytes 
which have Fc receptors on their surface. Monocyte Fc receptors bind the 
antibody bound to the merozoite and either phagocytose the complex, or 
release toxic radicals which kill the parasite. 
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Results 
(1) Characterisation of antibodies which compete with mAb 
binding 
(la) Human polyclonal antibodies inhibit the binding of invasion 
inhibitory mAbs 
In order to determine whether antibodies induced by malaria infection in 
humans recognise the same epitopes as mAbs (one of which, 12.8, inhibits 
merozoite invasion of RBCs), competition ELISAs were performed. Three 
mAbs were tested: 111.4 recognises Well-EGF1; 12.8 and 14-1C both 
recognise conserved epitopes in the first EGF-like motif (Well-EGF1 and 
MAD-EGF1) (Chappel and Holder 1993, Burghaus and Holder 1994). 
Results are summarised in table 5.1. 
Four human sera with high titres of antibodies to PfMSP119 were 
tested and all were able to block the binding of all three mAbs in a dose-
dependent manner (figures 5.2.a. and c. show two examples) indicating that 
the epitopes recognised by these mAbs are also recognised by human sera. 
However, in the reciprocal experiments, mAbs were not able to block 
binding of human antibodies (figures 5.2.b. and d.) suggesting that human 
sera recognise many epitopes in addition to those recognised by mAbs. 
(ib) Characterisation of serum from PfMSP119-vaccinated 
monkeys by ELISA 
Sera from immunised monkeys were assessed in ELISA to determine the 
specificity of the antibodies to epitopes within PfMSP1 19. The titres of 
PfMSP1 19-specific antibodies in the monkey serum samples were 
determined on the E. co/i-derived, cleaved Well-i 9/GST, (figure 5.3.). All 
Well-1 9/GST-vaccinated monkey sera (except number 11) gave very similar 
titration curves and had end point titres of >1/48,000 to PfMSP119. There 
were no differences in antibody titre in monkeys who were given a 
homologous challenge compared to those given heterologous challenge. 
One vaccinated monkey (number 11) had a significantly lower antibody titre 
with an end point titre of 1/6000. Also included were three unvaccinated 
monkeys which had undergone malarial infection and been drug cured, and 
so would be expected to be immune on rechallenge (Diggs eta! 1995). 
These monkeys had the lowest antibody titres (<1/3000) to PfMSP1 19, with 
one monkey (number 12) almost seronegative for PfMSP119. Five monkeys 
were vaccinated with the GST fusion partner of the protein alone (monkeys 
1,2,3,7,8), and had no PfMSP1 19-specific antibodies. 
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human serum 
50% reduction in OD for 	- 
mAb 14-1C 
50% reduction in OD for 
mAb 111.4 
50% reduction in OD for 
mAb 12.8 
on Well-EGF1 on MAD-EGF1 on Well-EGF1 on MAD-EGF1 on Well-EGF1 on MAD-EGF1 
1001 1/1500-1/3000 1/750+ 1/1500-1/3000 - 1/6000 1/750-1/1500 
1120 1/1500-1/3000 1/750+ 1/1500 - 1/6000 1/500-1/750 
1019 1/400-1/800 1/200 1/100+ - 1/200-1/400 - 
1189 1/750+ 1/750+ 1/750+ - 1/750-1/1500 1 	1/750-1/1500 
Table 5. 1. Human antibodies block the binding of PfMSP1 19-specific mAbs to recombinant PfMSP1 19. 
4 human sera were tested at varying concentrations. The concentration of serum which resulted in a 50% decrease in OD of the mAb is shown. 
N 
Figure 5.2. Competition ELISAs. 
Human serum 1120 was able to inhibit the binding of mAbs in a dose-dependent manner,' but 
mAbs were not able to inhibit binding of human antibody. 
Serum 1120 inhibits binding of mAb 111.4 (mAb 111.4 recognises only Well-EGF1). 
MAb 111.4 does not inhibit binding of serum 1120. 
C) Serum 1120 inhibits binding of mAb 14-1C. 
d) MAb 14-1C does not inhibit binding of serum 1120. 
0, Well-EGF1 ,D, MAD-EGF2. 
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1/0.375 	1/0.750 	1/1.5 	1/3 	1/6 	1/12 	1/24 	1/48 
monkey sera dilution 
(xl 0) 
Figure 5.3. Titration of monkey sera on cleaved Well-1 9/GST. 
Titrations were carried out to determine the serum dilution needed to obtain an OD at the top of 
the sigmodial titration curve for subsequent competition ELISAs. 
monkeys 4, 5, 6 = vaccinated heterologous challenge infection 
monkeys 9, 10, 11 = vaccinated homologous challenge infection 
monkeys 12, 13, 14 = infected and cured 
monkeys 1,2,3,7,8 = GST control infection 
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(ic) Sera from PfMSP11-vaccinated monkeys compete with 
protective mAbs for antigen binding 
All 14 monkey sera were assayed for their ability to block the binding, to 
cleaved Well-19/GST, of mAbs 12.8 and 12.10 which are invasion inhibitory; 
111.2 which does not inhibit invasion; and 2.2 and 7.5 which block the 
invasion inhibitory effect of 12.8 and 12.10. Results are summarised in table 
5.2. 
MAb 12.10 recognises the double EGF-like motif. The sera from 
vaccinated monkeys are able to compete out the binding of this mAb, but 
only at very high serum concentrations (1/25-1/50), (figure 5.4.a.). 
MAb 12.8 recognises the first EGF-like motif. The sera from 
vaccinated monkeys are able to compete out the binding of this mAb, (figure 
5.4.b.); inhibition begins at a dilution of around 1/250 (compared to 1/50 for 
mAb 12.10). Serum number 11, which had a low titre to Well-19/GST, 
began to compete with mAb 12.8 at a higher concentration than the others, 
but resulted in a similar level of inhibition at a dilution of 1/25; i.e. reduction 
in OD from 2.5 to background level of 0.5. 
Serum from the vaccinated and challenged monkeys competed out 
the binding of the mAbs more effectively than the infected and cured monkey 
sera. Infected and cured monkey sera had little effect on either 12.8 or 12.10 
mAb binding, except for monkey number 13 which resulted in approximately 
a 40% reduction in OD at 1/25 sera dilution for both mAbs. 
The monkey sera were also tested for their ability to inhibit the binding 
of a non-invasion inhibitory mAb (111 .2), and two mAbs which have been 
shown to block the inhibitory affect of 12.8 and 12.10 (2.2 and 7.5). For mAb 
111 .2, once again the sera from the vaccinated monkeys caused the 
greatest reduction of mAb binding. Sera from monkeys given a homologous 
challenge caused inhibition at a lower concentration than did sera from 
monkeys given heterologous challenge (figure 5.4.c.) suggesting that this 
mAb epitopé includes a dimorphic amino acid residue. Sera from infected 
and cured monkeys inhibited binding of mAb 111.2 but at much higher 
concentrations than for vaccinated animals and serum 12 caused no 
reduction in mAb binding. 
In the case of mAb 2.2, homologous challenged monkey sera 
competed at lower concentrations than the heterologous challenged 
monkeys, but both vaccinated groups totally inhibited mAb binding at higher 
concentrations (figure 5.4.d.). Infected and cured monkey sera were unable 
to inhibit this mAb from binding. Inhibition of mAb 7.5 binding by the monkey 
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mAb 12.10 mAb 12.8 mAb 111.2 mAb2.2 - 	mAb7.5 
treatment monkey beginning of % decrease beginning of % decrease beginning of % decrease beginning of % decrease beginning of % decrease 
sera inhibition in 00 at inhibition in OD at inhibition in 00 at inhibition in 00 at inhibition in 00 at 
number  1/25 dilution  1/25 dilution  1/25 dilution  1/25 dilution  1/25 dilution 
4 1/50- 67 1/250- 100 1/500- 60 1/250- 100 1/25- 11 
1/250 1/500 1/2500 1/500 1/50 
vaccinated 5 1/50- 50 1/500- 96 1/500- 56 1/500- 93 1/500- 48 
heterologous 1/250 1/2500 1/2500 1/2500 1/2500 
challenge 
6 1/50- 78 1/250- 87 1/500- 100 1/500- 91 1/500- 75 
1/250 1/500 1/2500 1/2500 1/2500 
9 1/50- 33 1/250- 87 1/250- 64 1/2500- 84 1/500- 44 
1/250 1/500 1/500 1/5000 1/2500 
vaccinated 10 1/50- 73 1/500- 97 1/500- 78 1/2500- 94 1/500- 54 
homologous 1/250 1/2500 1/2500 1/5000 1/2500 
challenge 
11 1/50- 68 1/50- 81 1/250- 78 1/500- 94 1/50- 33 
1/250 1/250 1/500 1/2500 1/250 
12 - 0 - 0 - 0 - 0 1/25- 18 
1/50 
infected 13 1/25- 35 1/25- 43 1/50- 69 1/25- 11 1/50- 90 
and 1/50 1/50 1/250 1/50 1/250 
cured 
14 1/25- 5 1/50- 10 1/50- 34 - 0 1/25- 49 
1/50 1/250 1/250 1/50 
Table 5.2. Vaccinated monkey sera block the binding of PfMSP1 19-specific mAbs to PfMSP1 19 recombinant proteins. 
The lowest concentration of serum which caused some inhibition of mAb binding is shown. 
The % decrease in OD is calculated as OD with 1/25 serum - background 00 
maximum OD (no serum) - background OD 
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Figure 5.4. Competition ELISAs of monkey sera with mAbs. 
Cleaved Well-i 9/GST coated plates were preincubated with monkey sera. Subsequent inhibition 
of binding by mAbs is measured. 
a) mAb 12.10, b) mAb 12.8, c) mAb 111.2, d) mAb 2.2, and e) mAb 7.5. 
monkeys 9, 10, ii = vaccinated homologous challenge infection 
monkeys 12, 13, 14 = infected and cured 
monkeys 1 = GST control infection 
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sera was mixed, with each test group resulting in a high, medium or low 
inhibitory effect (figure 5.4.e.). 
In summary, these experiments show that antibodies competing with 
inhibitory, non-inhibitory and blocking mAbs are stimulated during both 
vaccination and 'natural' infection, although lower antibody concentrations 
and antibody with lower affinity, are produced in 'natural' infection than with 
vaccination (see figure 5.3). 
In the reciprocal experiments, the mAbs were unable to compete with 
the binding of the monkey sera, indicating that the monkey sera contain 
antibodies to a number of epitopes, of which those recognised by these 
mAbs may be only minor components (figures 5.5.a.b.). 
Characterising the human polyclonal IgG subclass response 
to the C-terminus of PfMSP1 
IgG subclass was determined by subclass-specific ELISA for all individuals, 
in the study population who were seropositive to proteins representing 
PfMSP1 19 (see previous chapter). I also measured the IgG subclass of 
antibodies against PfMSP133. 
The lgG response to the PfMSP119 proteins was predominantly of the 
IgGi subclass (figures 5.6.a-d. and table 5.3.). Occasionally individuals 
produced lgG3 antibodies instead of, or as well as, IgGl. The predominant 
IgG subclass did not vary among persons of different ages. However, both 
IgGi and IgG3 antibodies were produced against PfMSP133, with an 
occasional IgG4 response, see figure 5.6.a. 
Invasion inhibition/parasite growth assays 
(3a) Affinity, purification of PfMSP119-specific IgG 
Having shown that some of the human antibody response is similar to the 
invasion inhibitory mAbs 12.8 and 12.10 (section la), I determined whether 
human antibodies can inhibit RBC invasion in vitro, using antibodies affinity 
selected to PfMSP1 19. IgG specific to epitopes within Well-EGF1, MAD-
EGF2 and Well-19 were absorbed on to an affinity column from a sample of 
900mg of lgG. which had been purified from 178 adult inhabitants of The 
Ivory Coast (Sabchareon et a! 1991). Antibody was then eluted off the 
column and used for growth inhibition assays and competition ELISAs. Dr. 
J. Chappel affinity purified antibodies to the first EGF-like motif (APEGF1-
lgG). I used the APEGF1 -lgG-depleted IgG to affinity purify antibodies to the 
second EGF-like motif (APEGF2-lgG) and then to the double-motif protein 
(APi 9-lgG). 
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Figure 5.5. Competition ELISAs of mAbs with monkey sera. 
Cleaved Well-i 9/GST coated plates were preincubated with mAbs. MAbs were unable to inhibit 
the binding of monkey sera. 
a) mAb 12.10 and b) mAb 12.8. 
monkeys 9, 10, ii = vaccinated homologous challenge infection 
monkeys 12, 13, 14 = infected and cured 
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Figure 5.6. Dot plots showing lgG subclass-specific responses. 
Only lgG positive Gambian sera were tested; 24 European sera are shown as controls. All sera 
were tested at a dilution of 1:1000. 
MAD-33; 175 Gambian sera tested. 
MAD-1 9; 54 Gambian sera tested. 
Well-1 9/GST; 52 Gambian sera tested. 
Well-EGF1; 32 Gambian sera tested. 
MAD-EGF2; 24 Gambian sera tested. 
Number and percentage of the sera with lgG subclass antigen specific antibody above the mean 
plus 2 SD of control (malaria non-exposed) sera are shown. 
X, European sera; 0, Gambian sera. 
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n lgGl lgG3 lgG4 lgG1+2 lgG1+3 lgG1+4 lgG2+3 lgG1,2 lgGl,2+ lgGl,3 lgG1,2, 
only only only  +3 4 - +4 3+4 
Well-EGF1 21 14 1 0 0 5 1 0 0 0 0 0 
(66.7) (4.8) (0.0) (0.0) (23.8) (4.8) (0.0) (0.0) (0.0) (0.0) (0.0) 
MAD-EGF2 12 1 7 1 2 0 0 0 0 0 0 1 
(8.3) (58.3) (8.3) (16.7) (0.0) (0.0) (0.0) (0.0) (0.0) (0.0) (8.3) 
Well-19/GST 48 39 1 0.0 1 6 1 0 1 0 0 0 
(79.6) (2.0) (0) (2.0) (12.2) (2.0) (0.0) (2.0) (0.0) (0.0) (0.0) 
MAD-19 49 27 1 1 0 6 6 0 0 2 3 2 
(56.3) (2.1) (2.1) (0.0) (12.5) (12.5) (0.0) (0.0) (4.2) (6.3) (4.2) 
MAD-33 156 38 32 0 1 65 5 1 5 1 7 1 
(24.4) 	1 (20.5) 	1 (0.0) 	1 (0.6) 	1 (41.7) 	1 (3.2) (0.6) 	1 (3.2) (0.6) (4.5) (0.6) 
Table 5.3. lgG subclass response to the C-terminus of PfMSP1. 
lgG subclass antibodies were measured in individuals who were seroposive to each antigen. Figures show the number 
(percentage) of lgG subclass 'responders' to each antigen, indicating how many individuals produced different combinations of IgG 
subclass antibodies. None of the sera contained only lgG2 antibodies. Responders are those where the specific 00 of the lgG 
subclass antibody response to each antigen was greater than the mean plus 2 SD of the control (malaria non-exposed) sera. 
Characterisation of affinity purified human antibodies by 
ELISA 
Affinity selected antibodies were tested in ELISA to demonstrate the 
specificity, and to quantify the amount, of PfMSP1 19-specific antibodies in 
the AP-lgG in comparison with other lgG preparations (figure 5.7.). 
Differences in lgG concentrations were estimated by comparison of the 
parallel titration curves (Kemeny 1992). 
APEGF1-IgG was estimated to contain 100-fold more Well-19/GST-
specific lgG than the void-lgG. APEGF2 and APi 9-lgG contained 10-fold 
more Well-i 9/GST-specific lgG than the void-lgG. 
I also determined the lgG subclass of the PfMSP1 19 affinity 
preparations, and found they contained only IgGi antibodies (ODs above 
background level only for IgGi; APEGF1=1.810, APEGF2=0.938, 
AP19=0.345) (data not shown). 
Affinity purified antibodies compete with protective mAbs for 
antigen binding 
The different lgG preparations were assayed for their ability to block the 
binding of mAbs; 12.8, 12.10 and 5131 which are invasion inhibitory; 111.2 
which does not inhibit invasion; and 2.2 and 7.5 which block the invasion 
inhibitory effect of 12.8, 12.10 and 5131 (figure 5.8.). 
The APEGF1-lgG fraction was able to compete with all of the mAbs 
which bind to the first EGF-like motif (i.e. 12.8, 5131, 2.2 and 7.5) but was 
especially effective at inhibiting 12.8 and 2.2. Inhibition of binding of all 4 of 
these mAbs began at between 2-4pg/ml of APEGF1-lgG. iOpg/ml of lgG 
resulted in 90-100% reduction in OD of mAbs 2.2 and 12.8, but caused only 
a 30% and 20% reduction of mAbs 7.5 and 5131 respectively. This suggests 
that APEGF1 -lgG has a higher affinity for the 12.8 and 2.2 -like epitopes. As 
expected, none of the other lgG preparations were able to inhibit binding of 
these four mAbs. 
AP19-lgG was able to compete with mAbs 111.2 and 12.10 which 
bind to epitopes formed by sequences from both EGF-like motifs (figures 
5.9.a.b.). Inhibition of binding began between 2-4pg/ml of lgG resulting in 
80-100% reduction in OD at 4pg/ml. The other lgG preparations were not 
able to inhibit. 
No mAbs directed to epitopes of the second EGF-like motif were 
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Figure 5.7. Titration of human IgG preparations. 
Titrations were carried out to assess AP-IgG specificity and to determine the IgG concentration of 
each preparation needed to obtain an OD at the top of the sigmodial titration curve for 
subsequent competition ELISAs. 
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Figure 5.9. Competition ELISAs to determine whether affinity purified human lgG preparations 
inhibits binding of mAbs. 
Cleaved Well-19/GST coated plates were preincubated with human lgG. Subsequent inhibition of 
binding by mAbs (at optimal concentration) is measured. 
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Parasite in vitro invasion assay 
Highly synchronous late trophozoites/early schizonts were incubated with 
the various lgG preparations at a parasitaemia of 0.5%. Parasitaemias were 
determined after 36 hours, thus giving parasites ample time to rupture from 
the old RBCs and to allow reinvasion of new RBCs. The parasitaemia might 
be expected to increase approximately six fold in one reinvasion cycle, so 
should equal 3% if no inhibition of invasion had occurred. In the case of the 
Ki strain, parasites grown in complete RPMI, European-lgG, total-lgG and 
void-lgG resulted in a parasitaemia of approximately 3% (table 5.4.). The 
31D7 strain, however, grew much more slowly in culture and only reached a 
parasitaemia of approximately 1.2% in complete RPMI and in European-IgG. 
EGTA was very effective in blocking invasion, resulting in 70-80% reduction 
in parasitaemia. 
Parasites grown in human malaria-immune lgG affinity selected to 
PfMSP1 19 and the second EGF-like motif (but not the first EGF-like motif, see 
Chappel et a! 1993) resulted in significantly lower parasitaemias compared 
to those obtained .for parasites grown in complete RPMI (see figures 
5.10.a.b.). Percentage inhibition of parasite invasion is highly statistically 
significant: PfMSP1 19-specific antibodies were able to inhibit parasite growth 
by up to 70%. Test lgG's were used at three concentrations; 1 mg/ml, 
lOOpg/ml and lOpg/ml. The most highly significant inhibition obtained with 
1 mg/mI of antibody. However, significant inhibition was obtained with as 
little as lOpg/mlof antibody (table 5.4.). 
Antibodies selected to the Wellcome PfMSP1 19 and the MAD20 
second EGF-like motif were equally effective against parasites from either 
PfMSP1 family. The morphology of the remaining parasites was normal on 
Giemsa-stained smears for all cultures, and no agglutinated clusters of 
merozoites were observed, indicating that the antibody was probably acting 
at the level of merozoite invasion. 
Antibody-dependent cellular-inhibition (ADCI) assay 
Results from the ADCI assay are less easy to interpret. There was 
considerable variation between the replicates of each treatment leading to 
wide standard deviations (table 5.5.). In the 31D7 cultures (but not the Ki 
cultures) there was some evidence that the control lgG (void-lgG and Eur-
lgG) preparations actually enhanced parasite growth when compared with 
cultures without lgG, but this was not statistically significant. 
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1 mg/ mI 100p /ml lOpg/ml 
- 
parasitaemia inhibition parasitaemia inhibition parasitaemia inhibition 
European-IgG 3.02+0.89 7.23 2.17+0.84 33.38 2.23+0.51 31.34 
total-IgG 3.08+ 1.83 5.14 2.79+0.68 14.22 2.22+0.55 31.75 
K  void-lgG 2.43+0.75 25.14 2.30+0.32 29.14 2.17+0.52 33.23 
AP-Well-19/GST 1.74 + 0.28** 46.62* 1.43 + 0.46** 56 00** 1.69 + 0.51** 47.91 - 
 
AP-MAD-EGF2 1.37 + 0.22*** 57.94*** 1.73 + 0.66* 46.77* 1.31 + 0.49** 59.60""  
EGTA 0.99 + 0 . 16*** 69 . 3*** 
RPMI 3.25+0.75  
European-IgG 1.07+0.39 11.00 0.94+0.71 21.42 1.23+0.62 +2.33 
total-lgG 0.61 +0.63 48.92 0.70+0.57 41.83 0.80+0.52 33.33 
void-lgG 0.66+0.24 45.00 0.74+0.27 38.03 0.63+0.55 47.50 
3D7 AP-WeIl-19/GST 0.35 + 0 . 24** 71 . 25** 0.47 + 0 . 25** 60 . 58** 0.60 + 0 . 11* 50 . 00* 
AP-MAD-EGF2 0.49 + 0.19 5933**  0.63+0.23 47.92 0.59 + 0 . 21* 50 . 83* 
EGTA 0.26 + 0 . 22** 78 . 3** 
RPMI 	11.20+0.39 1 
Table 5.4. In vitro parasite invasion inhibition assay. 
Percentage parasitaemia (plus SD) and percentage inhibition of parasite growth relative to parasites grown in RMPI only. 
= p<0.005 
** = p<0.02 
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Figure 5.10. Bar chart of invasion inhibition assay. 
Bars on chart represent mean final percentage parasitaemias, error bars indicate the standard 
deviation between parasitaemias for each test sample. 
a) Ki parasites, b) 3D7 parasites. 
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1mg/m1 100p /ml lOpg/mi 
parasitaemia inhibition parasitaemia inhibition parasitaemia inhibition 
European-lgG 1.07+0.59 1.58+0.70 1.62 + 0.71 
total-igG 1.82+0.96 +70.84 1.69 + 1.34 +6.65 1.69+0.72 +4.64 
void-igG 1.36+0.78 +27.10 2.76+0.14 +74.36 1.93+ 1.40 +19.16 
K  AP-Well-19/GST 1.22+0.37 +13.55 1.17 + 0.56 25.76 1.54+0.63 4.51 
AP-Well-EGF1 nd n  0.67+0.22 57.91 1.12+0.35 30.78 
AP-MAD-EGF2 1.71 + 1.22 +60.09 1.05+0.51 33.67 1.61 + 1.37 0.62 
RPMI n  
RPMI+monocytes 1.96+ 1.12  
European-lgG 1.51 +0.39 2.12+0.44 1.62+0.75 
total-IgG 0.39 + 0 . 25*** 74 . 50*** 1.60+ 1.14 24.35 nd nd 
void-lgG 1.30+0.45 13.90 1.19 +0.39 43.97 1.34+0.35 17.56 
3D7 AP-Well-19/GST 0.62 + 0 . 27*** 58 . 94*** 1.49+ 1.11 29.55 0.79+0.09 51.51 
AP-Well-EGF1 nd nd 0.61 + 0 . 36*** 71 . 16*** 0.60 + 0 . 20* 63 . 15* 
AP-MAD-EGF2 1.47+0.55 2.78 1.61 +0.83 23.8 nd nd 
RPMI 0.66+0.23 
RPM1+monocytes 10.90 + 0.51 	1  
Table 5.5. Antibody-dependent cellular -inhibition assay. 
Percentage parasitaemia (plus SD) and percentage inhibition of parasite growth obtained in the presence of different 




In Ki cultures, lOOpg/ml APEGF1-lgG reduced parasite growth by 
approximately 60% compared to Eur-lgG but, due to interassay variation, 
this was not statistically significant (figure 5.11.a.). However, APEGF1-lgG 
inhibited growth of 31D7 by 71 %, this was dose-dependent and highly 
significant (p<0.005) (figure 5.1 1 .b.). Total-lgG and AP1 9-lgG were able to 
significantly inhibit growth of 31D7 (but not Kl) at a concentration of 1mg/mi 
but had no effect at lower concentrations. APEGF2-lgG had no significant 
effect on either K1 or 3D7. 
Therefore, 31D7 seemed to be more susceptible to ADCI reactions 
than Ki. Total-lgG and AP19-lgG were able to mediate ADCI only at 
relatively high concentration whilst APEGF1-lgG was able to mediate ADCI 
at antibody concentrations of 10-100pg/ml. The inhibition by APi 9-lgG may 
be a residual effect of its invasion inhibitory activity. In contrast, APEGF1-lgG 
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Figure 5.11. Bar chart of antibody-dependent cellular-inhibition assay. 
Bars on chart represent mean final percentage parasitaemias, error bars indicate the standard 
deviation between parasitaemias for each test sample. 
a) Ki parasites, b) 3D7 parasites. 
Discussion 
The mechanism of protection against clinical malaria remains unclear, but it 
has been demonstrated that immunity can be passively transferred by the 
administration of lgG from immune adults to young children who have not yet 
developed an effective immune response (Cohen eta! 1961, Edozien eta! 
1962, McGregor et a! 1963). However, the mechanism by which antibody 
protects an immune person from clinical symptoms of malaria is unknown. 
Blackman et a! (1990) suggest that antibody may neutralise the ability of 
merozoites to penetrate erythrocytes by blocking the secondary processing 
Of PfMSP142, which is thought to be a prerequisite for RBC invasion. Or 
perhaps antibody may cause the agglutination of merozoites, at the time of 
schizont rupture, preventing merozoites from invading new RBC5 (Epstein et 
a! 1981, Lyon eta! 1989): anti-PfMSP1 antibodies are found in polyspecific 
sera which mediate the formation of clusters of agglutinated merozoites. 
Perkins and co-workers have demonstrated that unprocessed PfMSP1 can 
bind to ABCs, and that a mAb to PfMSP11 can inhibit this binding, 
suggesting that antibody may inhibit merozoite attachment to RBC5 (Perkins 
and Rocco 1988). Druilhe and Bouharoun-Tayoun (Bouharoun-Tayoun et a! 
1990) have shown that antibodies which have proved to be protective in vivo 
do not directly limit parasite growth but act indirectly by stimulating blood 
monocytes via their Fc receptors after binding to the parasite target. This 
could be tested by comparing lgG Fab fragments with intact 1g. The lack of 
the Fc region would prevent co-operation with monocytes. 
Competition ELISA5 demonstrate that polyclonal, malaria-immune 
human sera can inhibit the binding of mAbs whose epitopes map to either 
single or double EGF-like motif proteins. However, none of the mAbs could 
inhibit binding of human antibodies suggesting that human sera may 
recognise a number of epitopes within PfMSP1 19, only some of which are 
recognised by mAbs. Some of the epitopes which are recognised by human 
polyclonal sera include those recognised by invasion inhibitory mAbs. 
Human polyclonal sera contain antibodies which recognise the same 
epitopes as invasion inhibitory mAbs (12.8 and 12.10) but many sera also 
contain antibodies which recognise the same epitopes as blocking mAbs. 
The same pattern was seen for the vaccinated monkey sera and the affinity 
purified EGF-1 lgG. Presence of both inhibitory and blocking antibody may 
be the reason why sera had no protective effect in vitro, or in vivo (in 
monkeys). 
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It is possible that human polyclonal antibodies with similar biological 
properties to these inhibitory mAbs may be responsible, at least in part, for 
protection observed in vitro. The total-lgG preparation used here had no 
direct inhibitory effect on either parasite growth or invasion in vitro at 
concentrations of 1-5mg/mI (Bouharoun-Tayoun eta! 1990), but was able to 
inhibit parasite growth in vitro in co-operation with monocytes and was very 
effective in vivo, drastically reducing asexual parasitaemia when 
administered to human malaria patients (Sabchareon et a! 1991). 
Antibodies to the first EGF-like motif were affinity purified by Dr. J. 
Chappel. From 900mgs of total-lgG, 2.9mgs of EGF-1 -specific IgG were 
selected by affinity chromatography. Assuming that the APEGF1-lgG was 
wholly specific for PfMSP1 ig, approximately 0.3% of the total-IgG population 
was specific for epitopes within the first EGF-like motif. Similarly, 3.2mgs or 
0.35% of the total-IgG population (once antibodies to the first EGF-like motif 
had been depleted out) was specific for epitopes within the second EGF-like 
motif and 1 .7mgs or 0.2% of the total-IgG (once antibodies to the two single 
EGF-like motifs had been depleted out) was specific for additional epitopes 
within PfMSP1 ig. Taking into consideration the fact that higher-affinity 
antibodies will remain bound to the column during the elution process 
(Chappel et a! 1993), the results suggest that a substantial proportion of the 
lgG is directed against PfMSP1 19. However some of the IgG selected here 
could be specific for GST which makes up part of the fusion proteins. 
Murine mAbs mapping to epitopes within PfMSP1 19 have been 
shown to directly inhibit in vitro parasite invasion of RBCs in the absence of 
monocytes. Invasion inhibition is believed to be due to mAb inhibition of the 
secondary processing of PfMSP142 to PfMSP11 (Blackman eta! 1990). 
The invasion inhibition assay used here was similar to the one used by 
Blackman eta! (1990) in which merozoite invasion was significantly 
inhibited by mAb at a concentration of lOOpg/ml. In this study, affinity 
purified antibodies to PfMSP1 19 were able to block the binding of the 
invasion inhibitory mAbs, and in in vitro invasion inhibition assays, purified 
antibodies to PfMSP1 19 and the second EGF-like motif (but not the first, see 
Chappel et al 1993) were able to inhibit parasite growth by up to 70%. 
Significant inhibition was obtained with as little as lOpg/ml of antibody. 
Antibodies selected to either of the two allelic forms of PfMSP1 19 (i.e. Well- 
19/GST and MAD-EGF2) were equally effective against parasites from either 
PfMSP1 allelic family suggesting this invasion inhibitory antibody is cross-
reactive for the two allelic forms of PfMSP1. 
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Pretreating merozoites with some PfMSP1 19-specific mAbs blocks the 
effect of invasion inhibitory mAbs by blocking the binding of mAbs which 
inhibit secondary processing (Blackman eta! 1994). Through competition 
ELISAs, I have been able to show that the AP-lgG preparations also contain 
blocking type antibodies, i.e. AP-lgG competes with mAbs 2.2 and 7.5. 
These results suggest that several different anti-PfMSP1 19 antibodies 
may be produced during natural infection or immunisation with PfMSP119, 
only a subset of which exert protective biological effect(s). An effective 
PfMSP11 vaccine will have to induce primarily invasion inhibitory, rather 
than blocking, antibody. One way of assessing the efficacy of PfMSP1 19 
vaccination is by use of primate models. Aotus monkeys are the best 
monkey models for human malaria because as well as having evolutional 
kinship to humans, they support the development of high density of P. 
falciparum parasites and are available in relatively large numbers 
(Anonymous 1988). 
Aotus monkeys immunised with the E. co/i-derived Well-19/GST of P. 
falciparum were not protected from either heterologous or homologous 
challenge (A. Ballou, A. Holder et a!). I have conducted ELISAs to 
determine whether antibodies induced in this vaccination experiment were 
able to compete with invasion inhibitory mAbs and/or blocking (non-invasion 
inhibitory) mAbs. I found that sera from vaccinated monkeys competed with 
all these mAbs, indicating that the monkey sera contain all of these types of 
antibodies. It took very high concentrations of monkey sera to inhibit mAb 
binding. This suggests that the target epitopes of these invasion inhibitory 
mAbs are not particularly immunodominant in monkeys. The relative 
concentrations and affinities of the inhibitory versus the blocking antibodies 
may determine the protective effect of serum antibodies. The presence of 
relatively high titre blocking antibody in the vaccinated monkey serum may 
explain why the monkeys were not protected. There does not seem to be 
any difference, by titration or competition ELISA, in the antibody titres of 
vaccinated monkeys which underwent a heterologous or homologous 
challenge infection. 
I decided that it would be useful to determine the lgG subclass of 
human polyclonal antibodies produced to PfIVISP119 in natural malarial 
infections, as work by Bouharoun-Tayoun and Druilhe has emphasised the 
need to determine the biological function of antibody responses produced in 
malaria. I found that predominantly IgGi antibodies are produced to 
PfMSP119, suggesting that C-terminal PfMSP1 -specific antibodies may play 
a role in opsonisation or complement-mediated lysis of free merozoites. 
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However, these antibodies were able to inhibit merozoite invasion in the 
absence of either complement or monocytes, indicating that (despite their 
subclass) they were in fact acting primarily by physically blocking active sites 
on the PfMSP119 molecule. 
So in conclusion, the data presented in this chapter indicate that 
natural malarial infections in humans, and artificial vaccination of monkeys 
with PfMSP1 ig, induces invasion inhibitory type antibodies, as shown by 
their ability to compete with invasion inhibitory mAbs. Affinity purified human 
antibodies to PfMSP1 ig, and to its constituent second EGF-like motif are 
able to inhibit the in vitro parasite invasion of RBCs. However, human 
antibody affinity purified to the first EGF-like motif, and antibody induced by 
vaccination of monkeys with a PfMSP11 recombinant protein, has no 
protective effect in vitro or in vivo. This may be due to the presence of other 
PfMSP119-specific antibodies which block the effect of invasion inhibitory 
antibodies. This may explain the paradoxical findings that, despite the 
presence of high levels of serum antibodies to PfMSP1, many individuals in 
malaria-endemic areas have parasites in their peripheral blood (Riley et al 
1992a). The relative concentrations and affinities of inhibitory and blocking 
antibodies may determine whether secondary processing of the MSP1 
complex occurs which, in turn, will affect the ability of the merozoites to 
invade RBCs. Obtaining an appropriate balance between inhibitory and 
blocking antibodies will determine whether PfMSP1 19 vaccination is 
successful or not. 
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CHAPTER SIX: 
Identification of C-terminal PfMSP1-specific human serum 
antibodies associated with resistance to clinical malaria 
Introduction 
The previous chapter suggests that antibodies to the C-terminus of PfMSP1 
may mediate a protective function in vitro. The next step was to look at naturally 
occurring antibodies in a population living in a malaria endemic area, to 
determine whether there is an association between the prevalence of 
antibodies to the C-terminus of PfMSP1 and protection from clinical symptoms 
of malaria. 
There is no direct relationship between levels of antimalarial antibodies 
and resistance to clinical malaria. It seems that much of the antibody response 
is probably not protective, and in some cases may even be associated with an 
increased risk of developing clinical symptoms (Tolle et a! 1993, Riley et a! 
1990). (It has been noted that the in vitro growth of parasites may even be 
enhanced in immune serum suggesting that some antibody specificities may 
facilitate parasite growth or invasion into RBCs [Bouharoun-Tayoun et a! 
1990].) Individuals with high levels of antimalarial antibodies often have high 
parasitaemias. The reason for these paradoxical findings is not understood, but 
part of the antibody response may be a form of immune evasion by the parasite. 
It has been suggested that some regions of malarial antigens contain 
immunodominant B-cell epitopes for this precise reason (Day and Marsh 1991, 
Schofield 1991). 
Many immunodominant epitopes are within areas of antigenic diversity, 
i.e. polymorphic or dimorphic amino acid sequences. An individual may be 
confronted with so many variants of these epitopes that the immune response 
becomes overloaded and responds poorly to critical protective epitopes, 
effectively causing a 'smoke screen' effect. Many malarial antigens are highly 
repetitive 'in their amino acid sequence (Weber 1988), and it has been 
suggested that these repeats have evolved to frustrate the selection of high 
affinity antibody responses by somatic mutation of immunologlobulin genes 
(Anders eta! 1988). Schofield (1991) has suggested that repeat regions 
contribute to the lack of effective immunity to malaria, as they are effectively 
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'seen' by the immune system as thymus-independent antigens (analogous to 
polysaccharides) and so result in thymus-independent antibody formation, 
which would lead to failures in T cell help, antibody affinity maturation and 
memory formation. 
These lines of thought would suggest that, 1) variable/polymorphic 
regions of antigens would be immunodominant, 2) conserved regions may be 
under some functional and/or structural constraint but have evolved to be poorly 
immunogenic, and 3) antibody responses to the former are not protective, and 
may even be associated with an increase risk of clinical infection, whereas 
antibody responses to the latter, though rare, are associated with protection. In 
the case of PfMSP1, both conserved (recombinant protein p19OL representing 
conserved block 3) (Riley et al 1992a) and dimorphic (recombinant proteins 
M6, M7 and Ml 1 representing blocks 6, 6-8 and 16 respectively) (Tolle eta! 
1993) regions have been shown to be immunodominant, and are also 
associated with protection from clinical malaria. 
The two longitudinal protection studies of antibodies to PfMSP1 (Riley et 
a! 1992a, Tolle eta! 1993), were carried out in West Africa, where parasites 
predominantly express the MAD20 allelic prototype (Conway and McBride 
1991, Fruh eta! 1991). In this region, the so called 'variable', i.e. dimorphic, 
regions of the protein will essentially be 'seen' as conserved regions by the host 
population. MAD20 dimorphic recombinant proteins were predominantly 
recognised in the Tolle study. Wellcome sequence proteins were used to detect 
antibody responsiveness in the study by Riley et a!, so responses to dimorphic 
proteins were underestimated. The only truly polymorphic region of PfMSP1 is 
the repeat sequence of block 2, corresponding to the N-terminal PfMSP183 
processing fragment. Tolle et a! (1993) have found that antibody responses to 
this region are associated with an increased risk of infection and inability to 
control parasitaemia. However, this work, and their previous findings (Muller et 
a! 1989, Fruh eta! 1991), suggests that the polymorphic repeat region is not 
immunodominant. (Also noted in our laboratory; Dr. D. Cavanagh, personal 
communication.) Tolle eta! (1993) suggest that this association of antibodies 
with polymorphic regions and increased risk of clinical malaria may reflect the 
number of infections a person has had, in that the sequences are so variable 
that the chance that a person would have antibodies to any particular variant 
would be increased in someone who has experienced many infections, and so 
may be indicative of a person who is particularly susceptible to infection. 
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There seems to be some disagreement about whether antibody 
responses to the PfMSP183 processing fragment are protective. It has been 
noted that unparasitised individuals have higher levels of antibodies to 
PfMSP1 83 than do parasitised individuals (Chizzolini et a! 1988, Kramer and 
Oberst 1993). Antibody responses to native PfMSP183 tended to be associated 
with resistance to clinical malaria in partially immune children in one study, 
though this was not statistically significant (Riley eta! 1992a), but in a later 
study (Riley et a! 1993) it was found that parasitised susceptible adults had 
higher levels of anti-PfMSP183 antibodies, this may reflect recent exposure 
(again this was not significant, possibly due to the small sample size). 
However, PfMSP183 has been shown to contain both protective regions, e.g. 
block 3 (Riley et a! 1992a) and blocks 6-8 (Tolle et al 1993) and non-protective 
regions e.g. block 4 (Tolle eta! 1993). 
Antibody responses to the C-terminal PfMSP142 have also been 
demonstrated to be associated with resistance to clinical malaria in partially 
immune children (Riley et a! 1992a). However prevalence of antibodies to this 
protein is low in children, and not particularly high in adults (see chapter 4). 
This association of antibody responses to PfMSP142 with protection was also 
observed in a later study where it was found that susceptible urban dwelling 
adults had lower levels of PfMSP142 antibodies than healthy adults living in 
rural areas (Riley et a! 1993). Again, the recombinant protein used in this study 
represents the (Wellcome) allelic form of PfMSP142 rarely expressed by 
parasites in this study area, so the antibody assay would have measured 
responses to epitopes which are conserved between the two allelic forms of 
PfMSP1, in either the conserved PfMSP1 19 region and/or in the dimorphic 
PfMSP133 region, which make up PfMSP142. I have carried out further studies 
to investigate the association between antibody responses to PfMSP142 and 
resistance to clinical malaria. I have evaluated the antibody response (in a 
population mainly exposed to parasites expressing the MAD20 allele of 
PfMSP1), to the complete version of the MAD20 allelic form of the dimorphic 
PfMSP133 and to both sequences of PfMSP1 19 and to its constituent EGF-like 
motifs, to determine whether naturally acquired immunity to malaria involves 
antibody responses to this region of PfMSP1. The study was conducted using 
samples from two different regions of West Africa; The Gambia, where malaria is 
seasonally endemic, and Sierra Leone, where perennial malaria transmission 
occurs. 
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Methods and materials 
(1) Study population and study design 
The study concentrated on children who were actively acquiring immunity to 
malaria (aged 3-8 years in The Gambia, n=327; 0-8 years in Sierra Leone, 
n=645). In The Gambia, malaria transmission is seasonally endemic 
(Greenwood et al 1987a), with most new infections occurring during the three 
month long rainy season (July to October). Children receive between 1 and 5 
infective mosquito bites per year (Lindsay et al 1989), and become clinically 
immune to malaria by the age of 8-10 years (Greenwood eta! 1987a). 
In the southern region of Sierra Leone, annual rainfall is higher than in 
The Gambia, extending over a period of 8-9 months each year, with inhabitants 
receiving approximately 30 infective mosquito bites per year (Barnish et a! 
1993a, 1993b, Bockarie eta! 1994). As a result, malaria transmission is 
perennial. Due to the high intensity of malaria in this region, antimalarial 
immunity develops rapidly; most children are clinically immune to malaria by the 
age of 5 years (Barnish et al in press). Immediately prior to the annual rainy 
season (May 1988 in The Gambia and March 1990 in Sierra Leone), blood 
samples were taken. Blood smears were made, stained with Giemsa and 
examined for malaria parasites and serum was retained for immunological 
assays. A morbidity survey was carried out every week for the duration of the 
malaria transmission season in The Gambia, and for one whole year in Sierra 
Leone. During these weekly surveys, blood smears were taken from all febrile 
children (axillary temperature 37.5°C or greater). During the weekly survey in 
the Sierra Leonean study, 30 randomly chosen, afebrile children were 
monitored for parasites to give a more accurate measure of the prevalence of 
asymptomatic malaria in this study group. 
Children were re-examined at the end of the study. Blood smears were 
taken to detect malaria parasitaemia, and children were classified into one of 
four morbidity groups depending on their experience of malaria during this 
malaria transmission season. Children who had a febrile episode ( ~37.5°C) 
coincident with parasitaemia of 5000 or more P. fa/ciparum parasites per p1 of 
blood, were classed as having had an attack of clinical malaria. Children who 
had any level of P. falciparum parasites in their blood smear but experienced 
no fever in the study period were classed as having had an asymptomatic 
infection. Children who experienced fever associated with low parasitaemia 
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(indeterminate group) or had no evidence of infection (no infection group) were 
not included in the statistical analysis of morbidity as it is not certain that the 
former children were ill from malaria or whether the latter children were 
exposed to malaria. 
Control European serum samples were obtained from 28 adults and 14 
children with no previous exposure to malaria. All serum samples were stored 
at -20°C until used. 
Antigens 
The recombinant proteins used in this study have previously been described in 
chapter 2. E. co/i derived GST fusion proteins representing; the first EGF-like 
motif of Wellcome (Well-EGF1) and MAD20 (MAD-EGF1) sequences of 
PfMSP1 ig, the second EGF-like motif of the MAD20 PfMSP1 19 (MAD-EGF2) 
and, the MAD20 PfMSP133 (MAD-33), were used in this study to detect PfMSP1 
antibody responses. 
Yeast recombinant proteins representing full length PfMSP1 19 were also 
tested; 31D7 represents the MAD20 version of PfMSP1 19 (MAD-i 9), and FVO/E 
is a hybrid of the first EGF-like motif of MAD20 and the second EGF-like motif of 
Wellcome (MAD/Well-19). 
ELISA 
Previously described in chapter 4. 
ELISA to determine IgG subclass 
Previously described in chapter 5. 
Statistical methods 
Specific OD values obtained for sera from malaria-unexposed European 
donors were used to establish a normal range for each antigen. The OD values 
for these control sera tended to be normally distributed; thus, African sera giving 
an OD value greater than the mean plus 2SD of the European sera were 
considered to contain antibody specific for the relevant recombinant protein. 
X2 test for linear trend was used to assess age-related trends in 
prevalence of clinical malaria and in the prevalence of antibody response. X2 
was used to detect differences in antibody responsiveness between different 
groups. 
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To determine the relationship between anti-PfMSP1 antibodies and 
malaria morbidity, only children experiencing either clinical or asymptomatic 
malaria were compared, since the clinical status of children in the other two 
morbidity categories could not be ascertained with any degree of certainty. The 
association between clinical status and possession of antibodies to a certain 
protein was calculated as an odds ratio (OR), i.e. the likelihood that an antibody 
positive child would experience a clinical infection compared to the likelihood of 
experiencing an asymptomatic infection. An OR of less than 1.0 is indicative of 
a decreased risk of infection. 
Confounding factors which might have an effect on PfMSP1 antibody 
prevalence included; sex of a child, carriage of the sickle cell trait, age, and in 
the Gambian study; ethnic group and the use of bed nets. The appropriate 
significant confounders were allowed for by logistic regression analysis before 
calculating the OR. 
Statistical analysis was done by D. McGuinness (University of Edinburgh, 
Scotland, UK) and J. Morris (London School of Tropical Medicine, London, UK). 
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Results 
Relationship between age and malaria morbidity 
The prevalence of asymptomatic infections, measured here as a positive P. 
falciparum parasitaemia in the absence of fever, increased with age in both 
study groups, see table 6.1. This increase was more apparent in the Sierra 
Leonean children than in Gambian children (X 2 for trend; The Gambia X 2=3.5, 
p=0.06; Sierra Leone X 2=78.2, p=0.00). The prevalence of clinical disease 
declined with age in a similar fashion. These results confirm that the age 
groups being studied were those in which clinical immunity was developing. In 
the Sierra Leonean study, more than 20% of the children below the age of one 
showed no evidence of infection, compared with 5-10% of children aged 2-5 
years. This apparent resistance of infants to malaria infection probably reflects 
a combination of factors; 1) infants will probably have a lower exposure rate to 
infective mosquitoes due to wrapping of the infants and constant physical 
proximity to the mother, 2) the protective effects of maternal Ig transferred via the 
placenta (McGregor 1986), 3) a milk diet; 'breast milk' is deficient in paramino 
benzoic acid (PABA), a vital growth factor for malaria parasites; experiments 
with rodent malarias show that parasitaemia develops more slowly in mice fed a 
PABA-deficient diet (Wernsdorter and McGregor 1988) and 4) foetal 
haemoglobin (Pasvol et al 1976). However, infants who did become infected 
were more likely to be symptomatic than were older children; 103/131 (79%) of 
infected 0-1 year olds were symptomatic compared with 90/147 (61%) of 2-3 
year olds and 51/149 (34%) of 4-5 year olds, indicating that infants have little 
'anti-disease' immunity (Playfair et al 1990). 
The geometric mean level of parasitaemia was significantly lower in 
children with asymptomatic infections than in children with clinical infections 
(table 6.4.; Student's t test, for The Gambia, t=1 2.99, df=1 98, p<0.0001; for 
Sierra Leone, t=24.2, df=506, p<0.0001), confirming that children who 
experience asymptomatic infections are able to control parasite growth. 
Relationship between anti-Pt MSP1 antibodies and age 
Up to 13% of the Gambian children and 20% of Sierra Leonean children had 
antibodies to recombinant proteins representing the double-motif PfMSP1 19 
protein at the beginning of the study, see table 6.2. 5-6% of the Gambian 




The Gambia    Sierra Leone  
age (years) 3-4 5-6 7-8 total X2 trend 	p 01 2-3 45 68 total X2 trend 	P 
n 120 110 97 327 167 162 157 159 645 
clinical 42 42 25 109 1.8 	0.18 103 90 51 25 269 86.0 	0.00 
(35.0) (38.2) (25.8) (33.3) (61.7) (55.6) (32.5) (15.7) (41.7) 
asymptomatic 29 27 35 91 3.5 	0.06 19 51 83 86 239 78.2 	0.00 
(24.2) (24.5) (36.0) (27.8) (11.4) (31.5) (52.9) (54.1) (37.1) 
indeterminate 8 13 15 36 4.3 	0.04 9 6 15 12 42 2.00 	0.16 
(6.6) (11.8) (15.5) (11) (5.4) (3.7) (9.6) (7.5) (6.5) 
no infection 41 28 22 91 3.7 	0.06 36 15 8 36 95 0.02 	0.89 
(34.2) (25.5) 1 	(22.7) 1 	(27.0) (21.6) (9.3) (5.1) 1 	(22.6) 1 	(14.7) 
Table 6. 1. Malaria morbidity in the Gambian and Sierra Leonean cohorts. 
The children were categorised by age (years) and malaria morbidity. Figures show the number (percentage) of children in each group. 
No effect of sex or sickle cell gene carriage was observed in relation to either malaria morbidity or antibody responses (data not shown). 
The Gambia    Sierra Leone  
Age (years) 3-4 5-6 7-8 total X2 trend 	p 01 2-3 4-5 6-8 total X2trend 	P 
n 120a 97C 327d 167e 162' 1579 159
h 645' 
MAD-19 6 8 14 28 5.9 	0.01 11 31 25 43 110 19.6 	
<0.001 
(5) (7.3) (14.4) (8.6) (6.6) (19.1) (15.9) (27.0) (17.1) 
MAD/Well-19 9 15 19 43 6.9 	0.01 17 36 30 49 132 17.4 	<0.001 
(7.5) (13.6) (19.6) (13.1) (10.2) (22.2) (19.1) (30.8) (20.5) 
Well-EGF1 5 6 7 18 0.9 	0.33 15 20 11 21 67 0.5 	
0.49 
(4.2) (5.4) (7.2) (5.5) (9.0) (12.3) (7.0) (13.2) (10.4) 
MAD-EGF1 6 7 7 20 0.5 	0.49 15 28 15 25 83 1.2 	0.28 
(5.0) (6.4) (7.2) (6.1) (9.0) (17.3) (9.5) (15.7) (12.9) 
MAD-EGF2 1 3 7 11 6.5 	0.01 1 3 7 11 22 11.4 	0.001 
(0.8) (2.7) (7.2) (3.4) (0.6) (1.8) (4.5) (6.9) (3.4) 
MAD-33 26 40 38 104 7.9 	0.005 45 72 90 90 297 70.7 	
0.000 
(22.2) 1 	(37.0) 1 	(40.0) 1 	(32.5)  (30.4) (56.7) 1 	(70.9) (78.9) 1 	(57.6) 1 
Table 6.2. The relationship between age and antibody responses to the C-terminal of PfMSP1. 
Figures show the number (percentage) of antibody positive children ('responders) in each group, for each antigen. 
Responders are those where the specific OD was greater than the mean plus 2 SD of the control (malaria non-exposed) sera. 
n values for MAD-33 are smaller: a=117, b=108, c=954=320, e=148,f=127, g=127, h=114, i=516. 
(0 
EGF-like motif proteins. Only 3.4% of children in both study groups have 
antibodies to the second EGF-like motif. 30% of Gambian children and 60% of 
Sierra Leonean children have antibodies to PfMSP133. (Dot plots showing 
antibody responses to MAD-19 and MAD-33 are shown in figure 6.1.) These 
findings are broadly similar to those seen in chapter 4. 
The prevalence of antibody responses to MAD-33, PfMSP1 19 and the 
MAD-EGF2 increases with age in both study groups (table 6.2.). Antibody 
responses to EGF1 do not increase with age. These age differences in 
antibody responsiveness to the PfMSP1 proteins agree with my previous 
findings in chapter 4 (except for MAD-EGF2; but this may be due to the larger 
sample size in each age group in this study). Again, antibody responses to the 
two allelic forms of the PfMSP1 19 and the first EGF-like motif proteins are highly 
correlated (data not shown). 
Relationship between anti-PfMSP1 antibodies and ethnic group 
The vast majority of Sierra Leonean children come from the same ethnic group 
(Mende, 94%) (Barnish eta! 1993a), whilst the Gambian children came from 
three separate, and genetically distinct ethnic groups (Olerup eta! 1991). In 
The Gambia, malaria morbidity was found to differ between children of different 
ethnic group, in that Fula children are less likely to be infected (table 6.3.a.). 
The prevalence of antibodies to the double-motif PfMSP1 19 proteins differed 
significantly between the three groups, being higher in children of the Fula 
ethnic group than in Mandinka or Wollof children (table 6.3.b.) 
Relationship between anti-PfMSP1 antibodies and malaria 
morbidity 
Antibodies measured in the children's sera at the beginning of the malaria 
transmission season were compared with their subsequent malaria morbidity, 
after allowing for confounding effects of age and, in The Gambia, ethnic group. 
In both the Gambian and the Sierra Leonean studies, the prevalence of 
antibodies to epitopes within the C-terminus of PfMSP1 was higher in children 
who experienced only asymptomatic infections than in children who 
experienced clinical infections (except for antibody responses by Gambian 
children to the first EGF-like motif proteins). However, the odds ratio for this 
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-0.5 iI 	I 	I 	I I 
control 0 	1 2 	3 	4 	5 	6 	7 	8 
sera 	 Age (years) 
n 
Fula Mandinka Wollof X2 	p 
157 83 78 
31.1 	0.000 clinical 45 34 52 
(28.7) (41.0) (33.3) 
asymptomatic 40 21 25 1.31 	0.518 
(25.5) (25.3) (32.1) 
indeterminate 14 9 13 3.14 	0.208 
(8.9) (10.8) (16.7) 
no infection 58 19 14 11.01 	0.004 
(36.9) 1 	(22.9) 1 	(17.9)  
Table 6.3.a. Malaria morbidity in the Gambian in relation to ethnic group. 
The children were categorised by ethnic group and malaria morbidity. 
Figures show the number (percentage) of children in each group. 
p value at 2 degrees of freedom. 
ethnic group Fula Mandinka Wollof X2 	p 
n=79b  n=165a n=83 
MAD-19 20 (12.1) 3(3.6) 5(6.3) 5.8 0.06 
MAD/Well-19 31(18.8) 6(7.2) 6(7.6) 9.3 0.01 
Well-EGF1 11(7.2) 2(2.4) 3(3.8) 2.0 0.37 
MAD-EGF1 12(7.3) 2(2.4) 4(5.1) 1.1 0.57 
MAD-EGF2 5(3.0) 0(0.0) 0(0.0) 4.5 0.11 
MAD-33 44 (28.0) 30 (36.1) 28 (35.9) 2.3 0.31 
Table 6.3.b. The association between ethnicity and antibody responses to the C-terminus 
of PfMSP1 in The Gambian cohort. 
Figures represent the number (percentage) of children with detectable antibody to each antigen. 





The Gambia Sierra Leone 
asymptomatic clinical OR for clinical malaria* asymptomatic clinical 
OR for clinical malaria 
% (n=91) (n=109) 
(n=239) (n=269) 
(n) J ) (95% Cl) p 
(95% Cl) p 
MAD-19 11 8 0.7(0.3-2.0) 0.52 53 
34 0.7(0.4-1.2) 0.16 
(12.1) (7.3) (22.2) (12.6)  
MAD/Well-19 16 12 0.7 (0.3-1.6) 0.35 65 40 
0.6 (0.4-1.0) 0.06 
(17.6) (11.0) (27.2) (14.9) 
Well-EGF1 5 8 1.7 (0.5-5.7) 0.38 26 24 
0.9 (0.5-1.8) 0.79 
(5.5) (7.3) (10.9) (8.9)  
MAD-EGF1 5 9 1.8 (0.6-5.9) 0.31 32 32 
1.0 (0.5-1.7) 0.90 
(5.5) (8.3) (13.4) (11.9)  
MAD-EGF2 10 0 0.0 (0.0-0.5) <0.001 12 4 
0.4 (0.1-1.4) 0.14 
(11.0) (0.0) (5.0) (1.5)  
MAD-33 40 27 0.4 (0.2-0.8) <0.05 121 114 
0.8 (0.5-1.3) 0.37 











Table 6.4. The relationship between antibody responses to the C-terminal of PfMSP1 and malaria morbidity. 
Figures show the number (percentage) of antibody positive children (responders') in the clinical and asymptomatic morbidity groups for each antigen. 
* Odds ratio adjusted for age and ethnic group 
** Odds ratio adjusted for age 
p value represents significance of likelihood ratio test, obtained using logistic regression. 
n values for MAD-33 are smaller: The Gambia; asymptomatic=86, clinical=105, Sierra Leone; asymptomatic=171, clinical=234. 
In Gambian children, the prevalence of antibodies to MAD-EGF2 was 
significantly higher in children with asymptomatic infections than in those 
experiencing clinical malaria. The significance of this association remained 
high (p<0.001) even after adjusting for the confounding factors of age and 
ethnic group. In the Sierra Leonean study there was a suggestion of a reduced 
risk of clinical malaria associated with antibody responses to MAD-EGF2, but 
this was not significant since four antibody positive children experienced clinical 
infections. 
In both populations, there seems to be an association of antibody 
prevalence to the double-motif PfMSP1 19 proteins and protection. In the Sierra 
Leonean children, responses to the MAD/Well-19 proved to be associated with 
protection, reducing the risk of clinical malaria by 40%. 
Antibody responses to MAD-33 are also associated with protection from 
clinical malaria in Gambian children, resulting in a 60% reduced risk of 
developing clinical malaria. 
(5) Comparison of antibody responses in Gambian and Sierra 
Leonean children 
The prevalence of antibody responses to all of the C-terminal PfMSP1 proteins 
(except MAD-EGF2) was higher in Sierra Leonean children than in Gambian 
children, see table 6.2. This may reflect the higher intensity of malaria 
transmission in Sierra Leone. The longer rainfall season in Sierra.Leone results 
in a longer malaria transmission season, but also the level of rainfall is very 
high, producing a year-round habitat for mosquito breeding, resulting in a 
higher incidence of infective mosquito bites. 
In Sierra Leone, at the time of blood sample collection, children were 
monitored for the presence of parasites. Significant associations were 
observed between the presence of asymptomatic parasitaemia at the time of 
serum sample collectionand the presence of antibody to the double EGF-like 
PfMSP1 19 proteins and PfMSP133, but not to the single EGF-like proteins (table 
6.5.). This suggests that recent boosting may be required to maintain significant 
antibody titres to PfMSP1 ig, and may partially explain the low prevalence of 
anti-PfMSP1 19 antibodies in children, especially in The Gambia, as these serum 






X2 	 p 
MAD-19 72 (19.1) 38 (13.6) 4.16 0.041 
MAD/Well-19 87 (23.8) 45 (16.1) 5.75 0.016 
Well-EGF1 39 (10.7) 28(9.4) 0.16 0.686 
MAD-EGF1 45 (12.3) 38 (12.8) 0.00 0.951 
MAD-EGF2 15(4.1) 7(2.4) 1.07 0.301 
MAD-33 196 (83.4) 39 (32.8) 44.12 0.000 
Table 6.5. The association between concurrent parasitaemia and antibody 
responses to the C-terminal of PfMSP1 in the Sierra Leonean cohort. 
Figures represent the number (percentage) of children with or with out 
parastaemia at time of blood sample collection. 
For MAD-33 n is smaller; a=286, b=1 19. p  value at 2 degrees of freedom. 
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(6) lgG subclass response of C-terminal PfMSP1 seropositive 
children 
The lgG subclass of MAD-19-specific antibodies in seropositive individuals in 
Sierra Leone was determined by subclass specific ELISA. Mainly IgGi 
antibodies reacted with MAD-19. lgG subclass response was not associated 
with an increased or reduced risk of clinical malaria (see table 6.6.). 
.; 
asymptomatic clinical OR for clinical mal aria* 
(n=239) (n=269) 
(%) (95% Cl) p 
IgGi 37/53 23/35 0.9 (0.4-2.3) 0.83 
(69.8) (65.7) 
lgG2 0/53 0/35 
(0.0) (0.0) 
lgG3 18/53 6/35 0.5 (0.2-1.4) 0.18 
(34.0) (17.1) 
lgG4 10/53 11/35 2.2 (0.8-6.2) 0.13 
(18.9) (31.4) 
Table 6.6. The relationship between lgG subclass antibody responses to PfMSP119 (MAD-1 9) 
and malaria morbidity in Sierra Leone. 
Figures show the number (percentage) of lgG subclass antibody positive children in the clinical 
and asymptomatic morbidity groups for the total lgG antibody positive children to MAD-1 9. 
* Odds ratio adjusted for age. 
p value represents significance of likelihood ratio test, obtained using logistic regression. 
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Discussion 
Epidemiological studies cannot demonstrate absolute correlations between a 
particular immune response to an antigen and protection from clinical malaria, 
but these associations can give an indication of antigens which may be 
important in the induction of clinical immunity. The interpretation of 
epidemiological studies is complicated by difficulties of defining morbidity 
caused by malaria. Here, clinical malaria is defined as a child who has at least 
one episode of fever associated with a parasitaemia of 5000 or more parasites 
per p1 of blood. Asymptomatic malaria is defined here as a child who has 
parasites in their blood film at least once during the study period, with any level 
of parasitaemia, but no clinical symptoms. 
The relationship between fever, parasitaemia and clinical malaria has 
recently been re-examined for areas of high malaria transmission intensity 
where the majority of the population harbour parasites at any one time 
(Armstrong-Schellenberg eta! 1994, Smith eta! 1995). These authors are in 
agreement that the method used above is adequate for children over the age of 
one year. However, in children ill with malaria under this age, temperature did 
not correlate with parasite levels. Also fevers last for a shorter duration and so 
may go unmonitored. So this method of diagnosis will probably underestimate 
the number of cases of clinical malaria in infants. In addition, as many children 
have a parasitaemia, to say that any fever a child experiences is due to malaria 
will over estimate the cases of clinical malaria in older children: However, there 
is evidence that parasitaemia decreases in the prevalence of fever 
(Kwiatkowski 1995), which would result in an increase in the indeterminate 
group and an under estimation of clinical malaria (Armstrong-Schellenberg et a! 
1994). Many children will have been classed as having no infection, as they 
had no detectable parasites in their peripheral blood smear, however, blood 
films will underestimate the prevalence of sub clinical infections (Hang et a! 
1995). So if anything, these definitions will underestimate asymptomatic 
malaria and overestimate clinical malarial cases. Nevertheless, data from this 
chapter confirms previous findings of Riley eta! (1992a) that there is a 
significant association between antibody responses to epitopes within the C-
terminus of PfMSP1 and resistance to clinical malaria. 
Data presented here suggest that antibody responses to epitopes within 
both the conserved PfMSP11 protein, and the dimorphic PfMSP133, are 
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associated with the ability to control clinical symptoms of malaria. The 
significance of this association is enhanced by the fact that the same 
observations, though not always significant, have been made in two distinct 
populations with different genetic backgrounds, from areas of differing malarial 
intensity, on samples collected two years apart. The association of the 
protective effect of these antibodies is in marked contrast with the lack of such 
an association with antibodies to other malarial antigens with protection tested 
in a similar fashion (Riley et a! 1990). 
As in chapter 4, I have noted that the prevalence of antibodies to 
PfMSP1 19 and MAD-33 increase with age. The age correlation of acquisition of 
antibodies suggests repeated exposure to infection may be required to develop 
sufficient memory. With the case of PfMSP119, this may possibly reflect 
increased recognition of a conserved region which is exposed to the immune 
system for a short time during RBC invasion, and at other times may be hidden 
by the rest of the molecule. 
As in chapter 5, mainly IgGi antibodies were detected to PfMSP11 
epitopes. I was unable to demonstrate an association between subclass and 
protection from clinical malaria in this study since nearly all positive sera 
contained predominantly IgGi antibodies. A similar study was conducted in 
Madagascar, measuring lgG subclass of antibodies to Pf155/RESA in adults 
newly exposed to malaria. They also found that predominantly IgGi and lgG3 
antibodies were produced but the level of Pf155/RESA-specific lgG tended to 
be higher in non-protected, rather than in protected, individuals (Dubois et a! 
1993). 
The highest degree of protection was observed with antibody responses 
to MAD-EGF2. Even though the number of seropositive children is low, all ten 
Gambian children with antibodies to this protein prior to the malarial 
transmission season, experienced only asymptomatic malarial infections during 
the following months. This indicates that these children were able to control 
their parasitaemia to below levels at which clinical symptoms are manifest. A 
similar trend was seen for the Sierra Leonean children, however, of the 16 
children which had antibodies to MAD-EGF2, 4 (25%) did succumb to clinical 
infections. The second EGF-like motif is more polymorphic than the first, with 
three dimorphic amino acid differences compared to one in the first EGF-like 
motif. There is the possibility that the non-protected Sierra Leonean children 
were infected with parasites expressing the alternative sequence. Some 
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antibody responses to PfMSP1 19 may be sequence-specific, as Tolle et a! 
(1993) have shown that dimorphic areas may be critical in the induction of 
protective immunity. However, Riley et a! (1 992a), have shown, using 
recombinant proteins representing Wellcome sequences, that there is a certain 
degree of strain-transcending immunity, as antibodies to two conserved 
regions, block 3 of PfMSP183 and block 17 of PfMSP142, were associated with 
protection from clinical malaria in Gambian children, an area where expression 
of the Wellcome allele is rare. This suggests that there is strain-transcending 
immunity, caused by epitopes within conserved sequences. Alternatively, in 
susceptible children, the second EGF-like motif-specific antibodies may have 
been of a non-protective lgG subclass or may have been of a non-invasion 
inhibitory type (see chapter 5). 
A short and relatively conserved (dimorphic) antigen, which is the target 
of protective anti-malarial immune responses, would be an ideal component for 
a subunit malaria vaccine which could be manufactured using recombinant 
DNA technology. One potential problem for the use of PfMSP1 19 in a vaccine, 
is its apparently poor immunogenicity, especially of the second EGF-like motif. 
Despite multiple infections, only 27-30% of Sierra Leonean children aged 6-8 
years possessed antibodies to PfMSP1 19, and only 7% possessed antibodies to 
MAD-EGF2. Only 60% and 14% of Gambian adults (chapter 4) are seropositive 
to PfMSP119 and MAD-EGF2 respectively, indicating that even life long 
exposure to this essentially conserved protein may be insufficient to induce an 
antibody response. 
Reasons for this non-responsiveness are unknown. Data from chapter 4 
indicates that antibody responses to PfMSP1 19 are not limited by HLA class II 
genotype and genetic background is not a major factor in determining 
responsiveness. However, there is a suggestion, from a larger study of 
Gambian twins (Jepson eta!) that antibody responses to PfMSP142 (which 
contains PfMSP133 and PfMSP119) may be regulated by non-MHC genes. If 
this antigen is to be used as a vaccine it will have to be confirmed that 
individuals of different genotypes can successfully be immunised. 
From work presented here, ethnic background appears to affect antibody 
responsiveness to PfMSP1 19 (in The Gambia), however when ethnic group was 
allowed for in multiple logistic regression, the associations of antibody 
responsiveness to PfMSP133 and the second EGF-like motif of PfMSP11 with 
resistance to clinical malaria were still highly significant. Whether this 
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difference in antibody responsiveness between the ethnic groups is genetic or 
environmental is unknown. However, it is known that malaria transmission is 
higher in Fula villages, primarily due to village location and housing conditions 
(Greenwood eta! 1987b). 
Recent boosting appeared to account for elevated levels of antibody 
responsiveness to PfMSP119 and PfMSP133 in Sierra Leone, suggesting that 
antibodies levels to these proteins do not remain stable throughout the year in 
children (in confirmation of data presented in chapter 4), and may explain the 
low prevalence of antibodies in Gambian children as their antibody responses 
were measured at the end of the dry season. Successful immunisation with 
these proteins may require T cell help to maintain the production of protective 
antibody (as has been demonstrated in mouse models; Daly and Long 1995). 
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CHAPTER SEVEN: 
T cell responses to PfMSP119 
Introduction 
Despite evidence of the importance of B cell/antibody responses in the 
development of immunity against malaria (see chapter 4), there is evidence that 
cell-mediated immunity may be just as important. 
Freeman and Holder (1983) immunised BALB/c mice with affinity purified 
PyMSP1 and found that vaccinated mice were significantly protected against 
homologous challenge infection. However, despite obtaining high titre 
antibodies specific to PyMSP1, the passive transfer of serum from these 
resistant animals to naive recipients had no protective effect against 
subsequent challenge infection. This suggested to the authors that the 
protective response observed was, to a major extent, cell-mediated. This 
inability of sera from immune hosts to transfer protection has been noted by 
other investigators (reviewed in Weidanz and Long 1988). Other evidence for 
the importance of cell-mediated immunity in rodent malaria includes; 1) passive 
transfer of immune sera to splenectomised or T cell-deprived recipients proves 
not to be protective; 2) B cell deficient mice can spontaneously resolve malarial 
infections or resist reinfection; 3) immunity to P. chabaudi adami can be 
transferred to nude mice using immune T cells but not with B cells; 4) immunity 
can be transferred using antigen-specific T cell lines and clones against P. 
chabaudi adami; 5) mice which lack B cells are more sensitive to primary 
malarial infections, however the function of B cells is not only to produce Ig but 
also to act as antigen presenting cells (APCs), so this increased sensitivity to 
infection may be a result of a lack of T cell activation; 6) p-suppressed mice can 
be made immune to malaria by infection followed by drug cure; 7) 
thymectomised mice are unable to make a protective response to P. yoelii or P. 
berghei, these mice were unable to control parasitaemia after drug cure, unlike 
mice which received a thymus tissue graft or immune serum; 8) Playfair et a! 
(1985) found that stimulation of T cells resulting in delayed hypersensitivity 
(rather than stimulation of T helper cells resulting in antibody production) 
correlated with protection of mice from P. yoelii following immunisation with 
purified PyMSP1; the classes of Ig responsible for the passive transfer of 
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immunity in mice are of the IgGi and lgG2 subclasses, production of which is T 
cell dependent. Nude mice fail to produce antibodies and die, suggesting that T 
cell help is important for the production of protective antibodies. However, 
optimal protection against P. yoelii appears to depend on the cooperation of 
immune I and B cells, whereas immunity to P. chabaudi adami appears to be 
less dependent on antibody (see Del Giudice et a! 1988, Troye-Blomberg and 
Perlmann 1988, Weidanz and Long 1988 for reviews). 
The extent to which these rodent model systems mimic human responses 
in malaria is unclear. To measure T cell responses of malaria-immune 
individuals, antigens are added to peripheral blood mononuclear cells in vitro. 
T cells will proliferate if the antigen contains appropriate T cell epitopes and is 
processed by APCs, which present peptide fragments on their surface in 
conjunction with a major histocompatibility complex (MHC) molecule. Only if 
the T cell receptor (TCR)-antigen complex recognises both the antigen fragment 
and the MHC molecule will the T cell proliferate. 
T cell proliferation assays only measure whether T cells have been 
activated to undergo clonal expansion. They give no indication of which subset 
of T cells has been stimulated. This, however, can be determined by analysis of 
cytokines produced by the T cell population. There are two main subsets of T 
cells; CD4+ cells and CD8+ cells. CD8+ I cells are cytotoxic, recognise MHC 
class I molecules, are involved in the intracellular killing of infected cells and 
have been shown to be important in immunity against the intracellular/liver 
stage of the parasites life cycle (Schofield et a! 1987). CD4+ T cells are MHC 
class II restricted and perform regulatory, helper functions in immunity. CD4+ T 
helper cells (Th cells) can be further categorised as either Thi cells which are 
involved in the regulation of cell-mediated immunity through the release of such 
cytokines as interferon-gamma (IFNy) and interleukin-2 (IL-2), or Th2 cells 
which are involved in the regulation of B cells and control the lgG subclass 
response through the release of such cytokines as IL-4 (Cox and Liew 1992).n 
However the production of these cytokines is not absolute proof of aThl or Th2 
response as other cell can also produce these cytokines, for example natural 
killer cells also produce IFNy. 
In humans, the association of T cell responses (proliferation or cytokine 
production) with immunity to blood stage parasites has been demonstrated 
(Riley eta! 1992a). It is thought that CD4+ T cells contribute to immunity 
against blood stage parasites both by helping antibody responses (Troye- 
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Blomberg et a! 1990) and by activating macrophages. It would be necessary to 
include T cell epitopes in a vaccine against blood stage parasites to provide T 
cell help to induce optimal antibody synthesis and long term immunological 
memory as well as antibody-independent effector mechanisms. It would be 
advantageous to select conserved I cell epitopes for inclusion within a vaccine. 
T cell epitopes of PfMSP1 were first identified by screening for human I 
cell proliferation to a recombinant protein (190-L) representing the highly 
conserved block 3 region (Sinigaglia et a! 1988). In total, four separate T cell 
epitopes have been identified in this conserved region (Crisanti et a! 1988, 
Rzepczyk et a! 1989). T cell clones, were reactive with purified PfMSP1 from 
three P. falciparum isolates (Rzepczyk eta! 1989), and uncloned T cells from 
the majority of individuals tested proliferated to peptides representing these 
conserved epitopes (Rzepczyk et a! 1989, Simitsek et a! 1990). This is 
encouraging for vaccine development, as despite the marked polymorphism of 
PfMSP1, immunisation with a conserved T cell epitope may be sufficient to 
induce I cell help, and would be boosted after exposure to parasites 
expressing the alternative PfMSP1 allele from that used for immunisation. 
Research for vaccines against blood stage parasites has centred on 
humoral immunity, with only limited success (Hall et a! 1984a, Perrin et a! 
1984, Siddiqui eta! 1987, Patarroyo eta! 1987a, 1987b, 1988). However, 
once it was realised that T cell epitopes should also be included the 
immunogenicity and protective effect of these antibody inducing vaccine 
antigens was improved. Herrera et a! (1990) immunised monkeys with the 
190-L recombinant protein construct and only obtained partial protection 
despite the presence of four known T cell epitopes. They repeated the study, 
but immunised monkeys with the recombinant protein 190-N (which contains 
the 190-L protein) fused with a universal T cell epitope (CS33) from the 
circumsporozoite protein of P. falciparum (Herrera eta! 1992). This epitope is 
recognised by T cells in association with many different MHC class II molecules 
(Sinigaglia eta! 1988). Improved protection correlated with the levels of lFNy 
produced, suggesting that cell-mediated immunity rather than antibody was 
responsible for protection. 
Antibody responses to PfMSP1 19 appear to be associated with protection 
from clinical malaria (see chapters 5 and 6) but the prevalence of such 
antibodies is low. It is possible that this is due to a lack of T cell helper epitopes 
in the native PfMSP119 protein. Immunisation of mice with PyMSP115 protected 
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8 out of 11 from a lethal challenge infection (Daly and Long 1993). However, 
this protection was only obtained with the PyMSP115 GST fusion protein, and 
not with the GST-cleaved protein even though both constructs induced 
antibodies which recognise native PyMSP1. This suggests that GST may 
contain T cell epitopes which provide T cell help for the production of protective 
antibodies. However, GST would not be an appropriate carrier for a malaria 
vaccine as natural infection with malaria parasites would not boost GST T cell 
responses. In a recent study (Ling eta! 1994)15 out of 16 mice immunised with 
GST-cleaved PyMSP115 were protected from a lethal infection, and 15 out of 15 
mice immunised with the uncleaved protein were also protected; in this case, T 
cell help may have been provided by Freund's complete adjuvant which is 
unacceptable for use in humans. However, mice immunised with a smaller 
fragment of the C-terminus of PyMSP1 (PyMSP1 ii) were completely protected 
against challenge infection and passive transfer of their serum significantly 
delayed the onset of parasitaemia in naive mice (Daly and Long 1995). The 
authors show that CD4+ T cells become important in immunity 12 days after 
immunisation, suggesting that CD4+ T cells are important in maintaining high 
levels of antibody. CD4+ T cells may also play an auxiliary role in protection 
through the production of cytokines resulting in the activation of other effector 
mechanisms of immunity. The authors proposed that in the shortened 
PyMSP1ii construct, cryptic T cell epitopes were unveiled which were able to 
provide the necessary T cell help for protective antibody responses to develop. 
Immunisation with PfMSP1 19-GST fusion proteins did not protect 
monkeys against challenge infection (Burghaus et al manuscript in 
preparation), while immunisation of monkeys with yeast recombinant proteins 
representing the same protein protected 2 out of the 4 vaccinated monkeys from 
a lethal challenge infection (Kumar eta! 1995). Both vaccination schemes 
induced invasion inhibitory type antibodies (see chapter 5); 3 of 5 sera in the 
Burghaus study were able to inhibit parasite invasion of RBCs in vitro, non of 
the sera from the Kumar study were able to inhibit. Possibly the lack of 
protection with the bacterial proteins was due to insufficient T cell help for th 
induction of a protective antibody response by antibody affinity maturation or 
isotype switching. This may result from post-translational differences between 
proteins formed in the two different expression systems, or may once again be 
due to the choice of adjuvant used (Kumar et a! used Freund's adjuvant, while 
Burghaus et al used liposomes and alum as an alternative to Freund's). 
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I have found that in individuals naturally exposed to malaria, PfMSP1 19 is 
poorly antigenic compared to other regions of the molecule (see chapter 4). 
This low prevalence may be due to few people ever making antibodies to 
PfMSP1 19, or it may be that lots of people make antibodies, but memory is poor 
so antibody levels fall quickly and lots of people are seronegative at any one 
time. So, in this chapter, I have investigated whether this poor antibody 
response to PfMSP1 19 is due to lack of T cell help. I have considered that this 
may be due to a lack of I cell epitopes per se and that the presence of 
disulphide bonds within PfMSP1 19 may hinder linearisation of the peptides for 
presentation within the peptide binding groove of MHC molecules, thus 
preventing T cell recognition. In this study I have measured peripheral 
lymphocyte proliferative responses in malaria immune adults to recombinant 
proteins representing PfMSP1 19 in a native and a reduced form. 
Methods and materials 
Antigens 
Recombinant proteins used in this study have previously been described in 
chapter 2. E. co/i-derived GST fusion proteins representing the first EGF-like 
motif of the Wellcome and MAD20 sequences of PfMSP1 19 (Well-EGF1, MAD-
EGF1), the second EGF-like motif of MAD20 PfMSP1 19 (MAD-EGF2), and the 
double EGF-like motif of Wellcome PfMSP11 (Well-19/GST) were used. Yeast 
recombinant proteins representing the full length MAD20 sequence of 
PfMSP11 were also tested (MAD-19), see figure 2.1. Proteins were used in a 
reduced and non reduced form at 1 pg/mI (see chapter 2). 
T cell proliferative responses were also measured to the mitogen 
Phytohemagglutinin (PHA; Difco Laboratories, Detroit, Mich.; 2pg/ml final 
concentration), Tuberculin purified protein derivative (PPD; Evans Medical Ltd, 
Leatherhead, England; lpg/ml final concentration) and to the disulphide-
constrained tetanus toxoid (Wellcome;. 4pg/ml final concentration). These 
proteins acted as positive controls in the assays. 
Study population 
Blood was collected from 19 adults living in a rural area of The Gambia. 
Malaria transmission in this area is seasonally endemic during and immediately 
following the rainy season (July - December) (Greenwood eta! 1987a). 
Samples were obtained prior to (March) the rainy season. 
T cell proliferation assay 
Cells from non-exposed European donors were used to test the toxicity of the 
proteins and to determine the extent of non-specific T cell activation. 
20mls of blood were collected from each donor. Plasma was separated 
from heparinised blood by centrifugation, aliquoted and stored at -20°C. 
Mononuclear cells (MNC) were isolated by density dependent gradient 
centrifugation (Lymphoprep, Nycomed, Norway). Cells were washed and 
suspended in RPMI supplemented with 2mM L-glutamine, 100u/ml penicillin 
and streptomycin, 30mM HEPES, 0.22% (v/v) sodium bicarbonate and 10% 
(v/v) non-immune human A+ serum (heat inactivated). MNC (10 5 per well) were 
added to 96-well round bottomed microtitre plates in a total volume of 200pl. 
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Triplicate wells contained optimal concentrations of antigen. Cells were grown 
for seven days in a CO2 (5%) incubator at 37°C. 
The cells were left 7 days to proliferate as this has previously been 
determined to be the optimal culture period time from kinetic experiments 
carried out by Riley eta! (1993). Eighteen hours prior to harvesting; 1 00p of 
cell free supernatant was removed from each well and lOOi.Jl of complete RPMI 
containing 1 pCi 3 H-thymidine was added to each well. Supernatants were 
collected for the measurement of lFNy responses after 6 days as this is when 
their concentration is highest (Riley et a! 1993). Cells were harvested and 
incorporation of 3 H-thymidine was measured by liquid scintillation counting: 
The geometric mean counts per minute (cpm) of triplicate wells was determined 
for each antigen and the mean stimulation index (SI) was calculated as shown; 
Sl= geometric mean triplicate antigen cpm 
geometric mean triplicate control cpm 
where the control is either the unstimulated (background) count for non-fused 
proteins, i.e. MAD-1 9, or the value obtained with the GST fusion partner alone 
for the GST fusion proteins (Bennett and Riley 1992). 
Interferon 'y ELISA 
IFN-y in culture supernatants was measured by a two site ELISA assay 
(Andersson et a! 1989) using two mouse mAbs to human recombinant IFNy 
(Chromogenix, Molndal, Sweden). IFNy concentration was determined by 
reference to the international human IFNy standard GG23-901 -530 (National 
Institute of Allergy and Infectious Diseases, Bethesda, MD, USA). The IFNy 
ELISAs were performed by Dr. E. Riley, (University of Edinburgh, Scotland, UK). 
Statistical methods 
To determine whether T cell proliferative responses to the PfMSP1 proteins 
increased with reduction and alkylation of the proteins, a non parametric 
Wilcoxon signed rank test was carried out measuring differences in the cpm 
obtained for the two versions of the protein. 
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Results 
Toxicity testing of PfMSP119 proteins 
European cells were tested to see if antigens were toxic and to see whether 
they activate non-immune cells. T cell proliferation was measured in samples 
containing 1 p and lOpg/ml of non-reduced antigen. As cpm were similar or 
greater than RPMI alone it was evident that the proteins were not toxic (table 
7.1.). As high cpm was obtained to the positive control PPD it was evident that 
the cells were alive and activated. At lOpg/ml the antigens caused some non-
specific activation of non-immune cells; thus, for subsequent studies, PfMSP1 19 
proteins were used at 1 pg/mI only. 
Lymphoproliferative responses to native PfMSP1 19 
Background lymphoproliferative responses in control wells, containing either 
GST or RPMI alone, are at an acceptable level (table 7.2.). Lymphoproliferative 
responses to positive control proteins are high (100% respond to PHA) 
indicating that the assay was working and that the cells were alive and activated 
(see table 7.3. and figures 7.1.a. and 7.2.). 
Responses to PfMSP1 19 are extremely low, with no positive SI response 
to any of the PfMSP1 19 proteins apart from the Well-EGF1 protein (a positive 
response is considered to be a SI greater than 3). SI produced to the EGF-1 
and double-motif proteins appear to be cross-reactive for the two allelic forms of 
the protein. 
For individual results of the proliferation assays see appendix 1. 
Lymphoproliferative responses to reduced PfMSP119 
Proteins were reduced and alkylated to test whether the disulphide structure of 
PfMSP1 19 may be responsible for lack of responsiveness to this protein (see 
figure 7.3. for confirmation of protein reduction). For the majority of individuals, 
reduction and alkylation of the disulphide-constrained PfMSP119 proteins did 
result in an increase in proliferation, significantly increasing T cell proliferative 
responses to the reduced proteins (see table 7.2. and figures 7.1 and 7.2.). T 
cell responses seemed to increase more for the MAD20 proteins; The Gambia 
is an area where the MAD20 form of PfMSP1 predominates (Conway and 
McBride 1991), so people may recognise this form of the protein more. 
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Donor Antigen 1W( /ml lOpg/mI 
mean cpm SI mean cpm SI 
Well-EGF1 1518.7 0.8 3857.7 3.5 
MAD-EGF1 1616.7 0.9 2082.7 1.9 
SD MAD-EGF2 779.0 0.4 4944.0 4.5 
Well-19/GST 628.7 0.3 1278.4 1.2 
MAD-19 693.7 0.6 631.4 0.5 
GST 1829.4 1.6 1096.7 0.9 
PPD 44705.0 38.5 
RPMI 1160.7  
Well-EGF1 1819.0 2.3 2132.0 1.4 
MAD-EGF1 1283.0 1.6 1464.7 1.0 
KS MAD-EGF2 977.4 1.3 5583.7 3.8 
Well-19/GST 715.7 0.9 1427.7 1.0 
MAD-19 782.7 0.9 679.0 0.8 
GST 781.0 0.9 1480.0 1.6 
PPD 31522.7 34.8 
RPMI 905.3 
Table 7.1. Mean cpm and SI obtained from two representative European donors. 
c) 
co 
mean, (range), [SE] cpm mean, (range), [SE] SI n (%) with SI greater than 3 increase or decrease (*) in 
response to reduced protein 
non reduced reduced non reduced reduced non reduced reduced Wilcoxon p valve 
Statistic  
1618.1 1535.9 1.5 1.9 2 4 
Well-EGF1 (148-3805) (81-12445) (0.8-3.5) (0.7-5.9) (10.5) (21.1) 144.0 0.05 
[264.3] [634.0] [0.2] [0.3]  
1100.8 2988.3 1.1 2.4 0 6 
MAD-EGF1 (159-2606) (87-10236) (0.4-2.2) (0.6-7.2) (0.0) (31.6) 189.0 0.00 
[164.61 [692.9] [0.1] [0.5]  
988.3 2416.2 1.0 2.1 0 5 
MAD-EGF2 (77-3365) (93-8047) (0.3-2.1) (0.6-7.1) (0.0) (26.3) 190.0 0.00 
[173.4] [502.8] [0.1] [0.4]  
1176.7 2597.6 1.1 1.9 0 4 
Well-19/GST (147-2768) (109-14419) (0.7-2.3) (0.5-5.1) (0.0) (21.1) 176.0 0.00 
[167.5] [739] [0.1]  
221.3 1315.6 0.8 5.2 0.0 6 
MAD-19 (74-1069) (127-7492) (0.4-1.6) (0.7-39.9) (0) (31.6) 190.0 0.00 
[50.9] [483.3] [0.1] [2.1]  
25123.0 13089.1 102.4 54.8 19 18 
PPD (103-78889) (189-42889) (0.5-475.8) (1.3-234.8) (100) (94.7) 13 . 0* 0.00 
[5952.2] [3102.0] [29.1]  
12719.0 50.8 3239.8 13.3 7 6 
IT° (98-35891) (0.77-159.4) (342-13832) (1.8-73.6) (70.0) (60.0) 6 . 0* 0.03 
[4672.9] [19.7] [1491.1] [6.9]  
1111.1 1624.9 5.0 7.12 9 11 
GST (127-2798) (1161-7799) (1.0-14.9) (0.9-41.5) (47.4) (57.9) 119.0 0.34 
[167.5] [4455.7] [1.0] [2.3]  
128690.2 547.6 19 




RPMI (124-744) - - - - - - - 
[32.8]  
Table 7.2. T cell proliferative responses for PfMSP11 recombinant proteins. 
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Figure 7.1. Lymphoproliferative responses (SI) to; a) non reduced and b) reduced PfMSP1 ig 
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Figure 7.3. SDS-PAGE gel of reduced and non reduced PfMSP1 19 and control proteins. 
lanel=MW markers in kDa 
lane 2=Well-EGF1 reduced 
lane 3=Well-EGF1 non reduced 
lane 4=MAD-EGF1 reduced 
lane 5=MAD-EGF1 non reduced 
lane 6=MAD-EGF2 reduced 
lane 7=MAD-EGF2 non reduced 
lane 8=GST reduced 
lane 9=GST non reduced 
lane 10=MW markers 
lanel=MW markers in kDa 
lane 2=MAD-1 9 reduced 
lane 3=MAD-19 non reduced 




lane 8=PHA reduced 
lane 9=PHA non reduced 
lane 1O=MW markers 
C) 	lanel=MW markers in kDa 
lane 2=MAD-19 reduced 
lane 3=MAD-19 non reduced 
lane 4=MAD/Well-19 reduced 
lane 5=MAD/Well-19 non reduced 
lane 6=Well-19 reduced 
lane 7=Well-19 non reduced 
• lane 8=Well19/GST reduced 
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Reduction and alkylation of the non disulphide-constrained proteins 
(GST and PPD) did not result in an increase in proliferation in the majority of 
cases, and actually caused a significant reduction in responses to PPD and TT 
(see figures 7.1 and 7.2. and table 7.2.). U is a large disulphide-constrained 
molecule. Reduction of this protein mainly resulted in a decreased proliferative 
response. This may be due to its large size; most of its epitopes need the 
disulphide structure to stimulate proliferation. 
However, lymphoproliferative responses to the reduced disulphide-
bonded PfMSP1 19 recombinant proteins are still low compared to the positive 
control proteins PPD and U. Very few individuals' MNC5 proliferated to the 
reduced form of the protein; prevalence of responsiveness ranging from 20 to 
30% of adults (table 7.2.). 
(4) IFNy responses to PfMSP119 
There is a linear relationship between the OD obtained in the lFNy ELISAs and 
log IFNy units (U), so OD values can be converted into U/mi of IFNy by 
comparison with a standard curve (see figure 7.4.). IFNy responses to the 
positive controls PHA and PPD are high (100% for PHA), demonstrating that the 
assay worked and that the cells produced IFNy if appropriately stimulated. 
IFNy responses to PfMSP1 19 recombinant proteins are extremely low, in 
both prevalence and levels; EGF-2 seems to be particularly poor at inducing 
IFNy responses (see table 7.3.). However, individuals that did respond to EGF-
1 and/or the double-motif proteins, produced lFNyto both the Wellcome and 
MAD20 versions indicating that IFNy stimulating T cell epitopes are cross-
reactive for the two forms of PfMSP1 ig. Some donors who produced IFNy in 
response to EGF-1 did not respond to the double-motif protein, indicating that 
processing of the molecule may be important for T cell recognition. 
In the case of lFNy, there is no evidence that reduction of disulphide 
bonds affected the response, either for the PfMSP1 proteins or the control 
proteins. 
... 
1 	I 	111111 I 	I IlIII I 	III1L. 
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log IFN? U/mi 
Figure 74. Standard curve of OD and IFNy U/mi. 
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Antigen Donor  -- n(%) 
responders 4 12 13 15 35 45 50 53 69 79 95 104 110 112 116 117 120 125 167 
RPMI 1 0(0.0) Well-EGF1 3 4 6 2 4(21.1) Weil-EGF1 R 3 23 2(10.5) 
MAD-EGF1 3 3 2(10.5) 
MAD-EGF1 R 3 3 7 3(15.8) 
MAD-EGF2 0(0.0) 
MAD-EGF2 A 3 1 (5.3) 
Well-19/GST 0(0.0) 
Well-19/GST R 2 8 2(10.5) 
MAD-1 9 0(0.0) 
MAD-19R 3 3 2(10.5) 
GST 2 4 2(10.5) 
GSTR 6 3 2(10.5) 
PPD 13 28 40+ 9 40+ 8 31 9 10 16 7 3 5 13 (68.4) 
PPDR 5 10 40+ 3 40+ 25 17 4 8 3 11 11(57.9) 
IT 3 1(5.3) 
TIR 6 1(5.3) 
PHA 40+ 1 40+ 1 40+ 1 40+ 1 40+ 1 40+ 1 40+ 1 40+ 1 40+ 1 40+ 40+ 40+ 40+ 40+ 40+ 1 40+ 1 40+ 1 40+ 1 40+ 1 19 (100) 
Table 7.3. IFN1 responses (U/mi). 
R=reduced form of the protein. 
Measured in international units/mi. 
Blank space equals an IFNy response <2U/ml. 
0) 
Discussion 
Previous studies carried out in our laboratory show that lymphoproliferative 
responses to recombinant proteins representing PfMSP142 (Well-42), but not 
other regions of the PfMSP1 molecule, are associated with resistance to clinical 
malaria in children (Riley eta! 1992a). To further analyse this response, I have 
used recombinant proteins representing PfMSP1 19 and its constituent EGF-like 
motifs to try and map T cell epitopes within this region using peripheral blood T 
cells from malaria immune adult Gambian donors. 
There are several limitations to the measurement of T cell responses to 
malarial antigens using this method (i.e. monitoring peripheral T cell 
proliferation) and these limitations should be taken in to account when 
assessing non-responsiveness. Only small volumes of peripheral blood are 
collected to perform the T cell assay, and only small numbers of T cells are 
tested (105 cell/well). Also many crucial cellular interactions occur deep within 
the body (i.e. within the spleen), so cells isolated from the peripheral blood at 
any one time may only represent a subset of the total malaria-reactive pool 
(Riley et a! 1993). It has also been demonstrated that the number of 
responding individuals will be seriously underestimated unless multiple 
parameters of T cell activation are measured, such as measuring cytokine 
production (Troy-Blomberg et a! 1990). Furthermore, responsiveness of 
individuals varies greatly from wet to dry seasons, and year to year, so total 
responsiveness cannot be predicted from only one survey (Riley eta! 1993). A 
possible drawback of stimulating T cell proliferation in vitro is that the low 
responsiveness seen may actually be an artefact of inappropriate processing of 
the protein by the APCs present in the in vitro experiment. 
After in vitro culture with recombinant proteins, and appropriate control 
proteins, T cells from very few individuals either proliferated or produced IFNy in 
response to PfMSP1 ig. However, I did not measure IL-4 responses, so I may 
have underestimated T cell responses (Troy-Blomberg eta! 1990). Assays 
were performed on 19 adult donors in the low malaria transmission season. 
This is an appropriate time of year to measure T cell proliferative responses to 
malarial antigens as it has been demonstrated that T cells are depleted from the 
peripheral circulation during episodes of acute malaria, so there is a decrease 
in proliferative responses during and at the end of the malaria transmission 
season (Hviid and Theander 1993). T cell proliferative responses were 
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subsequently measured in 16 adults during the rainy season and, as expected, 
responsiveness was found to be much lower than during the dry season (Dr. M. 
Waterfall, University of Edinburgh, personal communication). 
A recent study has also noted low T cell responsiveness to PfMSP1 19 
(Udhayakumar eta! 1995). In this study, T cell responsiveness of malaria-
exposed Kenyan adults was measured to 8 synthetic peptides representing 
linear epitopes of PfMSP1 19. Only 3 of the 8 peptides induced T cell 
proliferative responses in more than 30% of the study population (n=40-104). 
This essentially confirms previous data by Riley eta! (1992a, 1993) that, 
although there are well recognised T cell epitopes within the N-terminus region 
Of PfMSP1, there are few such epitopes within PfMSP119. 
Poor T cell responsiveness to PfMSP1 19 in African adults may be due to 
down regulation of T cell responses in immune adults (reviewed in Riley et at 
1994). Both cell-mediated and antibody-mediated mechanisms of immunity are 
thought to contribute to immunity against malaria, but also contribute to the 
pathology caused by malaria. T cells produce IFNy which activate 
macrophages to produce tumour necrosis factor-alpha (TNF(X) which can result 
in damage to the host as well as the parasite (reviewed in Taverne 1993). Also 
unregulated activation of B cells can result in hypergammaglobulinaemia and 
hyper-reactive malaria splenomegaly (Crane 1986). So immune responses to 
malaria need to be carefully regulated to maintain the delicate balance between 
protection from infection and immune-mediated pathology. CD8+ T cells have 
been reported to suppress CD4+ T cell responses to PfMSP1, probably to avoid 
pathological consequences of persistent immune activation (Hviid and 
Theander 1993). Measuring T cell responses of partially-immune children or 
malaria-exposed travellers, where down regulation of immune responses would 
not have developed, may circumvent this problem. 
However, a factor attributing to the poor recognition of PfMSP1 19 may be 
its possession of disulphide bonds which may hinder the linearisation of 
peptides by APCs for their presentation within the MHC peptide binding groove. 
It has been demonstrated with other disulphide-bonded proteins that reduction 
of the bonds and unfolding of the protein is a prerequisite for antigen 
processing. This allows proteolytic processing enzymes access to the protein 
so forming linear peptides with exposed cysteine residues for T cell recognition 
(Collins eta! 1991). Reduction and alkylation of PfMSP1 19significantly 
increased the proliferative response indicating that processing of the protein 
may be a problem. 
However, correct tertiary structure of a protein has also been 
demonstrated to be important for recognition of the protein. Vidard eta! (1992) 
demonstrated that reduction and alkylation of cysteine residues within 
ovalbumin (OVA) drastically reduced its capacity to stimulate some OVA-
specific T cell clones. They found that presentation of some epitopes was not 
influenced by denaturation, while others were either increased or decreased. 
Similarly, Atassi et a! (1989) demonstrated that T cell lines responded well to 
native lysozyme but poorly to an unfolded version of the protein. As APCs 
internalise and digest the protein to peptide fragments, it would be expected 
that T cell recognition would be independent of tertiary structure of the protein. 
However in these cases, presentation of the tertiary structure to the APC is 
important for correct antigen presentation. In summary, alterations in the native 
form of an antigen can affect its processing pattern. Whether this is important for 
the presentation of T cell epitopes to PfMSP1 19 in vitro is unknown. 
Even with reduction of the protein, T cell lymphoproliferative responses to 
PfMSP1 19 are still low (20 to 30%). An effect of the disulphide structure on 
processing was also suggested by Udhayakumar eta! (1995), however, they 
measured T cell responses to linear peptides, so this does not explain the low 
responsiveness found in their study. So, even though antigen processing of the 
disulphide bonded antigen by APCs appears to be a limiting factor, the main 
reason for lack of T cell responsiveness to PfMSP1 19 appears to be that this 
region lacks T cell epitopes. Using a computer algorithm for predicting T cell 
activating epitopes, the above authors were unable to find any predicted T cell 
epitope within PfMSP1 ig, emphasising this possibility. This does not bode well 
for a PfMSP1 19 subunit vaccine. However, the inclusion of known helper T cell 
epitopes from elsewhere may allow an effective antibody response to be 
induced. 
Hui eta! (1994a) found that immunisation of rabbits with recombinant 
proteins representing PfMSP142 induces antibodies with strong inhibitory 
activity against parasite growth in vitro. These antibodies were specific for 
PfMSP11 as depletion of PfMSP1 19-specific antibodies on an affinity column 
abolished the growth inhibitory activity of the serum. However, immunisation of 
rabbits with PfMSP119 induced antibodies which did not inhibit parasite growth 
in vitro. This suggests that PfMSP1 19 contains epitopes for the production of 
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specific antibodies, but that T cell epitopes within PfMSP1 19 do not induce 
effective inhibitory antibodies, while presumably T cell epitopes within the N-
terminus of PfMSP142 construct, i.e. PfMSP133, do. The authors conclude that 
the nature/specificity of T helper epitopes is crucial to the induction of 
biologically relevant/protective antibodies. On the other hand, secondary 
processing of PfMSP142 may result in a conformational change in PfMSP142 
compared to PfMSP1 ig, which could affect the specify of PfMSP1 19-specific 
antibodies. 
However, it seems possible that the induction of protective antibodies to 
PfMSP11 is dependent on T cell epitopes located within PfMSP133. 
Secondary processing of PfMSP142 to PfMSP133 and PfMSPlig, may mean 
there is no cognate interaction between T and B cells to form an adequate 
antibody response to PfMSP119. In the Udhayakumar study (1995), it was 
found that T cell proliferative responses to synthetic peptides representing 
PfMSP133 were more prevalent than peptides representing PfMSP119. 
In a continuation of their work, Hui et a! (1 994b) tried to further 
characterise T helper cell epitopes within PfMSP142. Mice were primed with a 
sub-optimal dose of native PfMSP1 or baculovirus PfMSP142, and boosted with 
homologous or heterologous native PfMSP1 or PfMSP142. Cross priming with 
heterologous PfMSP1 was as effective as homologous PfMSP1 at inducing 
antibody of similar titre to PfMSP1 suggesting conserved or cross-reactive 
epitopes provide T cell help. Data presented here indicates that T cell epitopes 
in PfMSP11 are cross-reactive. However, these authors found PfMSP142 was 
not as effective at inducing PfMSP142-specific antibodies as native PfMSP1. 
This lead the authors to suggest that either recombinant PfMSP142 does not 
properly represent native PfMSP142 or dominant T helper cell epitopes for 
PfMSP142 antibody production do not come from PfMSP142. 
The ability of vaccination of mice with GST-cleaved recombinant 
PyMSP1 15 protein to induce a protective immune response against challenge 
infection (Ling eta! 1994) contrasts with the inability of PfMSP11 immunisation 
of rabbits to induce biologically relevant antibodies (Hui eta! 1994a). 
However, there are crucial differences between PfMSP11 and its analogue 
PyMSP115. Although most of the cysteine residues are conserved between 
PfMSP11 and PyMSP115, the intervening amino acid sequence is not. Also, the 
first cysteine pair of the first EGF-like motif of PyMSP1 15 is missing, suggesting 
that there is a structural/conformational difference between PfMSP119 and 
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PyMSP1 15. This may result in differences in antigen processing by APCs, 
leading to different immune responses. Also, the dissimilarities in amino acid 
sequences may result in differences in the repertoire of T and B cell epitopes. 
An alternative explanation is that relevant T helper epitopes may have 
been present in the PfMSP1 19 construct, but may have been rendered non-
immunogenic due to immunisation conditions. Adjuvant has been 
demonstrated to be important to both immunogenicity and protection (reviewed 
in Hui et al 1994a). Protection of animals immunised with PyMSP115 is 
dependent upon the adjuvant used (C. A. Long, Hahnemann University, 
Philadelphia, PA, personal communication in Hui et a! 1994a). Different 
adjuvant formulations may alter the selection/inhibition of different proteases or 
processing pathways, or activate/inhibit different types of APC which influence 
the generation of T cell epitopes. Interactions between adjuvant and genetic 
background have also been demonstrated. Various combinations of mouse 
strains and adjuvants affected the production of growth inhibitory antibodies, 
possibly as a result of differences in processing of the antigen, resulting in the 
generation of different peptide fragments, able to interact with different sets of 
MHC class II antigens (Hui and Chang 1992, Chang eta! 1994, Golding et al 
1994). 
Differences in MHC haplotype could be a reason for T cell non-
responsiveness to PfMSP119. The influence of MHC haplotype on immune 
responsiveness in mice has been reported for several malarial antigens, e.g. 
the circumsporozoite antigens of P. falciparum and P. vivax (Del Giudice et a! 
1988), RESA (Lew eta! 1989b), and gamete surface antigens (Good eta! 
1988b). Genetic responsiveness to PfMSP11 has been noted in mice, as 
BALB/c mice make antibodies to this protein while C57131/10 mice do not (Hui 
eta! 1994a). 
Even though there appears to be genetic restriction of T cell 
responsiveness in different inbred mouse strains, MHC restriction of T cells has 
been difficult to demonstrate in out bred human populations. Guttinger et a! 
(1991) found that the T cell epitopes of the conserved block 3 of PfMSP1 can be 
recognised in association with many different MHC class II molecules. 
Heterogeneity of the human class II gene complex and the fact that T cell 
epitopes can associate with several different class II molecules makes it unlikely 
that class II determined non-responsiveness will prove to be a problem in the 
development of a subunit vaccine for use in out bred human populations (Riley 
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et a! 1991, 1992b). Data presented in chapter 4 and in Taylor et a! (in press) 
suggests that antibody responses to PfMSP1 ig, by malaria-exposed individuals, 
is not genetically determined. However, I have only tested the Mandinka ethnic 
group. So in future work, may be the Fula and Wollof ethnic groups should also 
be tested. However, data presented here is similar to Udhayakumar et a! 
(1995) where they looked at genetically different populations in Kenya, which 
may mean that T cell responses are not genetically restricted. 
Previous data from our laboratory demonstrate that human T cells 
preferentially recognise protein constructs representing the N- rather than the 
C-terminus of PfMSP1 (Riley et a! 1993). My own findings show that there is 
poor T cell proliferative responses to this region. Strategies are needed to 
increase T cell help to result in the production of effective antibody responses 
against PfMSP119. The fact that the highly conserved T cell epitopes of p190L 
(Sinigaglia et a! 1988), recognised in association with many different HLA class 
II molecules (Guttinger et a! 1991), are recognised by a high proportion of 
Gambian adults (Riley et a! 1992a, 1993) is very promising for vaccine 
development. Inclusion of this region of PfMSP1 in a vaccine as well as 
PfMSP1 19 may induce T cell help for the production of antibody in most 
vaccinated individuals, but not necessarily antibodies of biological significance, 
i.e. protective/growth inhibitory antibodies. More attention will have to be paid 




1. PfMSP11 as a vaccine candidate 
Antigens on the merozoite surface are obvious candidates.for inclusion within a 
blood stage vaccine. There is a growing body of evidence that immune 
responses, mainly antibody-mediated, to the major surface antigen on the 
merozoite, MSP1, confer protection from clinical symptoms of malaria. This 
evidence comes from immunisation of animals with native or recombinant 
MSP1, passive transfer of immune serum from animals immunised with MSP1 
and the association of antibody to PfMSP1 with clinical immunity to malaria in 
semi-immune children. The highly conserved C-terminus of the molecule, 
PfMSP1 19, is the target of the majority of PfMSP1 -specific mAbs which inhibit 
merozoite invasion in vitro. Also, serum from rabbits immunised with PfMSP142 
was able to inhibit the in vitro growth of parasites from either PfMSP1 family 
suggesting, due to the dimorphic nature of PfMSP133, that the target(s) of the 
inhibitory antibody was located within the highly conserved PfMSP119 region. 
A major problem in the development of a vaccine against malaria is the 
extensive polymorphism of malaria antigens. PfMSP1 19, however, is a highly 
conserved protein; only four out of its 96 amino acid residues are not conserved 
and these are dimorphic. PfMSP1 ig-specific growth inhibitory antibodies, 
monoclonal or polyclonal, are effective against parasites expressing either 
PfMSP1 allele, which is encouraging evidence that a recombinant vaccine 
consisting of the highly conserved EGF-like motif region of PfMSP1 19 may be 
effective in vaccination against all parasite strains. 
Data presented here lend substantial additional support that PfMSP119 is 
a good candidate antigen for a blood stage vaccine: 
(1) I have found that PfMSP119 is naturally antigenic in a malaria-exposed 
human population and that antibody responses to the two allelic forms of 
PfMSP1 19 are cross-reactive. Despite the low prevalence of the Wellcome 
allele in The Gambia (<5%, Conway and McBride 1991), Gambian antibody 
responses to the two allelic forms of PfMSP1 19 are highly correlated, suggesting 
that immunisation with one allelic form of PfMSP1 19 can induce an antibody 
response against the other allelic form. This is encouraging for vaccine 
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development as antibody responses would be boosted by infection even if the 
infecting strain was not the same as the vaccinating strain. 
I have found that the prevalence of antibodies to the second and the double 
EGF-like motif proteins is higher in children who experience asymptomatic 
infections than in children who develop clinical malaria. I found that antibody 
responses to PfMSP133 are also associated with resistance to clinical malaria in 
Gambian children. 
Finally, I have found that human serum antibodies are able to inhibit the 
binding of invasion inhibitory mAbs to recombinant PfMSP1 19 in competition 
ELISAs and that human polyclonal lgG, affinity purified to PfMSP1 ig, is able to 
inhibit the in vitro growth of parasites. This inhibition was effective at 
physiological Ig levels and was functionally cross-reactive for the two allelic 
forms of PfMSP1. 
Taken together, my data strongly support a continued interest in 
PfMSP1 19 as a component of a malaria vaccine. However, there are a number 
of questions which remain to be answered, and a number of potential 
complications. 
2. Immune selection pressure within PfMSP119 
Although the C-terminus of PfMSP1 is highly conserved, it has been suggested 
that selection through immune pressure may result in mutations leading to 
amino acid diversity in protective epitopes (Miller et a! 1993). This may have 
important consequences. For example, the change in a single amino acid 
residue in the PfMSP1 19 analogue in P. yoelii (PyMSP1 15) destroys the 
protective effect of the mAb 302 (Burns eta! 1989b), and the antigen could no 
longer be immunoprecipitated by this mAb. The protective effect of mAb302 
varies for different P. yoe!ii cloned lines of the same sequence (Daly et a! 
1992). 
MAb NIMP M23, which binds to an epitope within the C-terminus of 
PcMSP1 (McKean eta! 1993a), significantly delays the onset of parasitaemia 
of P. chabaudi chabaudi (Boyle et a! 1982). The protection elicited by this mAb 
is strain-specific (Brown eta! 1985); a single amino acid determines this 
specificity (McKean eta! 1993b). Parasites can develop resistance to the 
inhibitory effect of NIMP M23 when grown in vivo in mAb-secreting hybridoma 
mice (Wood eta! 1989), although the C-terminal amino acid sequences of the 
susceptible and resistant parasites were not different (unpublished data cited in 
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McKean et a! 1993b). However, antibody resistance is not always associated 
with changes in amino acid sequence (Parry et a! 1990, Sadziene et a! 1992) 
and may be due to other factors such as post-translational modifications. 
This may not bode well for a vaccine based on PfMSP119. When the 
majority of the population has become immune to the parasite, immune 
pressure may select for parasites carrying point mutations in Pf MSP 119 that are 
no longer recognised by the host's protective antibodies. On the other hand, it 
is not clear that the findings in these two rodent malarias have direct 
implications for P. falciparum. MAb NIMP M23 is not a particularly protective 
mAb, delaying the onset of parasitaemia rather than preventing parasite growth 
completely. Also the sequences of the C-terminus of P. chabaudi chabaudi AS 
and CB are so dissimilar (only 78% homology) that hyper immune serum raised 
against one strain fails to cross-react with the heterologous strain (McKean et a! 
1993b), so it is not surprising that strain-transcending immunity was not induced 
by the passive transfer of the mAb NIMP M23. There is also little sequence 
homology between the C-terminus of P. yoelii strains (77%) (Daly eta! 1992). 
Until recently, the C-terminal sequence had only been determined for 
four P. falciparum isolates, and these were laboratory cultured lines, grown in a 
uniform environment in the absence of immune pressure (Blackman et a! 
1991a). The situation in the field may be different, with the presence of more 
diversity in this region of the molecule due to selection of new variants through 
immune pressure. However, a study carried out by Jongwutiwes et a! (1993) 
demonstrated limited diversity in the field. Of 19 Thai wild isolates, the authors 
identified 18 nucleotide substitutions in the C-terminus of PfMSP1, 9 of which 
were in PfMSP1 ig, all resulting in dimorphic amino acid substitutions. They 
found that residues at the PfMSP142 and Pf MSP 119 cleavage sites were 
conserved, as were all 12 cysteine residues. 
However, the question is: would this limited amount of variation within 
PfMSP1 19 be enough to impede the production of protective immunity? The 
four amino acid differences between the two allelic forms of PfMSP1 19 do not 
appear to alter the ability of PfMSP142-specific antibody to inhibit parasite 
invasion in vitro, as antibody raised to parasites of one allelic form inhibits 
parasite growth of either allelic family (Chang et a! 1992 and data presented in 
chapter 5). Also, all of the four PfMSP1 19-specific invasion inhibitory mAbs bind 
to both allelic forms of PfMSP1 19. These invasion inhibitory mAbs bind to 
different epitopes within PfMSP119; 12.8 and 5B1 bind to the first EGF-like motif 
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(Chappel and Holder 1993), 4H9/19 binds to the second EGF-like motif (Cooper 
eta! 1992) and 12.10 binds to the double EGF-like motif protein (Chappel and 
Holder 1993). It seems therefore that as there are multiple protective epitopes 
within PfMSP119; variation in sequence, if it develops, is unlikely to develop in 
every protective epitope. The use of a protein with multiple protective epitopes 
lessens the likelihood of the vaccine becoming ineffective through mutations in 
protective epitopes. Miller eta! (1993) point out that variation with polio strains 
is not a problem for the polio vaccine as there are also invariant epitopes which 
are fixed by structural requirements, and this could be the case with PfMSP1 19. 
Immunity based on a epitope which is conserved for structural and/or functional 
reasons means that problems due to antigenic diversity through point mutations 
are less likely to occur. PfMSP1 19 is likely to be under structural constraint (due 
to disulphide bonding and formation of the two putative EGF-like motifs), 
suggesting that the sequence of PfMSP1 19 may be able to vary only within very 
limited constraints. 
3. Strain-specificity within PfMSP119 
Despite the fact that invasion inhibitory mAbs recognise the two allelic forms of 
PfMSP1 19, and that polyclonal sera cross-react in their inhibitory action on 
merozoite invasion, it has not been unequivocally demonstrated that 
immunisation of animals with one allelic form of PfMSP1 protects animals from 
parasites expressing the heterologous allele. Etlinger eta! (1991) 
demonstrated that total protection from heterologous challenge infection could 
be induced in vaccination with PfMSP1. However, the vaccinating strain (Ki) 
and the challenge strain (FUP; MAD20 type) share 25% homology in the N-
terminus of PfMSP1 so the protection observed could not be definitely attributed 
to epitopes within conserved regions of the C-terminus of the molecule. Apart 
from the PatarrOyo SPf66 vaccine (contains block 1 of PfMSP1), humans have 
not been vaccinated with PfMSP1, so it is not known if a vaccine based on 
PfMSP1 19 would induce strain-specific immunity. It is not surprising that 
animals vaccinated with a recombinant protein representing PyMSP1 15 were 
not protected against a heterologous challenge infection as this is a region of 
heterogeneity in P. yoe!ii. The question of whether vaccination of monkeys with 
PfMSP119 would provide protection against a heterologous challenge infection 
has only once been addressed (Burghaus et al manuscript in preparation). In 
this study neither homologous nor heterologous challenge was controlled. In 
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the Kumar study (1995), protection was obtained with Pf MSP 119 vaccination, 
however, a heterologous challenge was not tested. 
It has been suggested that anti-malarial immunity is strain-specific in 
humans, as seen with the experimental infection with malaria for the treatment 
of neurosyphilis. The effect of a primary infection on the subsequent infection 
was monitored. It was found that prior infection did not totally protect individuals 
from a subsequent infection, but that homologous reinfections induced less 
clinical symptoms of malaria than a heterologous challenge (Jeffery 1966). 
However, it has also been demonstrated that a similar level of immunity to that 
obtained against homologous strains can be obtained against the heterologous 
strain (Boyd and Kitchen 1945). Complete susceptibility to heterologous strains 
has been reported (James eta! 1932, Boyd eta! 1936), but this has also 
occurred with secondary homologous infections (James and Shute 1926). In 
1936, Boyd and Kitchen reported that P. falciparum induced immunity to 
homologous, but not to heterologous strains; but in 1945 they changed their 
opinion (reviewed in Baird 1995). So, there appears to be a degree of 
uncertainty as to whether immunity to malaria in humans is strain-specific or not. 
The fact that pooled lgG from immune individuals, passively transferred 
into non-immune recipients, enables these individuals to control their 
parasitaemias to levels below which clinical symptoms occur (Cohen et a! 
1961, McGregor et a! 1963, Sabchareon et a! 1991) suggests that there is a 
broad strain-transcending antibody response made in immune individuals. On 
the other hand, in vitro studies have shown that human immune sera inhibit 
parasite growth in a strain-specific manner (Vernes et a! 1984, Haynes eta! 
1987, Sy et a! 1990). It is difficult to correlate these results with PfMSP1 - 
specific immunity due to the potential contribution of other malarial antigens, 
which may provide strain-specific immunity. However, PfMSP1 -specific 
antibody, polyclonal and monoclonal, inhibits merozoite invasion of parasites 
expressing either allele (see chapter 5). 
4. Antigenic integrity of the PfMSP119 vaccine antigen 
Siddiqui eta! (1987), found that monkeys immunised with native PfMSP1 were 
completely protected from challenge infection. The native PfMSP1 used for 
vaccination was affinity purified on a chromatography column using a mAb 
specific for the C-terminus of PfMSP1, so the vaccinating preparation would 
have been enhanced with C-terminal proteins (Chang eta! 1992). It is 
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encouraging for vaccine development that immunisation of animals with 
recombinant proteins representing PfMSP1 ig or its homologue in P. yoeIi 
protects animals from a lethal challenge infection. However, not all vaccinated 
animals are protected. 
A major factor in antigen quality may be the expression system used for 
the production of the recombinant protein. Correct disulphide linkages, within 
PyMSP115, have been demonstrated to be vital for inducing, and being 
recognised by, protective antibody (Ling eta! 1994). Immunisation of rabbits 
with PfMSP142 produced in a baculovirus expression system induces 
antibodies which inhibit merozoite invasion in vitro, but PfMSP142 produced in a 
yeast expression system does not (Chang eta! 1992). Production of the 
double EGF-like motif in a bacterial expression system results in an antigen 
which can protect mice from P. yoe!ii infection (Daly and Long 1993,1995, Ling 
et a! 1994) but a similar product does not protect monkeys from P. falciparum 
infection (Burghaus eta! manuscript in preparation). PfMSP142 produced in a 
bacteria expression system did not protect monkeys from infection, but 
PfMSP1 19 produced in yeast protected two of four vaccinated monkeys from a 
lethal challenge infection (Kumar eta! 1995). Proteins produced in different 
expression systems may have different post-translational modifications which 
could affect immunogenicity and production of protective immune responses. 
However, the difference in protection obtained in these immunisations 
may be due to the different adjuvants used rather than differences in the protein 
produced by the different expression systems. The choice of adjuvant has a 
profound effect on the protection obtained. Immunisation with MSP1 proteins in 
Freund's adjuvant seems to result in protection against challenge infection, 
whereas immunisation with the same protein in a different adjuvant does not 
(Daly and Long 1993, Ling et a! 1994, C. Long personal communication cited 
in Hui et a! 1994a, Kumar et a! 1995, Burghaus et al manuscript in 
preparation). However, Freund's adjuvant is not safe to use in humans. 
5. Imprinting PfMSP1 19 immunogenicity 
Another potential problem of the use of Pf MSP 119 in a vaccine is its apparently 
poor immunogenicity: that despite being a conserved protein, only 60% of an 
adult, malaria-exposed population possess antibodies to this protein. The 
immunogenicity of the protein will have to be increased for an effective immune 
response to be induced by vaccination. There are many theories as to why 
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PfMSP1 19 is poorly antigenic (see chapter 4), but hopefully the provision of Th 
epitopes and the high concentration of PfMSP119 in the immunogen will 
circumvent these problems. Vaccination of mice with the recombinant protein 
representing PyMSP1 15 provided better protection than with the whole PyMSP1 
molecule, suggesting that the immune response was concentrated on the 
critical epitopes for the induction of immunity (Ling et a! 1994). Also, monkeys 
immunised with PfMSP1 19 plus T cell epitopes from tetanus toxoid were 
protected from challenge infection (Kumar eta! 1995), while monkeys 
immunised with PfMSP1 19 alone were not (Burghaus et al manuscript in 
preparation). It may be possible to enhance the immunogenicity of PfMSP1 19 
by the inclusion of cytokines such as IL-2 (Kawamura et a! 1985, Good et a! 
1988a), by the use of immunomodulating adjuvants (Hui eta! 1991, Hui and 
Chang 1992), and by conjugating the immunogen to a larger protein (Ballou et 
a! 1985, Herrington et a! 1987, Daly and Long 1993), see chapter 7. 
6. Should other epitopes of PfMSP1 be included in a vaccine? 
MSP1. has been shown to contain other protective regions. Passive transfer of 
the mAb Pca5C10/66, which maps to epitopes within blocks 4 and 8, protects 
mice against challenge infection with P. chabaudi (Lew et a! 1989, 1990). 
However, its epitope is in a region of microheterogeneity, and so is likely to be 
strain-specific (Lew and Beck 1990). 
A small sequence from block 1 is included in the SPf66 synthetic peptide 
vaccine, and has been suggested to confer some degree of protection (Molano 
eta! 1992). Antibody responses to the N-terminus of PfMSP1 have been 
demonstrated to be associated with resistance to clinical malaria in malaria-
exposed individuals (Riley et a! 1992a, Tolle et a! 1993) and vaccination of 
monkeys with synthetic peptides representing PfMSP1 83 induced partial 
protection in monkeys (Cheung et al 1986, Patarroyo eta! 1987a, 1987b). 
However, bacterial recombinant proteins representing PfMSP183 did not 
protect monkeys from infection (Knapp eta! 1988). Rabbit antibodies raised to 
native PfMSP183 were unable to inhibit parasite growth in vitro. As this region 
of the molecule is shed from the merozoite before RBC invasion, it has been 
suggested that it may not be involved in the invasion process and may even 
protect fragments of the molecule which are important to the invasion process 
(Strych et a! 1987). It has been demonstrated that certain antibodies specific to 
PfMSP183 can block the binding of antibodies that bind to PfMSP119, 
suggesting that these N-terminal antibodies may contribute to immune evasion 
by blocking the binding of protective/functional antibodies to the C-terminus 
(Wilson eta! 1987). 
So other regions of the PfMSP1 molecule appear to confer some degree 
of protection, and appear to be important in inducing I cell help to produce 
protective/functional PfMSP1 19-specific antibody (Hui et a! 1994a). However, 
careful choice will have to be made for the inclusion of other epitopes from the 
PfMSP1 molecule as it has been demonstrated that non-protective PfMSP1-
specific antibodies can inhibit the binding of protective antibodies (Wilson et a! 
1987), and that immunodominant epitopes may divert antibody production away 
from protective epitopes (Schofield 1991). 
7. Mechanisms of immunity induced by PfMSP119 
The mechanism by which PfMSP1 19-specific antibodies inhibit merozoite 
invasion is unknown. MSP1-specific antibodies have been shown to 
agglutinate merozoites (Epstein eta! 1981) and MSP1 antibodies are found in 
immune clusters of merozoites formed in the presence of polyspecific antibody 
(Lyon et a! 1989). My data (chapter 5) show that antibody to PfMSP1 19 
prevents merozoite invasion. If secondary processing of PfMSP142 is a 
prerequisite for invasion (see below), PfMSP1 19-specific antibodies may 
sterically hinder the binding of the protease which causes the this proteolysis. 
Or, if the EGF-like motifs bind to an EGF receptor on the RBC, PfMSP1 19-
specific antibodies may sterically hinder this binding. As the majority of 
PfMSP1 19-specific human sera antibodies are of the lgGl subclass, it is 
possible that antibody may opsonise merozoites to be destroyed by phagocytes 
and compliment. I have not measured the effect of complement, but there is an 
indication of antibody-dependent cellular-inhibition (ADCI) as there is a 
reduction in parasitaemia of cultures grown in the presence of monocytes and 
PfMSP1 ig-specific (first EGF-like motif) Ig compared with parasites grown in 
antibody without monocytes (see chapter 5). 
From data presented here, antibody responses to PfMSP133 also appear 
to be associated with protection from clinical malaria, although only in the 
Gambian study (see chapter 6). The reason this was seen in The Gambia, and 
not in Sierra Leone, may be due to the high frequency of this allele (MAD20) in 
The Gambia (antibody responses were measured using recombinant protein 
representing the MAD20 version of PfMSP133). The frequency of expression of 
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this allele in Sierra Leone has not been measured. However, recognition of 
PfMSP133 by Sierra Leonean sera is high, so it is not known why it is 
associated with protection in one study and not in another. The function of 
PfMSP133-specific antibodies is unknown, but could include such mechanisms 
as the inhibition of secondary processing of PfMSP142. PfMSP133 may also 
provide T cell help for B cell production of protective/functional antibody. There 
is evidence that there are T cell epitopes within PfMSP133 that are important for 
protection elicited by PfMSP1 19. Hui et a! (1 994a) demonstrated that serum 
from rabbits immunised with PfMSP1 19 was unable to inhibit parasite growth in 
vitro, while serum from rabbits immunised with PfMSP142 could. The antibodies 
responsible for the growth inhibitory action could be absorbed out of the 
preparation on a PfMSP119 affinity column. This suggests that PfMSP1 19-
specific antibodies are responsible for growth inhibition, but that epitopes within 
PfMSP133 may be important for their induction. It would be interesting to 
measure T cell responses to PfMSP133 and see, through which cytokines are 
produced, whether a Th response is evoked. It is possible that antibody 
responses to PfMSP133 may also be important in the growth inhibitory effect of 
antibodies raised to PfMSP142. 
Contrary to a previous study (Freeman and Holder 1983), recent work by 
Daly and Long (1995) demonstrated that the passive transfer of serum from 
mice vaccinated with MSP1 (native MSP1-specific antibody was used in the 
Freeman and Holder 1983 study and PyMSP115-specific antibody in the Daly 
and Long 1995 study) conferred protection to naive recipients, suggesting that 
protection was antibody mediated. 
It has been demonstrated by Blackman etal. (1994) that inhibitory mAbs 
inhibit the secondary processing of PfMSP142 to PfMSP133 and PfMSP1 19 and 
that non-inhibitory mAbs can block the inhibition of secondary processing. This 
suggests that the specificity of the antibody induced determines its 
effectiveness. This may explain why vaccination of animals with PfMSP1 19 or 
PyMSP115 does not induce protection in all vaccinated animals; the relative 
concentrations and affinities of the blocking versus the inhibitory antibodies will 
determine whether the antibody response is protective or not. 
In the morbidity survey reported in chapter 6, the prevalence of antibody 
responsiveness to the double and second EGF-like motif proteins was always 
higher in children who experienced asymptomatic infections than in children 
who experienced clinical infections. However, there was never a 100% 
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association of antibody responsiveness with protection (except for Gambian 
children to the second EGF-like motif). This may be due to the presence of non-
protective, blocking PfMSP11 antibodies (the ELISA method used does not 
differentiate between inhibitory and blocking antibody). There is also the 
possibility that these unprotected children may have produced lgG antibodies of 
an inappropriate subclass, although, lgG antibodies of any subclass should be 
able to physically block the binding of other antibodies. 
Thus, a major concern, for the use of PfMSP1 19 in a vaccine, is that the 
correct specificity of antibody is produced. It is possible, and needs to be 
investigated, that this specificity may be controlled by Th epitopes. 
8. The function of MSP1 
As yet, no functional role has been attributed to MSP1. It has been postulated 
that MSP1 may be involved in a receptor/ligand interaction, binding to RBCs in 
a sialic-acid dependent manner (Perkins and Rocco 1988). MAb 5131, which 
binds to the first EGF-like motif (Chappel and Holder 1993), can inhibit the 
binding of MSP1 to the ABC, and can also inhibit RBC invasion in vitro, 
suggesting that the function of MSP1 may be to attach to the merozoite to the 
ABC so that invasion can occur. However, only intact MSP1 binds to the RBC, 
but the protein on the merozoite surface is fully processed, so there is some 
controversy whether MSP1 is important for binding to the RBC. 
However, PfMSP1 19 is taken into the ABC bound to the surface of the 
merozoite, and it has been suggested that the secondary processing event of 
PfMSP142 is a pre-requisite for parasite invasion (Blackman eta! 1991b). 
Comparison of the amino acid sequence of PfMSP1 identified two putative 
epidermal growth factor (EGF)-like motifs in PfMSP119 (Blackman eta! 1991a). 
EGF-like motifs have been found in a variety of diverse proteins, their common 
feature is that they are extracellular and are thought to be involved in cell-cell 
interactions (reviewed in Appella et a! 1988). EGF5 interact with specific 
receptor proteins; it has been suggested that bacteria and viruses use growth 
receptors to enter cells (Isberg 1991, Eppstein et a! 1985), and EGF receptors 
have been found on the RBC surface (Engelmann eta! 1992). EGFs are 
usually activated by proteolytic processing (Davis 1990), suggesting that the 
secondary processing of PfMSP142 may activate some function mediated 
through the EGF-like motifs of PfMSP1 19. This idea is supported by the finding 
that inhibition of secondary processing inhibits RBC invasion (Blackman et a! 
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1994). The majority of PfMSP1-specific mAbs which inhibit merozoite invasion 
in vitro bind to epitopes within the two EGF-like motifs of PfMSP1 i (Copper et 
a! 1992, Chappel and Holder 1993). 
Alternatively, it has been suggested that PfMSP1 19 may have other 
biochemical functions such as signal transduction, once inside the RBC, 
allowing differentiation to occur, and that this signalling may be inhibited by 
antibody binding (Holder and Blackman 1994). It is not known why primary and 
secondary processing occurs, but it has been suggested that they might induce 
conformational changes in the protein that result in activation or acquisition of 
function (Holder and Blackman 1994). It has also been suggested that primary 
processing may be a form of immune evasion, directing antibodies to 
immunodominant regions; the immune complex is then shed at invasion (Strych 
eta! 1987). Secondary processing is carried out by a parasite protease 
(Blackman and Holder 1992, Blackman et a! 1993), and these authors 
speculate that the function of this processing may be to expose PfMSP1 19 so 
that it can interact with a receptor on the RBC surface. However, attempts to 
answer this question, by demonstrating the binding of PfMSP1 19 on liposomes 
to a receptor on the RBC surface, have been unsuccessful (Holder and 
Blackman 1994). 
9. Closing comments 
Data presented here is in agreement with the general consensus that PfMSP1 19 
is a very promising candidate antigen for a blood stage vaccine against malaria 
(Diggs eta! 1993). Obstacles to be overcome in the future include; 1) to make 
PfMSP1 19 more immunogenic, probably by the inclusion of relevant T cell 
epitopes and choice of adjuvant, 2) to develop strategies to control the fine 
specificity of the antibody induced as, PfMSP1 19 can also induce non-protective 
antibodies which can compete with protective antibodies, and 3) to determine 
whether immune pressure will select different PfMSP1 19 sequences which 
would reduce the efficacy of the vaccine in subsequent years. 
KIN 
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Appendix 1 
Extra data for chapter 7 
cpm (SI) cpm (SI) Acpm (ASI) 
Donor Antigen unreduced reduced reduced-unreduced 
Well-EGF1 935.5 (1.1) 1181.0 (1.8) 245.5 (0.6) 
MAD-EGF1 675.6 (0.8) 794.2 (1.2) 118.6 (0.7) 
MAD-EGF2 554.5 (0.7) 896.9 (1.1) 342.4 (0.6) 
Well-19/GST 640.9 (0.8) 1049.9 (1.6) 409.0 (0.5) 
4 MAD-19 143.8 (0.6) 547.8 (2.3) 404.0 (0.3) 
PPD 19187.7 (78.7) 8191.8 (33.6) -10995.9 (2.3) 
11 1233.0 (5.1) 451.7 (1.9) -748.3 (2.7) 
GST 848.1 (3.5) 666.8 (2.7) -181.3 (1.3) 
RPMI 243.9 
PHA 31503.2 (129.2)  
Well-EGF1 921.2 (1.8) 1481.5 (1.0) 560.3 (1.9) 
MAD-EGF1 895.5 (1.8) 967.4 (0.6) 71.9 (2.8) 
MAD-EGF2 826.9 (1.6) 940.9 (0.6) 114.0 (2.6) 
Well-19/GST 698.9 (1.4) 1635.4 (1.1) 936.5 (1.3) 
12 MAD-19 204.4 (0.7) 1080.3 (3.4) 875.9 (0.2) 
PPD 36127.5 (114.9) 15436.3 (49.1) -20691.2 (2.3) 
IT. 
GST 507.2 (1.6) 1506.8 (4.8) 999.6 (0.3) 
RPMI 314.5 
PHA 48222.5 (153.3)  
Well-EGF1 148.2 (1.2) 80.6 (0.7) -67.6 (1.7) 
MAD-EGF1 158.6 (1.3) 87.2 (0.8) -70.8 (1.7) 
MAD-EGF2 76.5 (0.6) 92.8 	- (0.8) 16.3 (0.8) 
Well-19/GST 147.1 (1.2) 108.5 (1.0) -38.6 (1.3) 
13 MAD-19 74.3 (0.6) 126.7 (1.0) 52.4 (0.6) 
PPD 1025.3 (7.8) 188.8 (1.4) -836.5 (5.4) 
TI 
GST 127.3 (1.0) 116.1 (0.9) -11.2 (1.1) 
RPMI 130.8 
PHA 52611.7 (402.2)  
Well-EGF1 3432.2 (1.4) 3690.8 (0.9) 258.6 (1.6) 
MAD-EGF1 1992.0 (0.8) 9002.4 (2.2) 7010.4 (0.4) 
MAD-EGF2 1833.0 (0.8) 4444.5 (1.1) 2611.5 (0.7) 
Well-19/GST 1788.0 (0.8) 4428.2 (1.1) 2640.5 (0.7) 
15 MAD-19 265.8 (1.6) 2430.5 (14.7) 2164.7 (0.1) 
PPD 78888.6 (475.8) 38927.6 (234.8) -39960.9 (2.0) 
TI 
GST 2399 (14.5) 4035.2 (24.34) 1636.2 (0.6) 
RPMI 165.8 
PHA 50104.4 (302.2)  
Well-EGF1 682.2 (1.2) 1834.1 (3.0) 1151.9 (0.4) 
MAD-EGF1 358.0 (0.5) 2978.2 (4.8) 2620.2 (0.1) 
MAD-EGF2 797.8 (1.5) 2328.2 (3.8) 1530.4 (0.4) 
Well-19/GST 721.7 (1.3) 1310.4 (2.1) 588.7 (0.6) 
35 MAD-19 158.7 (0.8) 933.3 (4.4) 774.6 (0.2) 
PPD 12534.2 (59.5) 7226.8 (34.3) -5307.4 (1.7) 
TI 7213.5 (34.3) 3033.1 (14.4) -4180.4 (2.4) 
GST 551.9 (2.6) 619.9 (2.9) 68.0 (0.9) 
RPMI 210.5 
PHA 73522.2 (349.3)  
Well-EGF1 659.9 (1.4) 1385.2 (1.8) 725.3 (0.8) 
MAD-EGF1 608.0 (1.3) 997.4 (1.3) 389.4 (1.0) 
MAD-EGF2 484.0 (1.0) 1243.4 (1.7) 759.4 (0.6) 
Well-19/GST 528.8 (1.1) 1074.2 (1.4) 545.4 (0.8) 
45 MAD-19 116.1 (0.6) 241.8 (1.2) 125.7 (0.5) 
PPD 12090.5 (58.0) 8470.3 (40.7) -3620.2 (1.4) 
TI 
GST 475.4 (2.3) 754.9 (3.6) 279.5 (0.6) 
RPMI 208.3 
PHA 59154.9 (284.0)  
Well-EGF1 2167.2 (1.1) 3167.4 (4.1) 1000.2 (0.3) 
MAD-EGF1 1321.1 (0.7) 3422.3 (4.4) 2101.2 (0.2) 
MAD-EGF2 2240.3 (1.1) 2438.3 (3.2) 198.0 (0.4) 
Well-19/GST 1609.2 (0.8) 2379.8 (3.1) 770.6 (0.3) 
50 MAD-19 229.2 (0.8) 600.3 (2.1) 371.1 (0.4) 
PPD 76678.3 (267.5) 42351.7 (147.8) -34326.6 (1.8) 
TT 
GST 2018.7 (7.0) 773.8 (2.7) -1244.9 (2.6) 
RPMI 286.6 
PHA 53447.3 (186.5)  
cpm (SI) cpm (SI) Acpm (SI) 
Donor Antigen unreduced reduced reduced-unreduced 
Well-EGF1 1960.8 (2.3) 2961.0 (2.0) 1000.2 (1.2) 
MAD-EGF1 785.3 (0.9) 1954.8 (1.3) 1169.5 (0.7) 
MAD-EGF2 1131.8 (1.3) 1194.8 (0.8) 63.0 (1.7) 
Well-19/GST 1967.1 (2.3) 3071.3 (2.3 1104.2 (1.1) 
53 MAD-19 404.7 (0.9) 569.6 (1.3) 164.9 (0.7) 
PPD 25046.6 (55.4) 10928.1 (24.2) -14118.5 (2.3) 
rr 
GST 857.1 (1.9) 1520.1 (3.4) 663.0 (0.6) 
RPMI 451.9 
PHA 59251.8 (131.1)  
Well-EGF1 747.4 (1.0) 613.3 (0.9) -134.1 (1.1) 
MAD-EGF1 462.5 (0.6) 629.5 (0.9) 167.0 (0.7) 
MAD-EGF2 403.5 (0.5) 732.5 (1.0) 329.0 (0.5) 
Well-19/GST 543.4 (0.7) 534.1 (0.7) -9.3 (1.0) 
69 MAD-19 184.8 (0.6) 841.4 (2.7) 656.6 (0.2) 
PPD 37204.8 (117.8) 12821.2 (40.6) -24383.6 (2.9) 
rr 
GST 777.7 (2.5) 723.8 (2.3) -53.9 (1.1) 
RPMI 315.8 
PHA 101755.3 (322.2)  
Well-EGF1 659.2 (0.9) 685.5 (1.1) 26.3 (0.8) 
MAD-EGF1 562.4 (0.8) 639.9 (1.0) 77.5 (0.8) 
MAD-EGF2 391.4 (0.5) 733.5 (1.1) 342.1 (0.5) 
Well-19/GST 512.6 (0.7) 1118.9 (1.7) 606.3 (0.4) 
79 MAD-19 204.7 (0.4) 311.1 (0.7) 106.4 (0.7) 
PPD 20858.1 (45.2) 10843.4 (23.5) -10014.7 (1.9) 
rr 
GST 745.5 (1.6) 651.1 (1.4) -94.4 (1.2) 
RPMI 461.2 
PHA 106701.3 (231.4)  
Well-EGF1 1434.8 (0.8) 1151.5 (1.2) -283.3 (0.7) 
MAD-EGF1 1997.1 (1.1) 5827.6 (6.1) 3830.5 (0.2) 
MAD-EGF2 617.6 (0.3) 1496.0 (1.6) 878.4 (0.2) 
Well-19/GST 1874.4 (1.0) 4424.6 (4.7) 2550.2 (0.2) 
95 MAD-19 176.7 (0.8) 281.7 (1.3) 105.0 (0.6) 
PPD 21405.9 (95.0) 7107.8 (31.5) -14298.1 (3.0) 
11 1261.4 (5.6) 458.3 (2.0) -803.1 (2.8) 
GST 1823.1 (8.1) 951.1 (4.2) -872.0 (1.9) 
RPMI 225.4 
PHA 1161149.2 (5151.5)  
Well-EGF1 754.6 (1.5) 1243.4 (3.3) 488.8 (0.5) 
MAD-EGF1 722.4 (1.4) 2495.8 (6.7) 1773.4 (0.2) 
MAD-EGF2 763.4 (1.5) 2667.5 (7.1) 1904.1 (0.2) 
Well-19/GST 550.4 (1.1) 1436.1 (3.8) 885.7 (0.3) 
104 MAD-19 80.2 (0.4) 243.1 (1.1) 162.9 (0.3) 
PPD 74490.5 (348.1) 42889.5 (200.4) -31601 (1.7) 
U 142.4 (0.7) 384.6 (1.8) 242.2 (0.4) 
GST 503.1 (2.4) 374.0 (1.8) -129.1 (1.3) 
RPMI 214.0 
PHA 84290.5 (393.9)  
Well-EGF1 2294.7 (1.4) 1535.9 (0.9) -758.8 (1.6) 
MAD-EGF1 1066.3 (0.6) 2229.3 (1.3) 1163.0 (0.5) 
MAD-EGF2 867.0 (0.5) 2143.0 (1.2) 1276.0 (0.4) 
Well-19/GST 1670.9 (1.0) 947.1 (0.6) -723.8 (1.8) 
110 MAD-19 106.7 (0.9) 301.3 (2.4) 194.6 (0.4) 
PPD 3063.0 (24.7) 2629.5 (21.2) -433.5 (1.2) 
11 315.3 (2.5) 1003.3 (8.1) 688.0 (0.3) 
GST 1655.2 (13.4) 1731.3 (14.0) 76.1 (1.0) 
RPMI 123.9 
PHA 48454.3 (391.1)  
Well-EGF1 1522.4 (1.0) 5449.0 (1.1) 3926.6 (0.9) 
MAD-EGF1 1842.1 (1.2) 8384.7 (1.7) 6542.6 (0.7) 
MAD-EGF2 3364.4 (2.1) 7474.8 (1.5) 4110.4 (1.5) 
Well-19/GST 2768.0 (1.8) 5417.6 (1.1) 2649.6 (1.6) 
112 MAD-19 1069.0 (1.4) 6672.3 (9.0) 5603.3 (0.2) 
PPD 12052.0 (16.2) 15621.2 (21.0) 3569.2 (0.8) 
U 35891.5 (48.2) 9839.8 (13.2) -26051.7 (3.7) 
GST 1569.6 (2.1) 5083.8 (6.8) 3514.2 (0.3) 
RPMI 744.3 
PHA 133317.4 (179.1)  
cpm (SI) cpm (SI) Acpm (SI) 
Donor Antigen unreduced reduced reduced-unreduced 
Well-EGF1 2961.6 (3.5) 1540.1 (2.7) -1421.5 (1.3) 
MAD-EGF1 1876.8 (2.2) 4085.9 (7.2) 2209.1 (0.3) 
MAD-EGF2 1188.8 (1.4) 2612.4 (4.6) 1423.6 (0.3) 
Well-19/GST 1553.6 (1.8) 2915.5 (5.1) 1361.9 (0.4) 
116 MAD-19 272.7 (0.5) 390.6 (0.8) 117.9 (0.7) 
PPD 35278.7 (69.2) 10704.6 (21.0) -24574.1 (3.3) 
TT 
GST 855.1 (1.7) 568.8 (1.1) -286.3 (1.5) 
RPM[ 510.0 
PHA 104038.1 (204.0)  
Well-EGF1 3787.5 (3.1) 3904.2 (5.9) 116.7 (0.5) 
MAD-EGF1 2260.5 (1.8) 4035.5 (6.1) 1775.0 (0.3) 
MAD-EGF2 1072.1 (0.9) 3797.0 (5.8) 2724.9 (0.02) 
Well-19/GST 1765.0 (1.4) 966.0 (1.5) -799.0 (1.0) 
117 MAD-19 102.9 (0.5) 237.9 (1.3) 135.0 (0.4) 
PPD 8402.1 (40.9) 4342.6 (21.1) -4059.5 (1.9) 
U 32778.2 (159.4) 699.5 (3.4) -32078.7 (46.9) 
GST 1234.0 (6.0) 657.7 (3.2) -576.3 (1.9) 
RPMI 205.7 
PHA 42622.6 (207.2)  
Well-EGF1 696.5 (1.1) 760.1 (0.8) 63.6 (1.4) 
MAD-EGF1 264.0 (0.4) 690.1 (0.7) 426.1 (0.6) 
MAD-EGF2 298.2 (0.5) 540.6 (0.6) 242.4 (0.8) 
Well-19/GST 586.5 (0.9) 512.3 (0.5) -74.2 (1.8) 
120 MAD-19 86.9 (0.6) 387.5 (2.7) 300.6 (0.2) 
PPD 4000.4 (28.1) 2476.1 (17.4) -1524.3 (1.6) 
U 98.2 (0.7) 342.1 (2.4) 243.9 (0.3) 
GST 628.3 (4.4) 962.4 (6.8) 334.1 (0.7) 
RPMI 142.2 
PHA 74239.6 (552.1)  
Well-EGF1 3805.0 (1.4) 12445.4 (1.6) 8640.4 (0.9) 
MAD-EGF1 2606.2 (0.9) 10236.2 (1.3) 7630.0 (0.7) 
MAD-EGF2 1219.6 (0.4) 8047.1 (1.0) 6827.5 (0.4) 
Well-19/GST 1875.2 (0.7) 14419.3 (1.9) 12544.1 (0.4) 
125 MAD-19 234.3 (1.3) 7492.2 (39.9) 7257.9 (0.03) 
PPD 17392.4 (92.5) 18411.3 (97.9) 1018.9 (0.9) 
U 24690.3 (131.3) 13832.5 (73.6) -10857.8 (1.8) 
GST 2797.9 (14.9) 7799.2 (41.5) 5001.3 (0.4) 
RPMI 188.0 
PHA 69528.9 (369.8)  
Well-EGF1 1172.9 (1.6) 1878.4 (1.4) 705.5 (1.2) 
MAD-EGF1 1024.0 (1.4) 1994.7 (1.5) 970.7 (1.0) 
MAD-EGF2 637.2 (0.9) 2110.0 (1.5) 1472.8 (0.6) 
Well-19/GST 564.4 (0.8) 1605.3 (1.2) 1040.9 (0.7) 
167 MAD-19 89.1 (0.5) 1306.5 (6.7) 1217.4 (0.1) 
PPD 895.9 (4.6) 2168.0 (11.0) 1272.1 (0.4) 
U 23569.7 (119.9) 2353.3 (12.0) -21216.4 (10.0) 
GST 736.3 (3.8) 1375.4 (7.0) 639.1 (0.5) 
RPMI 196.6 
PHA 91180.6 (463.8)  
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The major merozoite surface protein of Plasmodium falciparum (PIMSP1) is a candidate antigen for a 
malaria vaccine. A 19-kDa C-terminal processing product of PIMSP1 (PfMSPI 19 ) is composed of two domains 
sharing a cysteine-rich motif with epidermal growth factor (EGF) and is the target of monoclonal antibodies 
which block erythrocyte invasion in vitro. We have evaluated human antibody responses to Pfi1SP1, 9 by using 
recombinant proteins representing the EGF motifs encoded by the two main alleles of the MSPI gene. We find 
that both EGF motifs are antigenic but that only 10 to 20% of malaria-exposed individuals have serum 
antibodies that recognized either of the motifs. When both EGF motifs were expressed together as a single 
protein, they were recognized by more than 40% of sera from malaria-exposed individuals. Major epitopes 
recognized by human antibodies are dependent upon the correct tertiary structure of the protein and are 
cross-reactive between the different allelic sequences of PfMSP1, 9. This suggests that antibodies induced by 
vaccination with one or the other allelic forms of the protein could recognize all strains of P. falciparum. 
Immunoglobulin G (IgG) subclass-specific enzyme immunoassays indicate that PfMSP1 19 antibodies are 
predominantly of the IgGi subclass. 
Clinical symptoms of malaria are associated with the asexual 
iltiplication of merozoites within erythrocytes. A prophylac-
malaria vaccine would need to block this stage of the par-
te's life cycle. The major merozoite surface protein-I (16, 
21) of Plasmodium falciparum (PfMSP1) is considered an 
portant vaccine candidate because monoclonal antibodies 
[Abs) against it can block erythrocyte invasion in vitro (1, 11, 
30, 32) and primates immunized with either purified native 
MSP1 or recombinant proteins or synthetic peptides repre-
iting parts of the protein are partially or completely pro-
:ted against experimental infections with P. falciparum (9, 13, 
17, 28, 29, 33). 
PfMSP1 is the precursor to several major surface proteins of 
merozoite (4, 14, 18, 26). After synthesis as a single pro-
n, PfMSP1 is processed to produce four major fragments 
1MSP1 83, PfMSP1 281 PfMSP1 38, and PfMSP1 42 ). At the time 
merozoite release, the PfMSP1 42 fragment undergoes sec-
daiy processing to form a 33-kDa (PfMSPI 33 ) product, 
ich is shed, and a 19-kDa fragment (PfMSP1, 9), which re-
tins on the merozoite surface during erythrocyte invasion 
d is present on ring stage parasites (1). It has been suggested 
it this secondary processing of PfMSP1 42  to PfMSPI 19  is 
Corresponding author. Mailing address: Institute of Cell, Animal 
J Population Biology, Division of Biological Sciences, Ashworth 
orato1y, University of Edinburgh, West Mains Road, Edinburgh 
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a prerequisite for erythrocyte invasion (1, 2, 4). The C-termi-
nal fragments of PfMSPI are of particular interest with re-
spect to vaccine development, since naturally acquired anti-
bodies to PfMSP1 4., are associated with resistance to clinical 
malaria in Gambian children (31) and MAbs mapping to the 
PfMSPI, 9 fragment inhibit merozoite invasion in vitro (1, 11, 
26, 30). In addition, an MAb recognizing an epitope within the 
C terminus of the PfMSPI homolog of Plasmodium yoe/ii 
(PyMSPI) is able to passively protect mice against this malaria 
infection (6). 
PfMSPI consists of two domains, each with six highly con-
served cysteine residues which are characteristic of epidermal 
growth factor (EGF) motifs (3, 10). The primary sequence of 
PfMSPI is highly conserved except for four amino acid res-
idues that are subject to dimorphic substitutions (22, 27). In 
the Wellcome sequence, these four residues are Q in the first 
motif and K-N-G in the second motif, while in the MAD20 
sequence, they are E and T-S-R, respectively (Fig. 1). 
In this study, we have evaluated the serological recognition 
of recombinant proteins representing the double and separate 
EGF motifs of PfMSPI, 9  by antibodies from people living 
in a malaria-endemic area. We conclude that the major epi-
topes within PfMSP1, 9 that are recognized by human antibod-
ies are conformation dependent and require the presence of 
both EGF motifs. Furthermore, we report that human anti-
bodies recognize epitopes which are conserved, or cross-reac-
tive, between the two commonly occurring allelic forms of 
PfMSP1, 9  and are mainly of the immunoglobulin GI (IgGI) 
subclass. 
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I 1A 	 1 
I 	 2A T' 
Wellcome NlsoHocvKKocpQ NSGCFRHLDEREECKCLLNYKOEGDKCVENPNPTCNENNGGCDADA KCTEEDSGSNG KKrrCECTKPDSYPLFDGIFCSSSN 
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FIG. I. Partial sequences of the Wellcome and MAD20 allelic forms of Pf?sISP l, showing the positions of sequence dimorphism, putative disulfide bonds (3, 22), 
and the recombinant proteins used. Dimorphic amino acids are shown, in boldface type: putative positions of disulfide bonds are indicated by dashed lines. Proteins 
IA. 2A. FVO. and Well/GST represent the Wellcome allelic sequence: proteins lB. 2B, and 3137 represent the M,AD20 sequence. The first EGF motif is represented 
by IA and IB: the second motif is represented by 2A and 2B. FVO (Wellcome MSPI I9), 3D7, and Well/GST represent both EGF motifs of PfMSPI 19 . FVO and 
WcIl/GST have the same PfMSPI , sequence but differ in the expression system used to produce them (S. cerevisiae and E. co/i, respectively). The protein FVOIE 
represents a recombinant form of PfMSPI , with the first motif of MAD20 and the second motif of Wellcome (MAD/Well MSP1 IS)  (not shown). **prOtein  2A was 
found to be insoluble and thus was not used in ELISA5. 
MATERIALS AND METHODS 
Recombinant Pfi'ISPI proteins. Primary sequences of the recombinant pro-
teins are shown in Fig. 1. Single first and second EGF motifs of the two allelic 
prototypes of PfMSPI. represented by the MAD20 and Wellcome isolates of P. 
falciparunt ( 27), and the double EGF motif of the Wellcome form were expressed 
as glutathtone S-transferase (GST) fusion proteins (34) in Esclterichia co/i trans-
formed with recombinant pGEX3 plasmids (8). Ass control. GST was produced 
by using the pGEX3 plasmid without any insert. The double EGF motif and 
three of the four single EGF motif constructs were expressed as soluble fusion 
proteins. The second EGF motif of the Wellcome allele (2A in Fig. 1) was 
insoluble in aqueous solution and only slightly soluble in 8 M urea and thus was 
not used. All the GST fusion proteins were recognized by conformation-depen-
dent MAbs. indicating that the proteins assumed an approximately native con-
formatton, with correctly formed disulfide bonds (5. 26). 
Proteins representing three different versions of PfMSPI , were produced in 
recombinant Sacc/raro,,,vces ccreii.viae (23). the MAD20 and Wellcome allelic 
prototypes (3137 and FVO) and a recombinant form (MAD20 first EGF motif 
with Wellcome second EGF motif FVO/Et: see Fig. 1). The addition of a 
histtdtne tag to the C terminus of these fusion proteins enabled them to be 
purified on nickel-nitrilo-triacetic acid-agarose (23). 
The purity of the fusion proteins was checked by sodium dodecyl sulfate-
polvacrvlamide gel electrophoresis (SDS-PAGE). and protein yield was esrf-
mated by comparison with bovine serum albumin standards. 
Human sera. Blood was collected from people living in rural areas close to the 
town of Farafennt in the Gambia. Malaria transmission in this area is seasonally 
endemic, with new infections occurring during and immediately following the 
rains' season (July to December) (IS). Serum samples were obtained at the end 
of the rainy season (October) from 195 children and adults (aged 1 to 70 years) 
and were stored at -20°C until used. Prior exposure to malaria was confirmed by 
serology: all sera were positive (by immunofluorescence) for antibodies to ma-
laria schtzonts, with titers ranging from 1:160 to >1:20.000. Control serum 
samples were obtained from 28 European adults and 14 European children with 
no previous exposure to malaria. 
MAbs. The following 'PfMSPI ,-specific murine MAbs were used: 7.5. 12.8. 
and 12.10 (26): 111.2 and 111.4 (20): 6E2153 and 4H4/34 (11) (a kind gift of A. 
Saul. Queensland Institute of Medical Research. Brisbane. Australia); and 14-IC 
(a kind gift of R. Reese. Agouron Institute. La Jolla. Calif.). 
Immunoassavs. (i) ELISA. Antibodies reacting with recombinant PfMSPI 
proteins were detected hr enzyme-linked immunosorbent assay (ELISA). Mi- 
crotiter plates (Immulon 4; Dynatech, Billingshurst, United Kingdom) were 
coated overnight at 4°C with proteins diluted in carbonate buffer (0.015 M 
Na,CO3, 0.035 M NaHCO3 [PH D• The saturating concentration of protein, 
determined by titration, was from 0.1 to 5 igIml, depending on the antigen. 
Plates were washed three times in phosphate-buffered .saline (PBS, pH 7.2)-
Tween 20, blocked with a 1% solution of nonfat powdered milk in PBS-Tween 20 
(blocking buffer), and washed again. Then 100 il of serum or MAb was diluted 
in blocking buffer, incubated at room temperature for 5 h, added to duplicate 
wells, and incubated overnight at 4°C. Optimal dilutions of serum or MAbs were 
determined by titration. For all human sera, the steepest slope of the titration 
curve was observed at concentrations between 1:1,000 and 1:10,000 (data not 
shown). The optimum concentration of human serum for the assay was thus 
selected as 1:3,000 (24). 
After washing, horseradish peroxidase (HRP)-conjugated rabbit anti-human 
IgG (100 p.1 of 1:5.000) or HRP-conjugated rabbit anti-mouse IgG (100 p.1 of 
1:1.000) (both from Dako Ltd., High Wycombe, United Kingdom) were added to 
the plates, incubated for 3 h at room temperature, and developed with H2O and 
o-phenylenediamine (Sigma, Poole, United Kingdom) for 10 min at 4°C. The 
reaction was stopped by the addition of 20 p.1 of 2 M H2SO4-  Plates were read at 
492 run. For CST fusion proteins, the optical density (OD) value of the GST 
control was subtracted from the 00 of GST recombinant fusion proteins to give 
a specific OD (SOD) for the response to the PfMSPI antigens. For yeast-derived 
proteins, when no fusion protein was involved, the original OD values are shown. 
(ii) Competition ELISA. To determine whether antibodies recognizing indi-
vidual recombinant proteins also recognized (cross-reacted with) other recom-
binant proteins, competition ELISA5 were performed. The test serum was di-
luted in blocking buffer to which was added recombinant protein at a range of 
concentrations. After incubation for 5 h at room temperature, the blocked serum 
was added to immunoplates coated with a second recombinant protein. The 
remainder of the assay was performed as above. 
Competition ELISAs were also performed to determine whether epitopes 
recognized by human antibodies were similar to those recognized by murine 
MAbs. To see if human antibodies could inhibit binding of the MAbs, plates 
coated with an antigen were first incubated with various concentrations of human 
serum. After extensive washing, a dilution of an MAb was added to the plate, 
incubated for 3 h, and developed with HRP-anti-mouse IgG and o-phenylenedi-
amine. The reciprocal experiment was also performed to see if MAbs could 
inhibit binding of the human sera. In this case, antigen-coated plates were first 
TABLE 1. Prevalence of antibodies to PfMSP1 19 in the Gambia 
No. () of sera recognizing recombinant protein": 
Age group No. Wellcome MAD2() MAD20 , 	 MAD20 MAD/Wellcome Wellcome Wellcome/GST 
1st motif 1st motif 2nd motif MSP1 19 MSPI MSPI , MSPI 
Children (<8 vr) 33 5 (15.2) 3(9.1) 6(18.2) 4(12.1) 7(21.2) 7(21.2) 11(33.3) 
Adolescents (9-I5 vr) 60 8(13.3) 11(18.3) 5 (8.3) 12(20) 22(36.7) 20(33.3) 25(41.7) 
Adults (>16 vr) 92 19(20.7) 19(20.7) 13(14.1) 38(43.1) 53(57.6) 50(54.3) 43(46.7) 
Total 195 32(16.4) 33(16.9) 24(12.3) 54(27.6) 82(42.1) 77(39.5) 79(40.5) 
"A positive response is one which is greater than the mean plus 2 SDS of the OD values for 42 control (malaria nonexposed) sera 
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TABLE 2. Effect of age on median levels of 
anti-PfMSPI antibodies" 
Median OD by Kruskal-Wallis 
age group test 
Antigen 
<Svr 9-15vr >l6vr 
(n = 43) (ii = 59) (n = 92) X P 
Wellcome 1st domain 0.047 0.028 0.019 3.9 0.141 
MAD20 1st domain 0.084 0.096 0.138 .4.5 0.103 
MAD20 2nd domain 0.042 0.057 0.058 1.7 0.428 
MAD20 MSPI 1Q 0.124 0.182 0.413 40.3 <0.001 
Wellcome MSPI 19 0.143 0.215 0.448 35.5 <0.00I 
MAD20/Wellcome MSPI 1q 0.120 0.200 0.411 36.0 <0.001 
Wellcome/GST MSP1 1 , 0.024 0.128 0.307 23.1 <0.001 
GST 0.111 0.115 0.135 12.7 0.002 
Sera were diluted 1:3.000 
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FIG. 2. Dot plots showing human antibody binding for 195 Gambian sera in 
ELISA for recombinant PfMSP1 proteins. (a) MAD20 PfMSP1 19 (3D7), OD 
lues; (b) MAD20 first motif (113), IOD values (See text for details); (c) 
AD20 second motif (213), AOD values. The OD values of 42 European control 
ra are also shown. All sera were tested at a dilution of 1:3,000. 
incubated with various concentrations of MAb. then with human serum, and 
finally with HRP-anti-human lgG. 
ELISA with reduced and nonreduced antigen. To determine whether 
epitopes recognized by human antibodies were dependent on the presence of 
intact disulfide bonds. ELISAs were performed with reduced and alkvlated or 
nonreduced recombinant antigens. To prepare reduced protein. 0.5 mg of an 
antigen was incubated at 37°C for 1 h in 0.5 M Tris-HCI (pH 8.1) containing 2 
mM EDTA and 60 mM dithiothreitol (Sigma). lodoacetic acid, dissolved in I M 
NaOH, was then added at a 2.5-fold molar excess over dithiothreitol. The 
samples were kept in the dark, the pH was monitored and maintained at 8.1 for 
30 mm, and then the proteins were dialyzed overnight at 4°C. Plates were coated 
for ELISA with the appropriate saturating concentration of the reduced protein 
and used as above. 
ELISA to determine IgG subclass. ELISAs were performed as above (I) 
except that monoclonal, subclass-specific, mouse anti-human lgG was used as the 
second-step reagent. Subclass-specific assays were optimized by titration so that 
the titration curves for each reagent were coincident; i.e.. that for a given 
absolute concentration of lgGl, lgG2, IgG3, or lg64, the same OD value was 
obtained. The reagents used were mouse monoclonal anti-human IgGI (code 
1170317: Boehringer, Mannheim, Germany). IgG2 (code 1170309: Boehringer). 
lgG3 (code MCA5I6; Serotec. Oxford, United Kingdom), and lgG4 (code 
1170287; Boehringer). 
Statistical methods. Specific OD values obtained for sera from malaria-unex-
posed European donors were used to establish a normal range for each antigen: 
The OD values for these control sera tended to be normally distributed: thus. 
Gambian sera giving an OD value greater than the mean plus standard devia-
tions (SD5) of the European sera were considered to contain antibody specific 
for the relevant recombinant protein. 
The association between OD values of individual sera to the different antigens 
was assessed by using scatter plots and Spearman's rank correlation coefficient. 
To determine whether levels of antibody to PfMSPI proteins are associated 
with age, the distributions of OD values for each antigen were compared be-
tween the age groups by using the Kruskal-Wallis one-way analysis of variance. 
It was necessary to use a nonparametric test because the distributions of the OD 
values were highly skewed within each age group, and hence median OD values 
are presented. 
RESULTS 
Recognition of recombinant PfMSP1 proteins by human 
antibody. More than 40% of sera from 195 malaria-exposed 
donors Contain antibodies which specifically recognize the dou-
ble EGF motif of PfMSP 1 J9 (Table 1 and Fig. 2a). In Contrast, 
less than 20% of the sera show reactivity with the single EGF 
motif proteins (Fig. 2b and c [reactivity with the first EGF 
motif of the Wellcome version is almost identical to the data in 
Fig. 2b; not shown]). Of the sera which recognized MSPI 19 , 
approximately 50% recognized only MSP1, and did not rec-
ognize any of the single EGF motif proteins. This indicates that 
there are epitopes present in PfMSP1 19 that are not present 
when either EGF motif is expressed alone. 
Responses to the double-motif protein produced in E. co/i 
(Wellcome MSPI, 9  [19-GST]) and to the same sequence pro-
duced in S. cerevisiae (FVO) were highly correlated (Spear-
man's rank correlation coefficient: r = 0.901, n = 195, P < 
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FIG.' 3. Comparison of antibody recognition of different PfMSPI sequences. (a) Wellcome PfMSPI (FVO: Q-KNG) versus MAD20 PfMSPI 19 (31317: E-TSR); 
(h) MAD20/Wejlcome PfMSPI , (FVO/E: E-KNG) versus MAD2() PfMSPI ., (3D7: E-TSR): (c) MAD20/Wellcome PfMSPI 1 , ( FVO/E; E-KNG) versus Wellcome 
PfMSPI ., (FVO: Q-KNG): (d) MAD2() PfMSPI (3D7) versus MAD20 first motif (I B): (e) MAD20 MSPI ,, (3D7) versus MAD20 second motif (2B): (f) MAD20 
first motif (I B) versus MAW)) second motif (2B). - 
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FIG. 4. Competition ELISAs demonstrate that additional epitopes are present within the double EGF motif protein (3137). Eight sera which react with the single 
EGF motif (lB) and with the double EGF motif (3D7) were tested; the results for two sera are shown here. (a) Serum 1493. Preincubation of the serum with lB reduces 
the level of binding to 3137 but does not abolish it. This serum may recognize an epitope in 3137 which overlaps with an epitope in lB. (b) Serum 1515. Preincubation 
of the serum with I  has no effect on the recognition of 3137. This serum appears to recognize an epitope(s) in 3D7 which is distinct from the epitope(s) in lB. •. 
preincubation with 3137, tested on 3137; 0, preincubation with 3D7. tested on IB; 0, preincubation with lB. tested on 113; U. preincubation with lB. tested on 3137. 
AG, antigen. 
0.001), indicating that proteins produced in the two expression 
systems are very similar. 
For the double-motif proteins, there is an apparent increase 
in antibody levels with age (Table 2); such a trend is not 
apparent for the single EGF motif proteins. 
Serological cross-reactivity between Wellcome and MAD20 
antigens of PIMSP1 19. ( i) Comparison of antibody recognition 
of proteins representing different PIMSP1 19 sequences. Sera 
with high levels of antibody to the Wellcome proteins also tend 
to have high levels of antibody to the MAD20 proteins. When 
recognition of two double-motif proteins is directly compared,  
there is a high degree of correlation between them (Fig. 3a to 
C). However, occasional sera do react more strongly with one 
sequence than with the other; this seems to be due more to a 
differential recognition of three dimorphic amino acid residues 
in the second EGF motif (Fig. 3a and b) than to detection of 
the single-amino-acid change in the first motif (Fig. 3c). Some 
sera show similar levels of reactivity to both the double motif 
and the single first motif (Fig. 3d), whereas other sera recog-
nize only the double motif. Similarly, occasional sera recognize 
both the double motif and the second single motif (Fig. 3e), 
and one or two sera recognize both the first and second motifs 
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FIG. 5. Human sera recognize epitopes which are cross-reactive between MAD20 and Wellcome sequences of PfMSPI 1 ,. (a) Human serum 1275 recognizes both 
sequences of the first EGF motif (IA and IB) but not the second motif (2131). (b) Human serum 1579 recognizes all three yeast double-motif PfMSPI 1) constructs. (a 
and b) 0. IA: 0. IB: 0. 2131: •. 3D7: L. FVO: M. FVO/E. Dilutions are in thousands. (c and d) Preincubation of human serum 1592 (c) or 1614 (d) with I p.g of either 
protein IA or protein I  per ml inhibits subsequent binding of that serum to plates coated with either IA or lB. •. serum preincubated with IA on IA-coated plates: 
U. serum preincuhated with lB on IA.coated plates. 0. serum preincuhatcd with IA on lB-coated plates: 0. serum preincubatcd with I  on lB-coated plates. 
(Fig. 3f). However, many sera (54%) which recognize the dou-
ble motif do not recognize either of the single motifs. Compe-
tition ELISAs.show that, of the sera which recognize both the 
single- and double-motif proteins, most recognize additional 
epitopes that are present only in the double-domain construct 
(two examples are shown in Fig. 4). 
(ii) Titration of individual human sera against different 
PtMSP1, 9 proteins. The above data suggested that most hu-
man antibodies do not differentiate between the variant se-
quences of PfMSPI . The two allelic forms of the first EGF 
motif differ in sequence by only one amino acid (glutamine in 
the Wellcome form and glutamate in the MAD20 form at 
position 14 [Fig. I]); it. is thus possible that the two sequences 
are immunologically cross-reactive. Six sera containing anti-
-body to the first EGF motif were titrated against the three 
single EGF motif recombinant proteins; an example is shown 
in Fig. 5a. All six sera gave identical titration curves for the 
proteins representing the two allelic types of the first EGF 
motif, suggesting that a single population of antibodies recog-
nized both proteins. All of these sera also gave identical titra-
tion curves for the three yeast-derived double-motif proteins 
(an example is shown in Fig. 5b). 
(iii) Polyclonal sera contain cross-reactive populations of 
antibodies. To confirm that there was a single cross-reactive 
antibody population, competition ELISAs were performed. In-
dividual sera which recognized MAD20 and Wellcome-derived 
proteins with equal avidity were selected. As shown in Fig. Sc 
(serum 1592), preincubation of the serum with 1 to 10 p.g of 
either protein IA or protein lB per ml inhibits subsequent 
binding of that serum to plates coated with either 1A or lB. 
For another serum (1614, Fig. 5d), inhibition was obtained by 
preincubation with 0.1 to 1.0 ig  of protein per ml. 
Human antibodies inhibit the binding of MAbs. PfMSP1 m 
specific MAbs can block merozoite invasion of erythrocytes in 
vitro (I). To see if human sera recognized the same epitopes as 
inhibitory MAbs, competition ELISAs were performed. Five 
MAbs were tested: 111.4 recognizes the first motif of Well-
come specifically (IA), 12.8 and 14-IC recognize a conserved 
epitope in the first motif, and 12.10 and 111.2 recognize the 
double motif only (8; our unpublished data). Human sera with 
high titers of antibodies to PfMSP1 9 were able to block the 
binding of all these MAbs in a dose-dependent manner (ex-
amples in Fig. 6a and c), indicating, that the epitopes recog-
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FIG. 6. Competition ELISAs. Human serum 1120 was able to inhibit the binding of MAbs in a dose-dependent manner, but MAbs were notable to inhibit binding 
)f human antibody. (a) Serum 1120 inhibits binding of MAb 111.4 (MAb 111.4 recognizes only IA). (b) MAb 111.4 does not inhibit binding of serum 1120. (c) Serum 
[120 inhibits binding of MAb 14-1C. (d) MAb 14-IC does not inhibit binding of serum 1120. 0, IA: 0, lB. Dilutions are in thousands. 
ever, in the reciprocal experiments, MAbs were not able to 
:ompletely block binding of human antibodies (Fig. 6b and d), 
;uggesting that human sera recognize other epitopes in addi-
ion to those recognized by MAbs. 
Human antibodies recognize disulfide-dependent epitopes. 
fMSP1 is believed to contain three disulfide bonds in each 
jf the two EGF motifs (3) (Fig. 1). To determine whether 
ecognition of PfMSP1 19 by human antibodies is dependent on 
he presence of intact disulfide bonds, an ELISA comparing 
he reactivity of reduced and nonreduced forms of the recom-
)inant antigens was performed (Table 3). We were able to 
how that epitopes recognized by human polyclonal antibodies 
ire disulfide dependent, since reactivity with antigen was re-
luced or completely abolished after reduction and alkylation 
)f the recombinant proteins. Recognition of the individual 
EGF motifs is entirely abolished after reduction, though some 
eactivity to the double-motif proteins remains. This suggests 
hat minor, linear epitopes are also recognized by polyclonal 
iuman antibodies. In contrast, all the MAbs tested recognized 
)nly nonreduced antigen (Table 3). 
Predominant antibody response is IgGi. The subclass of 
IgG produced in response to a given antigen determines the 
function of the antibody. IgG subclass was determined by sub-
class-specific ELISA. In most positive sera, the IgG was pre-
dominantly of the IgGi subclass (Fig. 7). Occasional individ-
uals produced mainly IgG3, and there was a single IgG4 
positive serum for antigen 1A. The predominant lgG subclass 
did not vary among persons of different ages (data not shown). 
DISCUSSION 
Recent studies have indicated that antibodies recognizing 
epitopes within the PfMSP1 4, and PfMSP1, 9 processing prod-
ucts of PfMSP1 may be involved in protective immunity to 
malaria (1, 6-8, 31). The amino acid sequence of the 19-kDa 
fragment of PfMSP1 is relatively highly conserved between 
parasite isolates (22), and thusPfMSP1 19 is an attractive vac-
cine candidate. However, murine MAbs appear to recognize 
this protein in a sequence-specific manner (8, II). 
We have screened sera from a population from the Gambia 
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TABLE 3. Comparison of OD values for ELISA with nonreduced and reduced recombinant antigens" 
Antigen 




4H4/34 1559 1572 
Human sera 
1579 	1584 1592 1599 
Wellcome 1st motif 
Nonreduced 21 8 0.170 0.150 0.193 .1.43 0.129 0.153 0.145 1.856 1.1 88  
Reduced 0.117 0.199 0.172 0.102 0.137 0.113 0.089 0.127 0.112 0.121 0.151 0,41 
MAD20 1st motif 
Nonreduced 2.475 0.479 0.137 0.181 0.199 0.130 0.184 0.100 0.126 1.878 1.1 
Reduced 0.124 0.118 0.106 0.114 0.135 0.109 0.095 0.125 0.113 0.113 0.160 Qlaa 
MAD20 2nd motif 
Nonreduced 0.311 0.123 0.148 1.496 0.309 0.133 1.491 0.329 0.194 1.40 0.163 
Reduced 0.159 0.138 0.113 0.191 0.135 0.125 0.198 0.251 0.284 0, 0.108 041.0 
MAD20 MSP1 19 
Nonreduced 1.914 0.995 0.142 0.710 jfll 1.9 0.24 ZdL6 j0 1.5 2.623 
Reduced 0.157 0.114 0.086 0.099 0.104 0.093 0.295 0.220 0.282 0.222 0.612 0.813 
MAD20/Wellcome MSPI 
Nonreduced 1.932 0.241 0.152 0.140 0.309 0.104 La2a Q.J. 2.333 0.829 .1.521 2.334 
Reduced 0.287 0.106 0.089 0.092 0.104 0.108 0.664 0.316 0.851 0.132 .1.016 1,4 
Wellcome MSPI 
Nonreduced 1.998 1,971 2.124 0.126 1.712 0.105 £212 Q2i 2 .408 £410 24.12 
Reduced 0.211 0.158 0.249 0.094 0.132 0.087 0.523 0.272 0., 0.121 0.824 .1.314 
Wellcome/GST MSPI 
Nonreduced 1549 2.403 2.449 0.125 2.324 0.225 2.176 0.646 2jj 1,159 1.747 24 
Reduced 0.138 0.138 0.188 0.091 0.178 0.080 0.686 0.272 0.593 0.143 QfthO 0.905 
GST 
Nonreduced 0.262 0.119 0.208 0.235 0.234 0.169 0.105 0.101 0.108 0.102 0.121 0.120 
Reduced 0.134 0.124 0.101 0.122 0.128 0.116 0.078 0.084 0.087 0.078 0.105 0.120 
Underlining is used to highlight values for positive antigen-antibody combinations. Human sera were tested at a dilution of 1:3.000. which represents the midpoint 
of the titration curve. MAbs were tested at a dilution of 1:1.000. which represents a saturating concentration of antibody. 
with documented previous exposure to malaria for antibodies 
recognizing recombinant proteins representing the two allelic 
forms of the single and double EGF motifs of PfMSPI t9  We 
find that recombinant PfMSP1 proteins produced either in E. 
co/i or in S. ceret'isiae are equally suitable for ELISAs. Direct 
comparison of antibody binding to proteins produced in the 
two expression systems showed that they were essentially iden-
tical. The secondary structure of PfMSP1 19, which is known to 
be necessary for optimal recognition by MAbs raised against 
the native protein, appears to be appropriately formed in 
recombinant proteins produced in both S. ceret'isiae and E. 
co/i. Antibodies to PfMSP1 in immune human sera tend 
to recognize disulfide-dependent epitopes; however, there is 
some serum reactivity with reduced double-motif proteins, sug-
gesting that conformation-independent antibodies are also 
present. 
The prevalence of antibodies to the double EGF motif in-
creases with age, and serum from up to 60% of adult donors 
aged 16 years and above contained antibodies which recog-
nized these constructs (Table 1). However, only a minority of 
individuals (either children or adults) had antibodies recogniz-
ing either of the two EGF motifs when these were expressed 
singly. This indicates that a dominant epitope(s) requires the 
presence of both EGF motifs and is missing when either motif 
is expressed on its, own. 
PfMSP1 	antibodies in human sera tend to recognize 
epitopes which are conserved or cross-reactive between variant 
sequences. Although occasional sera were shown to contain 
two separate, non-cross-reacting populations of antibodies, the 
majority of positive sera clearly recognize an epitope which is 
conserved or cross-reactive between the two sequences. A few 
sera contain antibodies which appear to bind with, higher avid-
irv to one sequence of the protein than to the other sequence. 
This was particularly apparent when antigens which differed in 
the sequence of the second EGF motif (where there are three 
amino acid differences) were compared, suggesting that there 
is a minor epitope in the second EGF motif which involves the 
dimorphic residues. In contrast, substitution of glutamate for 
glutamine in the first motif has very little effect on recognition 
by human antibodies. In this respect, human antibodies differ 
substantially from murine MAbs (such as 111.4), which recog-
nize epitopes involving dimorphic amino acid residues. This 
cross-reactivity bodes well for the development of a malaria 
vaccine which could provide protection against all variants of 
the. parasite. 
Human sera can inhibit the binding of MAbs whose epitopes 
map to either EGF motif and MAbs which recognize the dou-
ble-motif structure. However, none of the MAbs could inhibit 
binding of human antibodies. Thus, human sera may recognize 
a number of epitopes within PfMSPI 19, some of which are also 
recognized by MAbs. Alternatively, binding of human Ig to 
other epitopes may sterically interfere with MAb binding. 
The reason why 40% of adult donors from our cross-sec-
tional study did not possess antibodies to PfMSP1 is not 
known. All donors are known to have been exposed to malaria 
over many years and had high titers of antibody to malaria 
schizonts. Preliminary analysis of the data with respect to the 
known human leukocyte antigen (HLA) class II genotype of 
the donors (12a) does not indicate that the response to 
PfMSPI is genetically restricted. It is possible that the sero-
negative donors may have antibody to other regions of PfMSP1 
which inhibit the formation of antibodies to PfMSP1. Steric 
interference has been shown between MAbs binding to appar-
ently. distant PfMSPI. epitopes (35), suggesting that the N-
terminal region of PfMSPI may physically obscure PfMSPI , 
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FIG. 7. Dot plots showing IgG subclass-specific responses. Only IgG-positive Gambian sera were tested; 24 European sera are shown as controls. All sera were 
tested at a dilution of 1:1.000. (a) Wellcome first motif (IA); 32 Gambian sera tested. (b) MAD20 second motif (213); 24 Gambian sera tested. (c) Wellcome PfMSP1, 9 
(19/GST); 52 Gambian sera tested. (d) MAD20 PfMSP1 19 (3D7); 54 Gambian sera tested. X, European sera; 0, Gambiansera. 
patterns of antibody recognition of other regions of PfMSPI by 
these sera. Alternatively, seronegative individuals may not 
have been recently infected with malaria, and in the absence of 
boosting, antibody may have fallen below detectable levels. 
An important outstanding question is whether antibodies to 
PfMSPI are protective or not. The fact that PfMSP1 appears 
to induce predominant IgGi antibodies suggests that such an-
tibodies may play a role in opsonization or complement-medi-
ated lysis of free merozoites. Recent experiments have shown 
that the membrane-bound 15-kDa fragment of MSP1 from P. 
yoelii (PyMSPI5) is the target of a protective MAb (6), and 
vaccination of mice with a recombinant protein representing 
the double EGF motifs of PyMSP1 15 protects against challenge 
infection with the I7XL and YM strains of P. yoelii (12, 25). A 
longitudinal immunoepidemological study suggested that anti-
bodies to PfMSP1 42 were associated with resistance to clinical 
malaria and high parasitaemia in young children (31). We have 
recently completed a similar longitudinal study of antimalarial 
antibody levels and malaria morbidity, which indicates that 
antibodies to PfMSP1 9 are associated with protection from 
clinical malaria (unpublished data). Further studies are in 
progress in our laboratories to determine the functional role of 
human antibodies to PfMSP1 19 and their role in protective 
immunity to malaria. 
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Naturally Acquired Human Antibodies Which Recognize the First 
Epidermal Growth Factor-Like Module in the Plasmodium 
falciparum Merozoite Surface Protein 1 Do Not 
Inhibit Parasite Growth In Vitro 
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Merozoite surface protein 1. one of the major surface proteins of the invasive blood stage of the malaria 
parasite, is a prime candidate for the development of a vaccine against the human disease. Previously, 
monoclonal antibodies which both inhibited the growth ofPlasmodiumfalciparum in vitro and bound to the first 
of two epidermal growth factor-like modules located near the carboxy terminus of the protein had been 
identified. In this study, we have used affinity chromatography on a recombinant fusion protein corresponding 
to the first epidermal growth factor-like module in P. J'alciparum merozoite surface protein 1 to prepare 
antibody induced by natural infection. The antibody was purified from the total immunoglobulin C fraction of 
adult West African donors, shown to passively confer immunity against falciparum malaria. Such affinity-
purified antibodies were shown to recognize the native protein by a number of separate criteria and to block 
the binding of an inhibitory monoclonal antibody, but they failed to inhibit parasite invasion in an in vitro 
growth assay. These results indicate that antibody alone is not sufficient to interfere with erythrocyte invasion. 
There is an urgent need to develop a more effective vaccine 
against malaria. Much work on vaccine development has been 
focused on merozoite surface protein I (MSP- I). a high-
molecular-mass protein synthesized h the intracellular schi-
zoni of the asexual blood and liver stages and expressed on the 
surface of merozoites released from the ruptured schizont ( IS. 
N). \ISP- I preparations purified front a number of malaria 
parasites have. by immunization, induced significant levels of 
protection against challenge with blood-stage parasites in both 
rodent ( 2(i) and simian )20. 21. 41. 40) experimental model 
'\'siems. Investigators have used parts of \ISP- I. either ex-
pressed in Escltcric/tia co/i (17. 20. 23. 28. 33) or as synthetic 
peptides (13. 40). to induce, complete or partial protection or to 
delay the progress of infection A synthetic peptide polvnier. 
Inch includes a sequence from the N terminus of P/asniodiii,,i 
!o/cipiiioii NISP-I. produced encouraging results in a recent 
clinical trial (49). 
\ISP-1 is modified by proteolsis leading to shedding of the 
UI iiecule except for a small C-terniinal !ragment, which can he 
Ictected on the sLirlace ol the parasite in a newly infected 
crvthroc ic Prior to the release of nicrozoites from the mature 
chtz nit. / ta/cipoi -ioii NISP- I is processed by proteasel s I to at 
leasi four major polvpeptides. held together in a noncovalent 
•:omplex on the tncrozoite surface I 3 I. One of these, a 42-kDa 
membrane-bound fragment from the C terminus (designated 
\ISP- I t. undergoes a second proieolvtic cleavage to produce 
\ISP- 1 z, and NISP-1 ,, I I. (1) The membrane-hound \ISP-1 
'r re' p'  id rig a Ut In r. NI :i Ii rig .tdd ress: DR i.R m of Pa rasi it il tgv. 
\atitiial Institute R'r Medical Research. Null lull. London N'tV7 IX-\. 
t .k. Ph'iie: iJ-ti Nl_'i-lthit. Fax: 44 	t .hl!_.oi3. Electronic mail 
.idJrc-.: i-li Ider' nimr.rnrc.:jeuk. 
t'rc-.eiir .iddrcss: 'FIie Scripr 	Rc-.etreli ln'.tiitite. La Jolla. C.-\  
polvpeptide. comprising two cvsteine-rich epidermal growth 
factor (EGF)-like modules (4). is carried into the new ervih-
t -oevte on the surface of the invading merozoitc (2). 
The EGF-like modules are found in MSP-1 in all species of 
malaria parasite examined (In. 25). and there is evidence to 
suggest that thev are an important target of protective immu-
nity. In studies using the rodent malaria models P/asnu_vIiunt 
toe/i, and Plasmodium c/tahaudi. .'vISP- I-specific monoclonal 
antibodies (MAbs) passively protected mice against challenge 
infection with homologous blood-stage parasites (S. 32.34). 
Two of these antibodies bind to discontinuous disulfide-
constrained epitopes within the EGF-like modules (1(1. 37). 
Mice immunized with the cvsteine-rich region of P. voelii 
\ISP-l. expressed as a fusion protein in E. co/i. were partially 
or completely protected against challenge infection with P. 
toe/ti parasites (17 33).A A. number of investigators have 
reported l fo/cipantni N4SP I-specific MAbs which inhibit the 
in vitro growth of the parasite (2. IS, 42). and these antibodies 
react with \1SP- I,. The EGF-like modules have been ex-
pressed in a correctly folded form in insect cells f II. 3 1)). Yeast 
cells 1 30). and E. co/i cells ('9, 12). Serum from rabbits 
immunized with a correctly folded insect cell product repre-
senting MSP-1 4 2. but not with an identical but incorrectly 
folded 'east cell product. completely inhibited P. jalciparwn 
growth in vitro (11). We have reproduced the individual 
EG F-like modules of the P. fiilciparwn MSP- I by expression as 
fusion proteins in E. co/i and have shown that a number of 
MSP-l-specific MAbs. including the invasion-inhibitor anti-
bodies SBl (42) and 12.8 (2). bound to disulfide-constrained 
epitopes in the first of the EGF-like modules (MSP-1-EGFI) 
(12). 
We show here that. in contrast to results obtained with 
\ISP-I-specific MAbs. immunoglohulin G (IgG) affinity se-
lected on \ISP-I---EGFI from the naturally acquired repertoire 
VOL 62. 1994 
	
HUMAN ANTIBODIES TO EGF-LIKE REGION OF MSP-1 	4489 
of adults with immunity to malaria did not prevent the invasion 
of erythrocytes by malarial merozoites in vitro. These antibod-
ies did recognize the native protein and competed for antigen 
binding with a protective MAb. 
MATERiALS AND METHODS 
Expression construct and protein purification. The first 
EGF-like module in the Wellcome\T9-94 MSP-1 (4, 29), 
designated MSP-1-EGFI. was expressed as a fusion protein 
with glutathione S-transferase (GST) in E. coli. The produc-
tion and characterization of the expression construct and the 
purification of the protein by chromatography on glutathione-
agarose (47) have been described in detail elsewhere (12). The 
protein was dialyzed against 50 mM ammonium bicarbonate 
(pH 7.4) and quantified (the A-. () of I mg of protein solution 
ml -' was estimated at 1.9). Alternatively, the soluble EGF-like 
polypeptide was cleaved from the immobilized. GST fusion 
partner by proteolysis , with bovine factor Xa (Boehringer) (47). 
Human IgG preparations. IgG derived from 178 adult 
inhabitants of Ivory Coast, West Africa (designated total-IgG), 
was used; the source and purification of this IgG and its clinical 
effect upon transfer to P. fa/ciparum-infected recipients have 
been described previously in detail (43). Control IgG (desig-
nated control-IgG) was purified from heat-inactivated, pooled 
sera of healthy European A+ blood donors never exposed to 
malaria, by chromatography on protein A bound to glass beads 
(Prosep-A: Bioprocessing), according to the manufacturers' 
instructions. lgG purity was estimated by analysis of Coom-
assie blue-stained sodium dodecyl sulfate-polyacrvlamide gel 
electrophoresis (SDS-PAGE) gels and quantified on the as-
sumption that 1 mg of lgG m1' has an A,,,, of 1.4 (22). IgG 
preparations were concentrated to 5 to 10 mg ml by ultra-
filtration (Amicon) and stored at 4°C, supplemented with 
0.02% (wt/vol) sodium azide. 
Affinity purification of MSP-1-specific IgG. IgG was affinity 
purified by chromatography on fusion protein representing 
MSP-1-EGF1 covalently linked to an insoluble matrix (22). 
Briefly, 35 mg of purified fusion protein (32.274 Da) was 
coupled to 7 ml (swollen gel volume) of cyanogen bromide-
activated Sepharose (Pharmacia) according to the manufactur-
er's instructions. This affinity matrix was estimated to be of 
sufficient capacity to bind approximately 16 mg of lgG (on the 
assumption of only I lgG molecule bound per 10 fusion 
protein molecules). Nine hundred mg of total lgG was passed 
over the affinity matrix; IgG which did not bind (designated 
void-IgG) was collected. After being extensively washed with 
100 mM and then 10 mM Tris-HCI (pH 8.0), bound IgG was 
eluted into 100 mM glycine-HCI (pH 2.5) and neutralized with 
1/10 volume of I M Tris-HCI (pH 8.0). IgG reactive with the 
OST fusion partner or with native E. co/i polypeptides was then 
removed by use of a bacteiial acetone powder (22). Briefly. E. 
co/i transformed with plasmid pGex-3X was induced to express 
GST and then lysed and clarified by centrifugation. Bacterial 
proteins in the supernatant were precipitated with acetone, 
harvested, and then dried. This powder was added at a ratio of 
20:1 (wt/wt) over IgG. and then. after incubation at 4°C for I 
h. insoluble immunocomplexes were removed by centrifuga-
tion at 39.000 X g for 15 min. Affinity-purified lgG specific for 
MSP-1 (designated AP-lgG) was extracted from. the superna-
tant by use of the immobilized fusion protein, concentrated by 
ultrafiltration, and stored as described earlier. 
Culture and metabolic radiolabelling of P.falciparum. Clone 
T9/94 (48) was maintained in culture and synchronized when 
required, essentially as described previously (27): growth me-
dium was supplemented with 0.5% (wt/vol) AIbuMAX (Life 
Technologies) instead of serum (34a). Synchronous cultures 
containing predominantly schizont-stage parasites with 2 to 4 
nuclei were washed once in methionine-free RPMI 1640 and 
resuspended at a 10% hematocrit in the same medium supple-
mented with AIbuMAX plus 1.85 MBq of [35Sjmethionine 
(Amersham) ml'. After 3 to 4 h of growth, cells were 
pelleted, washed three times in RPMI 1640. and then frozen at 
-.0°C until required. 
Immunoprecipitation and Western blotting methods. IgG 
specificities were analyzed by immunoprecipitation followed by 
SDS-PAGE and fluorographv of the. radiolabelled parasite 
proteins, by previously described procedures (27). 
For analysis by Western blotting (immunoblotting). identical 
samples of the MSP-1-EGFI polypeptide without the GST 
fusion partner were subjected to nonreducing SDS-PAGE by a 
Tricine buffer system (45) and then electrophoretically trans-
ferred to. nitrocellulose, essentially as described previously (6). 
Primary antibody binding was detected with appropriate anti-
IgG alkaline phosphatase conjugates and a chromogenic sub-
strate. In both immunoprecipitation and Western blotting 
procedures, the murine MAb 111.4 (29) was used as a positive 
control: this antibody binds to a disulfide-constrained epitope 
of MSP-1-EGFI (12). 
Molecular mass markers used were obtained from Gibco 
BRL (high molecular mass, prestained; 14.3 to 200 kDa) or 
BDH. Poole, United Kingdom (CNBr-cleaved horse heart 
myoglobin; 2,512 to 16,949 Da). 
ELtSA to measure anti-MSP-1 antibodies. The titer of lgG 
specific for MSP-1 was measured by enzyme-linked immu-
nosorbent assay (ELISA), essentially as described previously 
(3). Briefly, ELISA plates were coated with S42XA (39), a 
recombinant insect cell product which includes the carboxy-
terminal 271 amino acids (D-1433 to S-1723 [38]) of the 
Wellcome\T9-94 MSP-1 and includes both EGF-like modules. 
Plates were washed, and twofold serial dilutions of each IgG (2 
X lO to 4.9 X 10 g ml - ') were applied to duplicate wells. 
Following incubation with enzyme-conjugated anti-human 
lgG, plates were developed with a chromogenic substrate and 
A 491 values were measured. 
Competition ELISA. To determine whether the human 
antibodies could inhibit the binding of MAbs, the plates were 
first incubated with serial dilutions of each human IgG frac-
tion. The plates were washed, and an optimal dilution of MAb 
determined by titration was added to the plate. The binding of 
MAb was measured by use of an enzyme-conjugated anti-
mouse IgG and chromogenic substrate. 
In vitro parasite invasion inhibition assay. Mature schi-
zonts, purified from highly synchronous cultures by centrifu-
gation onto a cushion of 63% isotonic Percoll (Pharmacia). 
were added to erythrocytes to give a parasitemia of 0.5 to 1%. 
Each test lgG was dialyzed extensively against RPM! 1640 and 
then added to four identical microcultures of P. falciparurn. at 
a final concentration of I mg ml (the final hematocrit was 
2%). Control cultures (six of each) containing either no added 
IgG or 5 mM EGTA [ethylene glvcol-bis(-aminoethyl ether)-
N,N.NN'-tetraacetic acid] were also included; EGTA at this 
concentration effectively inhibits merozoites' invasion of eryth-
rocytes (36. 50). After 24 h of growth at 37°C. duplicate blood 
smears were made from each well and then fixed with metha-
nol and stained with Giemsa stain. Parasitemia was determined 
by counting of the number of young parasites within 8.500 or 
more erythrocytes. Multiple parasites within a single erthro-
cyte were recorded as one count 
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FIG. 1. The titers of MSP-l-specific Ig within four serially diluted 
antibody preparations (defined in Materials and Methods) were com-
pared by ELISA utilizing the recombinant protein S42A: a represen-
tative experiment is shown. The ordinate represents .4.. versus the 
lgG concentration plotted on a semilogarithmic scale for clarity. Serial 
dilutions of AP-lgG (i2). total-lgG (0). void-lgG (•). and control-IgG 
(7) were used. 
RESULTS 
Affinity purification of MSP-1-specific human IgG. IgG was 
purified from pooled IgG of West African adults (total-lgG) b9 
affinity chromatography on MSP-1-EGFI fusion protein rep-
resenting the first EGF-like module in the P. falciparwn 
Wellcome\T9-94 type MSP- I. A two-stage affinity selection 
protocol. utilizing elution by acid at pH 2.5. yielded 2.9 mg of 
IgG (AP-[gG). 0.3% of the 900 mg of total-lgG starting 
material. Analysis of each lgG fraction by SDS-PAGE under 
reducing conditions revealed essentially only two polvpeptides. 
corresponding to the lgG heavy and light chains (data not 
shown). A significant quantity of IgG remained bound to the 
affinity matrix following sequential washes at pH 2.5 and 
subsequent washes with buffers at neutral pH containing 8 M 
urea or l% SDS: such lgG was only eluted by boiling in 
SDS-PAGE sample buffer (data not shown). and further 
analysis of this lgG was not attempted. 
Characterization of affinity-purified human antibodies. 
ELISA. immunoprecipitation. and Western blotting experi-
ments were carried out to demonstrate the specificity and to 
quantify the amount of MSP-l-specific antibody in AP-IgG in 
comparison with other Ig preparations. 
The titers of MSPI-specific antibodies in the four Ig samples 
were compared by use of an ELISA based on the insect cell 
product S42..A. as shown in Fig. I. Differences in anti-S42.A 
antibody titers between samples were estimated by comparison 
of lgG concentrations at fixed absorbance values: such approx-
imations are valid in regions where plotted data lines remain 
parallel (31). By this method, the AP-IgG preparation was 
estimated to contain 100-fold more S42.A-specific Ig than the 






FIG. 2. Immunoprecipitation of radiolabelled parasite proteins by 
a selection of antibodies. Separate immunoprecipitation reactions 
were Set up, containing equal amounts of parasite material plus 5 i.Lg of 
one of the following: AP-IgG (lane 3), total-lgG (lane 4), and void-lgG 
(lane 5). Control reactions were set up with either no added lgG 
(protein A-Sepharose only. lane I). 5 VI of MAb 111.4 ascites (lane 2). 
or 5 g of control-lgG (lane 6). Immune complexes were subjected to 
SDS-PAGE under reducing conditions on a 7.5% polvacrylamide gel, 
and radiolabelled proteins were visualized by fluorography. Molecular 
mass marker proteins indicated are myosin heavy chain (200 kDa), 
phosphorvlase b (97 kDa), bovine serum albumin (68 kDa), and 
ovalbumin (43 kDa). F indicates the gel dye front. 
void-IgG. Note that the level of S42A-specific Ig present in 
the void-IgG sample was reduced from that present in the 
total-I9G to approximately that in control-1 ,1G. which was 
assumed to represent the background level. This result sug-
gested that a substantial proportion of the S4IXA-specific Ig 
originally present in the total-IgG preparation had been re-
moved by the affinity purification procedure. 
Immunoprecipitation experiments were conducted to dem-
onstrate that the affinity purification procedure selected IgG 
which could recognize and bind to the native MSP-1. Figure 2 
shows that the AP-lgG preparation (lane 3) and the control 
MAb 111.4 (lane 2) both immunoprecipitated a 190-kDa 
species from radiolabelled parasite material, corresponding in 
size to the intact MSP-1. No equivalent species was observed in 
immunoprecipitation reactions with either the total-IgG (Fig. 
2. lane 4). void-lgG (lane 5), or control-lgG (lane 6) prepara-
tion or with protein A-Sepharose alone (lane I). Other faster-
migrating species were immunoprecipitated by all three poly-
clonal lgG preparations. and most of these were common 
among the samples (Fig. 2. compare lanes 3. 4. and 5): such 
species were not characterized further. 
Western blotting was used to demonstrate that the AP-I,-,G
preparation had enhanced levels of antibodies against the first 
MSP-I EGF-like module compared with the other antibody 
preparations. Digestion of the GST fusion protein with factor 
Xa produced a 52-amino-acid polypeptide comprising MSP-l-
EGF1 (residues 1631 to 1678 of MSP-l) preceded by four 
additional residues (GIQM), with a calculated molecular mass 
of 6.022 Da. Identical samples of this polpeptide were sub-
jected to Tricine-S DS- PAGE under nonreducing conditions 
and transferred to nitrocellulose. Figure 3 shows that both 
MAb 111.4 (lane 1) and the AP-lgG preparation (lane 3) 
clearly detected the MSP-1-EGFI polypeptide; this species 
was not detectable in the conditions of this assay with the 
total-IgG (lane 2), and neither the void-IgG nor the control-
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FIG. 3. The titers of lgG specific for MSP-I—EGF1 within two 
polvclonal antibody preparations were compared by Western blotting. 
Identical amounts of the 52-residue (6.022 Da) polypeptide represent-
ing MSP-l—EGFI. derived from an E. coli-expressed fusion protein by 
site-specific proteolysis. were subjected to Tricine-SDS-PAGE and 
then transferred to nitrocellulose. Blots were probed with either MAb 
111.4 (lane I). totallgG (lane 2), or AP-lgG (lane 3). Color develop-
ment reactions were conducted in parallel and stopped at the same 
time. Protein molecular mass markers indicated were derived from 
CNBr-cleaved horse heart moglobin, at 16.949 Da. 14.404 Da. 8159 
Da. 6.214 Da. and 2.512 Da. 
These experiments indicate that compared with the void-
JOG sample. a significantly greater proportion (approximately 
100-fold by ELISA) of the antibodies within the AP-IgG 
preparation were directed against determinants present in the 
first EGF-like module of MSP-I. 
Affinity-purified antibodies compete with a protective MAb 
for antigen binding. The different IgG preparations were 
assayed for their abilities to block the binding of two inhibiton' 
MAbs to S42AA (Fig: 4). The AP-lgG fraction was able to 
compete with MAb 12.8 at a concentration of 2 .i.g  ml — '. but 
none of the other IgG was effective in this range. None of the 
antibodies inhibited the binding of MAb 12.10 at 10 I.Lg m1' 
(data not shown). 
Parasite in vitro invasion assay. Highly synchronous micro-
cultures of P. falciparum containing predominantly schizonts 
were incubated in the presence of various IgG preparations. 
After 24 h. encompassing schizont rupture-merozoite release 
and reinvasion of new erythrocytes. parasitemias were deter-
mined. The final parasitemia in cultures supplemented with 
African IgG preparations did not differ significantly from that 
of the control (Fig. 5), although EGTA was very effective at 
blocking invasion. The morphology of the parasites was normal 
on Giemsa-stained smears for all cultures. incubated with or 
without antibodies, and no agglutinated clusters of merozoites 
were observed in any sample. 
DISCUSSION 
We have investiated whether antibodies to the first EGF-
like module of  induced by natural infection are inhib-
itory to parasite growth in vitro. This biological properly is 
manifested by some but not all MAbs specific for the C- 
FIG. 4. Affinity-purified antibodies block the binding of an inhibi-
tory MAb. ELISA plates coated in S42A were preincubated with 
various concentrations of human IgG. Serial dilutions of AP-12G (Lx). 
total-lgG (D). void-IgG (•), and control-lgG (V) were used in 
triplicate. An optimal concentration of MAb 12.8 was then added. and 
the amount bound was determined. The ordinate represents .-4. 4 as a 
measure of bound MAb. and the abscissa represents the IgG concen-
tration. 
terminal cysteine-rich region of MSP-1. Four murine MAbs 
which are specific for MSP-1 and which inhibit the growth of P. 
falciparuni in vitro (2, 15. 42) have been described previously. 
Two of these antibodies, 12.8 (2) and 5B1 (42), bind to the first 
of two EGF-like modules in MSP-1 (12); another. 12.10. binds 
only if the two EGF-like modules are expressed together (9. 
12). The present study was aimed at investigating whether or 
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FIG. 5. Invasion inhibition assay. Various IgG preparations were 
added to individual microcultures of P. falciparuni to test for their 
abilities to inhibit parasite invasion of ervthrocvtes. Growth was also 
monitored in cultures containing either no added lgG or 5 mM EGTA. 
previously shown to effectively inhibit merozoite entry into eithro-
cvtes. Bars on the chart represent mean final percentage parasitemias: 
error bars indicate standard distribution within each sample. 
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could manifest the same biological activity and therefore be 
responsible (at least in part) for the protection observed in 
immune individuals and in nonimmune individuals protected 
by passive transfer. 
By affinity chromatography on the first EGF-like module of 
MSP-1 expressed as a fusion protein in E. coli. we selected a 
subset of IgG from a polyspecific IgG pool derived from West 
African adults and shown to passively confer immunity to 
malaria. We have previously concluded that MSP-l-EGFI 
expressed in bacteria adopts the correct disulfide structure: it is 
reactive with MSP-l-specific MAbs. and this binding is dimin-
ished or abolished by prior treatment with thiol reagents (12). 
From 900 mg of total-IgG, 2.9 mg of IgG was selected by the 
affinity chromatography procedure. On the basis of these 
figures, and on the assumption that the AP-IgG is wholly 
specific for MSP-1, approximately 0.3% of the total-IgG pop-
ulation was recovered. Taking into consideration the fact that 
higher-affinity antibodies remained bound to the column dur -
ing the elution process, the results suggest that large amounts 
of IgG are directed against the first EGF-like structure in 
MSP-I. No similar quantitative estimates for the proportion of 
MSP-1-specific antibodies in human serum' have been previ-
ously reported. 
The AP-IgG preparation was shown by ELISA to contain 
approximately 100-fold-enhanced levels of S42.A-specific an-
tibodies compared with the void-IgG preparation. S42A 
includes both EGF-like modules and parts of MSP-1 N termi-
nal to this region: antibodies to these regions will increase 
absorbance values measured in the ELISA for the nonselected 
samples. - - 
We found that only the AP-lgG preparation contained 
enough antibodies of the correct specificity to generate an 
MSP-1-specific signal in Western blotting and immunoprecipi-
tation experiments. Successful immunoprecipitation of radio-
labelled MSP-1 demonstrates that AP-IgG can bind to the 
native protein. These data support the ELISA results and 
suggest that a substantial proportion of antibodies within the 
AP-lgG preparation are specific for MSP-l-EGFI. In addi-
tion, the selected antibodies inhibited the binding of MAb 12.8. 
which binds specifically to the first domain, but had no effect on 
the binding of MAb 12.10. which is known to be directed to a 
conformational epitope distinct from that of 12.8, when S42A 
was used as the -antigen. - 
Immunity against malaria, which may be acquired by long-
term residents in regions where malaria is endemic, can be 
passively transferred to young children who have not yet 
developed an effective immunity by the administration of IgG 
from immune adults (14. 19. 43j. The mechanism for this 
protection remains unclear. Our findings that a concentration 
of I mg of total-lgG ml - ' did not significantly affect parasite 
multiplication were not surprising. In previous experiments. 
identical IgOs had no inhibitors' effect on either parasite 
growth or invasion in vitro at concentrations of up to 5 mg 
mV. indeed sometimes stimulating parasite growth. at least of 
some strains (7). Nevertheless. this antibody preparation ex-
erted a profound reduction in asexual parasitemia when ad-
ministered to human malaria patients by intravenous inocula-
tion (43). and it is perhaps significant that it was shown to 
inhibit parasite growth in vitro in cooperation with monocytes 
(7). Although the invasion inhibition assay used in the present 
study was similar to that used previously (2).. in which mero-
zoite invasion was significantly inhibited by MAb at a concen-
tration of only 100 i.g ml °. a 10-fold-higher concentration of 
the polvspecific AP-lgG preparation of human origin did not 
hinder merozoite enrry into ervthrocytes. This discrepancy 
INFEC7. IMMUN. 
suggests that minor differences in the target epitopes may be 
critical in the function of the corresponding antibodies. 
It has been demonstrated that MSP-1 1 displays multiple 
distinct Ig-binding sites, and competition assays suggest that 
these are clustered or overlapping (12. 51). Fine-structure 
mapping of these epitopes will be difficult to achieve, in view of 
their conformational nature. Expression of the constituent 
EGF-like domains individually does not reproduce all anti-
genie determinants formed when they are expressed together. 
such as the binding site for the invasion-inhibitory MAb 12.10 
(12). Idiotypes of the 12.8-like specificity should be present in 
the AP-IgG, and this is confirmed by our results, but these 
antibodies do not have inhibitory activity. The method of 
affinity purification used here would not be expected to - select 
antibodies with 12.10-like specificities. The antibodies which 
bound to the affinity matrix and could only be eluted after 
denaturation may have had a very high affinity for MSP-1-
EGF1: although it was not possible to assay them, this subset 
of affinity-selected IgG may have possessed invasion-inhibiting 
activity. - 
Natural infection or immunization with MSP-1-EGFI may 
stimulate the production of several different anti-MSP-1-
EGF1 idiotypes of which only a subset exert the required 
biological effect(s). Hence, it may be difficult to achieve the 
requirement for relatively high concentrations of inhibitory Ig 
suggested both by a kinetic model of merozoite invasion (44) 
and by experiments using MAbs (2. 15, 42). In addition, the 
binding of inhibitory MAbs such as 12.8 may be blocked by the 
binding of other antibodies which are themselves not inhibitory 
in vitro (5. 51). It is encouraging that polyclonal Ig in serum 
from rabbits immunized with an insect cell product represent-
ing the carboxyl-terminal processing product MSPI 4 , com-
pletely inhibited the multiplication of the malaria parasite in 
vitro (11). Further experiments in primates and human volun-
teers will be critical to determine whether or not the artificial 
antigen can induce blocking antibodies whereas natural infec-
tion does not, or alternatively whether or not it is the host 
species which determines the type of antibody produced. At 
least in a mouse malaria, immunization with the two EGF-like 
modules of P. yoelii has provided- very significant protection 
against challenge infection (17. 31). In these experiments, it is 
possible that epitopes in the second EGF module or formed 
from the interaction of the two domains are most important as 
targets of inhibitory antibodies. - 
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Abstract. 
The development of an effective malaria vaccine depends upon 
identification of antigens that are targets of protective immune 
responses. Animmuno-epidemiological approach has been used to 
investigate the relationship between antibody responses to a 
d 	
merozOite surface protein of 
efined region of the major  
Plasmodium falciPaZP (PfMSP-119) and resistance to clinical. 
malaria in two populations of children from West Africa. After 
allowing for the confounding effects of age, antibodies to PfMSP 
119 were shown to provide approximately 40% protection against 
clinical malaria in Sierra Leonean children and antibodies to one 
of the EGF-like motifs of pfMSP-119 were shown to be strongly 
associated with resistance to both clinical malaria and high 
levels of parasitemia in Gambian children. 
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Introduction. 
The Plasmodium falciparum merozoite surface protein, PfMSP-1, is 
a prime candidate for a vaccine against the erythrocytic stage 
of the malaria parasite, which is responsible for the pathology 
of malaria infection. Antibodies to PfMSP-1 can block parasite 
invasion of red blood cells in vitro and primates immunised with 
native PfMSP-1 are partially or completely protected against 
homologous challenge [1-3]. PfMSP-1 is synthesised during 
schizogony; post-synthetic processing gives rise to multiple 
fragments including a C-terminal l9kDa polypeptide (PfMSP-119) 
which is made up of two epidermal growth factor (EGF)-like motifs 
and which may be involved in attachment of the parasite to 
specific red cell surface receptors [3]. immunization of mice 
with recombinant proteins representing the corresponding 
membrane-bound component of the major merozoite surface protein 
from Plasmodium yoelii has been shown to induce high levels of 
protection against challenge with a lethal P. voelii strain [4]. 
In Gambian children, IgG antibodies recognising the 42kDa C-
terminal fragment of PfMSP-1 (PfMSP-142) are significantly 
associated with resistance to clinical malaria [5]. In this study 
we have investigated the hypothesis that it is antibody directed 
against the PfMSP-119 component of PfMSP-142 that is associated 
with protective immunity. 
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Materials and Methods. 
Study population and study design. 
The study concentrated on children who were actively acquiring 
immunity to malaria (327 children aged 3-8 years in the Gambia 
and 645 children aged 0-8 years in Sierra Leone). 
Malaria in The Gambia is seasonally endemic [6]. Children are 
bitten by between 1 and 5 infective mosquitoes each year and 
become clinically immune to malaria by the age of 8-10 years [6]. 
In Sierra Leone, malaria is perennial with an average of 30 
infective bites/adult/year; clinical cases are uncommon in 
children over the age of 5 years [7]. 
Serum samples were collected immediately before the commencement 
of the annual rainy season. The children were monitored weekly 
for the presence of fever (T > 37.5 0C); a blood film was made 
from all febrile children and examined for malaria parasites. 
Morbidity analysis continued until the end of the malaria 
transmission season in The Gambia (November 1988) and for one 
complete year in Sierra Leone, at which time children were 
classified into one of four morbidity groups on the basis of 
their clinical experience of malaria. Clinical malaria was 
defined as at least one episode of malaria parasitemia () 5,000 
parasites per pL blood) together with fever (T > 37.5 0C). 
Asymptomatic malaria was defined as malaria parasitemia (of any 
level) in the absence of fever. Fever (T > 37.5°C) in the 
presence of low parasiternia (< 5,000/jiL) was classified as an 
indeterminate infection, since the fever may not have been 
directly attributable to the presence of parasites. Children in 
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whom there was no evidence of parasitemia were classified as "no 
infection'. This may be due to lack of exposure to infected 
mosquitoes or immune clearance of parasites in the absence of 
clinical, symptoms. 
Recombinant antigens. 
PfMSP-1 is a dimorphic protein encoded by genes belonging to two 
major allelic families (MAD20I3D7 and Wellcome/Kl) [8]. The MAD20 
family accounts for more than 95% of clinical infections in The 
Gambia [9]. The sequence of PfMSP-119 is highly conserved (four 
amino acid differences, out of 95 residues) between the two 
allelic sequences. 
The first and second EGF motifs of the MAD20 allele were 
expressed as glutathione S_transferaSe (GST) fusion proteins in 
E. coli transformed with recombinant pGEX3 plasmids [10]. As a 
control, unfused GST was prepared from bacteria transformed with 
PGEX3. The complete MAD20 PfMSP-119 protein and a protein 
representing a recombinant allele which has the MAD20 sequence 
of the first EGF motif and the Wellcome sequence of the second 
motif (FVO/E), were expressed in recombinant S. cerevisi [11]. 
ELISA assays. 
Sera were tested for reactivity with the PfMSP-1 proteins by 
enzyme-linked immunosorbent assay (ELISA) as described previously 
[12]. Briefly, microtiter plates (Dynatech, BillingShUrSt, UK) 
were coated with recombinant protein; serum was added to 
duplicate wells and incubated overnight at 4°C. plates were 
developed with peroxidas e_cofliUgated rabbit anti-human igG (Dako 
7 
Ltd, High Wycombe, UK) and developed with H 202 and o-
phenylenediamine (both Sigma, Poole, UK). Plates were read at 
492nm. For GST fusion proteins the optical density (OD) values 
for binding to the GST control protein were subtracted from the 
OD values obtained for the PfMSP-1-GST fusion protein to obtain 
the PfMSP-l-specific OD. Antibody positive sera ('responders") 
are defined as those giving an OD > normal range (mean plus 2 SD 
of OD's of 42 European sera tested in parallel with the malaria-
exposed samples). 
Statistical Methods. 
Only the clinical and asymptomatic malaria categories were 
compared since the status of the other two morbidity groups was 
not certain. The x2 test for trend assessed age-related trends in 
the prevalence of positive antibody responses and clinical 
malaria. The association between malaria morbidity and antibody 
response was assessed using odds ratios (OR); an OR of less than 
1.0 would indicate a protective antibody effect. To allow for 
potential confounders of the association between morbidity and 
antibody response, multiple logistic regression was used to 
obtain adjusted OR's and significance assessed by the likelihood 
ratio test. 
Results. 
1. Relationship between age, clinical symptoms of malaria 
infection and anti-PfMSpl 19 antibody levels. 
The prevalence of clinical malaria declined with age in both 
cohorts and the incidence of asymptomatic infections increased 
with age (Table 1). This confirms that the age groups being 
studied were those in which clinical immunity was developing 
rapidly. 
Within the Sierra Leonean cohort, children below one year of age 
were less likely to become infected than children aged 2 to 5 
years. The resistance of infants to malaria infection is due to 
a combination of the protective effects of maternal 
immunoglobulin and fetal hemoglobin and lower exposure to 
infective mosquitoes. However, infants who did become infected 
were more likely to be symptomatic than were older children (79% 
of infected 0-1 year olds were symptomatic compared with 61% of 
2-3 year olds and 34% of 4-5 year olds). 
The geometric mean level of parasitemia was significantly lower 
in children with asymptomatic infections than in children with 
clinical infections (Table 2; for The Gambia, t = 12.99, df 
198, p < .001; for Sierra Leone, t = 24.2, df = 506, p < .001), 
confirming that children with asymptomatic infections were able 
to control parasite growth. 
Both the prevalence (Table 1) and mean concentration (data not 
shown) of IgG antibodies to PfMSP-1 19 increased with age. The 
prevalence of antibody responses to some of the PfMSP-1 19 
constructs was higher in Sierra Leonean children than in Gambian 
children; this may reflect the less seasonal pattern of malaria 
transmission in Sierra Leone. 
2. Relationship between anti-PfNSP1 19  antibodies and malaria 
morbidity. 
Antibodies measured in the children's sera at the beginning of 
the malaria transmission season were compared with their 
subsequent malaria morbidity. Neither the sex of the child nor 
carriage of the sickle cell gene (data not shown) had any 
confounding effect on PfMSP-1 19 antibody prevalence or OD value. 
However, age appeared to have a major confounding effect on the 
association between malaria morbidity and antibody responses, and 
was allowed for using multiple logistic regression analysis. For 
the Gambian children, ethnic group was also allowed for since 
there were differences in antibody prevalence between ethnic 
groups (data not shown). 
The prevalence of antibodies to PfMSP-1 19 tended to be higher in 
children who experienced only asymptomatic infections (and who 
are thus deemed to have acquired a significant degree of immunity 
to malaria) than in children who experienced clinical infections 
(Table 2). In Gambian children the prevalence of antibodies to 
the second EGF-like domain was significantly higher in 
asymptomatic children than in those experiencing clinical 
malaria. This association remained highly significant (P < .001) 
after allowing for age and ethnic group. For the Sierra Leonean 
children, response to the MAD/Well 19 antigen offered protection 
against clinical malaria, reducing the risk of clinical malaria 
by an estimated 40% and there was a suggestion of a reduced risk 
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of clinical malaria associated with positive responses to the 
MAD2019 and MAD20-second EGF motif, although these were not 
statistically significant. 
The subclass specificity of the PfMSP-119 antibodies was 
determined by a subclass specific ELISA [12]. There was no 
detectable association between IgG subclass and age or morbidity 
(data not shown). The vast majority of positive sera (> 95%) 
contained IgGl (and only IgGl) antibodies for PfMSP-119. 
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Discussion. 
This study establishes that there is a significant association 
between antibody responses to epitopes within the EGF motifs of 
the 19kDa, membrane-bound fragment of PfMSP-1 and resistance to 
clinical malaria infection and provides evidence that a vaccine 
which induces an appropriate antibody response to PfMSP-1 19 might 
protect children from high levels of asexual stage parasitaemia 
and clinical malaria. The protective effect of antibodies to 
PfMSP-1 19 is in marked contrast with the lack of such an effect 
for antibodies to other malaria antigens tested in similar 
studies [13,14]. Clearly, however, possession of PfMSP-1 19-
specific. antibodies is not the only means of protection as many 
antibody-negative children appeared to be protected. These 
children presumably possess antibodies, or specific cellular 
responses, to other erythrocytic stage antigens. 
The prevalence and mean OD of antibody responses were higher to 
constructs representing the entire PfMSP-1 19 protein (i.e.both 
EGF motifs) than to constructs representing either of the single 
EGF motifs; this is consistent with our previous studies with 
these constructs [12] and indicates that immunodominant B cell 
epitopes are dependent upon the presence of sequences from both 
EGF motifs. However, the highest degree of protection was 
associated with antibodies to the second EGF-like domain: all ten 
Gambian children who were seropositive to this antigen 
experienced only asymptomatic malaria infections indicating that 
they were able to control parasite growth to below levels at 
which clinical symptoms become manifest. 
A similar trend was seen for the Sierra Leonean children, but 4 
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children who were seropositive to the second EGF-like domain did 
experience clinical infections. It is possible that the non-
protected Sierra Leonean children possessed antibodies which 
recognise the MAD20 sequence of the second EGF-like motif but 
were infected with parasites expressing the alternate (Wellcome) 
sequence. (The prevalence of parasites carrying the Wellcome 
allele of PfMSP-1 is less than 5% in The Gambia, but may be 
higher in Sierra Leone). 
The identification here of a short and relatively conserved 
antigen which is the target of protective anti-malarial immune - 
responses marks a significant step forward in the search for a 
subunit malaria vaccine which could be manufactured using 
recombinant DNA technology. One potential problem is the 
apparently poor immunogenicity of PfMSP-1 19 and particularly of 
the second EGF-like motif. Despite multiple infections, no more 
than 20% of Sierra Leonean children possessed antibodies to 
PfMSP-1 19 and only 3-4% possessed antibodies to the second EGF-
like motif. Only 60% and 14% respectively of adult Gambians are 
seropositive to PfMSP-1 19 and the second EGF-like motif [12], 
indicating that even lifelong exposure to this essentially 
conserved protein may be insufficient to induce an antibody 
response. 
Poor natural irnmunogenicity may be a consequence of the way in 
which the protein is presented to the immune system during 
malaria infection. For example, secondary processing of PfMSP-1 42  
is a pre-requisite for erythrocyte invasion [3,15] but may 
substantially affect the antigenic integrity of the resulting 
PfMSP1 19 polypeptide. In addition, recent data from our 
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laboratory indicate that few malaria-immune donors show in vitro 
T cell proliferative or cytokine responses to PfMSP-1 19 , 
suggesting that lack of T cell help for antibody production may 
be a problem (A. Egan and E. Riley, unpublished data). If so, 
immunization with a polypeptide incorporating additional T cell 
epitopes, from other regions of PfMSP-1 or from heterologous 
proteins, may induce a significantly better antibody response 
than that induced by the native protein during natural infection. 
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Table 1: The relationship between age and malaria morbidity, and between age and anti-PfMSP-119 
antibody reactivity. The number (percentage) of positive children in each age group is shown. 
The Gambia 	 Sierra Leone 
Age (years) 	x2 	P 	
Age (years) 	 x 	 P 
trend trend 
3-4 	5-6 	7-8 	 0-1 	2-3 	
4-5 	6-8 
n 120 110 97 
167 162 157 159 
Morbidity: - 














35 3.5 .06 19 51 83 • 86 78.2 
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.89 
(34) (26) (23) (22) (9) (5) 
(23) 
Antibody: 
MAD2019 6 8 14 5.9 .01 11 
31 25 43 19.6 < 	.001 
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. 	(1) (2) (5) (7) 
The Gambia 




11 	(12) 8 	(7) 0.7 .52 
0.3-2.0 
16 	(18) 12 	(11) 0.7 .35 
0.3-1.6 
5 	(6) 8 	(7) 1.7 .38 
0.5-5.7 
5 	(6) 9 	(8) 1.8 .31 
0.6-5.9 
10 	(11) 0 	(0) 0.0 	- <.001 
0.0-0.5 
Sierra Leone 




53 	(22) 34 	(13) 0.7 
0.4-1.2 
65 	(27) 40 	(15) 0.6 
0.4-1.0 
26 	(11) 24 	(9) 0.9 
0.5-1.8 
32 	(13) 32 	(12) 1.0 
0.5-1.7 













Table 2: The relationship between anti-PfMSP-119 antibodies and malaria morbidity. The number 
(percentage) of responders to each antigen, in each morbidity group, is shown. 
* Odds Ratio for clinical malaria adjusted for age and ethnic group 
** Odds Ratio for clinical malaria adjusted for age 	+ Confidence Interval 
P value represents significance of likelihood ratio test, obtained using logistic regression. 








(667-1043) 	(37,008 - 
44,606) 
